|
G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions decreases expression
|
ISO
|
caffeic acid phenethyl ester promotes the reaction [Nitrogen Mustard Compounds results in decreased expression of AHR protein]
|
CTD |
PMID:17204746 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Alb
|
albumin
|
increases alkylation
|
ISO
|
Nitrogen Mustard Compounds results in increased alkylation of ALB protein
|
CTD |
PMID:18269793 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
G
|
Brca1
|
BRCA1, DNA repair associated
|
decreases expression multiple interactions
|
ISO
|
Nitrogen Mustard Compounds results in decreased expression of BRCA1 mRNA Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA1 mRNA]
|
CTD |
PMID:10344722 |
|
NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,917,693...86,977,763
|
|
G
|
Brca2
|
BRCA2, DNA repair associated
|
multiple interactions increases expression decreases expression
|
ISO
|
Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA2 mRNA] Nitrogen Mustard Compounds results in increased expression of BRCA2 mRNA
|
CTD |
PMID:10344722 PMID:27342729 |
|
NCBI chr12:4,895,092...4,939,340
Ensembl chr12:4,895,447...4,936,194
|
|
G
|
Cdh2
|
cadherin 2
|
decreases expression multiple interactions
|
ISO
|
Nitrogen Mustard Compounds results in decreased expression of CDH2 mRNA; Nitrogen Mustard Compounds results in decreased expression of CDH2 protein Plant Extracts inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of CDH2 mRNA]; Plant Extracts inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of CDH2 protein]
|
CTD |
PMID:18572855 |
|
NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288
|
|
G
|
Dhfr
|
dihydrofolate reductase
|
decreases response to substance
|
ISO
|
DHFR protein polymorphism results in decreased susceptibility to Nitrogen Mustard Compounds
|
CTD |
PMID:12872145 |
|
NCBI chr 2:25,320,895...25,346,004
|
|
G
|
Erbb2
|
erb-b2 receptor tyrosine kinase 2
|
decreases expression
|
ISO
|
Nitrogen Mustard Compounds results in decreased expression of ERBB2 mRNA
|
CTD |
PMID:16417271 |
|
NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481
|
|
G
|
Fancd2
|
FA complementation group D2
|
increases expression
|
ISO
|
Nitrogen Mustard Compounds results in increased expression of FANCD2 mRNA; Nitrogen Mustard Compounds results in increased expression of FANCD2 protein
|
CTD |
PMID:27342729 |
|
NCBI chr 4:148,234,633...148,299,035
Ensembl chr 4:148,234,708...148,299,035
|
|
G
|
Gsta3
|
glutathione S-transferase alpha 3
|
decreases response to substance
|
EXP
|
GSTA3 protein results in decreased susceptibility to Nitrogen Mustard Compounds
|
CTD |
PMID:9414483 PMID:12872145 |
|
NCBI chr 9:31,154,989...31,180,653
Ensembl chr 9:31,154,989...31,180,654
|
|
G
|
H2ax
|
H2A.X variant histone
|
multiple interactions increases expression
|
ISO
|
MGMT protein affects the reaction [Nitrogen Mustard Compounds results in increased expression of H2AX protein]; Nitrogen Mustard Compounds results in decreased expression of and results in increased phosphorylation of H2AX protein Nitrogen Mustard Compounds results in increased expression of H2AX mRNA; Nitrogen Mustard Compounds results in increased expression of H2AX protein
|
CTD |
PMID:27342729 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Igf1r
|
insulin-like growth factor 1 receptor
|
affects response to substance
|
ISO
|
IGF1R protein affects the susceptibility to Nitrogen Mustard Compounds
|
CTD |
PMID:15499378 |
|
NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:130,959,997...131,248,664
|
|
G
|
Mgmt
|
O-6-methylguanine-DNA methyltransferase
|
multiple interactions decreases expression
|
ISO
|
MGMT protein affects the reaction [Nitrogen Mustard Compounds results in increased expression of H2AX protein]; MGMT protein affects the reaction [Nitrogen Mustard Compounds results in increased expression of SPRTN protein] Nitrogen Mustard Compounds results in decreased expression of MGMT mRNA
|
CTD |
PMID:27342729 |
|
NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:201,140,661...201,367,482
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
increases expression multiple interactions
|
ISO
|
Nitrogen Mustard Compounds results in increased expression of NFE2L2 protein caffeic acid phenethyl ester promotes the reaction [Nitrogen Mustard Compounds results in increased expression of NFE2L2 protein]
|
CTD |
PMID:17204746 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
increases degradation
|
ISO
|
Nitrogen Mustard Compounds results in increased degradation of NFKBIA protein
|
CTD |
PMID:17204746 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Rps6ka2
|
ribosomal protein S6 kinase A2
|
multiple interactions increases phosphorylation
|
ISO
|
caffeic acid phenethyl ester inhibits the reaction [Nitrogen Mustard Compounds results in increased phosphorylation of RPS6KA2 protein]
|
CTD |
PMID:17204746 |
|
NCBI chr 1:55,178,988...55,454,271
Ensembl chr 1:55,179,319...55,454,338
|
|
G
|
Sprtn
|
SprT-like N-terminal domain
|
multiple interactions increases expression
|
ISO
|
MGMT protein affects the reaction [Nitrogen Mustard Compounds results in increased expression of SPRTN protein] Nitrogen Mustard Compounds results in increased expression of SPRTN mRNA; Nitrogen Mustard Compounds results in increased expression of SPRTN protein
|
CTD |
PMID:27342729 |
|
NCBI chr19:52,857,612...52,864,864
Ensembl chr19:69,754,980...69,762,237
|
|
G
|
Tp53
|
tumor protein p53
|
multiple interactions increases phosphorylation
|
ISO
|
caffeic acid phenethyl ester inhibits the reaction [Nitrogen Mustard Compounds results in increased phosphorylation of TP53 protein]
|
CTD |
PMID:17204746 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Vim
|
vimentin
|
decreases expression
|
ISO
|
Nitrogen Mustard Compounds results in decreased expression of VIM mRNA; Nitrogen Mustard Compounds results in decreased expression of VIM protein
|
CTD |
PMID:17192600 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746
|
|
G
|
Xrcc5
|
X-ray repair cross complementing 5
|
affects response to substance
|
ISO
|
XRCC5 protein affects the susceptibility to Nitrogen Mustard Compounds
|
CTD |
PMID:10717383 |
|
NCBI chr 9:81,404,507...81,493,293
Ensembl chr 9:81,375,863...81,493,293
|
|
|
G
|
Abl1
|
ABL proto-oncogene 1, non-receptor tyrosine kinase
|
increases expression
|
ISO
|
perfosfamide results in increased expression of ABL1 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 3:35,377,587...35,480,843
Ensembl chr 3:35,377,391...35,480,846
|
|
G
|
Actb
|
actin, beta
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of ACTB mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr12:16,776,664...16,779,634
Ensembl chr12:16,776,661...16,780,242
|
|
G
|
Agt
|
angiotensinogen
|
decreases response to substance
|
ISO
|
AGT protein results in decreased susceptibility to perfosfamide
|
CTD |
PMID:11034089 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944
|
|
G
|
Aifm1
|
apoptosis inducing factor, mitochondria associated 1
|
multiple interactions increases response to substance
|
ISO
|
Acetylcysteine inhibits the reaction [perfosfamide results in increased localization of AIFM1 protein]; perfosfamide results in increased expression of and results in increased localization of AIFM1 protein AIFM1 results in increased susceptibility to perfosfamide
|
CTD |
PMID:18034189 |
|
NCBI chr X:132,528,107...132,567,237
Ensembl chr X:132,528,107...132,567,237
|
|
G
|
Akr1b10
|
aldo-keto reductase family 1 member B10
|
affects response to substance
|
ISO
|
AKR1B10 protein affects the susceptibility to perfosfamide
|
CTD |
PMID:18473730 |
|
NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847
|
|
G
|
Aldh1a1
|
aldehyde dehydrogenase 1 family, member A1
|
decreases response to substance
|
ISO
|
ALDH1A1 protein results in decreased susceptibility to perfosfamide
|
CTD |
PMID:8662658 PMID:16614850 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500
|
|
G
|
Aldh1a2
|
aldehyde dehydrogenase 1 family, member A2
|
decreases response to substance
|
ISO
|
ALDH1A2 protein results in decreased susceptibility to perfosfamide
|
CTD |
PMID:22079344 |
|
NCBI chr 8:80,758,641...80,837,891
Ensembl chr 8:80,758,142...80,837,883
|
|
G
|
Aldh1b1
|
aldehyde dehydrogenase 1 family, member B1
|
affects response to substance
|
ISO
|
ALDH1B1 protein affects the susceptibility to perfosfamide
|
CTD |
PMID:18473730 |
|
NCBI chr 5:64,859,000...64,864,008
Ensembl chr 5:64,858,934...64,864,365
|
|
G
|
Aldh2
|
aldehyde dehydrogenase 2 family member
|
decreases response to substance
|
ISO
|
ALDH2 protein results in decreased susceptibility to perfosfamide
|
CTD |
PMID:22079344 |
|
NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219
|
|
G
|
Aldh3a1
|
aldehyde dehydrogenase 3 family, member A1
|
decreases response to substance
|
ISO
|
ALDH3A1 protein results in decreased susceptibility to perfosfamide
|
CTD |
PMID:16614850 |
|
NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151
|
|
G
|
Apex1
|
apurinic/apyrimidinic endodeoxyribonuclease 1
|
decreases expression
|
EXP
|
perfosfamide results in decreased expression of APEX1 mRNA
|
CTD |
PMID:11754170 |
|
NCBI chr15:26,618,146...26,620,330
Ensembl chr15:26,618,224...26,620,329
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions affects folding increases expression
|
ISO
|
Acetylcysteine inhibits the reaction [perfosfamide affects the folding of BAX protein]; Acetylcysteine inhibits the reaction [perfosfamide results in increased localization of BAX]; perfosfamide results in increased expression of and results in increased localization of BAX perfosfamide results in increased expression of BAX protein
|
CTD |
PMID:16488414 PMID:18034189 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bbc3
|
Bcl-2 binding component 3
|
increases expression
|
ISO
|
perfosfamide results in increased expression of BBC3 mRNA
|
CTD |
PMID:17068108 |
|
NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666
|
|
G
|
Bmpr1b
|
bone morphogenetic protein receptor type 1B
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of BMPR1B mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 2:233,211,525...233,544,344
Ensembl chr 2:233,211,525...233,544,311
|
|
G
|
C1d
|
C1D nuclear receptor corepressor
|
increases expression
|
ISO
|
perfosfamide results in increased expression of C1D mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr14:95,862,550...95,874,796
Ensembl chr14:95,861,978...95,874,796
|
|
G
|
Casp3
|
caspase 3
|
increases activity multiple interactions
|
ISO
|
perfosfamide results in increased activity of CASP3 perfosfamide promotes the reaction [TNF results in increased activity of CASP3 protein]
|
CTD |
PMID:16488414 PMID:17434952 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp9
|
caspase 9
|
increases activity
|
ISO
|
perfosfamide results in increased activity of CASP9 protein
|
CTD |
PMID:16488414 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
ISO
|
perfosfamide results in increased expression of CDKN1A perfosfamide results in increased expression of CDKN1A mRNA; perfosfamide results in increased expression of CDKN1A protein
|
CTD |
PMID:17068108 PMID:18034189 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cxcl9
|
C-X-C motif chemokine ligand 9
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of CXCL9 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr14:16,007,166...16,012,077
Ensembl chr14:16,007,204...16,014,299
|
|
G
|
E2f1
|
E2F transcription factor 1
|
increases expression
|
ISO
|
perfosfamide results in increased expression of E2F1 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:163,524,739...163,535,563
|
|
G
|
Egr1
|
early growth response 1
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of EGR1 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843
|
|
G
|
Endog
|
endonuclease G
|
increases response to substance multiple interactions
|
ISO
|
ENDOG results in increased susceptibility to perfosfamide Acetylcysteine inhibits the reaction [perfosfamide results in increased localization of ENDOG protein]; perfosfamide results in increased expression of and results in increased localization of ENDOG protein
|
CTD |
PMID:18034189 |
|
NCBI chr 3:33,846,935...33,849,531
Ensembl chr 3:33,846,885...33,849,573
|
|
G
|
Epas1
|
endothelial PAS domain protein 1
|
increases expression
|
ISO
|
perfosfamide results in increased expression of EPAS1 protein
|
CTD |
PMID:23251655 |
|
NCBI chr 6:13,543,252...13,626,147
Ensembl chr 6:13,544,389...13,624,729
|
|
G
|
Epha6
|
Eph receptor A6
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of EPHA6 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr11:39,757,501...40,708,901
Ensembl chr11:53,226,954...54,166,987
|
|
G
|
Eya1
|
EYA transcriptional coactivator and phosphatase 1
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of EYA1 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 5:9,646,599...9,884,609
Ensembl chr 5:9,646,591...9,884,614
|
|
G
|
Faslg
|
Fas ligand
|
increases expression
|
ISO
|
perfosfamide results in increased expression of FASLG mRNA; perfosfamide results in increased expression of FASLG protein
|
CTD |
PMID:14760101 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503
|
|
G
|
Foxf1
|
forkhead box F1
|
affects expression
|
ISO
|
perfosfamide affects the expression of FOXF1 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr19:66,062,635...66,066,427
Ensembl chr19:66,062,369...66,066,428
|
|
G
|
Gjc1
|
gap junction protein, gamma 1
|
increases expression
|
ISO
|
perfosfamide results in increased expression of GJC1 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr10:87,758,192...87,785,443
Ensembl chr10:88,249,489...88,285,853
|
|
G
|
Gli2
|
GLI family zinc finger 2
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of GLI2 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr13:32,499,678...32,716,418
Ensembl chr13:32,499,678...32,716,418
|
|
G
|
Hes1
|
hes family bHLH transcription factor 1
|
increases expression
|
ISO
|
perfosfamide results in increased expression of HES1 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr11:84,210,632...84,213,045
Ensembl chr11:84,210,633...84,213,061
|
|
G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
increases expression
|
ISO
|
perfosfamide results in increased expression of HIF1A mRNA; perfosfamide results in increased expression of HIF1A protein
|
CTD |
PMID:19429390 PMID:23251655 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323
|
|
G
|
Hoxa11
|
homeobox A11
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of HOXA11 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 4:82,673,139...82,676,801
Ensembl chr 4:82,673,140...82,676,844
|
|
G
|
Hoxa13
|
homeo box A13
|
increases expression
|
ISO
|
perfosfamide results in increased expression of HOXA13 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 4:82,689,566...82,691,701
Ensembl chr 4:82,689,566...82,691,701
|
|
G
|
Hoxd10
|
homeo box D10
|
increases expression
|
ISO
|
perfosfamide results in increased expression of HOXD10 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 3:80,001,947...80,005,156
Ensembl chr 3:80,001,689...80,005,156
|
|
G
|
Hras
|
HRas proto-oncogene, GTPase
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of HRAS mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590
|
|
G
|
Kl
|
Klotho
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of KL mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr12:5,326,003...5,367,016
Ensembl chr12:5,325,959...5,367,015
|
|
G
|
Lig3
|
DNA ligase 3
|
decreases expression
|
EXP
|
perfosfamide results in decreased expression of LIG3 mRNA
|
CTD |
PMID:11754170 |
|
NCBI chr10:68,215,371...68,238,705
Ensembl chr10:68,215,407...68,238,704
|
|
G
|
Mdm2
|
MDM2 proto-oncogene
|
increases expression
|
ISO
|
perfosfamide results in increased expression of MDM2
|
CTD |
PMID:18034189 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791
|
|
G
|
Mgmt
|
O-6-methylguanine-DNA methyltransferase
|
decreases expression
|
EXP
|
perfosfamide results in decreased expression of MGMT mRNA
|
CTD |
PMID:11754170 |
|
NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:201,140,661...201,367,482
|
|
G
|
Mlh1
|
mutL homolog 1
|
decreases expression
|
EXP
|
perfosfamide results in decreased expression of MLH1 mRNA
|
CTD |
PMID:11754170 |
|
NCBI chr 8:120,074,871...120,112,109
Ensembl chr 8:120,065,900...120,112,011
|
|
G
|
Mpg
|
N-methylpurine-DNA glycosylase
|
decreases expression
|
EXP
|
perfosfamide results in decreased expression of MPG mRNA
|
CTD |
PMID:11754170 |
|
NCBI chr10:15,900,697...15,906,981
Ensembl chr10:15,899,635...15,907,052
|
|
G
|
Mre11
|
MRE11 homolog, double strand break repair nuclease
|
decreases expression
|
EXP
|
perfosfamide results in decreased expression of MRE11A mRNA
|
CTD |
PMID:11754170 |
|
NCBI chr 8:19,900,211...19,961,906
Ensembl chr 8:19,913,772...19,961,904
|
|
G
|
Myo1b
|
myosin Ib
|
increases expression
|
ISO
|
perfosfamide results in increased expression of MYO1B mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 9:57,182,059...57,344,335
Ensembl chr 9:57,181,987...57,344,328
|
|
G
|
Myog
|
myogenin
|
increases expression
|
ISO
|
perfosfamide results in increased expression of MYOG mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr13:48,297,476...48,300,065
Ensembl chr13:48,297,235...48,300,065
|
|
G
|
Ndn
|
necdin, MAGE family member
|
increases expression
|
ISO
|
perfosfamide results in increased expression of NDN mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 1:125,261,059...125,262,658
Ensembl chr 1:125,260,997...125,262,785
|
|
G
|
Odc1
|
ornithine decarboxylase 1
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of ODC1 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146
|
|
G
|
Pea15
|
proliferation and apoptosis adaptor protein 15
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of PEA15 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr13:87,190,189...87,199,811
Ensembl chr13:87,187,295...87,199,859
|
|
G
|
Pmaip1
|
phorbol-12-myristate-13-acetate-induced protein 1
|
increases expression
|
ISO
|
perfosfamide results in increased expression of PMAIP1 mRNA
|
CTD |
PMID:17068108 |
|
NCBI chr18:62,255,970...62,262,384
Ensembl chr18:62,255,598...62,262,382
|
|
G
|
Pms1
|
PMS1 homolog 1, mismatch repair system component
|
decreases expression
|
EXP
|
perfosfamide results in decreased expression of PMS1 mRNA
|
CTD |
PMID:11754170 |
|
NCBI chr 9:55,721,393...55,832,225
Ensembl chr 9:55,745,374...55,832,221
|
|
G
|
Pms2
|
PMS1 homolog 2, mismatch repair system component
|
decreases expression
|
EXP
|
perfosfamide results in decreased expression of PMS2 mRNA
|
CTD |
PMID:11754170 |
|
NCBI chr12:15,790,478...15,814,790
Ensembl chr12:15,790,478...15,815,248
|
|
G
|
Polb
|
DNA polymerase beta
|
decreases expression
|
EXP
|
perfosfamide results in decreased expression of POLB mRNA
|
CTD |
PMID:11754170 |
|
NCBI chr16:76,081,903...76,105,174
Ensembl chr16:76,081,864...76,108,180
|
|
G
|
Pold1
|
DNA polymerase delta 1, catalytic subunit
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of POLD1 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 1:104,161,984...104,178,074
Ensembl chr 1:104,162,016...104,172,982
|
|
G
|
Rad21
|
RAD21 cohesin complex component
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of RAD21 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 7:85,177,715...85,204,657
Ensembl chr 7:85,177,716...85,204,657
|
|
G
|
Rad50
|
RAD50 double strand break repair protein
|
decreases expression
|
EXP
|
perfosfamide results in decreased expression of RAD50 mRNA
|
CTD |
PMID:11754170 |
|
NCBI chr10:38,310,147...38,362,100
Ensembl chr10:38,310,147...38,362,100
|
|
G
|
Rad51
|
RAD51 recombinase
|
decreases expression
|
EXP
|
perfosfamide results in decreased expression of RAD51 mRNA
|
CTD |
PMID:11754170 |
|
NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469
|
|
G
|
Sdf4
|
stromal cell derived factor 4
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of SDF4 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 5:171,868,591...171,885,827
Ensembl chr 5:171,868,563...171,888,884
|
|
G
|
Sfrp2
|
secreted frizzled-related protein 2
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of SFRP2 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 2:171,387,536...171,395,081
Ensembl chr 2:171,387,385...171,395,079
|
|
G
|
Slc30a4
|
solute carrier family 30 member 4
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of SLC30A4 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 3:130,206,852...130,228,888
Ensembl chr 3:130,206,852...130,228,888
|
|
G
|
Smad1
|
SMAD family member 1
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of SMAD1 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr19:45,417,430...45,477,962
Ensembl chr19:45,417,433...45,477,957
|
|
G
|
Tap1
|
transporter 1, ATP binding cassette subfamily B member
|
affects response to substance
|
ISO
|
TAP1 protein affects the susceptibility to perfosfamide
|
CTD |
PMID:18473730 |
|
NCBI chr20:4,658,171...4,668,543
Ensembl chr20:4,658,172...4,668,810
|
|
G
|
Tcf12
|
transcription factor 12
|
increases expression
|
ISO
|
perfosfamide results in increased expression of TCF12 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 8:72,490,447...72,799,265
Ensembl chr 8:81,373,321...81,679,922
|
|
G
|
Terc
|
telomerase RNA component
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of TERC mRNA
|
CTD |
PMID:24571982 |
|
NCBI chr 2:114,744,148...114,744,535
|
|
G
|
Tert
|
telomerase reverse transcriptase
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of TERT mRNA
|
CTD |
PMID:24571982 |
|
NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:31,466,056...31,488,111
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO
|
perfosfamide promotes the reaction [TNF results in increased activity of CASP3 protein]
|
CTD |
PMID:16488414 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
multiple interactions increases expression
|
ISO
|
Acetylcysteine inhibits the reaction [perfosfamide results in increased expression of TP53] perfosfamide results in increased expression of and results in increased phosphorylation of and results in increased activity of TRP53 protein
|
CTD |
PMID:17068108 PMID:18034189 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Trim27
|
tripartite motif-containing 27
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of TRIM27 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr17:48,233,999...48,246,348
Ensembl chr17:48,234,002...48,246,348
|
|
G
|
Ttf1
|
transcription termination factor 1
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of TTF1 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 3:32,782,544...32,807,202
Ensembl chr 3:32,782,308...32,807,201
|
|
G
|
Ubb
|
ubiquitin B
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of UBB mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr10:47,746,923...47,748,628
Ensembl chr10:47,727,701...47,750,335
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
increases expression
|
ISO
|
perfosfamide results in increased expression of VEGFA mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
G
|
Vim
|
vimentin
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of VIM mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746
|
|
G
|
Wnt11
|
Wnt family member 11
|
increases expression
|
ISO
|
perfosfamide results in increased expression of WNT11 mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 1:162,545,660...162,565,456
Ensembl chr 1:162,545,680...162,564,660
|
|
G
|
Xrcc1
|
X-ray repair cross complementing 1
|
decreases expression
|
EXP
|
perfosfamide results in decreased expression of XRCC1 mRNA
|
CTD |
PMID:11754170 |
|
NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:89,268,644...89,296,613
|
|
G
|
Xrcc5
|
X-ray repair cross complementing 5
|
decreases expression
|
EXP
|
perfosfamide results in decreased expression of XRCC5 mRNA
|
CTD |
PMID:11754170 |
|
NCBI chr 9:81,404,507...81,493,293
Ensembl chr 9:81,375,863...81,493,293
|
|
G
|
Ywhaz
|
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta
|
decreases expression
|
ISO
|
perfosfamide results in decreased expression of YWHAZ mRNA
|
CTD |
PMID:19429390 |
|
NCBI chr 7:69,826,404...69,848,702
Ensembl chr 7:69,826,404...69,849,007
|
|
|
G
|
Alox5
|
arachidonate 5-lipoxygenase
|
multiple interactions
|
EXP
|
[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of ALOX5 mRNA
|
CTD |
PMID:25833159 |
|
NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:151,203,949...151,251,126
|
|
G
|
Bdkrb2
|
bradykinin receptor B2
|
multiple interactions
|
EXP
|
[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of BDKRB2 mRNA
|
CTD |
PMID:25833159 |
|
NCBI chr 6:130,237,055...130,267,205
Ensembl chr 6:130,237,255...130,267,209
|
|
G
|
Cd40
|
CD40 molecule
|
multiple interactions
|
EXP
|
[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of CD40 mRNA
|
CTD |
PMID:25833159 |
|
NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847
|
|
G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
increases chemical synthesis
|
ISO
|
CYP2B6 protein results in increased chemical synthesis of 4-hydroxycyclophosphamide
|
CTD |
PMID:24819615 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
multiple interactions
|
ISO
|
[CYP2C19 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of 4-hydroxycyclophosphamide
|
CTD |
PMID:30500380 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
multiple interactions
|
ISO
|
[CYP3A4 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of 4-hydroxycyclophosphamide
|
CTD |
PMID:30500380 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Il1r1
|
interleukin 1 receptor type 1
|
multiple interactions
|
EXP
|
[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of IL1R1 mRNA
|
CTD |
PMID:25833159 |
|
NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:50,000,566...50,076,579
|
|
G
|
Il2rg
|
interleukin 2 receptor subunit gamma
|
multiple interactions
|
EXP
|
[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of IL2RG mRNA
|
CTD |
PMID:25833159 |
|
NCBI chr X:70,435,340...70,439,052
Ensembl chr X:70,435,343...70,439,161
|
|
G
|
Klk15
|
kallikrein-related peptidase 15
|
multiple interactions
|
EXP
|
[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of KLK15 mRNA
|
CTD |
PMID:25833159 |
|
NCBI chr 1:94,699,422...94,706,626
Ensembl chr 1:103,834,215...103,843,321
|
|
G
|
Mapk14
|
mitogen activated protein kinase 14
|
multiple interactions
|
EXP
|
[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of MAPK14 mRNA
|
CTD |
PMID:25833159 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294
|
|
|
G
|
Aldh1a1
|
aldehyde dehydrogenase 1 family, member A1
|
multiple interactions increases oxidation
|
ISO
|
[ALDH1A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide ALDH1A1 results in increased oxidation of aldophosphamide
|
CTD |
PMID:8662658 PMID:10856427 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500
|
|
G
|
Aldh3a1
|
aldehyde dehydrogenase 3 family, member A1
|
multiple interactions
|
ISO
|
[ALDH3A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NADP] results in increased oxidation of aldophosphamide
|
CTD |
PMID:10856427 |
|
NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151
|
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
increases expression
|
ISO
|
Chlorambucil results in increased expression of ABCB1 protein
|
CTD |
PMID:15239124 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcc1
|
ATP binding cassette subfamily C member 1
|
affects export multiple interactions increases response to substance decreases response to substance
|
ISO
|
ABCC1 protein affects the export of Chlorambucil analog buthionine sulfoximine ethyl ester promotes the reaction [ABCC1 protein results in increased susceptibility to Chlorambucil]; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Chlorambucil]
|
CTD |
PMID:10900222 PMID:11115505 PMID:12504668 PMID:14569069 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
affects export multiple interactions
|
ISO
|
ABCC2 protein affects the export of Chlorambucil analog ABCC2 protein promotes the reaction [GSTA1 protein results in decreased susceptibility to Chlorambucil]
|
CTD |
PMID:14569069 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
G
|
Akr1b10
|
aldo-keto reductase family 1 member B10
|
decreases expression
|
ISO
|
Chlorambucil results in decreased expression of AKR1B10 mRNA
|
CTD |
PMID:26198647 |
|
NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847
|
|
G
|
Akr1c2
|
aldo-keto reductase family 1, member C2
|
decreases expression
|
ISO
|
Chlorambucil results in decreased expression of AKR1C2 mRNA
|
CTD |
PMID:26198647 |
|
NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686
|
|
G
|
Asf1a
|
anti-silencing function 1A histone chaperone
|
decreases expression
|
ISO
|
Chlorambucil results in decreased expression of ASF1A mRNA
|
CTD |
PMID:26198647 |
|
NCBI chr20:33,436,632...33,451,478
Ensembl chr20:33,436,707...33,449,639
|
|
G
|
Aurka
|
aurora kinase A
|
increases expression
|
ISO
|
Chlorambucil results in increased expression of AURKA protein
|
CTD |
PMID:22025197 |
|
NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771
|
|
G
|
Aurkb
|
aurora kinase B
|
decreases expression
|
ISO
|
Chlorambucil results in decreased expression of AURKB protein
|
CTD |
PMID:22025197 |
|
NCBI chr10:54,243,116...54,249,675
Ensembl chr10:54,242,850...54,252,285
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression
|
ISO
|
Chlorambucil results in increased expression of BAX protein
|
CTD |
PMID:11699414 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bbc3
|
Bcl-2 binding component 3
|
increases expression
|
ISO
|
Chlorambucil results in increased expression of BBC3 mRNA
|
CTD |
PMID:17476690 |
|
NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression multiple interactions
|
ISO
|
Chlorambucil results in decreased expression of BCL2 mRNA; Chlorambucil results in decreased expression of BCL2 protein IL4 protein inhibits the reaction [Chlorambucil results in decreased expression of BCL2 protein]
|
CTD |
PMID:8822937 PMID:11699414 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bik
|
BCL2-interacting killer
|
increases expression
|
ISO
|
Chlorambucil results in increased expression of BIK mRNA
|
CTD |
PMID:26198647 |
|
NCBI chr 7:116,552,303...116,571,317
Ensembl chr 7:116,552,303...116,571,317
|
|
G
|
Birc2
|
baculoviral IAP repeat-containing 2
|
decreases response to substance
|
ISO
|
BIRC2 protein results in decreased susceptibility to Chlorambucil
|
CTD |
PMID:10815900 |
|
NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:13,253,706...13,271,911
|
|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
affects expression decreases expression
|
ISO
|
Chlorambucil affects the expression of BIRC5 mRNA Chlorambucil results in decreased expression of BIRC5 protein
|
CTD |
PMID:17476690 PMID:22025197 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155
|
|
G
|
Bmp5
|
bone morphogenetic protein 5
|
increases mutagenesis
|
ISO
|
Chlorambucil results in increased mutagenesis of BMP5 gene
|
CTD |
PMID:10517996 |
|
NCBI chr 8:85,397,629...85,520,374
Ensembl chr 8:85,396,925...85,520,189
|
|
G
|
Casp3
|
caspase 3
|
increases activity
|
ISO
|
Chlorambucil results in increased activity of CASP3 protein
|
CTD |
PMID:11675354 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases activity
|
ISO
|
Chlorambucil results in increased activity of CASP8 protein
|
CTD |
PMID:11675354 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
multiple interactions
|
ISO
|
Chlorambucil promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein]
|
CTD |
PMID:36416909 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Cd59b
|
CD59b molecule
|
decreases lipidation
|
EXP
|
Chlorambucil results in decreased lipidation of CD59 protein
|
CTD |
PMID:27931811 |
|
NCBI chr 3:110,914,008...110,932,489
Ensembl chr 3:110,914,091...110,935,310
|
|
G
|
Cda
|
cytidine deaminase
|
decreases response to substance
|
ISO
|
CDA protein results in decreased susceptibility to Chlorambucil
|
CTD |
PMID:10830723 |
|
NCBI chr 5:155,839,929...155,866,541
Ensembl chr 5:155,839,929...155,866,541
|
|
G
|
Cdk1
|
cyclin-dependent kinase 1
|
multiple interactions
|
ISO
|
Chlorambucil analog results in increased phosphorylation of and results in decreased activity of CDK1 protein
|
CTD |
PMID:16861886 |
|
NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
ISO
|
Chlorambucil results in increased expression of CDKN1A protein
|
CTD |
PMID:16039525 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Dhfr
|
dihydrofolate reductase
|
decreases response to substance
|
ISO
|
DHFR protein polymorphism results in decreased susceptibility to Chlorambucil
|
CTD |
PMID:12872145 |
|
NCBI chr 2:25,320,895...25,346,004
|
|
G
|
Ednrb
|
endothelin receptor type B
|
increases mutagenesis
|
ISO
|
Chlorambucil results in increased mutagenesis of EDNRB gene
|
CTD |
PMID:10517996 |
|
NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765
|
|
G
|
Fancc
|
FA complementation group C
|
increases response to substance
|
ISO
|
FANCC protein results in increased susceptibility to Chlorambucil
|
CTD |
PMID:16243825 |
|
NCBI chr17:1,686,374...1,818,672
Ensembl chr17:1,687,017...1,835,096
|
|
G
|
Fancg
|
FA complementation group G
|
increases response to substance
|
ISO
|
FANCG protein results in increased susceptibility to Chlorambucil
|
CTD |
PMID:16243825 |
|
NCBI chr 5:62,027,494...62,037,202
Ensembl chr 5:62,027,500...62,035,787
|
|
G
|
Fas
|
Fas cell surface death receptor
|
increases expression
|
ISO
|
Chlorambucil results in increased expression of FAS mRNA
|
CTD |
PMID:11675354 PMID:17476690 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104
|
|
G
|
Fbxo30
|
F-box protein 30
|
decreases expression
|
ISO
|
Chlorambucil results in decreased expression of FBXO30 mRNA
|
CTD |
PMID:26198647 |
|
NCBI chr 1:7,475,636...7,491,719
Ensembl chr 1:7,475,575...7,493,199
|
|
G
|
Gclc
|
glutamate-cysteine ligase, catalytic subunit
|
multiple interactions
|
ISO
|
[GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Chlorambucil
|
CTD |
PMID:10900222 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893
|
|
G
|
Gclm
|
glutamate cysteine ligase, modifier subunit
|
multiple interactions
|
ISO
|
[GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Chlorambucil
|
CTD |
PMID:10900222 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003
|
|
G
|
Gsta1
|
glutathione S-transferase alpha 1
|
decreases activity decreases response to substance multiple interactions
|
ISO
|
Chlorambucil analog results in decreased activity of GSTA1 protein GSTA1 protein results in decreased susceptibility to Chlorambucil ABCC2 protein promotes the reaction [GSTA1 protein results in decreased susceptibility to Chlorambucil]; GSTA1 protein affects the metabolism of [Chlorambucil co-treated with Glutathione]
|
CTD |
PMID:11115505 PMID:14569069 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528
|
|
G
|
Gsta3
|
glutathione S-transferase alpha 3
|
decreases response to substance
|
EXP
|
GSTA3 protein results in decreased susceptibility to Chlorambucil
|
CTD |
PMID:8044793 PMID:8860835 PMID:10830723 PMID:12872145 |
|
NCBI chr 9:31,154,989...31,180,653
Ensembl chr 9:31,154,989...31,180,654
|
|
G
|
Gsta5
|
glutathione S-transferase alpha 5
|
decreases response to substance
|
EXP
|
GSTA5 protein results in decreased susceptibility to Chlorambucil
|
CTD |
PMID:12076520 |
|
NCBI chr 8:87,985,768...87,997,766
Ensembl chr 8:87,985,258...87,997,765
|
|
G
|
Gstm1
|
glutathione S-transferase mu 1
|
decreases response to substance
|
ISO
|
GSTM1 protein results in decreased susceptibility to Chlorambucil
|
CTD |
PMID:15044619 PMID:20067466 |
|
NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:198,338,008...198,343,569
|
|
G
|
Gstp1
|
glutathione S-transferase pi 1
|
affects binding increases metabolic processing decreases response to substance affects response to substance multiple interactions
|
ISO
|
Chlorambucil binds to GSTP1 protein GSTP1 protein results in increased metabolism of Chlorambucil GSTP1 protein results in decreased susceptibility to Chlorambucil GSTP1 gene affects the susceptibility to Chlorambucil GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Chlorambucil]
|
CTD |
PMID:10900222 PMID:11071881 PMID:18511072 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705
|
|
G
|
H2ax
|
H2A.X variant histone
|
increases phosphorylation
|
ISO
|
Chlorambucil analog results in increased phosphorylation of H2AX protein; Chlorambucil results in increased phosphorylation of H2AX protein
|
CTD |
PMID:16861886 PMID:32482060 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Il4
|
interleukin 4
|
multiple interactions
|
ISO
|
IL4 protein inhibits the reaction [[Theophylline co-treated with Chlorambucil] results in increased expression of MYC protein]; IL4 protein inhibits the reaction [[Theophylline co-treated with Chlorambucil] results in increased expression of TP53]; IL4 protein inhibits the reaction [Chlorambucil results in decreased expression of BCL2 protein]
|
CTD |
PMID:8822937 |
|
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549
|
|
G
|
Keap1
|
Kelch-like ECH-associated protein 1
|
multiple interactions
|
ISO
|
[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil]
|
CTD |
PMID:19608619 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042
|
|
G
|
Lif
|
LIF, interleukin 6 family cytokine
|
increases expression
|
ISO
|
Chlorambucil results in increased expression of LIF mRNA
|
CTD |
PMID:26198647 |
|
NCBI chr14:83,354,602...83,364,053
Ensembl chr14:83,358,164...83,364,053
|
|
G
|
Mdm2
|
MDM2 proto-oncogene
|
increases expression
|
ISO
|
Chlorambucil results in increased expression of MDM2 mRNA
|
CTD |
PMID:17476690 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
multiple interactions affects expression increases expression
|
ISO
|
[Theophylline co-treated with Chlorambucil] results in increased expression of MYC protein; IL4 protein inhibits the reaction [[Theophylline co-treated with Chlorambucil] results in increased expression of MYC protein] Chlorambucil affects the expression of MYC mRNA Chlorambucil results in increased expression of MYC protein
|
CTD |
PMID:8822937 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
G
|
Myo5a
|
myosin VA
|
increases mutagenesis
|
ISO
|
Chlorambucil results in increased mutagenesis of MYO5A gene
|
CTD |
PMID:10517996 |
|
NCBI chr 8:84,692,524...84,860,564
Ensembl chr 8:84,692,910...84,856,265
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions affects response to substance increases response to substance
|
ISO
|
[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil] [NFE2L2 affects the susceptibility to sulforaphane] which affects the susceptibility to Chlorambucil Buthionine Sulfoximine affects the reaction [[NFE2L2 affects the susceptibility to sulforaphane] which affects the susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to Chlorambucil]]; NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to Chlorambucil] NFE2L2 gene mutant form results in increased susceptibility to Chlorambucil
|
CTD |
PMID:19303893 PMID:19608619 PMID:20932822 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Pdk4
|
pyruvate dehydrogenase kinase 4
|
affects expression
|
ISO
|
Chlorambucil affects the expression of PDK4 mRNA
|
CTD |
PMID:32870474 |
|
NCBI chr 4:34,558,327...34,568,329
Ensembl chr 4:34,556,330...34,568,381
|
|
G
|
Piga
|
phosphatidylinositol glycan anchor biosynthesis, class A
|
increases mutagenesis multiple interactions
|
EXP
|
Chlorambucil results in increased mutagenesis of PIGA Chlorambucil results in increased mutagenesis of and results in decreased activity of PIGA protein
|
CTD |
PMID:22923490 PMID:27931811 |
|
NCBI chr X:33,672,832...33,687,747
Ensembl chr X:33,674,923...33,687,636
|
|
G
|
Rad51
|
RAD51 recombinase
|
increases expression
|
ISO
|
Chlorambucil results in increased expression of RAD51 protein
|
CTD |
PMID:10473103 |
|
NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469
|
|
G
|
RT1-Ha
|
RT1 class II, locus Ha
|
affects expression
|
ISO
|
Chlorambucil affects the expression of HLA-DPA1 mRNA
|
CTD |
PMID:25811541 |
|
NCBI chr20:4,762,425...4,772,439
Ensembl chr20:4,763,033...4,772,141
|
|
G
|
Sfn
|
stratifin
|
increases expression
|
ISO
|
Chlorambucil results in increased expression of SFN mRNA
|
CTD |
PMID:18092340 |
|
NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:151,110,530...151,111,995
|
|
G
|
Tnfrsf10b
|
TNF receptor superfamily member 10b
|
affects expression
|
ISO
|
Chlorambucil affects the expression of TNFRSF10A mRNA
|
CTD |
PMID:14614459 |
|
NCBI chr15:51,249,883...51,278,091
Ensembl chr15:51,250,112...51,278,082
|
|
G
|
Tp53
|
tumor protein p53
|
increases expression affects activity multiple interactions
|
ISO
|
Chlorambucil results in increased expression of TP53; Chlorambucil results in increased expression of TP53 protein Chlorambucil affects the activity of TP53 protein [Theophylline co-treated with Chlorambucil] results in increased expression of TP53; IL4 protein inhibits the reaction [[Theophylline co-treated with Chlorambucil] results in increased expression of TP53]
|
CTD |
PMID:8822937 PMID:18092340 PMID:35435491 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Txnrd1
|
thioredoxin reductase 1
|
decreases activity
|
EXP
|
Chlorambucil results in decreased activity of TXNRD1 protein
|
CTD |
PMID:16085187 |
|
NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817
|
|
G
|
Tyrp1
|
tyrosinase-related protein 1
|
increases mutagenesis
|
ISO
|
Chlorambucil results in increased mutagenesis of TYRP1 gene
|
CTD |
PMID:10517996 |
|
NCBI chr 5:100,327,111...100,345,657
Ensembl chr 5:100,327,125...100,345,657
|
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
multiple interactions decreases expression increases expression
|
ISO EXP
|
[Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; ABCB1 protein affects the susceptibility to [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil]; ABCB1 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]; NR1I2 protein promotes the reaction [Cyclophosphamide results in increased expression of ABCB1 protein] Cyclophosphamide results in decreased expression of ABCB1 mRNA; Cyclophosphamide results in decreased expression of ABCB1A mRNA
|
CTD |
PMID:12576456 PMID:20041327 PMID:20623750 PMID:30563925 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcc1
|
ATP binding cassette subfamily C member 1
|
multiple interactions decreases response to substance
|
ISO
|
ABCC1 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] ABCC1 protein results in decreased susceptibility to Cyclophosphamide
|
CTD |
PMID:11778547 PMID:12576456 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
multiple interactions
|
ISO
|
ABCG2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:12576456 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
G
|
Abhd3
|
abhydrolase domain containing 3, phospholipase
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of ABHD3 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr18:1,996,010...2,051,311
Ensembl chr18:1,993,525...2,075,492
|
|
G
|
Abi2
|
abl-interactor 2
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ABI2 mRNA
|
CTD |
PMID:27466211 |
|
NCBI chr 9:69,321,072...69,490,630
Ensembl chr 9:69,321,150...69,490,597
|
|
G
|
Ace
|
angiotensin I converting enzyme
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ACE mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr10:91,410,129...91,430,246
Ensembl chr10:91,409,819...91,430,942
|
|
G
|
Ace2
|
angiotensin converting enzyme 2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of ACE2 mRNA
|
CTD |
PMID:32808185 |
|
NCBI chr X:33,925,458...33,972,851
Ensembl chr X:33,925,458...33,971,596
|
|
G
|
Ache
|
acetylcholinesterase
|
multiple interactions increases activity increases expression
|
EXP
|
coenzyme Q10 inhibits the reaction [Cyclophosphamide results in increased activity of ACHE protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of ACHE protein]
|
CTD |
PMID:37419146 PMID:39209270 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410
|
|
G
|
Ackr3
|
atypical chemokine receptor 3
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ACKR3 mRNA
|
CTD |
PMID:20032115 |
|
NCBI chr 9:98,247,300...98,258,877
Ensembl chr 9:98,246,605...98,260,214
|
|
G
|
Acod1
|
aconitate decarboxylase 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of ACOD1 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr15:86,286,531...86,295,803
Ensembl chr15:86,286,579...86,295,687
|
|
G
|
Acsl4
|
acyl-CoA synthetase long-chain family member 4
|
increases expression multiple interactions
|
ISO
|
Cyclophosphamide results in increased expression of ACSL4 protein Dexrazoxane inhibits the reaction [Cyclophosphamide results in increased expression of ACSL4 protein]
|
CTD |
PMID:37690746 |
|
NCBI chr X:110,739,633...110,803,416
Ensembl chr X:110,739,648...110,803,261
|
|
G
|
Actb
|
actin, beta
|
decreases expression affects expression
|
ISO EXP
|
Cyclophosphamide results in decreased expression of ACTB mRNA Cyclophosphamide affects the expression of ACTB mRNA
|
CTD |
PMID:10859244 PMID:12167460 |
|
NCBI chr12:16,776,664...16,779,634
Ensembl chr12:16,776,661...16,780,242
|
|
G
|
Adam24
|
ADAM metallopeptidase domain 24
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ADAM24 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr16:51,578,278...51,584,265
Ensembl chr16:58,281,748...58,287,735
|
|
G
|
Adam4
|
a disintegrin and metalloprotease domain 4
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ADAM4 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 6:101,123,284...101,125,730
|
|
G
|
Adamts9
|
ADAM metallopeptidase with thrombospondin type 1 motif, 9
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ADAMTS9 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 4:126,847,726...127,019,924
Ensembl chr 4:126,847,729...127,019,876
|
|
G
|
Adcyap1
|
adenylate cyclase activating polypeptide 1
|
affects expression increases expression
|
EXP
|
Cyclophosphamide affects the expression of ADCYAP1 mRNA Cyclophosphamide results in increased expression of ADCYAP1 protein
|
CTD |
PMID:9776515 PMID:10754506 PMID:18563302 |
|
NCBI chr 9:120,550,236...120,569,096
Ensembl chr 9:120,550,328...120,556,383
|
|
G
|
Adcyap1r1
|
ADCYAP receptor type I
|
affects expression
|
EXP
|
Cyclophosphamide affects the expression of ADCYAP1R1 mRNA
|
CTD |
PMID:18563302 |
|
NCBI chr 4:85,924,171...85,972,973
Ensembl chr 4:85,924,100...85,972,973
|
|
G
|
Adm
|
adrenomedullin
|
affects response to substance
|
ISO
|
ADM protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371
|
|
G
|
Afp
|
alpha-fetoprotein
|
affects expression
|
ISO
|
Cyclophosphamide affects the expression of AFP protein
|
CTD |
PMID:6177358 |
|
NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649
|
|
G
|
Ager
|
advanced glycosylation end product-specific receptor
|
increases expression
|
EXP
|
[doxorubicin cotreated with cyclophosphamide] increased expression of Ager protein in prefrontal cortex and hippocampus
|
RGD |
PMID:36708885 |
RGD:597621662 |
NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685
|
|
G
|
Agl
|
amylo-alpha-1,6-glucosidase and 4-alpha-glucanotransferase
|
affects response to substance
|
ISO
|
AGL protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 2:207,389,949...207,445,959
Ensembl chr 2:207,389,949...207,445,724
|
|
G
|
Akap8
|
A-kinase anchoring protein 8
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of AKAP8 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 7:11,966,769...11,983,056
Ensembl chr 7:11,966,772...11,982,900
|
|
G
|
Akr1c14
|
aldo-keto reductase family 1, member C14
|
decreases expression affects expression
|
EXP
|
Cyclophosphamide results in decreased expression of AKR1C14 mRNA Cyclophosphamide affects the expression of AKR1C14 mRNA
|
CTD |
PMID:18246545 |
|
NCBI chr17:66,156,286...66,173,277
Ensembl chr17:71,066,200...71,083,157
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions decreases expression
|
EXP
|
Cyclophosphamide results in increased phosphorylation of and results in increased activity of AKT1 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of AKT1 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of AKT1 protein]
|
CTD |
PMID:19996110 PMID:25446862 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Alad
|
aminolevulinate dehydratase
|
multiple interactions
|
ISO
|
[Cyclophosphamide co-treated with Carmustine co-treated with Etoposide] results in decreased activity of ALAD protein
|
CTD |
PMID:19162187 |
|
NCBI chr 5:80,977,562...80,987,901
Ensembl chr 5:80,977,562...80,988,041
|
|
G
|
Alcam
|
activated leukocyte cell adhesion molecule
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of ALCAM mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr11:61,804,932...62,005,250
Ensembl chr11:61,805,049...62,006,876
|
|
G
|
Aldh1a1
|
aldehyde dehydrogenase 1 family, member A1
|
affects response to substance increases expression decreases response to substance
|
ISO
|
ALDH1A1 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of ALDH1A1 mRNA ALDH1A1 protein results in decreased susceptibility to Cyclophosphamide
|
CTD |
PMID:12513786 PMID:17403535 PMID:18854779 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500
|
|
G
|
Aldh2
|
aldehyde dehydrogenase 2 family member
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of ALDH2 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219
|
|
G
|
Aldh3a1
|
aldehyde dehydrogenase 3 family, member A1
|
affects response to substance
|
ISO
|
ALDH3A1 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:18854779 |
|
NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151
|
|
G
|
Alox5ap
|
arachidonate 5-lipoxygenase activating protein
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of ALOX5AP mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr12:10,785,254...10,809,295
Ensembl chr12:10,785,257...10,817,038
|
|
G
|
Alyref
|
Aly/REF export factor
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of ALYREF mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr10:105,871,424...105,875,076
Ensembl chr10:106,369,750...106,373,395
|
|
G
|
Amfr
|
autocrine motility factor receptor
|
multiple interactions
|
ISO
|
AMFR mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr19:11,002,451...11,038,182
Ensembl chr19:11,002,101...11,038,364
|
|
G
|
Amh
|
anti-Mullerian hormone
|
decreases expression multiple interactions
|
EXP ISO
|
Cyclophosphamide results in decreased expression of AMH protein Donepezil inhibits the reaction [Cyclophosphamide results in decreased expression of AMH protein]; Gly(14)-Humanin inhibits the reaction [Cyclophosphamide results in decreased expression of AMH protein]; Mots-C peptide, mouse inhibits the reaction [Cyclophosphamide results in decreased expression of AMH protein] Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of AMH protein]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of AMH protein]
|
CTD |
PMID:32456565 PMID:36154502 PMID:38825044 PMID:39079574 PMID:39952379 |
|
NCBI chr 7:9,557,451...9,559,867
Ensembl chr 7:9,557,451...9,559,867
|
|
G
|
Angpt1
|
angiopoietin 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of ANGPT1 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 7:75,415,959...75,668,696
Ensembl chr 7:75,418,218...75,668,696
|
|
G
|
Ankrd40
|
ankyrin repeat domain 40
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of TMPRSS2 mRNA
|
CTD |
PMID:32808185 |
|
NCBI chr10:79,282,075...79,295,322
Ensembl chr10:56,415,260...56,416,345 Ensembl chr10:56,415,260...56,416,345
|
|
G
|
Apaf1
|
apoptotic peptidase activating factor 1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of APAF1 mRNA
|
CTD |
PMID:29445054 |
|
NCBI chr 7:27,381,392...27,466,772
Ensembl chr 7:27,381,855...27,466,772
|
|
G
|
Apex1
|
apurinic/apyrimidinic endodeoxyribonuclease 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of APEX1 mRNA; Cyclophosphamide results in increased expression of APEX1 protein
|
CTD |
PMID:11599041 PMID:15928459 |
|
NCBI chr15:26,618,146...26,620,330
Ensembl chr15:26,618,224...26,620,329
|
|
G
|
Apob
|
apolipoprotein B
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of APOB mRNA
|
CTD |
PMID:18246545 |
|
NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:36,563,704...36,611,814
|
|
G
|
Apoe
|
apolipoprotein E
|
decreases expression increases expression
|
ISO
|
Cyclophosphamide results in decreased expression of APOE mRNA Cyclophosphamide results in increased expression of APOE mRNA
|
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:88,481,385...88,485,855
|
|
G
|
Apoh
|
apolipoprotein H
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of APOH protein
|
CTD |
PMID:15928459 |
|
NCBI chr10:93,841,992...93,855,897
Ensembl chr10:93,841,966...93,857,127
|
|
G
|
Arg1
|
arginase 1
|
increases expression decreases expression affects expression
|
ISO EXP
|
Cyclophosphamide results in increased expression of ARG1 mRNA Cyclophosphamide results in decreased expression of ARG1 mRNA Cyclophosphamide affects the expression of ARG1 mRNA
|
CTD |
PMID:18246545 PMID:21068404 |
|
NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713
|
|
G
|
Arhgdib
|
Rho GDP dissociation inhibitor beta
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of ARHGDIB mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 4:171,554,139...171,573,057
Ensembl chr 4:171,554,140...171,573,068
|
|
G
|
Arhgef26
|
Rho guanine nucleotide exchange factor 26
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of ARHGEF26 mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr 2:148,889,405...149,000,538
Ensembl chr 2:148,889,423...149,000,538
|
|
G
|
Asns
|
asparagine synthetase (glutamine-hydrolyzing)
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of ASNS mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050
|
|
G
|
Ass1
|
argininosuccinate synthase 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ASS1 protein
|
CTD |
PMID:15928459 |
|
NCBI chr 3:35,144,765...35,194,632
Ensembl chr 3:35,144,999...35,194,627
|
|
G
|
Atf2
|
activating transcription factor 2
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ATF2 mRNA
|
CTD |
PMID:11599041 |
|
NCBI chr 3:79,125,814...79,202,896
Ensembl chr 3:79,126,705...79,202,745
|
|
G
|
Atf5
|
activating transcription factor 5
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of ATF5 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:104,432,094...104,436,183
|
|
G
|
Atg3
|
autophagy related 3
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of ATG3 mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr11:55,624,914...55,653,249
Ensembl chr11:69,121,952...69,159,280
|
|
G
|
Atg5
|
autophagy related 5
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of ATG5 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of ATG5 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of ATG5 protein]
|
CTD |
PMID:32151603 |
|
NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821
|
|
G
|
Atg7
|
autophagy related 7
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of ATG7 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of ATG7 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of ATG7 protein]
|
CTD |
PMID:32151603 |
|
NCBI chr 4:149,390,000...149,597,534
Ensembl chr 4:149,391,390...149,598,319
|
|
G
|
Aurkb
|
aurora kinase B
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of AURKB mRNA
|
CTD |
PMID:11599041 |
|
NCBI chr10:54,243,116...54,249,675
Ensembl chr10:54,242,850...54,252,285
|
|
G
|
Axl
|
Axl receptor tyrosine kinase
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of AXL mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 1:90,392,864...90,424,123
Ensembl chr 1:90,392,864...90,424,009
|
|
G
|
B3galnt2
|
beta-1,3-N-acetylgalactosaminyltransferase 2
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of B3GALNT2 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr17:56,030,409...56,072,952
Ensembl chr17:56,030,409...56,072,952
|
|
G
|
Bad
|
BCL2-associated agonist of cell death
|
increases expression multiple interactions
|
EXP ISO
|
Cyclophosphamide results in increased expression of BAD mRNA Cyclophosphamide results in increased expression of BAD protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of BAD protein]
|
CTD |
PMID:11599041 PMID:29753871 |
|
NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034
|
|
G
|
Bag1
|
BAG cochaperone 1
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of BAG1 mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr 5:60,864,476...60,877,059
Ensembl chr 5:60,864,476...60,878,161
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression multiple interactions
|
EXP ISO
|
Cyclophosphamide results in increased expression of BAX mRNA; Cyclophosphamide results in increased expression of BAX protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]; Mots-C peptide, mouse inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]; TRPM2 protein affects the reaction [Cyclophosphamide results in increased expression of BAX mRNA] [Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in increased expression of BAX mRNA]; coenzyme Q10 inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]; herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of BAX mRNA]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]
|
CTD |
PMID:25446862 PMID:29753871 PMID:30506662 PMID:32197949 PMID:36154502 PMID:36198566 PMID:38211767 PMID:39079574 PMID:39209270 PMID:39952379 More...
|
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bbc3
|
Bcl-2 binding component 3
|
increases expression multiple interactions
|
EXP
|
Cyclophosphamide results in increased expression of BBC3 mRNA sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of BBC3 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BBC3 mRNA]
|
CTD |
PMID:32197949 |
|
NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666
|
|
G
|
Bbs4
|
Bardet-Biedl syndrome 4
|
multiple interactions
|
ISO
|
BBS4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr 8:68,627,739...68,661,232
Ensembl chr 8:68,627,656...68,661,358
|
|
G
|
Bche
|
butyrylcholinesterase
|
multiple interactions decreases activity
|
ISO
|
[Melphalan co-treated with Thiotepa co-treated with Cyclophosphamide] results in decreased expression of BCHE protein Cyclophosphamide results in decreased activity of BCHE protein
|
CTD |
PMID:4672170 PMID:4959505 |
|
NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:160,606,288...160,699,760
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions increases expression decreases expression
|
ISO EXP
|
[Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of BCL2 protein; [Cladribine co-treated with Cyclophosphamide] results in decreased expression of BCL2 protein; [Doxorubicin co-treated with Cyclophosphamide] affects the expression of BCL2 mRNA; [Doxorubicin co-treated with Dexamethasone co-treated with Vincristine co-treated with Cytarabine co-treated with Mercaptopurine co-treated with Methotrexate co-treated with Cyclophosphamide co-treated with Enzymes and Coenzymes] results in increased expression of BCL2 protein; BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP9 protein]; Cyclophosphamide promotes the reaction [SGI-1027 results in decreased expression of BCL2 protein]; PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; SGI-1027 promotes the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; Valproic Acid inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein] Cyclophosphamide results in increased expression of BCL2 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; Mots-C peptide, mouse inhibits the reaction [Cyclophosphamide results in increased expression of BCL2 protein] Cyclophosphamide results in decreased expression of BCL2 mRNA; Cyclophosphamide results in decreased expression of BCL2 protein [Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 mRNA]; coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; herbacetin inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 mRNA]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein] Cyclophosphamide results in increased expression of BCL2 mRNA
|
CTD |
PMID:11723234 PMID:14503796 PMID:15582267 PMID:16322899 PMID:21182165 PMID:25446862 PMID:29753871 PMID:30506662 PMID:32197949 PMID:33737021 PMID:34658283 PMID:36154502 PMID:36198566 PMID:38211767 PMID:39079574 PMID:39209270 PMID:39952379 More...
|
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bcl2l1
|
Bcl2-like 1
|
increases expression decreases expression
|
EXP ISO
|
Cyclophosphamide results in increased expression of BCL2L1 mRNA Cyclophosphamide results in decreased expression of BCL2L1 mRNA
|
CTD |
PMID:11599041 PMID:33737021 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907 Ensembl chr 1:161,745,540...161,764,907
|
|
G
|
Bcl2l11
|
Bcl2-like 11
|
increases expression multiple interactions
|
EXP
|
Cyclophosphamide results in increased expression of BCL2L11 mRNA sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of BCL2L11 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BCL2L11 mRNA]
|
CTD |
PMID:32197949 |
|
NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695
|
|
G
|
Bcl2l2
|
Bcl2-like 2
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of BCL2L2 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr15:32,326,686...32,337,834
Ensembl chr15:32,326,020...32,335,379
|
|
G
|
Bcl6
|
BCL6, transcription repressor
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of BCL6 mRNA Cyclophosphamide metabolite results in decreased expression of BCL6 mRNA
|
CTD |
PMID:21041162 PMID:24356939 |
|
NCBI chr11:90,358,753...90,382,049
Ensembl chr11:90,358,753...90,382,047
|
|
G
|
Bdh1
|
3-hydroxybutyrate dehydrogenase 1
|
affects response to substance
|
ISO
|
BDH1 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr11:82,806,125...82,848,133
Ensembl chr11:82,807,503...82,842,636
|
|
G
|
Bdkrb1
|
bradykinin receptor B1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of BDKRB1 mRNA
|
CTD |
PMID:10498854 PMID:15576455 |
|
NCBI chr 6:130,275,631...130,284,968
Ensembl chr 6:130,275,478...130,280,973
|
|
G
|
Bdkrb2
|
bradykinin receptor B2
|
affects expression
|
EXP
|
Cyclophosphamide affects the expression of BDKRB2 mRNA
|
CTD |
PMID:15576455 |
|
NCBI chr 6:130,237,055...130,267,205
Ensembl chr 6:130,237,255...130,267,209
|
|
G
|
Bdnf
|
brain-derived neurotrophic factor
|
increases expression decreases expression multiple interactions
|
EXP
|
Cyclophosphamide results in increased expression of BDNF mRNA; Cyclophosphamide results in increased expression of BDNF protein Cyclophosphamide results in decreased expression of BDNF protein coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of BDNF protein]; O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of BDNF protein]
|
CTD |
PMID:10683293 PMID:32615180 PMID:39209270 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657
|
|
G
|
Becn1
|
beclin 1
|
multiple interactions increases expression decreases expression
|
ISO
|
BECN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] Cyclophosphamide results in increased expression of BECN1 protein asperuloside promotes the reaction [Cyclophosphamide results in increased expression of BECN1 protein]; CSF2 protein promotes the reaction [Cyclophosphamide results in increased expression of BECN1 protein]; dorsomorphin inhibits the reaction [asperuloside promotes the reaction [Cyclophosphamide results in increased expression of BECN1 protein]]; dorsomorphin inhibits the reaction [Cyclophosphamide results in increased expression of BECN1 protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of BECN1 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of BECN1 protein]
|
CTD |
PMID:16896004 PMID:32151603 PMID:38348709 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002
|
|
G
|
Bik
|
BCL2-interacting killer
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of BIK mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 7:116,552,303...116,571,317
Ensembl chr 7:116,552,303...116,571,317
|
|
G
|
Birc3
|
baculoviral IAP repeat-containing 3
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of BIRC3 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590
|
|
G
|
Blvrb
|
biliverdin reductase B
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of BLVRB protein
|
CTD |
PMID:9006340 |
|
NCBI chr 1:91,866,258...91,883,921
Ensembl chr 1:91,866,258...91,884,225
|
|
G
|
Bpi
|
bactericidal/permeability-increasing protein
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of BPI mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 3:146,909,626...146,936,487
Ensembl chr 3:167,329,530...167,356,396
|
|
G
|
Brpf1
|
bromodomain and PHD finger containing, 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of BRPF1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 4:148,011,977...148,028,431
Ensembl chr 4:148,011,931...148,028,424
|
|
G
|
Bscl2
|
BSCL2 lipid droplet biogenesis associated, seipin
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of BSCL2 mRNA
|
CTD |
PMID:22003191 |
|
NCBI chr 1:215,160,764...215,172,540
Ensembl chr 1:215,160,957...215,172,536
|
|
G
|
Bsg
|
basigin
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of BSG mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 7:10,643,788...10,651,005
Ensembl chr 7:10,643,789...10,651,005
|
|
G
|
Btg1
|
BTG anti-proliferation factor 1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of BTG1 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 7:33,228,149...33,230,406
Ensembl chr 7:33,227,833...33,230,406
|
|
G
|
Btg2
|
BTG anti-proliferation factor 2
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of BTG2 mRNA
|
CTD |
PMID:29445054 |
|
NCBI chr13:48,083,931...48,087,690
Ensembl chr13:48,083,931...48,087,690
|
|
G
|
Btg3
|
BTG anti-proliferation factor 3
|
multiple interactions
|
ISO
|
BTG3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr11:17,030,156...17,046,069
Ensembl chr11:30,517,072...30,533,082
|
|
G
|
Bub3
|
BUB3 mitotic checkpoint protein
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of BUB3 mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr 1:186,330,358...186,340,969
Ensembl chr 1:195,758,105...195,791,028
|
|
G
|
C1qa
|
complement C1q A chain
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of C1QA mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 5:154,417,086...154,419,933
Ensembl chr 5:154,417,087...154,427,732
|
|
G
|
C3
|
complement C3
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of C3 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,174,412...2,201,339
|
|
G
|
Ca12
|
carbonic anhydrase 12
|
multiple interactions
|
ISO
|
CA12 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr 8:76,169,723...76,225,465
Ensembl chr 8:76,169,815...76,225,465
|
|
G
|
Ca3
|
carbonic anhydrase 3
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of CA3 protein
|
CTD |
PMID:15928459 |
|
NCBI chr 2:88,491,666...88,501,299
Ensembl chr 2:88,491,670...88,500,524
|
|
G
|
Cabp1
|
calcium binding protein 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of CABP1 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr12:47,045,914...47,109,614
Ensembl chr12:47,085,292...47,109,611
|
|
G
|
Cabp2
|
calcium binding protein 2
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of CABP2 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 1:201,374,649...201,380,469
Ensembl chr 1:210,804,096...210,809,940
|
|
G
|
Cacna1h
|
calcium voltage-gated channel subunit alpha1 H
|
increases expression multiple interactions
|
ISO
|
Cyclophosphamide results in increased expression of CACNA1H protein 3-cyanoalanine inhibits the reaction [[N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of CACNA1H protein]; [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of CACNA1H protein
|
CTD |
PMID:29129814 |
|
NCBI chr10:14,894,630...14,952,317
Ensembl chr10:14,894,641...14,952,771
|
|
G
|
Calca
|
calcitonin-related polypeptide alpha
|
increases expression multiple interactions
|
EXP
|
Cyclophosphamide results in increased expression of CALCA protein O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of CALCA protein]
|
CTD |
PMID:32615180 |
|
NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529
|
|
G
|
Calr
|
calreticulin
|
increases expression decreases expression
|
EXP
|
Cyclophosphamide results in increased expression of CALR mRNA; Cyclophosphamide results in increased expression of CALR protein Cyclophosphamide results in decreased expression of CALR mRNA
|
CTD |
PMID:11599041 PMID:11906922 PMID:15928459 PMID:18246545 |
|
NCBI chr19:40,213,367...40,218,262
Ensembl chr19:40,213,239...40,219,236
|
|
G
|
Canx
|
calnexin
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of CANX mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr10:35,124,941...35,157,954
Ensembl chr10:35,124,941...35,157,857
|
|
G
|
Capn2
|
calpain 2
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CAPN2 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr13:96,681,902...96,732,625
Ensembl chr13:96,681,848...96,732,625
|
|
G
|
Car2
|
carbonic anhydrase 2
|
decreases expression increases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CA2 mRNA Cyclophosphamide results in increased expression of CAR2 mRNA
|
CTD |
PMID:15331540 PMID:17403535 |
|
NCBI chr 2:88,462,883...88,478,012
Ensembl chr 2:88,462,872...88,478,064
|
|
G
|
Car7
|
carbonic anhydrase 7
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of CAR7 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr19:429,063...438,478
Ensembl chr19:435,522...452,384
|
|
G
|
Cars1
|
cysteinyl-tRNA synthetase 1
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of CARS1 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 1:208,183,092...208,225,425
Ensembl chr 1:208,182,788...208,225,407
|
|
G
|
Casp1
|
caspase 1
|
decreases expression increases expression multiple interactions
|
ISO EXP
|
Cyclophosphamide results in decreased expression of CASP1 mRNA Cyclophosphamide results in increased expression of CASP1 protein Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein] Cyclophosphamide results in increased expression of CASP1 mRNA
|
CTD |
PMID:17403535 PMID:21041162 PMID:35762198 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275
|
|
G
|
Casp12
|
caspase 12
|
increases cleavage
|
EXP
|
Cyclophosphamide results in increased cleavage of CASP12 protein
|
CTD |
PMID:38740238 |
|
NCBI chr 8:10,927,188...10,954,442
Ensembl chr 8:10,926,994...10,954,442
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions increases cleavage increases expression increases activity decreases response to substance
|
ISO EXP
|
[Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; Cyclophosphamide promotes the reaction [SGI-1027 results in increased cleavage of CASP3 protein]; Cyclophosphamide results in increased cleavage of and results in increased activity of CASP3 protein; PAX5 protein affects the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; SGI-1027 promotes the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; Valproic Acid inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein] Cyclophosphamide results in increased expression of CASP3 mRNA; Cyclophosphamide results in increased expression of CASP3 protein Berberine inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 protein]; Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 protein]; coenzyme Q10 inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; Curcumin inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 protein]; Cyclophosphamide results in increased expression of and results in increased activity of CASP3 protein; herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 mRNA]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of and results in increased activity of CASP3 protein]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein] Donepezil inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 protein]; Fenofibrate inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 protein]; levocabastine inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; TRPM2 protein affects the reaction [Cyclophosphamide results in increased expression of CASP3 mRNA] CASP3 protein alternative form results in decreased susceptibility to Cyclophosphamide
|
CTD |
PMID:11723234 PMID:14503796 PMID:16675587 PMID:17020986 PMID:17898787 PMID:30506662 PMID:32197949 PMID:32456565 PMID:34658283 PMID:35762198 PMID:36198566 PMID:37419146 PMID:37955270 PMID:38278497 PMID:38740238 PMID:38825044 PMID:39209270 PMID:39952379 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp4
|
caspase 4
|
increases cleavage multiple interactions
|
EXP
|
Cyclophosphamide results in increased cleavage of CASP4 protein sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP4 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP4 protein]
|
CTD |
PMID:32197949 |
|
NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:10,883,769...10,920,727
|
|
G
|
Casp8
|
caspase 8
|
multiple interactions increases response to substance
|
ISO
|
[Methotrexate results in increased expression of CASP8 protein] which results in increased susceptibility to Cyclophosphamide metabolite; Cyclophosphamide metabolite results in increased expression of and results in increased cleavage of CASP8 protein; Cyclophosphamide results in increased cleavage of and results in increased activity of CASP8 protein CASP8 protein results in increased susceptibility to Cyclophosphamide metabolite
|
CTD |
PMID:17898787 PMID:22010212 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions increases expression increases activity
|
ISO EXP
|
BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP9 protein]; Cyclophosphamide results in increased cleavage of and results in increased activity of CASP9 protein ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of CASP9 protein] Cyclophosphamide results in increased expression of CASP9 mRNA; Cyclophosphamide results in increased expression of CASP9 protein
|
CTD |
PMID:11723234 PMID:17898787 PMID:30506662 PMID:39952379 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cat
|
catalase
|
decreases expression decreases activity affects activity multiple interactions
|
EXP ISO
|
Cyclophosphamide results in decreased expression of CAT protein Cyclophosphamide results in decreased activity of CAT protein Cyclophosphamide results in decreased expression of CAT mRNA; Cyclophosphamide results in decreased expression of CAT protein Cyclophosphamide affects the activity of CAT protein Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]; cinnamic acid inhibits the reaction [Cyclophosphamide affects the activity of CAT protein]; Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of CAT protein]; Eicosapentaenoic Acid inhibits the reaction [Cyclophosphamide affects the activity of CAT protein]; Fenofibrate inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; levocabastine inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of CAT protein]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of CAT mRNA] coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; crocin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; herbacetin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; mangiferin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; naringin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; pimagedine inhibits the reaction [Cyclophosphamide results in decreased expression of CAT protein]; Quercetin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Rutin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Silymarin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]
|
CTD |
PMID:16076520 PMID:19107871 PMID:20052769 PMID:20957680 PMID:21772021 PMID:22285266 PMID:23488790 PMID:23542512 PMID:23695977 PMID:25753322 PMID:27633142 PMID:29753871 PMID:33992719 PMID:34748891 PMID:35906875 PMID:36198566 PMID:38278497 PMID:39209270 PMID:39952379 More...
|
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccin
|
calicin
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CCIN protein
|
CTD |
PMID:17475930 |
|
NCBI chr 5:63,002,427...63,004,314
Ensembl chr 5:63,000,138...63,010,123
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
decreases expression multiple interactions increases expression
|
EXP ISO
|
Cyclophosphamide results in decreased expression of CCL2 protein Cyclophosphamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein] naringin inhibits the reaction [Cyclophosphamide results in increased expression of CCL2 mRNA]
|
CTD |
PMID:18848347 PMID:21068404 PMID:33992719 PMID:36416909 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Ccl25
|
C-C motif chemokine ligand 25
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CCL25 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr12:7,505,231...7,514,402
Ensembl chr12:7,505,235...7,514,385
|
|
G
|
Ccl3
|
C-C motif chemokine ligand 3
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of CCL3 protein Cyclophosphamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein]
|
CTD |
PMID:21880982 PMID:36416909 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439
|
|
G
|
Ccl7
|
C-C motif chemokine ligand 7
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CCL7 mRNA
|
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr10:67,514,095...67,515,945
Ensembl chr10:67,514,091...67,515,947
|
|
G
|
Ccn1
|
cellular communication network factor 1
|
decreases expression multiple interactions
|
EXP
|
Cyclophosphamide results in decreased expression of CCN1 mRNA; Cyclophosphamide results in decreased expression of CCN1 protein Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of CCN1 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of CCN1 protein]
|
CTD |
PMID:36154502 |
|
NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883
|
|
G
|
Ccn2
|
cellular communication network factor 2
|
decreases expression multiple interactions
|
EXP
|
Cyclophosphamide results in decreased expression of CCN2 mRNA; Cyclophosphamide results in decreased expression of CCN2 protein Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of CCN2 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of CCN2 protein]
|
CTD |
PMID:36154502 |
|
NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976
|
|
G
|
Ccna2
|
cyclin A2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CCNA2 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701
|
|
G
|
Ccnd1
|
cyclin D1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CCND1 protein
|
CTD |
PMID:33737021 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Ccnd2
|
cyclin D2
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CCND2 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 4:161,653,048...161,675,422
Ensembl chr 4:161,653,048...161,680,301 Ensembl chr 4:161,653,048...161,680,301
|
|
G
|
Ccnd3
|
cyclin D3
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CCND3 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 9:20,891,696...20,987,199
Ensembl chr 9:20,891,704...20,987,033
|
|
G
|
Ccr5
|
C-C motif chemokine receptor 5
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CCR5 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 8:132,629,097...132,660,980
Ensembl chr 8:132,629,683...132,637,594
|
|
G
|
Ccr8
|
C-C motif chemokine receptor 8
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CCR8 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 8:128,703,966...128,705,926
Ensembl chr 8:128,702,349...128,705,955
|
|
G
|
Ccr9
|
C-C motif chemokine receptor 9
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CCR9 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 8:132,273,581...132,287,651
Ensembl chr 8:132,273,544...132,287,883
|
|
G
|
Cct3
|
chaperonin containing TCP1 subunit 3
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of CCT3 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 2:176,063,529...176,088,180
Ensembl chr 2:176,063,526...176,089,925
|
|
G
|
Cct5
|
chaperonin containing TCP1 subunit 5
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of CCT5 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 2:84,302,621...84,313,773
Ensembl chr 2:84,302,623...84,313,779
|
|
G
|
Cct7
|
chaperonin containing TCP1 subunit 7
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of CCT7 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 4:119,546,730...119,563,973
Ensembl chr 4:119,546,730...119,563,973
|
|
G
|
Cd14
|
CD14 molecule
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CD14 mRNA
|
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,608,883...28,611,292
|
|
G
|
Cd151
|
CD151 molecule (Raph blood group)
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CD151 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:205,994,738...205,998,784
|
|
G
|
Cd2
|
Cd2 molecule
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD2 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 2:188,710,895...188,724,044
Ensembl chr 2:191,399,510...191,413,665
|
|
G
|
Cd27
|
CD27 molecule
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD27 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 4:159,716,932...159,721,823
Ensembl chr 4:159,716,935...159,721,823
|
|
G
|
Cd28
|
Cd28 molecule
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD28 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 9:69,660,316...69,689,192
Ensembl chr 9:69,545,326...69,689,192
|
|
G
|
Cd38
|
CD38 molecule
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CD38 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505
|
|
G
|
Cd3d
|
CD3 delta subunit of T-cell receptor complex
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD3D mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 8:54,184,573...54,190,112
Ensembl chr 8:54,175,155...54,196,722
|
|
G
|
Cd3e
|
CD3 epsilon subunit of T-cell receptor complex
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD3E mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 8:54,200,617...54,211,770
Ensembl chr 8:54,200,617...54,211,876
|
|
G
|
Cd3g
|
CD3 gamma subunit of T-cell receptor complex
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD3G mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 8:54,177,572...54,184,087
Ensembl chr 8:54,177,977...54,183,918
|
|
G
|
Cd4
|
Cd4 molecule
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD4 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 4:159,355,147...159,381,636
Ensembl chr 4:159,356,337...159,381,461
|
|
G
|
Cd40
|
CD40 molecule
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD40 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847
|
|
G
|
Cd5
|
Cd5 molecule
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD5 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 1:216,790,245...216,811,209
Ensembl chr 1:216,790,245...216,811,209
|
|
G
|
Cd6
|
Cd6 molecule
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD6 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 1:216,867,767...216,906,642
Ensembl chr 1:216,867,771...216,879,432
|
|
G
|
Cd69
|
Cd69 molecule
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD69 mRNA Cyclophosphamide metabolite results in decreased expression of CD69 mRNA
|
CTD |
PMID:21041162 PMID:24356939 |
|
NCBI chr 4:164,411,485...164,419,403
Ensembl chr 4:164,411,485...164,419,509
|
|
G
|
Cd74
|
CD74 molecule
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD74 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr18:56,527,071...56,536,406
Ensembl chr18:56,527,132...56,536,410
|
|
G
|
Cd79b
|
CD79b molecule
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD79B mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr10:91,739,134...91,742,312
Ensembl chr10:91,739,137...91,742,405
|
|
G
|
Cd83
|
CD83 molecule
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD83 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr17:21,093,281...21,113,223
Ensembl chr17:21,093,281...21,113,047
|
|
G
|
Cd84
|
CD84 molecule
|
increases expression
|
ISO
|
Cyclophosphamide metabolite results in increased expression of CD84 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr13:86,859,979...86,899,984
Ensembl chr13:86,859,990...86,894,318
|
|
G
|
Cd8a
|
CD8 subunit alpha
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD8A mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 4:103,365,804...103,370,041
Ensembl chr 4:104,900,833...104,928,358
|
|
G
|
Cd8b
|
CD8 subunit beta
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CD8B1 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 4:103,312,596...103,328,523
Ensembl chr 4:104,870,893...104,886,868
|
|
G
|
Cdc20
|
cell division cycle 20
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of CDC20 mRNA
|
CTD |
PMID:11599041 |
|
NCBI chr 5:137,251,596...137,255,799
Ensembl chr 5:137,251,596...137,255,799
|
|
G
|
Cdh1
|
cadherin 1
|
affects expression
|
EXP
|
Cyclophosphamide affects the expression of CDH1 mRNA
|
CTD |
PMID:10859244 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565
|
|
G
|
Cdh2
|
cadherin 2
|
affects expression
|
EXP
|
Cyclophosphamide affects the expression of CDH2 mRNA
|
CTD |
PMID:10859244 |
|
NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288
|
|
G
|
Cdh3
|
cadherin 3
|
affects expression
|
EXP
|
Cyclophosphamide affects the expression of CDH3 mRNA
|
CTD |
PMID:10859244 |
|
NCBI chr19:51,303,414...51,353,900
Ensembl chr19:51,300,083...51,354,257
|
|
G
|
Cdk2
|
cyclin dependent kinase 2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CDK2 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CDKN1A mRNA
|
CTD |
PMID:15331540 PMID:21527772 PMID:29445054 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cdkn1b
|
cyclin-dependent kinase inhibitor 1B
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of CDKN1B mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498
|
|
G
|
Cdkn1c
|
cyclin-dependent kinase inhibitor 1C
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CDKN1C mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 1:208,084,801...208,087,680
Ensembl chr 1:208,084,787...208,087,498
|
|
G
|
Cdkn2d
|
cyclin dependent kinase inhibitor 2D
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CDKN2D mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 8:28,108,036...28,110,809
Ensembl chr 8:28,108,044...28,110,809
|
|
G
|
Cebpb
|
CCAAT/enhancer binding protein beta
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of CEBPB mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072
|
|
G
|
Cel
|
carboxyl ester lipase
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CEL mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 3:32,281,518...32,289,019
Ensembl chr 3:32,281,518...32,289,019
|
|
G
|
Cfb
|
complement factor B
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CFB mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr20:3,975,271...3,981,138
Ensembl chr20:3,955,776...3,981,740
|
|
G
|
Cfi
|
complement factor I
|
affects response to substance
|
ISO
|
CFI protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 2:221,062,206...221,104,790
Ensembl chr 2:221,062,212...221,104,786
|
|
G
|
Chac1
|
ChaC glutathione-specific gamma-glutamylcyclotransferase 1
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of CHAC1 mRNA; Cyclophosphamide results in decreased expression of CHAC1 mRNA
|
CTD |
PMID:23824090 PMID:24356939 |
|
NCBI chr 3:126,796,131...126,799,352
Ensembl chr 3:126,796,024...126,799,361
|
|
G
|
Champ1
|
chromosome alignment maintaining phosphoprotein 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of CHAMP1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr16:75,733,958...75,744,931
Ensembl chr16:82,434,823...82,458,984
|
|
G
|
Chd5
|
chromodomain helicase DNA binding protein 5
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of CHD5 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 5:168,130,851...168,181,705
Ensembl chr 5:168,130,575...168,179,441
|
|
G
|
Chga
|
chromogranin A
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CHGA mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 6:127,460,895...127,472,238
Ensembl chr 6:127,460,854...127,472,237
|
|
G
|
Chrm5
|
cholinergic receptor, muscarinic 5
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of CHRM5 protein
|
CTD |
PMID:16125470 |
|
NCBI chr 3:119,739,229...119,791,630
Ensembl chr 3:119,735,975...119,792,166
|
|
G
|
Cited2
|
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2
|
affects expression decreases expression
|
EXP
|
Cyclophosphamide affects the expression of CITED2 mRNA Cyclophosphamide results in decreased expression of CITED2 mRNA
|
CTD |
PMID:18246545 |
|
NCBI chr 1:14,132,303...14,134,746
Ensembl chr 1:14,103,457...14,134,782
|
|
G
|
Ckm
|
creatine kinase, M-type
|
multiple interactions increases expression
|
EXP
|
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein]
|
CTD |
PMID:35762198 |
|
NCBI chr 1:88,189,382...88,199,717
Ensembl chr 1:88,189,485...88,199,719
|
|
G
|
Cldn1
|
claudin 1
|
multiple interactions decreases expression
|
ISO
|
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN1 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN1 protein]
|
CTD |
PMID:32151603 |
|
NCBI chr11:87,926,376...87,941,533
Ensembl chr11:87,926,337...87,941,529
|
|
G
|
Cldn4
|
claudin 4
|
multiple interactions decreases expression
|
EXP
|
Anthocyanins inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN4 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN4 protein]
|
CTD |
PMID:25451569 |
|
NCBI chr12:27,388,160...27,389,958
Ensembl chr12:27,387,981...27,389,958
|
|
G
|
Clic4
|
chloride intracellular channel 4
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CLIC4 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 5:152,737,371...152,797,118
Ensembl chr 5:152,737,371...152,797,118
|
|
G
|
Clip1
|
CAP-GLY domain containing linker protein 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of CLIP1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr12:32,910,932...33,017,891
Ensembl chr12:38,571,834...38,678,779
|
|
G
|
Coch
|
cochlin
|
affects response to substance
|
ISO
|
COCH protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 6:74,766,485...74,780,504
Ensembl chr 6:74,766,419...74,780,502
|
|
G
|
Comt
|
catechol-O-methyltransferase
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of COMT mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533
|
|
G
|
Cox7a2
|
cytochrome c oxidase subunit 7A2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of COX7A2 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 8:80,716,824...80,720,922
Ensembl chr14:55,514,261...55,514,512 Ensembl chr 8:55,514,261...55,514,512
|
|
G
|
Crabp2
|
cellular retinoic acid binding protein 2
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CRABP2 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 2:175,714,862...175,719,208
Ensembl chr 2:175,707,312...175,728,385
|
|
G
|
Creb1
|
cAMP responsive element binding protein 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CREB1 protein modified form
|
CTD |
PMID:18299998 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339
|
|
G
|
Crem
|
cAMP responsive element modulator
|
decreases expression multiple interactions
|
EXP
|
Cyclophosphamide results in decreased expression of CREM mRNA; Cyclophosphamide results in decreased expression of CREM protein Drugs, Chinese Herbal inhibits the reaction [Cyclophosphamide results in decreased expression of CREM mRNA]; Drugs, Chinese Herbal inhibits the reaction [Cyclophosphamide results in decreased expression of CREM protein]
|
CTD |
PMID:17624719 |
|
NCBI chr17:58,932,011...59,001,160
Ensembl chr17:58,934,147...59,001,160
|
|
G
|
Crh
|
corticotropin releasing hormone
|
increases expression
|
EXP ISO
|
Cyclophosphamide results in increased expression of CRH mRNA; Cyclophosphamide results in increased expression of CRH protein
|
CTD |
PMID:15276878 PMID:16614059 PMID:17335920 |
|
NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386
|
|
G
|
Crhr2
|
corticotropin releasing hormone receptor 2
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of CRHR2 protein
|
CTD |
PMID:16614059 |
|
NCBI chr 4:85,553,163...85,596,203
Ensembl chr 4:85,554,268...85,596,318
|
|
G
|
Crp
|
C-reactive protein
|
multiple interactions increases secretion
|
EXP
|
allyl sulfide inhibits the reaction [Cyclophosphamide results in increased secretion of CRP protein]
|
CTD |
PMID:31779506 |
|
NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514
|
|
G
|
Csf1
|
colony stimulating factor 1
|
multiple interactions
|
ISO
|
[Cyclophosphamide co-treated with Sizofiran] results in increased expression of CSF1 mRNA
|
CTD |
PMID:10052129 |
|
NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:198,065,405...198,084,468
|
|
G
|
Csf2
|
colony stimulating factor 2
|
affects activity decreases expression multiple interactions increases expression
|
ISO EXP
|
CSF2 protein affects the activity of Cyclophosphamide Cyclophosphamide results in decreased expression of CSF2 protein asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of CSF2 protein]; CSF2 protein inhibits the reaction [Cyclophosphamide results in decreased expression of EPO protein]; CSF2 protein inhibits the reaction [Cyclophosphamide results in decreased expression of KIT protein]; CSF2 protein inhibits the reaction [Cyclophosphamide results in decreased expression of THPO protein]; CSF2 protein inhibits the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein]; CSF2 protein promotes the reaction [Cyclophosphamide results in increased expression of BECN1 protein]; CSF2 protein promotes the reaction [Cyclophosphamide results in increased lipidation of MAP1LC3B protein]; CSF2 protein promotes the reaction [Cyclophosphamide results in increased phosphorylation of PRKAA1 protein]; dorsomorphin inhibits the reaction [asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of CSF2 protein]] Cyclophosphamide results in increased expression of CSF2 protein
|
CTD |
PMID:8349185 PMID:18848347 PMID:38348709 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031
|
|
G
|
Csk
|
C-terminal Src kinase
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CSK mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 8:66,925,650...66,944,861
Ensembl chr 8:66,925,651...66,930,274
|
|
G
|
Cst7
|
cystatin F
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CST7 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 3:159,857,221...159,865,987
Ensembl chr 3:159,857,052...159,866,919
|
|
G
|
Csta
|
cystatin A
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of CSTA mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr11:78,125,813...78,136,818
Ensembl chr11:78,125,800...78,136,822
|
|
G
|
Cth
|
cystathionine gamma-lyase
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CTH protein
|
CTD |
PMID:29129814 |
|
NCBI chr 2:249,634,731...249,661,066
Ensembl chr 2:249,634,731...249,661,066
|
|
G
|
Ctnnb1
|
catenin beta 1
|
multiple interactions decreases expression
|
EXP
|
coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of CTNNB1 protein]
|
CTD |
PMID:39209270 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662
|
|
G
|
Ctnnbip1
|
catenin, beta-interacting protein 1
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of CTNNBIP1 mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr 5:165,245,019...165,293,994
Ensembl chr 5:165,245,098...165,293,991
|
|
G
|
Ctnnd2
|
catenin delta 2
|
multiple interactions
|
ISO
|
CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr 2:82,879,469...83,727,409
Ensembl chr 2:82,879,469...83,727,409
|
|
G
|
Ctsd
|
cathepsin D
|
multiple interactions increases activity
|
ISO EXP
|
[Cyclophosphamide co-treated with Mecamylamine] results in increased expression of CTSD mRNA Cyclophosphamide results in increased activity of CTSD protein Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of CTSD protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of CTSD protein]
|
CTD |
PMID:18433785 PMID:25451569 |
|
NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821
|
|
G
|
Ctsh
|
cathepsin H
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CTSH mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 8:99,488,756...99,507,639
Ensembl chr 8:99,488,874...99,509,181
|
|
G
|
Ctsl
|
cathepsin L
|
increases expression decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in increased expression of CTSL mRNA Cyclophosphamide results in decreased expression of CTSL mRNA 5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in decreased expression of CTSL mRNA]
|
CTD |
PMID:17403535 PMID:30760223 |
|
NCBI chr17:770,104...776,266
Ensembl chr17:770,093...777,113
|
|
G
|
Cx3cl1
|
C-X3-C motif chemokine ligand 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of CX3CL1 protein
|
CTD |
PMID:16651033 |
|
NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,233,329...10,242,999
|
|
G
|
Cx3cr1
|
C-X3-C motif chemokine receptor 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of CX3CR1 protein
|
CTD |
PMID:16651033 |
|
NCBI chr 8:128,661,294...128,679,048
Ensembl chr 8:128,654,833...128,685,983
|
|
G
|
Cxcl1
|
C-X-C motif chemokine ligand 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of CXCL1 protein
|
CTD |
PMID:18848347 |
|
NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811
|
|
G
|
Cxcl10
|
C-X-C motif chemokine ligand 10
|
affects expression increases expression increases response to substance
|
ISO
|
Cyclophosphamide affects the expression of CXCL10 mRNA Cyclophosphamide results in increased expression of CXCL10 protein CXCL10 protein results in increased susceptibility to Cyclophosphamide
|
CTD |
PMID:18957084 |
|
NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261
|
|
G
|
Cxcl11
|
C-X-C motif chemokine ligand 11
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CXCL11 protein
|
CTD |
PMID:18957084 |
|
NCBI chr14:15,973,728...15,976,503
Ensembl chr14:15,973,720...15,976,567
|
|
G
|
Cxcl12
|
C-X-C motif chemokine ligand 12
|
affects expression increases expression
|
ISO EXP
|
Cyclophosphamide affects the expression of CXCL12 mRNA Cyclophosphamide results in increased expression of CXCL12 mRNA; Cyclophosphamide results in increased expression of CXCL12 protein
|
CTD |
PMID:12624490 PMID:16337237 PMID:19066630 PMID:20032115 |
|
NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627
|
|
G
|
Cxcl2
|
C-X-C motif chemokine ligand 2
|
multiple interactions
|
ISO
|
[Cyclophosphamide co-treated with Dexamethasone] inhibits the reaction [Paraquat results in increased expression of CXCL2 mRNA]
|
CTD |
PMID:36031164 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255
|
|
G
|
Cxcl3
|
C-X-C motif chemokine ligand 3
|
increases expression affects expression multiple interactions
|
ISO
|
Cyclophosphamide results in increased expression of CXCL1 mRNA; Cyclophosphamide results in increased expression of CXCL1 protein Cyclophosphamide affects the expression of CXCL3 mRNA VIP protein inhibits the reaction [Cyclophosphamide results in increased expression of CXCL1 protein]
|
CTD |
PMID:15331540 PMID:18483878 PMID:18957084 |
|
NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624
|
|
G
|
Cxcl6
|
C-X-C motif chemokine ligand 6
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CXCL5 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr14:17,594,959...17,596,417
Ensembl chr14:17,594,959...17,596,417
|
|
G
|
Cxcl9
|
C-X-C motif chemokine ligand 9
|
affects expression decreases expression increases expression
|
ISO
|
Cyclophosphamide affects the expression of CXCL9 mRNA Cyclophosphamide results in decreased expression of CXCL9 protein Cyclophosphamide results in increased expression of CXCL9 mRNA; Cyclophosphamide results in increased expression of CXCL9 protein
|
CTD |
PMID:15331540 PMID:18957084 PMID:21041162 PMID:21880982 |
|
NCBI chr14:16,007,166...16,012,077
Ensembl chr14:16,007,204...16,014,299
|
|
G
|
Cxcr4
|
C-X-C motif chemokine receptor 4
|
multiple interactions decreases expression increases expression affects localization
|
EXP ISO
|
Cyclophosphamide promotes the reaction [MIF protein binds to CXCR4 protein] Cyclophosphamide results in decreased expression of CXCR4 mRNA Cyclophosphamide results in increased expression of CXCR4 mRNA; Cyclophosphamide results in increased expression of CXCR4 protein Cyclophosphamide affects the localization of CXCR4 protein
|
CTD |
PMID:19066630 PMID:20032115 PMID:21041162 |
|
NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459
|
|
G
|
Cxcr6
|
C-X-C motif chemokine receptor 6
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of CXCR6 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 8:123,434,417...123,439,568
Ensembl chr 8:132,306,600...132,322,498
|
|
G
|
Cyp11a1
|
cytochrome P450, family 11, subfamily a, polypeptide 1
|
decreases expression multiple interactions
|
EXP ISO
|
Cyclophosphamide results in decreased expression of CYP11A1 mRNA Flavonoids inhibits the reaction [Cyclophosphamide results in decreased expression of CYP11A1 mRNA]; Flavonoids inhibits the reaction [Cyclophosphamide results in decreased expression of CYP11A1 protein] Cyclophosphamide results in decreased expression of CYP11A1 mRNA; Cyclophosphamide results in decreased expression of CYP11A1 protein [Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in decreased expression of CYP11A1 mRNA]
|
CTD |
PMID:38211767 PMID:39239657 |
|
NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196
|
|
G
|
Cyp17a1
|
cytochrome P450, family 17, subfamily a, polypeptide 1
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of CYP17A1 mRNA; Cyclophosphamide results in decreased expression of CYP17A1 protein Flavonoids inhibits the reaction [Cyclophosphamide results in decreased expression of CYP17A1 protein]
|
CTD |
PMID:39239657 |
|
NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
decreases activity
|
ISO
|
Cyclophosphamide results in decreased activity of CYP1A1 protein
|
CTD |
PMID:18420780 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
decreases activity
|
ISO
|
Cyclophosphamide results in decreased activity of CYP1A2 protein
|
CTD |
PMID:18420780 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of CYP1B1 mRNA
|
CTD |
PMID:12167460 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
G
|
Cyp2a3
|
cytochrome P450, family 2, subfamily a, polypeptide 3
|
decreases activity
|
ISO
|
Cyclophosphamide results in decreased activity of CYP2A4 protein
|
CTD |
PMID:18420780 |
|
NCBI chr 1:91,299,584...91,307,650
Ensembl chr 1:91,299,561...91,307,649
|
|
G
|
Cyp2b1
|
cytochrome P450, family 2, subfamily b, polypeptide 1
|
multiple interactions increases response to substance affects metabolic processing increases activity increases hydroxylation increases expression increases metabolic processing
|
EXP
|
Cyclophosphamide results in increased expression of and results in increased activity of CYP2B1 protein; Metyrapone inhibits the reaction [CYP2B1 results in increased susceptibility to Cyclophosphamide] CYP2B1 protein results in increased susceptibility to Cyclophosphamide; CYP2B1 results in increased susceptibility to Cyclophosphamide CYP2B1 protein affects the metabolism of Cyclophosphamide CYP2B1 results in increased activity of Cyclophosphamide CYP2B1 protein mutant form results in increased hydroxylation of Cyclophosphamide; CYP2B1 protein results in increased hydroxylation of Cyclophosphamide Cyclophosphamide results in increased expression of CYP2B1 mRNA; Cyclophosphamide results in increased expression of CYP2B1 protein CYP2B1 protein results in increased metabolism of Cyclophosphamide; CYP2B1 results in increased metabolism of Cyclophosphamide
|
CTD |
PMID:2272335 PMID:7834628 PMID:8640822 PMID:9592392 PMID:10415877 PMID:11221871 PMID:11933215 PMID:15102956 PMID:15635577 PMID:16019949 PMID:17634551 PMID:19103281 PMID:20566340 More...
|
|
NCBI chr 1:90,646,098...90,669,762
|
|
G
|
Cyp2b2
|
cytochrome P450, family 2, subfamily b, polypeptide 2
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of CYP2B2 mRNA; Cyclophosphamide results in increased expression of CYP2B2 protein
|
CTD |
PMID:16019949 PMID:17634551 |
|
NCBI chr 1:90,722,243...90,736,272
|
|
G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
multiple interactions increases expression increases metabolic processing increases activity increases response to substance increases hydroxylation affects hydroxylation
|
ISO EXP
|
[Cyclophosphamide results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; [Doxorubicin co-treated with Cyclophosphamide] affects the expression of CYP2B6 mRNA; Cyclophosphamide results in decreased expression of and results in decreased activity of CYP2B6 protein; CYP2B6 protein polymorphism affects the activity of and affects the susceptibility to Cyclophosphamide; CYP2B6 protein results in increased metabolism of and results in increased susceptibility to Cyclophosphamide; POR promotes the reaction [CYP2B6 results in increased susceptibility to Cyclophosphamide]; POR protein promotes the reaction [CYP2B6 protein results in increased susceptibility to Cyclophosphamide] Cyclophosphamide results in increased expression of CYP2B10 mRNA CYP2B6 protein results in increased metabolism of Cyclophosphamide CYP2B6 protein results in increased activity of Cyclophosphamide CYP2B6 protein results in increased susceptibility to Cyclophosphamide; CYP2B6 results in increased susceptibility to Cyclophosphamide CYP2B6 protein results in increased hydroxylation of Cyclophosphamide CYP2B6 intron polymorphism affects the hydroxylation of Cyclophosphamide; CYP2B6 promoter polymorphism affects the hydroxylation of Cyclophosphamide
|
CTD |
PMID:9766669 PMID:10919648 PMID:11389073 PMID:11723234 PMID:12498089 PMID:12872138 PMID:15248218 PMID:15769884 PMID:16183265 PMID:16322899 PMID:17041008 PMID:17502835 PMID:18212249 PMID:18633247 PMID:24819615 PMID:25860621 More...
|
|
NCBI chr 1:90,780,468...90,859,852
|
|
G
|
Cyp2c11
|
cytochrome P450, subfamily 2, polypeptide 11
|
increases expression increases activity increases response to substance multiple interactions increases metabolic processing
|
EXP ISO
|
Cyclophosphamide results in increased expression of CYP2C11 mRNA CYP2C18 results in increased activity of Cyclophosphamide CYP2C18 results in increased susceptibility to Cyclophosphamide POR promotes the reaction [CYP2C18 results in increased susceptibility to Cyclophosphamide] CYP2C11 results in increased metabolism of Cyclophosphamide
|
CTD |
PMID:9241661 PMID:9766669 PMID:16019949 PMID:20566340 |
|
NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:246,174,711...246,211,853
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
increases metabolic processing increases expression increases response to substance increases hydroxylation increases activity multiple interactions decreases metabolic processing
|
EXP ISO
|
CYP2C6 results in increased metabolism of Cyclophosphamide Cyclophosphamide results in increased expression of CYP2C29 mRNA CYP2C19 protein results in increased susceptibility to Cyclophosphamide CYP2C19 protein results in increased hydroxylation of Cyclophosphamide CYP2C19 results in increased activity of Cyclophosphamide CYP2C19 protein results in increased metabolism of Cyclophosphamide [CYP2C19 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of 4-hydroxycyclophosphamide; [CYP2C19 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of Acrolein; CYP2C19 protein polymorphism affects the activity of and affects the susceptibility to Cyclophosphamide CYP2C19 gene polymorphism results in decreased metabolism of Cyclophosphamide
|
CTD |
PMID:9241661 PMID:15248218 PMID:16116487 PMID:20566340 PMID:24819615 PMID:30500380 More...
|
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
G
|
Cyp2c79
|
cytochrome P450, family 2, subfamily c, polypeptide 79
|
increases activity
|
ISO
|
CYP2C8 results in increased activity of Cyclophosphamide
|
CTD |
PMID:9241661 |
|
|
|
G
|
Cyp2d4
|
cytochrome P450, family 2, subfamily d, polypeptide 4
|
increases metabolic processing
|
ISO
|
CYP2D6 protein results in increased metabolism of Cyclophosphamide
|
CTD |
PMID:11377097 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837
|
|
G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
increases metabolic processing increases expression
|
EXP
|
CYP2E1 results in increased metabolism of Cyclophosphamide Cyclophosphamide results in increased expression of CYP2E1 protein
|
CTD |
PMID:20566340 PMID:38740238 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases expression increases response to substance increases hydroxylation affects metabolic processing affects response to substance increases metabolic processing multiple interactions
|
EXP ISO
|
Cyclophosphamide results in increased expression of CYP3A2 mRNA; Cyclophosphamide results in increased expression of CYP3A2 protein Cyclophosphamide results in increased expression of CYP3A4 mRNA CYP3A4 protein results in increased susceptibility to Cyclophosphamide CYP3A4 protein results in increased hydroxylation of Cyclophosphamide CYP3A4 protein affects the metabolism of Cyclophosphamide CYP3A4 gene polymorphism affects the susceptibility to Cyclophosphamide CYP3A4 protein results in increased metabolism of Cyclophosphamide [Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [CYP3A4 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of 4-hydroxycyclophosphamide; [CYP3A4 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of Acrolein; CYP3A4 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin]; CYP3A4 protein results in increased metabolism of and results in increased susceptibility to Cyclophosphamide
|
CTD |
PMID:11377097 PMID:16019949 PMID:16087946 PMID:17041008 PMID:18839173 PMID:25860621 PMID:26718876 PMID:30500380 More...
|
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Cyp3a23-3a1
|
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1
|
affects expression decreases expression
|
EXP
|
Cyclophosphamide affects the expression of CYP3A23-3A1 mRNA Cyclophosphamide results in decreased expression of CYP3A23-3A1 mRNA
|
CTD |
PMID:18246545 |
|
NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813
|
|
G
|
Cyp3a9
|
cytochrome P450, family 3, subfamily a, polypeptide 9
|
affects metabolic processing increases expression multiple interactions affects response to substance
|
ISO
|
CYP3A5 protein affects the metabolism of Cyclophosphamide Cyclophosphamide results in increased expression of CYP3A13 mRNA CYP3A5 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] CYP3A5 gene polymorphism affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16087946 PMID:24819615 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154
|
|
G
|
Dcn
|
decorin
|
multiple interactions
|
ISO
|
DCN protein inhibits the reaction [TGFB1 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Cisplatin co-treated with Melphalan co-treated with Thiotepa]]
|
CTD |
PMID:9509296 |
|
NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926
|
|
G
|
Ddb1
|
damage-specific DNA binding protein 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of DDB1 mRNA
|
CTD |
PMID:11056294 |
|
NCBI chr 1:216,677,810...216,703,605
Ensembl chr 1:216,677,810...216,703,596
|
|
G
|
Ddit3
|
DNA-damage inducible transcript 3
|
affects expression increases expression multiple interactions decreases expression
|
EXP ISO
|
Cyclophosphamide affects the expression of DDIT3 mRNA Cyclophosphamide results in increased expression of DDIT3 mRNA; Cyclophosphamide results in increased expression of DDIT3 protein sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 mRNA]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 protein] Cyclophosphamide metabolite results in decreased expression of DDIT3 mRNA
|
CTD |
PMID:18246545 PMID:24356939 PMID:32197949 PMID:38740238 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
G
|
Ddit4
|
DNA-damage-inducible transcript 4
|
affects response to substance
|
ISO
|
DDIT4 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037
|
|
G
|
Deaf1
|
DEAF1 transcription factor
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of DEAF1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 1:205,831,428...205,865,106
Ensembl chr 1:205,831,336...205,865,106
|
|
G
|
Dlc1
|
DLC1 Rho GTPase activating protein
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of DLC1 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr16:61,954,177...62,374,819
Ensembl chr16:61,995,001...62,374,819
|
|
G
|
Dnajb1
|
DnaJ heat shock protein family (Hsp40) member B1
|
affects expression increases expression
|
EXP ISO
|
Cyclophosphamide affects the expression of DNAJB1 mRNA Cyclophosphamide metabolite results in increased expression of DNAJB1 mRNA
|
CTD |
PMID:18246545 PMID:24356939 |
|
NCBI chr19:41,427,453...41,431,141
Ensembl chr19:41,427,453...41,431,416
|
|
G
|
Dnajb4
|
DnaJ heat shock protein family (Hsp40) member B4
|
increases expression
|
ISO
|
Cyclophosphamide metabolite results in increased expression of DNAJB4 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 2:243,790,296...243,819,042
Ensembl chr 2:243,790,297...243,819,042
|
|
G
|
Dnajb6
|
DnaJ heat shock protein family (Hsp40) member B6
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of DNAJB6 protein
|
CTD |
PMID:17475930 |
|
NCBI chr 4:6,010,081...6,232,052
Ensembl chr 4:6,128,070...6,232,005
|
|
G
|
Dnmt1
|
DNA methyltransferase 1
|
multiple interactions decreases expression increases expression decreases methylation
|
ISO
|
Cyclophosphamide promotes the reaction [KDM1A protein results in decreased methylation of and results in decreased degradation of DNMT1 protein]; SGI-1027 promotes the reaction [Cyclophosphamide results in decreased expression of DNMT1 protein] Cyclophosphamide results in increased expression of DNMT1 protein Cyclophosphamide results in decreased methylation of DNMT1 protein
|
CTD |
PMID:22007908 PMID:34658283 |
|
NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:27,716,797...27,763,119
|
|
G
|
Dnmt3b
|
DNA methyltransferase 3 beta
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of DNMT3B protein SGI-1027 promotes the reaction [Cyclophosphamide results in decreased expression of DNMT3B protein]
|
CTD |
PMID:34658283 |
|
NCBI chr 3:162,590,777...162,629,313
Ensembl chr 3:162,604,037...162,629,313
|
|
G
|
Dntt
|
DNA nucleotidylexotransferase
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of DNTT mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 1:249,805,802...249,837,685
Ensembl chr 1:249,805,802...249,837,684
|
|
G
|
Dpf3
|
double PHD fingers 3
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of DPF3 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 6:102,841,403...103,125,558
Ensembl chr 6:108,577,183...108,856,798
|
|
G
|
Dpysl4
|
dihydropyrimidinase-like 4
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of DPYSL4 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 1:193,883,039...193,898,916
Ensembl chr 1:203,311,694...203,328,523
|
|
G
|
Drd1
|
dopamine receptor D1
|
affects binding
|
ISO
|
Cyclophosphamide binds to DRD1 protein
|
CTD |
PMID:11180191 |
|
NCBI chr17:10,545,488...10,550,029
Ensembl chr17:10,545,111...10,567,166
|
|
G
|
Drd2
|
dopamine receptor D2
|
affects binding
|
ISO
|
Cyclophosphamide binds to DRD2 protein
|
CTD |
PMID:11180191 |
|
NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:58,605,403...58,669,339
|
|
G
|
Dusp10
|
dual specificity phosphatase 10
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of DUSP10 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr13:98,145,317...98,183,304
Ensembl chr13:98,145,893...98,183,304
|
|
G
|
Dusp2
|
dual specificity phosphatase 2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of DUSP2 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 3:135,009,636...135,011,821
Ensembl chr 3:135,009,590...135,011,809
|
|
G
|
Dzip1
|
DAZ interacting zinc finger protein 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of DZIP1 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr15:95,956,329...96,009,994
Ensembl chr15:102,363,392...102,417,085
|
|
G
|
E2f3
|
E2F transcription factor 3
|
multiple interactions
|
ISO
|
E2F3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr17:34,810,355...34,887,725
Ensembl chr17:34,809,998...34,887,725
|
|
G
|
Eda2r
|
ectodysplasin A2 receptor
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of EDA2R mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr X:62,224,763...62,269,333
Ensembl chr X:66,236,111...66,280,663
|
|
G
|
Edn1
|
endothelin 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of EDN1 protein
|
CTD |
PMID:17562616 PMID:18548196 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687
|
|
G
|
Ednrb
|
endothelin receptor type B
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of EDNRB mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765
|
|
G
|
Eef2
|
eukaryotic translation elongation factor 2
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of EEF2 mRNA
|
CTD |
PMID:18246545 |
|
NCBI chr 7:9,183,836...9,196,255
Ensembl chr 7:9,183,961...9,189,544
|
|
G
|
Egfr
|
epidermal growth factor receptor
|
multiple interactions
|
ISO
|
EGFR protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with Fluorouracil]
|
CTD |
PMID:15981280 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
|
|
G
|
Egr1
|
early growth response 1
|
increases expression multiple interactions decreases expression
|
ISO EXP
|
Cyclophosphamide results in increased expression of EGR1 mRNA 3-cyanoalanine inhibits the reaction [[N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of EGR1 protein]; [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of EGR1 protein Cyclophosphamide results in increased expression of EGR1 protein Cyclophosphamide results in decreased expression of EGR1 mRNA
|
CTD |
PMID:7498375 PMID:9776515 PMID:21041162 PMID:21527772 PMID:29129814 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843
|
|
G
|
Egr2
|
early growth response 2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of EGR2 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,050,149...21,057,748
|
|
G
|
Egr4
|
early growth response 4
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of EGR4 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 4:119,605,358...119,607,817
Ensembl chr 4:119,605,357...119,608,368
|
|
G
|
Eif1ax
|
eukaryotic translation initiation factor 1A, X-linked
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of EIF1AX mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr X:39,307,320...39,322,023
Ensembl chr X:39,307,137...39,322,021
|
|
G
|
Eif2ak3
|
eukaryotic translation initiation factor 2 alpha kinase 3
|
increases phosphorylation multiple interactions
|
EXP
|
Cyclophosphamide results in increased phosphorylation of EIF2AK3 protein sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased phosphorylation of EIF2AK3 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of EIF2AK3 protein]
|
CTD |
PMID:32197949 |
|
NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268
|
|
G
|
Eif4ebp1
|
eukaryotic translation initiation factor 4E binding protein 1
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of EIF4EBP1 mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874
|
|
G
|
Elovl2
|
ELOVL fatty acid elongase 2
|
affects response to substance
|
ISO
|
ELOVL2 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr17:23,750,350...23,790,601
Ensembl chr17:23,750,350...23,790,601
|
|
G
|
Emp1
|
epithelial membrane protein 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of EMP1 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 4:169,931,537...169,964,366
Ensembl chr 4:169,931,440...169,964,365
|
|
G
|
Emp3
|
epithelial membrane protein 3
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of EMP3 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 1:105,525,086...105,528,370
Ensembl chr 1:105,525,088...105,528,265
|
|
G
|
Epb41l2
|
erythrocyte membrane protein band 4.1-like 2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of EPB41L2 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 1:21,682,336...21,857,106
Ensembl chr 1:21,682,335...21,857,105
|
|
G
|
Ephx1
|
epoxide hydrolase 1
|
affects expression increases expression
|
EXP
|
Cyclophosphamide affects the expression of EPHX1 mRNA Cyclophosphamide results in increased expression of EPHX1 mRNA
|
CTD |
PMID:18246545 |
|
NCBI chr13:95,246,079...95,275,852
Ensembl chr13:95,246,080...95,321,981
|
|
G
|
Epo
|
erythropoietin
|
multiple interactions decreases expression increases response to substance
|
EXP ISO
|
angelicae sinensis extract inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA]; Astragali compound inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA] asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of EPO protein]; CSF2 protein inhibits the reaction [Cyclophosphamide results in decreased expression of EPO protein]; dorsomorphin inhibits the reaction [asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of EPO protein]] EPO protein results in increased susceptibility to Cyclophosphamide
|
CTD |
PMID:11245434 PMID:19627214 PMID:38348709 |
|
NCBI chr12:24,841,285...24,844,725
Ensembl chr12:24,841,285...24,844,725
|
|
G
|
Erap1
|
endoplasmic reticulum aminopeptidase 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ERAP1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 2:5,666,337...5,705,256
Ensembl chr 2:5,666,436...5,740,056
|
|
G
|
Erbb2
|
erb-b2 receptor tyrosine kinase 2
|
multiple interactions
|
ISO
|
ERBB2 affects the susceptibility to [Doxorubicin co-treated with Cyclophosphamide co-treated with docetaxel]; ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with docetaxel]; ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with pirarubicin co-treated with Fluorouracil]; ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]; ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]; ERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin]
|
CTD |
PMID:9816327 PMID:15834928 PMID:15940066 PMID:16446318 PMID:16682728 PMID:17010609 More...
|
|
NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481
|
|
G
|
Erbb4
|
erb-b2 receptor tyrosine kinase 4
|
multiple interactions
|
ISO
|
ERBB4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr 9:76,973,386...78,045,633
Ensembl chr 9:76,973,227...78,045,772
|
|
G
|
Ercc1
|
ERCC excision repair 1, endonuclease non-catalytic subunit
|
affects expression
|
EXP
|
Cyclophosphamide affects the expression of ERCC1 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 1:88,099,308...88,135,966
Ensembl chr 1:88,118,891...88,139,120
|
|
G
|
Ercc2
|
ERCC excision repair 2, TFIIH core complex helicase subunit
|
affects expression increases expression multiple interactions
|
EXP ISO
|
Cyclophosphamide affects the expression of ERCC2 mRNA Cyclophosphamide results in increased expression of ERCC2 mRNA 5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in increased expression of ERCC2 mRNA]
|
CTD |
PMID:11906922 PMID:30760223 |
|
NCBI chr 1:88,161,342...88,175,102
Ensembl chr 1:88,160,988...88,175,102
|
|
G
|
Erg
|
ETS transcription factor ERG
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of ERG mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr11:48,148,149...48,370,472
Ensembl chr11:48,148,153...48,370,688
|
|
G
|
Ern1
|
endoplasmic reticulum to nucleus signaling 1
|
increases phosphorylation multiple interactions
|
EXP
|
Cyclophosphamide results in increased phosphorylation of ERN1 protein sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased phosphorylation of ERN1 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of ERN1 protein]
|
CTD |
PMID:32197949 PMID:38740238 |
|
NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791
|
|
G
|
Esr1
|
estrogen receptor 1
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] results in increased expression of ESR1 mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354
|
|
G
|
Esr2
|
estrogen receptor 2
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] results in increased expression of ESR2 mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709
|
|
G
|
Esrra
|
estrogen related receptor, alpha
|
decreases expression increases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ESRRA mRNA Cyclophosphamide results in increased expression of ESRRA mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 1:213,533,309...213,543,432
Ensembl chr 1:213,533,310...213,543,811
|
|
G
|
Evi2a
|
ecotropic viral integration site 2A
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of EVI2A mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr10:64,983,727...64,987,627
Ensembl chr10:64,983,705...64,999,516
|
|
G
|
F2rl1
|
F2R like trypsin receptor 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of F2RL1 protein
|
CTD |
PMID:15643279 |
|
NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:28,507,003...28,519,954
|
|
G
|
F2rl2
|
coagulation factor II (thrombin) receptor-like 2
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of F2RL2 protein
|
CTD |
PMID:15643279 |
|
NCBI chr 2:28,706,766...28,711,808
Ensembl chr 2:28,706,501...28,712,473
|
|
G
|
F2rl3
|
F2R like thrombin or trypsin receptor 3
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of F2RL3 protein
|
CTD |
PMID:15643279 |
|
NCBI chr16:17,151,516...17,153,509
Ensembl chr16:17,151,516...17,153,823
|
|
G
|
F3
|
coagulation factor III, tissue factor
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of F3 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369
|
|
G
|
Fam107b
|
family with sequence similarity 107, member B
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of FAM107B mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr17:74,478,608...74,685,027
Ensembl chr17:79,387,795...79,594,288
|
|
G
|
Fam234b
|
family with sequence similarity 234, member B
|
multiple interactions
|
ISO
|
FAM234B mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr 4:168,048,313...168,124,017
Ensembl chr 4:169,779,737...169,828,678
|
|
G
|
Fas
|
Fas cell surface death receptor
|
multiple interactions decreases expression increases expression
|
ISO EXP
|
[Cyclophosphamide co-treated with cacalol] results in decreased expression of FAS protein; [Cyclophosphamide co-treated with NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt] results in increased expression of FAS Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of FAS mRNA] Cyclophosphamide metabolite results in decreased expression of FAS mRNA Cyclophosphamide results in increased expression of FAS mRNA; Cyclophosphamide results in increased expression of FAS protein
|
CTD |
PMID:10393266 PMID:16166447 PMID:20665104 PMID:24356939 PMID:25446862 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104
|
|
G
|
Faslg
|
Fas ligand
|
multiple interactions
|
ISO
|
[Cyclophosphamide co-treated with NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt] results in increased expression of FASLG
|
CTD |
PMID:16166447 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503
|
|
G
|
Fau
|
FAU ubiquitin like and ribosomal protein S30 fusion
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of FAU mRNA
|
CTD |
PMID:11599041 |
|
NCBI chr 1:212,779,429...212,781,028
Ensembl chr 1:212,779,473...212,781,026 Ensembl chr 1:212,779,473...212,781,026
|
|
G
|
Fbxo40
|
F-box protein 40
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of FBXO40 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr11:63,794,452...63,812,697
Ensembl chr11:77,300,013...77,318,086
|
|
G
|
Fbxw7
|
F-box and WD repeat domain containing 7
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of FBXW7 mRNA
|
CTD |
PMID:29445054 |
|
NCBI chr 2:172,447,738...172,609,591
Ensembl chr 2:172,447,738...172,609,591
|
|
G
|
Fcer1g
|
Fc epsilon receptor Ig
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of FCER1G mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr13:86,181,908...86,186,766
Ensembl chr13:86,181,908...86,186,859
|
|
G
|
Fcgr2a
|
Fc gamma receptor 2A
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of FCGR3 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr13:85,813,516...85,830,269
Ensembl chr13:85,855,437...85,864,394 Ensembl chr13:85,855,437...85,864,394
|
|
G
|
Fcgrt
|
Fc gamma receptor and transporter
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of FCGRT mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 1:95,574,436...95,584,171
Ensembl chr 1:104,710,909...104,720,532
|
|
G
|
Fhl1
|
four and a half LIM domains 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of FHL1 mRNA
|
CTD |
PMID:23558518 |
|
NCBI chr X:139,592,794...139,652,290
Ensembl chr X:139,592,604...139,652,282
|
|
G
|
Fkbp1b
|
FKBP prolyl isomerase 1B
|
affects response to substance
|
ISO
|
FKBP1B protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 6:33,551,583...33,570,055
Ensembl chr 6:33,558,517...33,568,129
|
|
G
|
Fkbpl
|
FKBP prolyl isomerase like
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of FKBPL mRNA
|
CTD |
PMID:14503796 |
|
NCBI chr20:4,104,457...4,105,927
Ensembl chr20:4,104,019...4,105,615
|
|
G
|
Flnc
|
filamin C
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of FLNC mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 4:58,999,445...59,027,240
Ensembl chr 4:58,999,547...59,027,240
|
|
G
|
Flt3lg
|
Fms related receptor tyrosine kinase 3 ligand
|
affects expression
|
ISO
|
Cyclophosphamide affects the expression of FLT3L mRNA
|
CTD |
PMID:12624490 |
|
NCBI chr 1:104,751,518...104,756,925
Ensembl chr 1:104,749,983...104,757,038
|
|
G
|
Fndc3b
|
fibronectin type III domain containing 3B
|
affects response to substance
|
ISO
|
FNDC3B protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 2:112,240,108...112,546,113
Ensembl chr 2:112,243,202...112,546,306
|
|
G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions increases expression
|
ISO EXP
|
Capsaicin inhibits the reaction [Cyclophosphamide results in increased expression of FOS mRNA] Cyclophosphamide results in increased expression of FOS protein alfuzosin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein]; Capsaicin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein]
|
CTD |
PMID:7498375 PMID:8801120 PMID:8808730 PMID:9776515 PMID:10749792 PMID:15099680 PMID:15217452 PMID:17240043 PMID:18093676 More...
|
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
G
|
Foxp3
|
forkhead box P3
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of FOXP3 mRNA; Cyclophosphamide results in decreased expression of FOXP3 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of FOXP3 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of FOXP3 protein]
|
CTD |
PMID:15591121 PMID:32151603 |
|
NCBI chr X:17,580,380...17,601,181
Ensembl chr X:17,580,380...17,595,894
|
|
G
|
Foxp4
|
forkhead box P4
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of FOXP4 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 9:20,556,270...20,612,967
Ensembl chr 9:20,556,270...20,612,967
|
|
G
|
Fpr2
|
formyl peptide receptor 2
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of FPR2 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 1:67,449,637...67,458,272
Ensembl chr 1:67,449,637...67,458,272
|
|
G
|
Fscn1
|
fascin actin-bundling protein 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of FSCN1 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr12:16,710,601...16,723,734
Ensembl chr12:16,710,601...16,723,734
|
|
G
|
Fshb
|
follicle stimulating hormone subunit beta
|
increases expression multiple interactions decreases secretion
|
ISO EXP
|
Cyclophosphamide results in increased expression of FSHB protein Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of FSHB protein]; Melatonin inhibits the reaction [Cyclophosphamide results in increased expression of FSHB protein]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased secretion of FSHB protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased secretion of FSHB protein]
|
CTD |
PMID:6788612 PMID:25446862 PMID:32197949 PMID:32456565 PMID:36154502 PMID:39952379 More...
|
|
NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072
|
|
G
|
Fshr
|
follicle stimulating hormone receptor
|
multiple interactions decreases expression
|
ISO
|
coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of FSHR mRNA]
|
CTD |
PMID:31557371 |
|
NCBI chr 6:10,952,329...11,160,288
Ensembl chr 6:10,952,329...11,160,288
|
|
G
|
Fth1
|
ferritin heavy chain 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of FTH1 protein
|
CTD |
PMID:32129080 |
|
NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:216,051,998...216,055,214
|
|
G
|
Ftl1
|
ferritin light chain 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of FTL1 protein
|
CTD |
PMID:32129080 |
|
NCBI chr 1:105,072,858...105,074,705
Ensembl chr X:45,399,355...45,399,915 Ensembl chr 2:45,399,355...45,399,915 Ensembl chr 1:45,399,355...45,399,915
|
|
G
|
Fyn
|
FYN proto-oncogene, Src family tyrosine kinase
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of FYN mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr20:44,322,635...44,514,498
Ensembl chr20:44,322,361...44,515,479
|
|
G
|
G3bp1
|
G3BP stress granule assembly factor 1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of G3BP1 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr10:40,087,533...40,120,931
Ensembl chr10:40,087,533...40,120,931
|
|
G
|
G6pc2
|
glucose-6-phosphatase catalytic subunit 2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of G6PC2 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 3:74,404,976...74,413,391
|
|
G
|
Gadd45a
|
growth arrest and DNA-damage-inducible, alpha
|
increases expression affects expression
|
EXP ISO
|
Cyclophosphamide results in increased expression of GADD45A mRNA Cyclophosphamide affects the expression of GADD45A mRNA
|
CTD |
PMID:18246545 PMID:29445054 |
|
NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807
|
|
G
|
Gal
|
galanin and GMAP prepropeptide
|
affects expression increases expression
|
EXP ISO
|
Cyclophosphamide affects the expression of GAL mRNA; Cyclophosphamide affects the expression of GAL protein Cyclophosphamide results in increased expression of GAL mRNA
|
CTD |
PMID:16491427 PMID:17335920 PMID:18563302 |
|
NCBI chr 1:210,079,709...210,084,572
Ensembl chr 1:210,079,702...210,084,229
|
|
G
|
Galc
|
galactosylceramidase
|
affects response to substance
|
ISO
|
GALC protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 6:123,182,636...123,252,024
Ensembl chr 6:123,182,643...123,245,578
|
|
G
|
Gamt
|
guanidinoacetate N-methyltransferase
|
multiple interactions
|
ISO
|
GAMT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr 7:10,099,267...10,102,083
Ensembl chr 7:10,098,571...10,102,083
|
|
G
|
Gap43
|
growth associated protein 43
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of GAP43 protein
|
CTD |
PMID:9486479 PMID:10536274 |
|
NCBI chr11:71,882,131...71,975,799
Ensembl chr11:71,882,131...71,975,797
|
|
G
|
Gas2
|
growth arrest-specific 2
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of GAS2 protein
|
CTD |
PMID:17475930 |
|
NCBI chr 1:101,452,361...101,582,619
Ensembl chr 1:110,717,312...110,718,541
|
|
G
|
Gata3
|
GATA binding protein 3
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of GATA3 mRNA; Cyclophosphamide results in decreased expression of GATA3 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of GATA3 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of GATA3 protein]
|
CTD |
PMID:21041162 PMID:32151603 |
|
NCBI chr17:73,544,234...73,575,670
Ensembl chr17:73,553,548...73,575,670
|
|
G
|
Gbp1
|
guanylate binding protein 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of GBP1 mRNA
|
CTD |
PMID:21621594 |
|
NCBI chr 2:234,071,366...234,106,012
Ensembl chr 2:234,190,708...234,206,802 Ensembl chr 2:234,190,708...234,206,802
|
|
G
|
Gbp4
|
guanylate binding protein 4
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of GBP3 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 2:233,978,163...233,992,124
Ensembl chr 2:233,978,486...233,992,120
|
|
G
|
Gclc
|
glutamate-cysteine ligase, catalytic subunit
|
multiple interactions decreases expression
|
ISO
|
Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of GCLC protein] Cyclophosphamide results in decreased expression of GCLC mRNA; Cyclophosphamide results in decreased expression of GCLC protein
|
CTD |
PMID:27633142 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893
|
|
G
|
Gclm
|
glutamate cysteine ligase, modifier subunit
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of GCLM mRNA TRPM2 protein affects the reaction [Cyclophosphamide results in decreased expression of GCLM mRNA]
|
CTD |
PMID:39952379 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003
|
|
G
|
Gdf9
|
growth differentiation factor 9
|
multiple interactions decreases expression
|
ISO
|
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GDF9 mRNA]
|
CTD |
PMID:37863343 |
|
NCBI chr10:38,090,021...38,100,801
Ensembl chr10:38,089,878...38,100,797
|
|
G
|
Gdnf
|
glial cell derived neurotrophic factor
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of GDNF mRNA
|
CTD |
PMID:10683293 |
|
NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:58,621,327...58,647,240
|
|
G
|
Gem
|
GTP binding protein overexpressed in skeletal muscle
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of GEM mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 5:25,214,309...25,225,222
Ensembl chr 5:30,011,592...30,022,542
|
|
G
|
Gfi1
|
growth factor independent 1 transcriptional repressor
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of GFI1 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr14:2,185,489...2,204,191
Ensembl chr14:2,187,286...2,196,730
|
|
G
|
Gfra1
|
GDNF family receptor alpha 1
|
multiple interactions
|
ISO
|
GFRA1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr 1:267,325,297...267,557,037
Ensembl chr 1:267,326,817...267,556,501
|
|
G
|
Gimap4
|
GTPase, IMAP family member 4
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of GIMAP4 mRNA
|
CTD |
PMID:27466211 |
|
NCBI chr 4:77,636,401...77,643,315
Ensembl chr 4:78,967,297...78,974,202
|
|
G
|
Gja1
|
gap junction protein, alpha 1
|
affects expression decreases expression multiple interactions
|
EXP ISO
|
Cyclophosphamide affects the expression of GJA1 mRNA Cyclophosphamide results in decreased expression of GJA1 mRNA Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GJA1 mRNA]
|
CTD |
PMID:10859244 PMID:37863343 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689
|
|
G
|
Gja4
|
gap junction protein, alpha 4
|
multiple interactions decreases expression
|
ISO
|
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GJA4 mRNA]
|
CTD |
PMID:37863343 |
|
NCBI chr 5:144,917,791...144,920,324
Ensembl chr 5:144,914,147...144,921,216
|
|
G
|
Gjb1
|
gap junction protein, beta 1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of GJB1 mRNA
|
CTD |
PMID:21621594 |
|
NCBI chr X:70,541,845...70,549,776
Ensembl chr X:70,541,862...70,549,843
|
|
G
|
Glis1
|
GLIS family zinc finger 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of GLIS1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 5:122,222,155...122,412,141
Ensembl chr 5:127,451,293...127,640,928
|
|
G
|
Glod4
|
glyoxalase domain containing 4
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of GLOD4 mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr10:61,077,535...61,095,876
|
|
G
|
Glrb
|
glycine receptor, beta
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of GLRB mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 2:168,432,736...168,505,614
Ensembl chr 2:168,432,736...168,505,614
|
|
G
|
Gls
|
glutaminase
|
increases expression affects response to substance
|
ISO
|
Cyclophosphamide results in increased expression of GLS mRNA GLS protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 PMID:21527772 |
|
NCBI chr 9:56,836,584...56,908,861
Ensembl chr 9:56,836,584...56,908,861
|
|
G
|
Gng12
|
G protein subunit gamma 12
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of GNG12 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 4:97,340,830...97,464,422
Ensembl chr 4:97,340,472...97,464,476
|
|
G
|
Gnrh1
|
gonadotropin releasing hormone 1
|
decreases secretion multiple interactions
|
ISO
|
Cyclophosphamide results in decreased secretion of GNRH1 protein Flavonoids inhibits the reaction [Cyclophosphamide results in decreased secretion of GNRH1 protein]
|
CTD |
PMID:39239657 |
|
NCBI chr15:46,147,878...46,152,086
Ensembl chr15:46,148,301...46,148,977 Ensembl chr15:46,148,301...46,148,977
|
|
G
|
Gpatch8
|
G patch domain containing 8
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of GPATCH8 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr10:87,432,020...87,512,594
Ensembl chr10:87,932,174...88,012,523
|
|
G
|
Gpr137b
|
G protein-coupled receptor 137B
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of GPR137B mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr17:92,987,792...93,026,003
Ensembl chr17:92,942,559...93,025,911
|
|
G
|
Gpr18
|
G protein-coupled receptor 18
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of GPR18 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr15:105,404,062...105,407,812
Ensembl chr15:105,404,077...105,408,836
|
|
G
|
Gpr20
|
G protein-coupled receptor 20
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of GPR20 mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr 7:105,601,761...105,611,959
Ensembl chr 7:107,490,713...107,500,966
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
increases expression affects activity increases activity multiple interactions
|
EXP ISO
|
Cyclophosphamide results in increased expression of GPT protein Cyclophosphamide affects the activity of GPT protein Cyclophosphamide results in increased activity of GPT protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein] naringin affects the reaction [Cyclophosphamide affects the activity of GPT protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein]; Rutin inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein]; Vitamin E inhibits the reaction [Cyclophosphamide results in increased expression of GPT protein]
|
CTD |
PMID:25753322 PMID:25779342 PMID:29753871 PMID:30506662 PMID:33992719 PMID:34748891 More...
|
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
Gpt2
|
glutamic--pyruvic transaminase 2
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of GPT2 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr19:37,700,023...37,734,551
Ensembl chr19:37,691,901...37,733,917
|
|
G
|
Gpx1
|
glutathione peroxidase 1
|
decreases expression decreases activity multiple interactions
|
ISO EXP
|
Cyclophosphamide results in decreased expression of GPX1 mRNA Cyclophosphamide results in decreased activity of GPX1 protein Quercetin inhibits the reaction [Cyclophosphamide results in decreased activity of GPX1 protein] Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of GPX1 mRNA]
|
CTD |
PMID:23542512 PMID:35906875 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581
|
|
G
|
Gpx3
|
glutathione peroxidase 3
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of GPX3 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr10:39,529,335...39,537,406
Ensembl chr10:39,529,448...39,537,405
|
|
G
|
Gpx4
|
glutathione peroxidase 4
|
increases expression multiple interactions decreases expression
|
ISO
|
Cyclophosphamide results in increased expression of GPX4 protein Cyclophosphamide promotes the reaction [Antimony results in decreased expression of and results in increased degradation of GPX4 protein] Cyclophosphamide results in decreased expression of GPX4 protein Dexrazoxane inhibits the reaction [Cyclophosphamide results in decreased expression of GPX4 protein]
|
CTD |
PMID:17475930 PMID:37690746 PMID:38097005 |
|
NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629
|
|
G
|
Gsk3b
|
glycogen synthase kinase 3 beta
|
decreases phosphorylation multiple interactions
|
EXP
|
Cyclophosphamide results in decreased phosphorylation of GSK3B protein coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased phosphorylation of GSK3B protein]
|
CTD |
PMID:39209270 |
|
NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
multiple interactions decreases activity
|
ISO EXP
|
[[Cyclophosphamide co-treated with Cisplatin co-treated with Carmustine] results in decreased activity of GSR protein] which results in increased abundance of Glutathione Disulfide; [Cyclophosphamide co-treated with Cisplatin co-treated with Carmustine] results in decreased activity of GSR protein; Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein] herbacetin inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein]; naringin inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Rutin inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein]
|
CTD |
PMID:12114195 PMID:21772021 PMID:23542512 PMID:25446862 PMID:25753322 PMID:33992719 PMID:36198566 More...
|
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
|
|
G
|
Gsta1
|
glutathione S-transferase alpha 1
|
multiple interactions decreases expression
|
ISO EXP
|
GSTA1 protein affects the metabolism of [Cyclophosphamide metabolite co-treated with Glutathione] Cyclophosphamide results in decreased expression of GSTA1 protein
|
CTD |
PMID:12516103 PMID:15928459 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528
|
|
G
|
Gstm1
|
glutathione S-transferase mu 1
|
multiple interactions
|
ISO
|
[GSTM1 protein co-treated with CYP2C9 protein] results in increased susceptibility to [Busulfan co-treated with Cyclophosphamide]; GSTM1 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin]
|
CTD |
PMID:16087946 PMID:28744217 |
|
NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:198,338,008...198,343,569
|
|
G
|
Gstm2
|
glutathione S-transferase mu 2
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of GSTM2 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 2:198,312,179...198,316,962
|
|
G
|
Gstp1
|
glutathione S-transferase pi 1
|
multiple interactions decreases response to substance affects response to substance increases expression
|
ISO EXP
|
GSTP1 gene SNP results in increased susceptibility to [Carmustine co-treated with Doxorubicin co-treated with Cyclophosphamide co-treated with Melphalan] GSTP1 protein results in decreased susceptibility to Cyclophosphamide GSTP1 protein affects the susceptibility to Cyclophosphamide GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]] Cyclophosphamide results in increased expression of GSTP1 mRNA; Cyclophosphamide results in increased expression of GSTP1 protein
|
CTD |
PMID:10954901 PMID:12791655 PMID:16141653 PMID:16242832 PMID:19696094 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705
|
|
G
|
Gtf2b
|
general transcription factor IIB
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of GTF2B mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 2:234,427,734...234,446,043
Ensembl chr 2:234,427,637...234,446,049
|
|
G
|
Gtf3c1
|
general transcription factor IIIC subunit 1
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of GTF3C1 mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr 1:189,634,645...189,700,848
Ensembl chr 1:189,634,645...189,700,995
|
|
G
|
Gusb
|
glucuronidase, beta
|
decreases expression increases activity multiple interactions
|
EXP
|
Cyclophosphamide results in decreased expression of GUSB protein Cyclophosphamide results in increased activity of GUSB protein Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of GUSB protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of GUSB protein]
|
CTD |
PMID:17686619 PMID:25451569 |
|
NCBI chr12:32,337,281...32,350,838
Ensembl chr12:32,334,075...32,363,024
|
|
G
|
Gzma
|
granzyme A
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of GZMA mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 2:46,473,763...46,485,696
Ensembl chr 2:46,473,763...46,485,696
|
|
G
|
Gzmb
|
granzyme B
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of GZMB mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr15:34,459,007...34,462,469
Ensembl chr15:34,459,007...34,462,469
|
|
G
|
H2ax
|
H2A.X variant histone
|
increases phosphorylation increases expression multiple interactions
|
ISO EXP
|
Cyclophosphamide results in increased phosphorylation of H2AX protein Cyclophosphamide results in increased expression of H2AX protein Dexrazoxane inhibits the reaction [Cyclophosphamide results in increased expression of H2AX protein]; TRPM2 protein affects the reaction [Cyclophosphamide results in increased expression of H2AX protein]
|
CTD |
PMID:32482060 PMID:33211169 PMID:34510228 PMID:37690746 PMID:39952379 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Hamp
|
hepcidin antimicrobial peptide
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of HAMP mRNA
|
CTD |
PMID:32129080 |
|
NCBI chr 1:95,298,332...95,300,271
Ensembl chr 1:95,298,307...95,300,297
|
|
G
|
Has2
|
hyaluronan synthase 2
|
multiple interactions decreases expression
|
ISO
|
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of HAS2 mRNA]
|
CTD |
PMID:37863343 |
|
NCBI chr 7:90,002,929...90,028,933
Ensembl chr 7:90,002,929...90,018,535
|
|
G
|
Havcr1
|
hepatitis A virus cellular receptor 1
|
increases expression multiple interactions
|
EXP
|
Cyclophosphamide results in increased expression of HAVCR1 protein herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of HAVCR1 protein]
|
CTD |
PMID:36198566 |
|
NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268
|
|
G
|
Hbegf
|
heparin-binding EGF-like growth factor
|
multiple interactions decreases expression
|
EXP
|
O-1602 compound inhibits the reaction [Cyclophosphamide results in decreased expression of HBEGF protein]
|
CTD |
PMID:32615180 |
|
NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220
|
|
G
|
Hcrt
|
hypocretin neuropeptide precursor
|
affects localization decreases expression
|
EXP
|
Cyclophosphamide affects the localization of HCRT protein Cyclophosphamide results in decreased expression of HCRT mRNA
|
CTD |
PMID:17881193 PMID:19666069 |
|
NCBI chr10:86,190,289...86,191,524
Ensembl chr10:86,189,775...86,191,524
|
|
G
|
Hes1
|
hes family bHLH transcription factor 1
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of HES1 protein SGI-1027 promotes the reaction [Cyclophosphamide results in decreased expression of HES1 protein]; Valproic Acid inhibits the reaction [Cyclophosphamide results in decreased expression of HES1 protein]
|
CTD |
PMID:34658283 |
|
NCBI chr11:84,210,632...84,213,045
Ensembl chr11:84,210,633...84,213,061
|
|
G
|
Hes5
|
hes family bHLH transcription factor 5
|
multiple interactions
|
ISO
|
PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of HES5 protein]
|
CTD |
PMID:34658283 |
|
NCBI chr 5:170,804,511...170,807,988
Ensembl chr 5:170,803,940...170,806,021
|
|
G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of HIF1A mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323
|
|
G
|
Hinfp
|
histone H4 transcription factor
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of HINFP mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 8:53,525,576...53,541,101
Ensembl chr 8:53,527,236...53,540,555
|
|
G
|
Hm13
|
histocompatibility minor 13
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of H13 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 3:141,145,792...141,183,557
Ensembl chr 3:161,606,052...161,644,805
|
|
G
|
Hmgb1
|
high mobility group box 1
|
increases expression
|
EXP
|
[doxorubicin cotreated with cyclophosphamide] increased expression of Hmgb1 protein in prefrontal cortex and hippocampus
|
RGD |
PMID:36708885 |
RGD:597621662 |
NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327 Ensembl chr12:39,039,050...39,041,327
|
|
G
|
Hmgcs1
|
3-hydroxy-3-methylglutaryl-CoA synthase 1
|
increases expression
|
ISO
|
Cyclophosphamide metabolite results in increased expression of HMGCS1 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:53,382,643...53,399,802
|
|
G
|
Hmgcs2
|
3-hydroxy-3-methylglutaryl-CoA synthase 2
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of HMGCS2 protein
|
CTD |
PMID:15928459 |
|
NCBI chr 2:188,564,348...188,590,872
Ensembl chr 2:188,547,767...188,592,242
|
|
G
|
Hmox1
|
heme oxygenase 1
|
affects expression multiple interactions decreases expression increases expression
|
EXP ISO
|
Cyclophosphamide affects the expression of HMOX1 mRNA TRPM2 protein affects the reaction [Cyclophosphamide results in decreased expression of HMOX1 mRNA] Cyclophosphamide results in decreased expression of HMOX1 mRNA; Cyclophosphamide results in decreased expression of HMOX1 protein [astaxanthine co-treated with Cyclophosphamide] results in increased expression of HMOX1 protein; Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 mRNA]; Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein]; Hemin inhibits the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein] Cyclophosphamide results in increased expression of HMOX1 mRNA; Cyclophosphamide results in increased expression of HMOX1 protein
|
CTD |
PMID:11906922 PMID:17979934 PMID:18206168 PMID:18246545 PMID:19952508 PMID:20038455 PMID:20433640 PMID:32197949 PMID:32456565 PMID:37419146 PMID:39952379 More...
|
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hmox2
|
heme oxygenase 2
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of HMOX2 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr10:11,303,512...11,337,640
Ensembl chr10:11,303,512...11,318,800
|
|
G
|
Hnrnpk
|
heterogeneous nuclear ribonucleoprotein K
|
increases expression
|
ISO EXP
|
Cyclophosphamide results in increased expression of HNRNPK protein Cyclophosphamide results in increased expression of HNRNPK mRNA
|
CTD |
PMID:11599041 PMID:17475930 |
|
NCBI chr17:6,269,302...6,280,429
Ensembl chr17:6,268,385...6,280,565
|
|
G
|
Hoxa1
|
homeobox A1
|
affects response to substance
|
ISO
|
HOXA1 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 4:82,586,505...82,589,209
Ensembl chr 4:82,586,505...82,589,209
|
|
G
|
Hprt1
|
hypoxanthine phosphoribosyltransferase 1
|
increases mutagenesis
|
ISO EXP
|
Cyclophosphamide results in increased mutagenesis of HPRT1 gene
|
CTD |
PMID:17116724 PMID:23677247 |
|
NCBI chr X:137,655,744...137,687,718
Ensembl chr X:137,655,680...137,687,712
|
|
G
|
Hsp90aa1
|
heat shock protein 90 alpha family class A member 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of HSP90AA1 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499
|
|
G
|
Hsp90ab1
|
heat shock protein 90 alpha family class B member 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of HSP90AB1 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:22,931,070...22,935,926
|
|
G
|
Hsp90b1
|
heat shock protein 90 beta family member 1
|
decreases expression increases expression
|
EXP
|
Cyclophosphamide results in decreased expression of HSP90B1 mRNA Cyclophosphamide results in increased expression of HSP90B1 mRNA
|
CTD |
PMID:11599041 PMID:11906922 |
|
NCBI chr 7:22,997,962...23,012,293
Ensembl chr 7:22,997,962...23,012,293
|
|
G
|
Hspa1a
|
heat shock protein family A (Hsp70) member 1A
|
affects expression increases expression
|
EXP ISO
|
Cyclophosphamide affects the expression of HSPA1A mRNA Cyclophosphamide results in increased expression of HSPA1A mRNA; Cyclophosphamide results in increased expression of HSPA1A protein
|
CTD |
PMID:8917683 PMID:18246545 |
|
NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979
|
|
G
|
Hspa1b
|
heat shock protein family A (Hsp70) member 1B
|
affects expression increases expression decreases expression
|
EXP ISO
|
Cyclophosphamide affects the expression of HSPA1B mRNA Cyclophosphamide metabolite results in increased expression of HSPA1B mRNA Cyclophosphamide results in decreased expression of HSPA1B mRNA
|
CTD |
PMID:16141653 PMID:18246545 PMID:24356939 |
|
NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,855,780...3,877,979
|
|
G
|
Hspa2
|
heat shock protein family A (Hsp70) member 2
|
affects response to substance increases expression
|
ISO EXP
|
HSPA2 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of HSPA2 mRNA; Cyclophosphamide results in increased expression of HSPA2 protein
|
CTD |
PMID:11599041 PMID:15928459 PMID:16217747 |
|
NCBI chr 6:100,864,172...100,866,946
Ensembl chr 6:100,864,553...100,867,133
|
|
G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
decreases expression increases expression
|
EXP ISO
|
Cyclophosphamide results in decreased expression of HSPA5 mRNA Cyclophosphamide results in increased expression of HSPA5 protein Cyclophosphamide metabolite results in increased expression of HSPA5 mRNA
|
CTD |
PMID:11906922 PMID:24356939 PMID:38740238 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
|
|
G
|
Hspa8
|
heat shock protein family A (Hsp70) member 8
|
affects response to substance
|
ISO
|
HSPA8 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:50,080,199...50,084,372
|
|
G
|
Hspa9
|
heat shock protein family A (Hsp70) member 9
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of HSPA9 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr18:26,810,004...26,832,958
Ensembl chr18:26,804,774...26,828,398
|
|
G
|
Hspb1
|
heat shock protein family B (small) member 1
|
decreases expression increases expression
|
EXP
|
Cyclophosphamide results in decreased expression of HSPB1 mRNA Cyclophosphamide results in increased expression of HSPB1 mRNA
|
CTD |
PMID:11599041 PMID:11906922 PMID:18246545 |
|
NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301
|
|
G
|
Hspd1
|
heat shock protein family D (Hsp60) member 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of HSPD1 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:64,073,611...64,084,037
|
|
G
|
Hspe1
|
heat shock protein family E (Hsp10) member 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of HSPE1 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 9:64,084,327...64,087,415
Ensembl chr 9:64,085,068...64,087,502
|
|
G
|
Hsph1
|
heat shock protein family H (Hsp110) member 1
|
increases expression
|
ISO
|
Cyclophosphamide metabolite results in increased expression of HSPH1 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891
|
|
G
|
Hyls1
|
HYLS1, centriolar and ciliogenesis associated
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of HYLS1 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 8:42,170,505...42,179,573
Ensembl chr 8:42,168,546...42,179,725
|
|
G
|
Hyou1
|
hypoxia up-regulated 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of HYOU1 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 8:53,602,882...53,614,998
Ensembl chr 8:53,602,604...53,614,997
|
|
G
|
Ica1
|
islet cell autoantigen 1
|
affects response to substance
|
ISO
|
ICA1 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:11751995 |
|
NCBI chr 4:36,656,475...36,804,705
Ensembl chr 4:37,622,759...37,770,569
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
affects response to substance multiple interactions
|
ISO
|
ICAM1 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide inhibits the reaction [Paraquat results in increased expression of ICAM1 mRNA]
|
CTD |
PMID:11591119 PMID:36031164 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Id2
|
inhibitor of DNA binding 2
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of ID2 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 6:47,469,162...47,470,995
Ensembl chr 6:47,457,554...47,472,961
|
|
G
|
Idi1
|
isopentenyl-diphosphate delta isomerase 1
|
increases expression
|
ISO
|
Cyclophosphamide metabolite results in increased expression of IDI1 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr17:66,539,761...66,547,524
Ensembl chr17:66,539,763...66,547,524
|
|
G
|
Ido1
|
indoleamine 2,3-dioxygenase 1
|
increases expression multiple interactions
|
EXP
|
Cyclophosphamide results in increased expression of IDO1 protein Cyclophosphamide results in increased expression of and results in increased activity of IDO1 protein; Quercetin inhibits the reaction [Cyclophosphamide results in increased activity of IDO1 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of and results in increased activity of IDO1 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of IDO1 protein]
|
CTD |
PMID:34748891 PMID:35906875 |
|
NCBI chr16:74,133,259...74,145,328
Ensembl chr16:74,133,259...74,145,328
|
|
G
|
Ier3
|
immediate early response 3
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of IER3 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377
|
|
G
|
Ier5
|
immediate early response 5
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of IER5 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr13:67,270,134...67,272,226
Ensembl chr13:69,820,451...69,822,543
|
|
G
|
Ifit2
|
interferon-induced protein with tetratricopeptide repeats 2
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of IFIT2 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 1:241,515,735...241,521,799
Ensembl chr 1:241,515,709...241,521,798
|
|
G
|
Ifna1
|
interferon, alpha 1
|
increases expression multiple interactions
|
EXP
|
Cyclophosphamide results in increased expression of IFNA1 mRNA naringin inhibits the reaction [Cyclophosphamide results in increased expression of IFNA1 mRNA]
|
CTD |
PMID:33992719 |
|
NCBI chr 5:108,143,240...108,143,809
Ensembl chr 5:108,143,240...108,143,809
|
|
G
|
Ifng
|
interferon gamma
|
affects expression multiple interactions decreases secretion increases expression decreases expression
|
ISO EXP
|
Cyclophosphamide affects the expression of IFNG mRNA Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of IFNG protein] [Cyclophosphamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA Cyclophosphamide results in decreased secretion of IFNG protein Cyclophosphamide results in increased expression of IFNG mRNA Cyclophosphamide results in decreased expression of IFNG mRNA; Cyclophosphamide results in decreased expression of IFNG protein (4-formyl-9-methoxy-5-methyl-naphtho(2,3-b)furan-3-yl)methyl acetate inhibits the reaction [Cyclophosphamide results in decreased secretion of IFNG protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IFNG mRNA]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IFNG protein]; IFNG protein inhibits the reaction [Cyclophosphamide results in increased abundance of Nitric Oxide]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IFNG mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IFNG protein]
|
CTD |
PMID:10607705 PMID:11006010 PMID:11014644 PMID:15331540 PMID:18848347 PMID:18957084 PMID:21068404 PMID:22842586 PMID:23395935 PMID:29594315 PMID:32151603 PMID:35906875 PMID:37853057 More...
|
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Ifngr1
|
interferon gamma receptor 1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of IFNGR1 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 1:16,152,811...16,171,439
Ensembl chr 1:16,152,879...16,171,437
|
|
G
|
Ifrd1
|
interferon-related developmental regulator 1
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of IFRD1 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 6:62,996,560...63,044,996
Ensembl chr 6:62,996,562...63,016,131
|
|
G
|
Igf1
|
insulin-like growth factor 1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of IGF1 protein
|
CTD |
PMID:39079574 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764
|
|
G
|
Igf2bp3
|
insulin-like growth factor 2 mRNA binding protein 3
|
affects response to substance
|
ISO
|
IGF2BP3 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 4:79,391,367...79,525,923
Ensembl chr 4:79,393,067...79,525,730
|
|
G
|
Igfbp3
|
insulin-like growth factor binding protein 3
|
affects response to substance decreases expression
|
ISO EXP
|
IGFBP3 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in decreased expression of IGFBP3 protein Cyclophosphamide results in decreased expression of IGFBP3 mRNA
|
CTD |
PMID:16141653 PMID:16217747 PMID:39079574 |
|
NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944
|
|
G
|
Igfbp4
|
insulin-like growth factor binding protein 4
|
multiple interactions
|
ISO
|
IGFBP4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr10:84,491,471...84,503,487
Ensembl chr10:84,485,775...84,503,473
|
|
G
|
Igfbp5
|
insulin-like growth factor binding protein 5
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of IGFBP5 mRNA
|
CTD |
PMID:15331540 PMID:20849824 |
|
NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:81,897,616...81,914,390
|
|
G
|
Ighg1
|
immunoglobulin heavy constant gamma 1
|
multiple interactions decreases expression
|
ISO
|
ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IGHG1 protein]
|
CTD |
PMID:37853057 |
|
|
|
G
|
Igkc
|
immunoglobulin kappa constant
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of IGKC mRNA
|
CTD |
PMID:15331540 |
|
|
|
G
|
Il10
|
interleukin 10
|
decreases expression multiple interactions increases expression
|
ISO EXP
|
Cyclophosphamide results in decreased expression of IL10 mRNA [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL10 protein Anthocyanins inhibits the reaction [Cyclophosphamide results in decreased expression of IL10 protein]; Berberine inhibits the reaction [Cyclophosphamide results in decreased expression of IL10 protein]; chrysin inhibits the reaction [Cyclophosphamide results in increased expression of IL10 protein]; Curcumin inhibits the reaction [Cyclophosphamide results in decreased expression of IL10 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of IL10 protein] Cyclophosphamide results in increased expression of IL10 mRNA
|
CTD |
PMID:11014644 PMID:11948286 PMID:18848347 PMID:21068404 PMID:25451569 PMID:31651976 PMID:37263553 PMID:37955270 More...
|
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il12a
|
interleukin 12A
|
multiple interactions decreases expression
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of [IL12A protein binds to IL12B protein]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IL12A protein]
|
CTD |
PMID:29228376 PMID:37853057 |
|
NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997
|
|
G
|
Il12b
|
interleukin 12B
|
affects expression decreases expression multiple interactions increases expression
|
ISO
|
Cyclophosphamide affects the expression of IL12B mRNA Cyclophosphamide results in decreased expression of IL12B protein Cyclophosphamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL12B protein] [Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of [IL12A protein binds to IL12B protein]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IL12B protein] Cyclophosphamide results in increased expression of IL12B mRNA
|
CTD |
PMID:15331540 PMID:18957084 PMID:22842586 PMID:29228376 PMID:36416909 PMID:37853057 More...
|
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194
|
|
G
|
Il13ra1
|
interleukin 13 receptor subunit alpha 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of IL13RA1 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr X:120,213,670...120,294,777
Ensembl chr X:120,214,075...120,274,461
|
|
G
|
Il15
|
interleukin 15
|
multiple interactions decreases secretion
|
ISO
|
(4-formyl-9-methoxy-5-methyl-naphtho(2,3-b)furan-3-yl)methyl acetate inhibits the reaction [Cyclophosphamide results in decreased secretion of IL15 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL15 protein]
|
CTD |
PMID:23395935 |
|
NCBI chr19:42,536,160...42,611,349
Ensembl chr19:42,545,346...42,611,348
|
|
G
|
Il15ra
|
interleukin 15 receptor subunit alpha
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of IL15RA mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr17:71,712,141...71,742,072
Ensembl chr17:71,712,141...71,742,149
|
|
G
|
Il16
|
interleukin 16
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of IL16 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 1:147,026,852...147,127,177
Ensembl chr 1:147,027,097...147,127,023
|
|
G
|
Il17a
|
interleukin 17A
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of IL17A protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL17A protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL17A protein]
|
CTD |
PMID:21880982 PMID:32151603 |
|
NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331
|
|
G
|
Il18
|
interleukin 18
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of IL18 protein
|
CTD |
PMID:18848347 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286
|
|
G
|
Il1a
|
interleukin 1 alpha
|
increases expression multiple interactions affects response to substance
|
ISO EXP
|
Cyclophosphamide results in increased expression of IL1A mRNA [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL1A protein Cyclophosphamide results in increased expression of IL1A protein IL1A promoter polymorphism affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:15331540 PMID:16636934 PMID:18848347 PMID:31651976 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013
|
|
G
|
Il1b
|
interleukin 1 beta
|
increases expression increases expression increases secretion decreases expression increases response to substance multiple interactions
|
ISO EXP
|
Cyclophosphamide results in increased expression of IL1B mRNA; Cyclophosphamide results in increased expression of IL1B protein [doxorubicin cotreated with cyclophosphamide] increased expression of Il1b protein in prefrontal cortex and hippocampus Cyclophosphamide results in increased secretion of IL1B protein Cyclophosphamide results in decreased expression of IL1B protein IL1B protein results in increased susceptibility to Cyclophosphamide [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL1B protein; [Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of IL1B protein; Fenofibrate inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL1B protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL1B protein]; levocabastine inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; VIP protein inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein] allyl sulfide inhibits the reaction [Cyclophosphamide results in increased secretion of IL1B protein]; Anthocyanins inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; chrysin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; crocin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; naringin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]]; O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]
|
CTD RGD |
PMID:8634684 PMID:11948286 PMID:15331540 PMID:18206168 PMID:18483878 PMID:18710439 PMID:18848347 PMID:20126887 PMID:23488790 PMID:23695977 PMID:25451569 PMID:29228376 PMID:29753871 PMID:30506662 PMID:31651976 PMID:31779506 PMID:32151603 PMID:32456565 PMID:32615180 PMID:33992719 PMID:35762198 PMID:36198566 PMID:37263553 PMID:38278497 PMID:36708885 More...
|
RGD:597621662 |
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il1r1
|
interleukin 1 receptor type 1
|
increases expression multiple interactions
|
EXP
|
Cyclophosphamide results in increased expression of IL1R1 mRNA naringin inhibits the reaction [Cyclophosphamide results in increased expression of IL1R1 mRNA]
|
CTD |
PMID:33992719 |
|
NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:50,000,566...50,076,579
|
|
G
|
Il1rn
|
interleukin 1 receptor antagonist
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of IL1RN mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732
|
|
G
|
Il2
|
interleukin 2
|
increases expression decreases expression decreases secretion multiple interactions
|
ISO EXP
|
Cyclophosphamide results in increased expression of IL2 mRNA Cyclophosphamide results in decreased expression of IL2 mRNA Cyclophosphamide results in decreased secretion of IL2 protein (4-formyl-9-methoxy-5-methyl-naphtho(2,3-b)furan-3-yl)methyl acetate inhibits the reaction [Cyclophosphamide results in decreased secretion of IL2 protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL2 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL2 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL2 protein] Cyclophosphamide results in decreased expression of IL2 protein
|
CTD |
PMID:11006010 PMID:11948286 PMID:18848347 PMID:23395935 PMID:32151603 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672
|
|
G
|
Il21
|
interleukin 21
|
multiple interactions decreases expression
|
ISO
|
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL21 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL21 protein]
|
CTD |
PMID:32151603 |
|
NCBI chr 2:122,045,240...122,055,142
Ensembl chr 2:122,045,240...122,055,142
|
|
G
|
Il23a
|
interleukin 23 subunit alpha
|
decreases secretion decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased secretion of IL23A protein Cyclophosphamide results in decreased expression of IL23A protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL23A protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL23A protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL23A protein]
|
CTD |
PMID:23395935 PMID:32151603 |
|
NCBI chr 7:1,306,320...1,308,434
Ensembl chr 7:1,306,320...1,308,434
|
|
G
|
Il3
|
interleukin 3
|
multiple interactions
|
ISO
|
[Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL3 protein
|
CTD |
PMID:31651976 |
|
NCBI chr10:38,906,460...38,908,810
Ensembl chr10:38,906,460...38,908,810
|
|
G
|
Il4
|
interleukin 4
|
decreases expression multiple interactions increases expression
|
ISO EXP
|
Cyclophosphamide results in decreased expression of IL4 mRNA; Cyclophosphamide results in decreased expression of IL4 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL4 protein]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IL4 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL4 protein] Cyclophosphamide results in increased expression of IL4 mRNA; Cyclophosphamide results in increased expression of IL4 protein
|
CTD |
PMID:11006010 PMID:11014644 PMID:11948286 PMID:18848347 PMID:22842586 PMID:32151603 PMID:37853057 More...
|
|
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549
|
|
G
|
Il5
|
interleukin 5
|
increases expression
|
ISO EXP
|
Cyclophosphamide results in increased expression of IL5 mRNA; Cyclophosphamide results in increased expression of IL5 protein
|
CTD |
PMID:11006010 PMID:18848347 |
|
NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions increases secretion increases expression decreases secretion
|
ISO EXP
|
[Cyclophosphamide co-treated with Dexamethasone] inhibits the reaction [Paraquat results in increased expression of IL6 mRNA]; [Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of IL6 protein; Donepezil inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Fenofibrate inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL6 protein]; levocabastine inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Sizofiran promotes the reaction [Cyclophosphamide results in increased expression of IL6 mRNA]; Sizofiran promotes the reaction [Cyclophosphamide results in increased expression of IL6 protein] Cyclophosphamide results in increased secretion of IL6 protein Cyclophosphamide results in increased expression of IL6 mRNA; Cyclophosphamide results in increased expression of IL6 protein allyl sulfide inhibits the reaction [Cyclophosphamide results in increased secretion of IL6 protein]; Berberine inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; chrysin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of IL6 mRNA]; crocin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Curcumin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Silymarin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]
|
CTD |
PMID:10052129 PMID:11948286 PMID:17010015 PMID:18848347 PMID:20126887 PMID:21068404 PMID:22842586 PMID:23395935 PMID:23488790 PMID:23695977 PMID:25753322 PMID:29228376 PMID:30506662 PMID:31779506 PMID:32456565 PMID:32615180 PMID:34748891 PMID:35906875 PMID:36031164 PMID:36198566 PMID:37263553 PMID:37955270 PMID:38278497 PMID:38825044 More...
|
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Ilf3
|
interleukin enhancer binding factor 3
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of ILF3 mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr 8:28,198,454...28,236,634
Ensembl chr 8:28,198,543...28,236,612
|
|
G
|
Irag2
|
inositol 1,4,5-triphosphate receptor associated 2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of IRAG2 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 4:179,819,526...179,874,408
Ensembl chr 4:179,820,188...179,874,406
|
|
G
|
Ireb2
|
iron responsive element binding protein 2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of IREB2 protein
|
CTD |
PMID:32129080 |
|
NCBI chr 8:64,124,152...64,207,702
Ensembl chr 8:64,154,945...64,205,520
|
|
G
|
Irs1
|
insulin receptor substrate 1
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of IRS1 mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:90,993,519...91,054,538
|
|
G
|
Isg15
|
ISG15 ubiquitin-like modifier
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of ISG15 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 5:172,066,369...172,067,656
Ensembl chr 5:172,066,369...172,067,656
|
|
G
|
Isl2
|
ISL LIM homeobox 2
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of ISL2 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 8:64,819,879...64,824,864
Ensembl chr 8:64,819,879...64,824,864
|
|
G
|
Itk
|
IL2-inducible T-cell kinase
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of ITK mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr10:31,254,667...31,316,004
Ensembl chr10:31,254,667...31,316,004
|
|
G
|
Jag1
|
jagged canonical Notch ligand 1
|
multiple interactions decreases expression
|
ISO
|
PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of JAG1 protein]; SGI-1027 promotes the reaction [Cyclophosphamide results in decreased expression of JAG1 protein]; Valproic Acid inhibits the reaction [Cyclophosphamide results in decreased expression of JAG1 protein]
|
CTD |
PMID:34658283 |
|
NCBI chr 3:144,859,453...144,894,883
Ensembl chr 3:144,859,453...144,894,872
|
|
G
|
Jchain
|
joining chain of multimeric IgA and IgM
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of JCHAIN mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr14:19,538,927...19,547,023
Ensembl chr14:19,822,976...19,838,307
|
|
G
|
Kbtbd11
|
kelch repeat and BTB domain containing 11
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of KBTBD11 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr16:74,618,291...74,638,010
Ensembl chr16:81,313,093...81,340,390
|
|
G
|
Kcnq4
|
potassium voltage-gated channel subfamily Q member 4
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of KCNQ4 mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr 5:134,275,145...134,326,992
Ensembl chr 5:139,560,366...139,612,102
|
|
G
|
Kdm1a
|
lysine demethylase 1A
|
multiple interactions increases expression
|
ISO
|
Cyclophosphamide promotes the reaction [KDM1A protein results in decreased methylation of and results in decreased degradation of DNMT1 protein] Cyclophosphamide results in increased expression of KDM1A protein
|
CTD |
PMID:22007908 |
|
NCBI chr 5:154,066,436...154,121,913
Ensembl chr 5:154,065,543...154,121,775
|
|
G
|
Kdm2a
|
lysine demethylase 2A
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of KDM2A mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 1:211,041,859...211,125,749
Ensembl chr 1:211,041,885...211,084,479
|
|
G
|
Kdm4b
|
lysine demethylase 4B
|
multiple interactions
|
ISO
|
KDM4B mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr 9:1,245,885...1,324,384
Ensembl chr 9:1,245,899...1,324,384
|
|
G
|
Kdr
|
kinase insert domain receptor
|
decreases expression increases expression
|
EXP
|
Cyclophosphamide results in decreased expression of KDR mRNA; Cyclophosphamide results in decreased expression of KDR protein Cyclophosphamide results in increased expression of KDR mRNA
|
CTD |
PMID:18632792 PMID:19701751 |
|
NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192
|
|
G
|
Keap1
|
Kelch-like ECH-associated protein 1
|
multiple interactions decreases expression
|
EXP
|
Quercetin inhibits the reaction [Cyclophosphamide results in decreased expression of KEAP1 mRNA]
|
CTD |
PMID:37419146 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042
|
|
G
|
Kif21b
|
kinesin family member 21B
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of KIF21B mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr13:50,127,842...50,177,822
Ensembl chr13:50,127,842...50,177,822
|
|
G
|
Kif3a
|
kinesin family member 3a
|
multiple interactions
|
ISO
|
KIF3A mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr10:38,226,388...38,263,062
Ensembl chr10:38,226,741...38,260,516
|
|
G
|
Kit
|
KIT proto-oncogene receptor tyrosine kinase
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of KIT protein [dorsomorphin co-treated with Cyclophosphamide] results in decreased expression of KIT protein; asperuloside inhibits the reaction [[dorsomorphin co-treated with Cyclophosphamide] results in decreased expression of KIT protein]; asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of KIT protein]; CSF2 protein inhibits the reaction [Cyclophosphamide results in decreased expression of KIT protein]
|
CTD |
PMID:38348709 |
|
NCBI chr14:32,901,615...32,978,895
Ensembl chr14:32,903,033...32,978,812
|
|
G
|
Kitlg
|
KIT ligand
|
affects expression increases expression multiple interactions
|
ISO
|
Cyclophosphamide affects the expression of KITL mRNA Cyclophosphamide results in increased expression of KITL mRNA [Cyclophosphamide co-treated with Sizofiran] results in increased expression of KITL mRNA
|
CTD |
PMID:10052129 PMID:12624490 PMID:12662436 |
|
NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:36,782,638...36,863,793
|
|
G
|
Klf13
|
KLF transcription factor 13
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of KLF13 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 1:117,505,857...117,536,626
Ensembl chr 1:126,916,781...126,961,056
|
|
G
|
Klf2
|
KLF transcription factor 2
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of KLF2 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr16:17,555,136...17,557,768
Ensembl chr16:17,555,136...17,557,768
|
|
G
|
Klf4
|
KLF transcription factor 4
|
decreases response to substance
|
ISO
|
KLF4 results in decreased susceptibility to Cyclophosphamide
|
CTD |
PMID:21833590 |
|
NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:75,074,236...75,078,592
|
|
G
|
Klf5
|
KLF transcription factor 5
|
affects response to substance
|
ISO
|
KLF5 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr15:82,472,081...82,487,267
Ensembl chr15:82,472,065...82,487,262
|
|
G
|
Krcc1
|
lysine-rich coiled-coil 1
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of KRCC1 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 4:104,819,958...104,832,987
Ensembl chr 4:104,819,190...104,855,484
|
|
G
|
Krt8
|
keratin 8
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of KRT8 mRNA
|
CTD |
PMID:21621594 |
|
NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:135,002,894...135,010,403
|
|
G
|
Krt80
|
keratin 80
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of KRT80 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 7:132,463,216...132,485,134
Ensembl chr 7:134,341,956...134,364,211
|
|
G
|
Lama5
|
laminin subunit alpha 5
|
increases expression multiple interactions
|
ISO
|
Cyclophosphamide results in increased expression of LAMA5 mRNA 5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in increased expression of LAMA5 mRNA]
|
CTD |
PMID:30760223 |
|
NCBI chr 3:187,647,904...187,695,974
Ensembl chr 3:187,647,904...187,696,173
|
|
G
|
Lamc2
|
laminin subunit gamma 2
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of LAMC2 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr13:67,835,199...67,894,694
Ensembl chr13:67,835,199...67,895,102
|
|
G
|
Lasp1
|
LIM and SH3 protein 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of LASP1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr10:83,290,820...83,331,989
Ensembl chr10:83,290,865...83,331,988
|
|
G
|
Lat
|
linker for activation of T cells
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of LAT mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 1:190,367,111...190,372,515
Ensembl chr 1:190,367,109...190,372,153
|
|
G
|
Lats1
|
large tumor suppressor kinase 1
|
multiple interactions
|
EXP
|
Cyclophosphamide results in decreased expression of and results in increased phosphorylation of LATS1 protein; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of and results in increased phosphorylation of LATS1 protein]
|
CTD |
PMID:36154502 |
|
NCBI chr 1:3,980,801...4,014,029
Ensembl chr 1:3,980,544...4,014,029
|
|
G
|
Lck
|
LCK proto-oncogene, Src family tyrosine kinase
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of LCK mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 5:147,172,642...147,201,267
Ensembl chr 5:147,172,642...147,201,267
|
|
G
|
Lcn2
|
lipocalin 2
|
increases expression multiple interactions
|
ISO EXP
|
Cyclophosphamide results in increased expression of LCN2 mRNA herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of LCN2 protein] Cyclophosphamide results in increased expression of LCN2 mRNA; Cyclophosphamide results in increased expression of LCN2 protein [Cyclophosphamide co-treated with Mecamylamine] results in increased expression of LCN2 mRNA
|
CTD |
PMID:15331540 PMID:18433785 PMID:20623750 PMID:36198566 |
|
NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:36,078,436...36,081,842
|
|
G
|
Ldhb
|
lactate dehydrogenase B
|
affects response to substance
|
ISO
|
LDHB protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 4:177,159,389...177,177,408
Ensembl chr 4:177,159,392...177,177,408
|
|
G
|
Lef1
|
lymphoid enhancer binding factor 1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of LEF1 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:222,340,704...222,453,929
|
|
G
|
Lgals1
|
galectin 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of LGALS1 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 7:112,365,695...112,368,801
Ensembl chr 7:112,361,850...112,368,800
|
|
G
|
Lgals7
|
galectin 7
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of LGALS7 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 1:84,148,612...84,152,016
Ensembl chr 1:93,273,836...93,279,528
|
|
G
|
Lhb
|
luteinizing hormone subunit beta
|
decreases secretion increases expression multiple interactions
|
EXP ISO
|
Cyclophosphamide results in decreased secretion of LHB protein Cyclophosphamide results in increased expression of LHB protein Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of LHB protein]; Melatonin inhibits the reaction [Cyclophosphamide results in increased expression of LHB protein]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased secretion of LHB protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased secretion of LHB protein]
|
CTD |
PMID:25446862 PMID:32197949 PMID:32456565 PMID:36154502 PMID:39952379 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445
|
|
G
|
Lhx2
|
LIM homeobox 2
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of LHX2 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 3:42,523,345...42,553,646
Ensembl chr 3:42,535,744...42,553,645
|
|
G
|
Limd1
|
LIM domain containing 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of LIMD1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 8:131,998,262...132,045,924
Ensembl chr 8:131,999,770...132,045,922
|
|
G
|
Lmcd1
|
LIM and cysteine-rich domains 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of LMCD1 mRNA
|
CTD |
PMID:23558518 |
|
NCBI chr 4:146,948,993...147,007,878
Ensembl chr 4:146,948,958...147,007,875
|
|
G
|
Lmnb1
|
lamin B1
|
multiple interactions
|
ISO
|
[Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of LMNB1 protein; [Cladribine co-treated with Cyclophosphamide] results in decreased expression of LMNB1 protein
|
CTD |
PMID:15582267 |
|
NCBI chr18:52,373,939...52,413,284
Ensembl chr18:52,373,757...52,413,283
|
|
G
|
Lonrf2
|
LON peptidase N-terminal domain and ring finger 2
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of LONRF2 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 9:41,033,125...41,070,551
Ensembl chr 9:48,530,549...48,570,807
|
|
G
|
Lsg1
|
large 60S subunit nuclear export GTPase 1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of LSG1 mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr11:70,132,919...70,168,526
Ensembl chr11:83,648,772...83,673,878
|
|
G
|
Ltbr
|
lymphotoxin beta receptor
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of LTBR mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 4:159,795,115...159,801,571
Ensembl chr 4:159,795,115...159,807,296
|
|
G
|
Ltf
|
lactotransferrin
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of LTF mRNA
|
CTD |
PMID:21621594 |
|
NCBI chr 8:119,878,344...119,901,189
Ensembl chr 8:119,878,344...119,901,189
|
|
G
|
Ly6a
|
lymphocyte antigen 6 family member A
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of LY6A mRNA
|
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr 7:107,177,191...107,189,436
|
|
G
|
Maged1
|
MAGE family member D1
|
affects response to substance
|
ISO
|
MAGED1 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr X:63,416,464...63,423,167
Ensembl chr X:63,416,466...63,423,112
|
|
G
|
Man2b2
|
mannosidase, alpha, class 2B, member 2
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of MAN2B2 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr14:73,969,079...73,994,089
Ensembl chr14:78,193,725...78,227,724
|
|
G
|
Maoa
|
monoamine oxidase A
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of MAOA mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr X:8,615,239...8,681,372
Ensembl chr X:8,615,239...8,682,631
|
|
G
|
Map1lc3b
|
microtubule-associated protein 1 light chain 3 beta
|
multiple interactions increases lipidation
|
ISO
|
asperuloside promotes the reaction [Cyclophosphamide results in increased lipidation of MAP1LC3B protein]; CSF2 protein promotes the reaction [Cyclophosphamide results in increased lipidation of MAP1LC3B protein]; dorsomorphin inhibits the reaction [asperuloside promotes the reaction [Cyclophosphamide results in increased lipidation of MAP1LC3B protein]]; dorsomorphin inhibits the reaction [Cyclophosphamide results in increased lipidation of MAP1LC3B protein]
|
CTD |
PMID:38348709 |
|
NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358 Ensembl chr16:66,574,407...66,584,358
|
|
G
|
Map3k12
|
mitogen activated protein kinase kinase kinase 12
|
affects expression
|
EXP
|
Cyclophosphamide affects the expression of MAP3K12 mRNA
|
CTD |
PMID:18246545 |
|
NCBI chr 7:133,630,267...133,648,464
Ensembl chr 7:135,508,790...135,515,137
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
increases phosphorylation multiple interactions increases expression
|
ISO EXP
|
Cyclophosphamide results in increased phosphorylation of MAPK1 protein Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] Cyclophosphamide results in increased expression of MAPK1 mRNA; Cyclophosphamide results in increased expression of MAPK1 protein modified form
|
CTD |
PMID:11599041 PMID:15733095 PMID:17110531 PMID:17409261 PMID:19638304 PMID:19696094 PMID:19996110 More...
|
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk14
|
mitogen activated protein kinase 14
|
multiple interactions increases expression decreases expression affects expression
|
ISO EXP
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of MAPK14 mRNA Cyclophosphamide results in increased expression of MAPK14 protein chrysin inhibits the reaction [Cyclophosphamide results in increased expression of MAPK14 protein] Cyclophosphamide results in decreased expression of MAPK14 mRNA Cyclophosphamide affects the expression of MAPK14 mRNA
|
CTD |
PMID:16322899 PMID:18246545 PMID:37263553 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
increases expression multiple interactions increases phosphorylation
|
EXP ISO
|
Cyclophosphamide results in increased expression of MAPK3 protein modified form Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] Cyclophosphamide results in increased phosphorylation of MAPK3 protein
|
CTD |
PMID:15733095 PMID:17110531 PMID:17409261 PMID:19638304 PMID:19696094 PMID:19996110 More...
|
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mapk7
|
mitogen-activated protein kinase 7
|
multiple interactions
|
EXP
|
Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK7 protein
|
CTD |
PMID:17110531 |
|
NCBI chr10:46,669,721...46,675,768
Ensembl chr10:46,669,721...46,675,806
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
increases phosphorylation multiple interactions
|
ISO EXP
|
Cyclophosphamide results in increased phosphorylation of MAPK8 protein Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK8 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK8 protein] GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; GSTP2 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]]; Mesna inhibits the reaction [GSTP2 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]]
|
CTD |
PMID:19696094 PMID:19996110 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Mapk9
|
mitogen-activated protein kinase 9
|
multiple interactions
|
EXP
|
Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK9 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK9 protein]
|
CTD |
PMID:19996110 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228
|
|
G
|
Mapt
|
microtubule-associated protein tau
|
multiple interactions
|
ISO
|
MAPT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108
|
|
G
|
Marchf7
|
membrane associated ring-CH-type finger 7
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of MARCHF7 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 3:44,680,229...44,720,172
Ensembl chr 3:65,090,310...65,128,864
|
|
G
|
Marcks
|
myristoylated alanine rich protein kinase C substrate
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of MARCKS mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr20:42,240,185...42,245,882
Ensembl chr20:42,240,185...42,245,882
|
|
G
|
Mcm5
|
minichromosome maintenance complex component 5
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of MCM5 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr19:13,488,813...13,510,131
Ensembl chr19:13,488,813...13,517,758
|
|
G
|
Mdfic
|
MyoD family inhibitor domain containing
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of MDFIC mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 4:44,938,301...45,018,157
Ensembl chr 4:44,938,480...45,018,156
|
|
G
|
Med13l
|
mediator complex subunit 13L
|
multiple interactions
|
ISO
|
MED13L mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr12:43,468,556...43,665,819
Ensembl chr12:43,468,556...43,665,819
|
|
G
|
Melk
|
maternal embryonic leucine zipper kinase
|
multiple interactions
|
ISO
|
MELK mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr 5:63,336,151...63,396,254
Ensembl chr 5:63,336,106...63,396,247
|
|
G
|
Metrn
|
meteorin, glial cell differentiation regulator
|
multiple interactions
|
ISO
|
METRN mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr10:15,321,200...15,323,218
Ensembl chr10:15,321,200...15,323,642
|
|
G
|
Mfge8
|
milk fat globule EGF and factor V/VIII domain containing
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of MFGE8 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 1:142,474,027...142,489,431
Ensembl chr 1:142,474,028...142,489,431
|
|
G
|
Mgmt
|
O-6-methylguanine-DNA methyltransferase
|
decreases expression decreases response to substance
|
ISO
|
Cyclophosphamide results in decreased expression of MGMT mRNA MGMT protein results in decreased susceptibility to Cyclophosphamide
|
CTD |
PMID:15741301 PMID:17403535 |
|
NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:201,140,661...201,367,482
|
|
G
|
Mgst1
|
microsomal glutathione S-transferase 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of MGST1 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 4:172,760,930...172,776,157
Ensembl chr 4:172,760,886...172,776,875
|
|
G
|
Mif
|
macrophage migration inhibitory factor
|
multiple interactions
|
EXP
|
Cyclophosphamide affects the localization of and affects the expression of MIF protein; Cyclophosphamide promotes the reaction [MIF protein binds to CXCR4 protein]
|
CTD |
PMID:19066630 |
|
NCBI chr20:12,767,138...12,791,222
Ensembl chr 4:134,041,774...134,042,121 Ensembl chr20:134,041,774...134,042,121
|
|
G
|
Mki67
|
marker of proliferation Ki-67
|
decreases expression increases expression multiple interactions
|
ISO EXP
|
Cyclophosphamide results in decreased expression of MKI67 protein Cyclophosphamide results in increased expression of MKI67 protein coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of MKI67 protein]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of MKI67 protein]
|
CTD |
PMID:33737021 PMID:36154502 PMID:39209270 PMID:39952379 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593
|
|
G
|
Mlh1
|
mutL homolog 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of MLH1 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 8:120,074,871...120,112,109
Ensembl chr 8:120,065,900...120,112,011
|
|
G
|
Mllt11
|
MLLT11, transcription factor 7 cofactor
|
decreases response to substance
|
ISO
|
MLLT11 protein results in decreased susceptibility to Cyclophosphamide
|
CTD |
PMID:31587870 |
|
NCBI chr 2:185,484,791...185,493,961
Ensembl chr 2:185,484,793...185,493,961
|
|
G
|
Mmel1
|
membrane metallo-endopeptidase-like 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of MMEL1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 5:170,713,602...170,744,058
Ensembl chr 5:170,713,627...170,744,058
|
|
G
|
Mmp11
|
matrix metallopeptidase 11
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of MMP11 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr20:12,730,284...12,739,067
Ensembl chr20:12,730,277...12,739,290
|
|
G
|
Mmp3
|
matrix metallopeptidase 3
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of MMP3 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:12,925,280...12,938,826
|
|
G
|
Mmp8
|
matrix metallopeptidase 8
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of MMP8 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 8:13,008,873...13,018,729
Ensembl chr 8:13,008,890...13,018,729
|
|
G
|
Mnda
|
myeloid cell nuclear differentiation antigen
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of IFI204 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr13:88,550,224...88,567,892
Ensembl chr13:88,550,228...88,566,537
|
|
G
|
Mpc2
|
mitochondrial pyruvate carrier 2
|
affects response to substance
|
ISO
|
MPC2 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr13:80,261,143...80,280,668
Ensembl chr13:80,259,727...80,280,668
|
|
G
|
Mpg
|
N-methylpurine-DNA glycosylase
|
affects expression
|
EXP
|
Cyclophosphamide affects the expression of MPG mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr10:15,900,697...15,906,981
Ensembl chr10:15,899,635...15,907,052
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions increases activity
|
EXP ISO
|
Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Hemin inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein] fosaprepitant inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]
|
CTD |
PMID:10749792 PMID:17979934 PMID:18710439 PMID:25451569 PMID:34748891 PMID:35906875 PMID:39378958 More...
|
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Mr1
|
major histocompatibility complex, class I-related
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of MR1 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr13:69,850,420...69,868,302
Ensembl chr13:69,850,420...69,868,502
|
|
G
|
Ms4a3
|
membrane spanning 4-domains A3
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of MS4A3 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 1:208,462,300...208,480,129
Ensembl chr 1:217,887,105...217,904,907
|
|
G
|
Msh2
|
mutS homolog 2
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of MSH2 mRNA
|
CTD |
PMID:11056294 PMID:11906922 |
|
NCBI chr 6:12,567,368...12,626,534
Ensembl chr 6:12,567,368...12,626,503
|
|
G
|
Msh3
|
mutS homolog 3
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of MSH3 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 2:25,179,400...25,320,857
Ensembl chr 2:25,179,400...25,321,102
|
|
G
|
Mss51
|
MSS51 mitochondrial translational activator
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of MSS51 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr15:3,805,240...3,819,385
Ensembl chr15:3,855,478...3,868,611
|
|
G
|
Mthfd2
|
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of MTHFD2 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 4:117,368,833...117,380,350
Ensembl chr 4:117,368,835...117,380,350
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
multiple interactions increases phosphorylation
|
ISO
|
asperuloside inhibits the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein]; asperuloside inhibits the reaction [dorsomorphin promotes the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein]]; CSF2 protein inhibits the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein]; dorsomorphin inhibits the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein]; dorsomorphin promotes the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein]
|
CTD |
PMID:38348709 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
G
|
Mtr
|
5-methyltetrahydrofolate-homocysteine methyltransferase
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of MTR mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr17:62,911,705...62,996,544
Ensembl chr17:62,911,771...62,996,541
|
|
G
|
Muc13
|
mucin 13, cell surface associated
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of MUC13 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr11:66,957,208...66,980,264
Ensembl chr11:80,465,737...80,485,474
|
|
G
|
Mx2
|
MX dynamin like GTPase 2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of MX2 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr11:50,375,101...50,399,373
Ensembl chr11:50,375,191...50,402,478
|
|
G
|
Mxi1
|
MAX interactor 1, dimerization protein
|
affects response to substance
|
ISO
|
MXI1 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 1:252,323,915...252,383,682
Ensembl chr 1:262,328,875...262,389,036
|
|
G
|
Myd88
|
MYD88, innate immune signal transduction adaptor
|
multiple interactions
|
ISO
|
[fosaprepitant co-treated with Cyclophosphamide] results in decreased expression of MYD88 protein
|
CTD |
PMID:39378958 |
|
NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230
|
|
G
|
Myh10
|
myosin heavy chain 10
|
affects response to substance
|
ISO
|
MYH10 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr10:53,891,955...54,024,032
Ensembl chr10:53,893,166...54,024,036
|
|
G
|
Naip6
|
NLR family, apoptosis inhibitory protein 6
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of NAIP mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr 2:33,241,520...33,293,184
Ensembl chr 2:33,241,521...33,276,859
|
|
G
|
Nampt
|
nicotinamide phosphoribosyltransferase
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of NAMPT mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 6:55,152,756...55,189,547
Ensembl chr 6:55,151,926...55,189,544
|
|
G
|
Nanos1
|
nanos C2HC-type zinc finger 1
|
increases expression
|
ISO
|
Cyclophosphamide metabolite results in increased expression of NANOS1 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 1:269,883,713...269,887,611
Ensembl chr 1:269,883,536...269,895,417
|
|
G
|
Nasp
|
nuclear autoantigenic sperm protein
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of NASP mRNA
|
CTD |
PMID:16141653 |
|
NCBI chr 5:135,294,599...135,319,992
Ensembl chr 5:135,294,032...135,319,591
|
|
G
|
Ncoa7
|
nuclear receptor coactivator 7
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of NCOA7 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 1:28,674,614...28,835,891
Ensembl chr 1:28,675,426...28,835,886
|
|
G
|
Ndufs2
|
NADH:ubiquinone oxidoreductase core subunit S2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of NDUFS2 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr13:86,186,867...86,203,914
Ensembl chr13:86,186,870...86,203,608
|
|
G
|
Neto2
|
neuropilin and tolloid like 2
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of NETO2 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr19:37,517,518...37,588,961
Ensembl chr19:37,517,587...37,591,413
|
|
G
|
Nfatc3
|
nuclear factor of activated T-cells 3
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of NFATC3 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr19:50,870,464...50,944,992
Ensembl chr19:50,870,489...50,944,992
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions decreases expression increases response to substance increases expression
|
EXP ISO
|
[astaxanthine co-treated with Cyclophosphamide] results in increased expression of NFE2L2 protein; [Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in decreased expression of NFE2L2 mRNA]; Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of NFE2L2 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of NFE2L2 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of NFE2L2 mRNA] Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of CAT protein]; Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of GCLC protein]; Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of NQO1 protein]; NFE2L2 gene mutant form inhibits the reaction [Cyclophosphamide results in increased expression of NQO1 mRNA]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of CAT protein]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of NQO1 protein] NFE2L2 gene mutant form results in increased susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of NFE2L2 mRNA; Cyclophosphamide results in increased expression of NFE2L2 protein Cyclophosphamide results in decreased expression of NFE2L2 mRNA; Cyclophosphamide results in decreased expression of NFE2L2 protein
|
CTD |
PMID:20038455 PMID:20433640 PMID:27633142 PMID:32129080 PMID:32456565 PMID:37419146 PMID:38211767 More...
|
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfe2l3
|
NFE2 like bZIP transcription factor 3
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of NFE2L3 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 4:81,837,404...81,865,258
Ensembl chr 4:81,837,404...81,865,532
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
increases phosphorylation multiple interactions
|
ISO
|
Cyclophosphamide results in increased phosphorylation of NFKBIA protein ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased phosphorylation of NFKBIA protein]
|
CTD |
PMID:30506662 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nfkbiz
|
NFKB inhibitor zeta
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of NFKBIZ mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr11:58,251,720...58,279,767
Ensembl chr11:58,251,721...58,279,767
|
|
G
|
Ngf
|
nerve growth factor
|
multiple interactions increases expression decreases expression
|
ISO EXP
|
3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazoleacetic acid methyl ester inhibits the reaction [Cyclophosphamide results in increased expression of NGF protein]; Cyclophosphamide promotes the reaction [NGF results in increased expression of VEGFA mRNA]; VIP protein affects the reaction [Cyclophosphamide results in increased expression of NGF protein] NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of AKT1 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK8 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK9 protein]; O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of NGF protein]; rofecoxib inhibits the reaction [Cyclophosphamide results in increased expression of NGF protein] Cyclophosphamide results in increased expression of NGF mRNA; Cyclophosphamide results in increased expression of NGF protein Cyclophosphamide results in decreased expression of NGF protein
|
CTD |
PMID:10683293 PMID:16879691 PMID:18299998 PMID:18632792 PMID:19996110 PMID:20127836 PMID:32615180 More...
|
|
NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834
|
|
G
|
Ngfr
|
nerve growth factor receptor
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of NGFR mRNA; Cyclophosphamide results in increased expression of NGFR protein
|
CTD |
PMID:8817519 PMID:18189308 PMID:18842820 |
|
NCBI chr10:81,012,077...81,030,305
Ensembl chr10:81,012,089...81,030,305
|
|
G
|
Nid1
|
nidogen 1
|
affects response to substance
|
ISO
|
NID1 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr17:93,069,013...93,142,416
Ensembl chr17:93,069,278...93,142,386
|
|
G
|
Nkain1
|
Sodium/potassium transporting ATPase interacting 1
|
multiple interactions
|
ISO
|
NKAIN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr 5:142,747,702...142,792,665
Ensembl chr 5:148,031,338...148,076,834
|
|
G
|
Nlrp3
|
NLR family, pyrin domain containing 3
|
multiple interactions increases expression
|
EXP ISO
|
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein] Donepezil inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein]; Fenofibrate inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein]; levocabastine inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein]
|
CTD |
PMID:35762198 PMID:38278497 PMID:38825044 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394
|
|
G
|
Nme1
|
NME/NM23 nucleoside diphosphate kinase 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of NME1 mRNA
|
CTD |
PMID:11599041 |
|
NCBI chr10:79,403,939...79,426,620
Ensembl chr10:79,403,940...79,413,310
|
|
G
|
Nos1
|
nitric oxide synthase 1
|
increases expression multiple interactions decreases expression
|
EXP
|
Cyclophosphamide results in increased expression of NOS1 protein allyl sulfide inhibits the reaction [Cyclophosphamide results in decreased expression of NOS1 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of NOS1 protein]
|
CTD |
PMID:31779506 PMID:35906875 |
|
NCBI chr12:44,276,011...44,456,371
Ensembl chr12:44,287,614...44,371,837
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions decreases expression increases expression increases activity
|
EXP ISO
|
allyl sulfide inhibits the reaction [Cyclophosphamide results in decreased expression of NOS2 protein]; Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 mRNA]; Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; chrysin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; ginkgolide B inhibits the reaction [Cyclophosphamide results in increased activity of NOS2 protein]; herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Cyclophosphamide results in increased activity of NOS2 protein]; pimagedine inhibits the reaction [Cyclophosphamide results in increased activity of NOS2 protein]; rofecoxib inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 mRNA]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein] Cyclophosphamide results in increased expression of NOS2 mRNA; Cyclophosphamide results in increased expression of NOS2 protein
|
CTD |
PMID:9006340 PMID:10607705 PMID:11046124 PMID:15821589 PMID:16879691 PMID:18206168 PMID:18296739 PMID:18710439 PMID:19691848 PMID:21068404 PMID:25753322 PMID:29753871 PMID:31779506 PMID:32197949 PMID:36198566 PMID:37263553 More...
|
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Nos3
|
nitric oxide synthase 3
|
decreases activity decreases expression multiple interactions increases expression
|
EXP
|
Cyclophosphamide results in decreased activity of NOS3 protein Cyclophosphamide results in decreased expression of NOS3 protein Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein] Cyclophosphamide results in increased expression of NOS3 protein
|
CTD |
PMID:9006340 PMID:16125470 PMID:35762198 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664
|
|
G
|
Notch1
|
notch receptor 1
|
multiple interactions decreases expression
|
ISO
|
PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of NOTCH1 protein]; SGI-1027 promotes the reaction [Cyclophosphamide results in decreased expression of NOTCH1 protein]; Valproic Acid inhibits the reaction [Cyclophosphamide results in decreased expression of NOTCH1 protein]
|
CTD |
PMID:34658283 |
|
NCBI chr 3:29,676,040...29,721,613
Ensembl chr 3:29,676,171...29,721,613
|
|
G
|
Nppb
|
natriuretic peptide B
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of NPPB protein
|
CTD |
PMID:17562616 PMID:18548196 PMID:18999883 |
|
NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310
|
|
G
|
Nprl2
|
NPR2-like, GATOR1 complex subunit
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of NPRL2 mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr 8:117,094,443...117,097,639
Ensembl chr 8:117,094,441...117,097,637
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
decreases expression multiple interactions increases expression
|
EXP ISO
|
Cyclophosphamide results in decreased expression of NQO1 mRNA; Cyclophosphamide results in decreased expression of NQO1 protein Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of NQO1 protein]; NFE2L2 gene mutant form inhibits the reaction [Cyclophosphamide results in increased expression of NQO1 mRNA]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of NQO1 protein]; TRPM2 protein affects the reaction [Cyclophosphamide results in decreased expression of NQO1 mRNA] Cyclophosphamide results in increased expression of NQO1 protein [astaxanthine co-treated with Cyclophosphamide] results in increased expression of NQO1 protein; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein]
|
CTD |
PMID:11906922 PMID:20038455 PMID:20433640 PMID:21041162 PMID:27633142 PMID:32197949 PMID:39952379 More...
|
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of NR1H4 mRNA
|
CTD |
PMID:28391356 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
G
|
Nr1i2
|
nuclear receptor subfamily 1, group I, member 2
|
increases activity multiple interactions
|
ISO
|
Cyclophosphamide results in increased activity of NR1I2 protein [Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; [Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Cyclophosphamide binds to and results in increased activity of NR1I2 protein; NR1I2 protein promotes the reaction [Cyclophosphamide results in increased expression of ABCB1 protein]
|
CTD |
PMID:17041008 PMID:18839173 PMID:20041327 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380
|
|
G
|
Nr1i3
|
nuclear receptor subfamily 1, group I, member 3
|
multiple interactions
|
ISO
|
[Cyclophosphamide results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA
|
CTD |
PMID:17041008 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370
|
|
G
|
Nr2c2
|
nuclear receptor subfamily 2, group C, member 2
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of NR2C2 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 4:124,610,216...124,666,813
Ensembl chr 4:126,168,085...126,223,942
|
|
G
|
Nrap
|
nebulin-related anchoring protein
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of NRAP mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 1:255,350,113...255,427,704
Ensembl chr 1:265,355,327...265,432,950
|
|
G
|
Nrdc
|
nardilysin convertase
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of NRDC mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 5:128,983,395...129,047,578
Ensembl chr 5:128,984,446...129,050,141
|
|
G
|
Nrg1
|
neuregulin 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of NRG1 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr16:65,954,084...67,007,484
Ensembl chr16:65,953,865...66,999,849
|
|
G
|
Nrp1
|
neuropilin 1
|
decreases expression increases expression
|
ISO EXP
|
Cyclophosphamide results in decreased expression of NRP1 mRNA Cyclophosphamide results in increased expression of NRP1 mRNA
|
CTD |
PMID:15331540 PMID:18632792 |
|
NCBI chr19:73,256,557...73,411,705
Ensembl chr19:73,256,557...73,411,702
|
|
G
|
Nrp2
|
neuropilin 2
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of NRP2 mRNA
|
CTD |
PMID:18632792 |
|
NCBI chr 9:71,616,602...71,731,869
Ensembl chr 9:71,616,657...71,731,871
|
|
G
|
Nt5c2
|
5'-nucleotidase, cytosolic II
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of NT5C2 mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr 1:255,712,797...255,838,285
Ensembl chr 1:255,713,909...255,838,403
|
|
G
|
Ntf3
|
neurotrophin 3
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of NTF3 mRNA
|
CTD |
PMID:10683293 |
|
NCBI chr 4:160,601,161...160,670,623
Ensembl chr 4:160,600,770...160,676,349
|
|
G
|
Ntf4
|
neurotrophin 4
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of NTF4 mRNA
|
CTD |
PMID:10683293 |
|
NCBI chr 1:105,030,035...105,032,866
Ensembl chr 1:105,029,764...105,034,038
|
|
G
|
Ntrk1
|
neurotrophic receptor tyrosine kinase 1
|
multiple interactions
|
EXP
|
Cyclophosphamide results in increased phosphorylation of and results in increased expression of NTRK1 protein
|
CTD |
PMID:12412144 |
|
NCBI chr 2:175,534,844...175,551,664
Ensembl chr 2:175,534,844...175,551,787
|
|
G
|
Ntrk2
|
neurotrophic receptor tyrosine kinase 2
|
multiple interactions
|
EXP
|
Cyclophosphamide results in increased phosphorylation of and results in increased expression of NTRK2 protein
|
CTD |
PMID:12412144 |
|
NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,564,570...5,874,628
|
|
G
|
Nup42
|
nucleoporin 42
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of NUP42 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 4:11,877,957...11,894,991
Ensembl chr 4:11,877,957...11,894,991
|
|
G
|
Ocln
|
occludin
|
decreases expression increases expression multiple interactions
|
ISO EXP
|
Cyclophosphamide results in decreased expression of OCLN protein Cyclophosphamide results in increased expression of OCLN protein O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of OCLN protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of OCLN protein]
|
CTD |
PMID:32151603 PMID:32615180 |
|
NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411
|
|
G
|
Odc1
|
ornithine decarboxylase 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ODC1 mRNA
|
CTD |
PMID:11599041 |
|
NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146
|
|
G
|
Ogg1
|
8-oxoguanine DNA glycosylase
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of OGG1 protein
|
CTD |
PMID:27032448 |
|
NCBI chr 4:148,030,237...148,037,599
Ensembl chr 4:148,030,349...148,037,604
|
|
G
|
Opn3
|
opsin 3
|
affects response to substance
|
ISO
|
OPN3 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr13:90,121,560...90,152,076
Ensembl chr13:90,121,560...90,152,076
|
|
G
|
Osm
|
oncostatin M
|
affects expression
|
ISO
|
Cyclophosphamide affects the expression of OSM mRNA
|
CTD |
PMID:12624490 |
|
NCBI chr14:83,327,202...83,332,073
Ensembl chr14:83,327,554...83,331,827
|
|
G
|
P2rx3
|
purinergic receptor P2X 3
|
increases expression multiple interactions
|
EXP
|
Cyclophosphamide results in increased expression of P2RX3 protein GR 82334 inhibits the reaction [Cyclophosphamide results in increased expression of P2RX3 protein]; Suramin inhibits the reaction [Cyclophosphamide results in increased expression of P2RX3 protein]
|
CTD |
PMID:23666265 |
|
NCBI chr 3:90,487,506...90,531,315
Ensembl chr 3:90,487,506...90,531,794
|
|
G
|
P2ry2
|
purinergic receptor P2Y2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of P2RY2 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 1:164,764,119...164,779,578
Ensembl chr 1:164,759,213...164,781,852
|
|
G
|
Paip1
|
poly(A) binding protein interacting protein 1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of PAIP1 mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr 2:53,255,916...53,282,965
Ensembl chr 2:53,237,924...53,282,966
|
|
G
|
Pakap
|
paralemmin A kinase anchor protein
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of PALM2AKAP2 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 5:76,976,906...77,443,656
Ensembl chr 5:76,977,112...77,443,656
|
|
G
|
Pard3
|
par-3 family cell polarity regulator
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of PARD3 mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr19:71,977,420...72,527,273
Ensembl chr19:71,977,470...72,526,941
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions increases expression increases cleavage decreases expression
|
ISO EXP
|
[Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of PARP1 protein; [Cladribine co-treated with Cyclophosphamide] results in decreased expression of PARP1 protein Cyclophosphamide results in increased expression of PARP1 protein chrysin inhibits the reaction [Cyclophosphamide results in increased expression of PARP1 protein] Cyclophosphamide results in increased expression of PARP1 mRNA; Cyclophosphamide results in increased expression of PARP1 protein Cyclophosphamide results in increased cleavage of PARP1 protein Cyclophosphamide results in decreased expression of PARP1 mRNA
|
CTD |
PMID:11599041 PMID:11723234 PMID:11906922 PMID:15582267 PMID:17898787 PMID:37263553 PMID:39952379 More...
|
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Pax5
|
paired box 5
|
increases expression multiple interactions decreases methylation
|
ISO
|
Cyclophosphamide results in increased expression of PAX5 protein Cyclophosphamide promotes the reaction [SGI-1027 results in increased expression of PAX5 protein]; PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of HES5 protein]; PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of JAG1 protein]; PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of NOTCH1 protein]; PAX5 protein affects the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; SGI-1027 promotes the reaction [Cyclophosphamide results in decreased methylation of PAX5 gene]; SGI-1027 promotes the reaction [Cyclophosphamide results in increased expression of PAX5 protein]
|
CTD |
PMID:34658283 |
|
NCBI chr 5:63,554,784...63,741,380
Ensembl chr 5:63,560,722...63,739,987
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
affects expression multiple interactions decreases expression increases expression
|
EXP ISO
|
Cyclophosphamide affects the expression of PCNA mRNA coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of PCNA mRNA] Cyclophosphamide results in decreased expression of PCNA protein Cyclophosphamide results in increased expression of PCNA mRNA
|
CTD |
PMID:11056294 PMID:18246545 PMID:19701751 PMID:21041162 PMID:31557371 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
G
|
Pcsk2
|
proprotein convertase subtilisin/kexin type 2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of PCSK2 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 3:151,333,938...151,636,628
Ensembl chr 3:151,333,234...151,638,849
|
|
G
|
Pdcd4
|
programmed cell death 4
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of PDCD4 mRNA
|
CTD |
PMID:21873647 |
|
NCBI chr 1:262,912,659...262,949,581
Ensembl chr 1:262,926,656...262,950,189
|
|
G
|
Pdia3
|
protein disulfide isomerase family A, member 3
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of PDIA3 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 3:128,841,781...128,865,733
Ensembl chr 3:128,841,917...128,867,327
|
|
G
|
Pdia4
|
protein disulfide isomerase family A, member 4
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of PDIA4 mRNA
|
CTD |
PMID:11599041 |
|
NCBI chr 4:78,134,144...78,153,191
Ensembl chr 4:78,134,144...78,153,191
|
|
G
|
Pebp1
|
phosphatidylethanolamine binding protein 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of PEBP1 protein
|
CTD |
PMID:15928459 |
|
NCBI chr12:44,946,307...44,967,890
Ensembl chr12:44,963,675...44,971,780
|
|
G
|
Peli1
|
pellino E3 ubiquitin protein ligase 1
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of PELI1 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr14:99,455,970...99,510,474
Ensembl chr14:99,455,811...99,510,466
|
|
G
|
Per1
|
period circadian regulator 1
|
multiple interactions decreases expression
|
ISO
|
5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in decreased expression of PER1 mRNA]
|
CTD |
PMID:30760223 |
|
NCBI chr10:54,299,002...54,313,804
Ensembl chr10:54,302,641...54,314,211
|
|
G
|
Phlda2
|
pleckstrin homology-like domain, family A, member 2
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of PHLDA2 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 1:208,126,302...208,127,241
Ensembl chr 1:208,126,302...208,127,920
|
|
G
|
Piga
|
phosphatidylinositol glycan anchor biosynthesis, class A
|
increases mutagenesis
|
EXP
|
Cyclophosphamide results in increased mutagenesis of PIGA
|
CTD |
PMID:22923490 |
|
NCBI chr X:33,672,832...33,687,747
Ensembl chr X:33,674,923...33,687,636
|
|
G
|
Pigr
|
polymeric immunoglobulin receptor
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of PIGR mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr13:44,851,001...44,879,143
Ensembl chr13:44,851,182...44,879,141
|
|
G
|
Pla2g4a
|
phospholipase A2 group 4A
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of PLA2G4A mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641
|
|
G
|
Plau
|
plasminogen activator, urokinase
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of PLAU mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030
|
|
G
|
Plod1
|
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of PLOD1 mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr 5:163,623,847...163,650,737
Ensembl chr 5:163,623,848...163,651,110
|
|
G
|
Plod3
|
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of PLOD3 mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr12:25,313,070...25,323,631
Ensembl chr12:25,313,072...25,323,631
|
|
G
|
Pms1
|
PMS1 homolog 1, mismatch repair system component
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of PMS1 mRNA
|
CTD |
PMID:11056294 |
|
NCBI chr 9:55,721,393...55,832,225
Ensembl chr 9:55,745,374...55,832,221
|
|
G
|
Pms2
|
PMS1 homolog 2, mismatch repair system component
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of PMS2 mRNA
|
CTD |
PMID:11056294 |
|
NCBI chr12:15,790,478...15,814,790
Ensembl chr12:15,790,478...15,815,248
|
|
G
|
Polm
|
DNA polymerase mu
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of POLM mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr14:84,921,039...84,930,649
Ensembl chr14:84,921,045...84,930,622
|
|
G
|
Pomc
|
proopiomelanocortin
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of POMC protein
|
CTD |
PMID:15276878 |
|
NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173
|
|
G
|
Pon1
|
paraoxonase 1
|
increases activity
|
EXP
|
Cyclophosphamide results in increased activity of PON1 protein
|
CTD |
PMID:17874068 |
|
NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:34,261,289...34,287,924
|
|
G
|
Por
|
cytochrome p450 oxidoreductase
|
multiple interactions increases expression
|
ISO EXP
|
POR promotes the reaction [CYP2B6 results in increased susceptibility to Cyclophosphamide]; POR promotes the reaction [CYP2C18 results in increased susceptibility to Cyclophosphamide]; POR protein promotes the reaction [CYP2B6 protein results in increased susceptibility to Cyclophosphamide] Cyclophosphamide results in increased expression of POR mRNA
|
CTD |
PMID:9766669 PMID:10919648 PMID:11599041 |
|
NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809
|
|
G
|
Postn
|
periostin
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of POSTN mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 2:140,677,774...140,709,304
Ensembl chr 2:140,677,754...140,709,300
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of PPARA protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of PPARA protein]
|
CTD |
PMID:29753871 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
decreases expression increases expression multiple interactions
|
EXP
|
Cyclophosphamide results in decreased expression of PPARG mRNA Cyclophosphamide results in increased expression of PPARG mRNA Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of PPARG mRNA]
|
CTD |
PMID:25446862 PMID:27281708 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
G
|
Prdm13
|
PR/SET domain 13
|
affects expression
|
EXP
|
Cyclophosphamide affects the expression of PRDM13 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 5:40,017,607...40,029,658
Ensembl chr 5:40,017,607...40,038,207
|
|
G
|
Prkaa1
|
protein kinase AMP-activated catalytic subunit alpha 1
|
increases phosphorylation multiple interactions
|
ISO
|
Cyclophosphamide results in increased phosphorylation of PRKAA1 protein asperuloside promotes the reaction [Cyclophosphamide results in increased phosphorylation of PRKAA1 protein]; CSF2 protein promotes the reaction [Cyclophosphamide results in increased phosphorylation of PRKAA1 protein]
|
CTD |
PMID:38348709 |
|
NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:55,967,351...56,003,450
|
|
G
|
Prkcg
|
protein kinase C, gamma
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of PRKCG mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 1:74,748,272...74,777,611
Ensembl chr 1:74,748,272...74,774,814
|
|
G
|
Prlr
|
prolactin receptor
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of PRLR mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 2:60,861,391...61,051,883
Ensembl chr 2:60,861,658...61,051,882
|
|
G
|
Procr
|
protein C receptor
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of PROCR mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 3:164,714,727...164,718,994
Ensembl chr 3:164,711,636...164,718,989
|
|
G
|
Prss3
|
serine protease 3
|
affects response to substance
|
ISO
|
PRSS3 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 4:71,169,749...71,173,223
Ensembl chr 4:71,169,749...71,173,223
|
|
G
|
Prtn3
|
proteinase 3
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of PRTN3 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 7:10,472,750...10,482,037
Ensembl chr 7:10,472,755...10,482,474
|
|
G
|
Psma5
|
proteasome 20S subunit alpha 5
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of PSMA5 protein
|
CTD |
PMID:17475930 |
|
NCBI chr 2:195,896,369...195,919,733
Ensembl chr 2:198,584,505...198,607,867
|
|
G
|
Ptcra
|
pre T-cell antigen receptor alpha
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of PTCRA mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 9:14,218,907...14,229,141
Ensembl chr 9:21,716,522...21,726,751
|
|
G
|
Ptger1
|
prostaglandin E receptor 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of PTGER1 protein
|
CTD |
PMID:20346049 |
|
NCBI chr19:41,374,983...41,379,593
Ensembl chr19:41,374,471...41,378,284
|
|
G
|
Ptger4
|
prostaglandin E receptor 4
|
multiple interactions increases expression
|
EXP
|
Botulinum Toxins, Type A inhibits the reaction [Cyclophosphamide results in increased expression of PTGER4 protein]
|
CTD |
PMID:18514386 PMID:20346049 |
|
NCBI chr 2:56,061,699...56,074,594
Ensembl chr 2:56,062,890...56,074,135
|
|
G
|
Ptges3
|
prostaglandin E synthase 3
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of PTGES3 mRNA
|
CTD |
PMID:11599041 |
|
NCBI chr 7:1,075,230...1,092,363
Ensembl chr 7:1,075,227...1,092,695
|
|
G
|
Ptgs1
|
prostaglandin-endoperoxide synthase 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of PTGS1 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
affects response to substance multiple interactions increases expression
|
ISO EXP
|
PTGS2 protein affects the susceptibility to Cyclophosphamide Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein] Cyclophosphamide results in increased expression of PTGS2 mRNA; Cyclophosphamide results in increased expression of PTGS2 protein Botulinum Toxins, Type A inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein]; crocin inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein]; herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein]; parthenolide inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 mRNA]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein]; Silymarin inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein]
|
CTD |
PMID:12388444 PMID:15331540 PMID:16217747 PMID:17537839 PMID:18514386 PMID:19303104 PMID:23488790 PMID:25753322 PMID:29753871 PMID:36198566 PMID:37419146 More...
|
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Ptp4a1
|
protein tyrosine phosphatase 4A1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of PTP4A1 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 9:40,710,250...40,718,176
Ensembl chr 9:40,710,250...40,718,176
|
|
G
|
Ptprc
|
protein tyrosine phosphatase, receptor type, C
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of PTPRC mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr13:52,147,717...52,259,810
Ensembl chr13:52,147,717...52,259,746
|
|
G
|
Pura
|
purine rich element binding protein A
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of PURA mRNA
|
CTD |
PMID:11599041 |
|
NCBI chr18:28,159,103...28,179,539
Ensembl chr18:28,125,126...28,211,111
|
|
G
|
Rad50
|
RAD50 double strand break repair protein
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of RAD50 mRNA
|
CTD |
PMID:11056294 |
|
NCBI chr10:38,310,147...38,362,100
Ensembl chr10:38,310,147...38,362,100
|
|
G
|
Rad51
|
RAD51 recombinase
|
decreases expression increases expression
|
ISO EXP
|
Cyclophosphamide results in decreased expression of RAD51 mRNA Cyclophosphamide results in increased expression of RAD51 mRNA
|
CTD |
PMID:11599041 PMID:21041162 |
|
NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469
|
|
G
|
Rad54l
|
RAD54 like
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of RAD54L mRNA
|
CTD |
PMID:11056294 |
|
NCBI chr 5:134,812,158...134,841,821
Ensembl chr 5:134,811,532...134,841,425
|
|
G
|
Rag1
|
recombination activating 1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of RAG1 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 3:108,372,087...108,383,184
Ensembl chr 3:108,371,978...108,383,261
|
|
G
|
Ramp1
|
receptor activity modifying protein 1
|
increases expression multiple interactions
|
ISO
|
Cyclophosphamide results in increased expression of RAMP1 mRNA RAMP1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 PMID:17403535 |
|
NCBI chr 9:99,213,031...99,263,696
|
|
G
|
Rapsn
|
receptor-associated protein of the synapse
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of RAPSN mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 3:97,470,891...97,480,196
Ensembl chr 3:97,470,881...97,480,196
|
|
G
|
Rara
|
retinoic acid receptor, alpha
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of RARA mRNA
|
CTD |
PMID:16141653 |
|
NCBI chr10:84,379,780...84,424,371
Ensembl chr10:84,389,622...84,425,160
|
|
G
|
Rarg
|
retinoic acid receptor, gamma
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of RARG mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 7:135,246,427...135,268,889
Ensembl chr 7:135,246,427...135,268,889
|
|
G
|
Rbpms
|
RNA binding protein, mRNA processing factor
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of RBPMS mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr16:64,942,159...65,098,504
Ensembl chr16:64,942,530...65,098,503
|
|
G
|
Rc3h1
|
ring finger and CCCH-type domains 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of RC3H1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr13:75,707,098...75,779,114
Ensembl chr13:75,707,338...75,772,816
|
|
G
|
Rc3h2
|
ring finger and CCCH-type domains 2
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of RC3H2 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 3:21,121,531...21,186,711
Ensembl chr 3:41,531,617...41,589,715
|
|
G
|
Reg3b
|
regenerating family member 3 beta
|
increases expression
|
ISO EXP
|
Cyclophosphamide results in increased expression of REG3A mRNA; Cyclophosphamide results in increased expression of REG3B mRNA Cyclophosphamide results in increased expression of REG3B protein
|
CTD |
PMID:15331540 PMID:18295254 |
|
NCBI chr 4:112,419,776...112,423,014
Ensembl chr 4:112,419,776...112,423,014
|
|
G
|
Reg3g
|
regenerating family member 3 gamma
|
increases expression
|
ISO EXP
|
Cyclophosphamide results in increased expression of REG3G mRNA Cyclophosphamide results in increased expression of REG3G protein
|
CTD |
PMID:15331540 PMID:18295254 |
|
NCBI chr 4:112,482,183...112,484,738
Ensembl chr 4:112,482,183...112,484,738
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
increases expression increases expression increases phosphorylation increases activity multiple interactions
|
EXP ISO
|
Cyclophosphamide results in increased expression of RELA mRNA; Cyclophosphamide results in increased expression of RELA protein; Cyclophosphamide results in increased expression of RELA protein modified form [doxorubicin cotreated with cyclophosphamide] increased expression of Rela protein in prefrontal cortex and hippocampus Cyclophosphamide results in increased phosphorylation of RELA protein Cyclophosphamide results in increased activity of RELA protein Cyclophosphamide results in increased localization of and results in increased activity of RELA protein; Dexamethasone inhibits the reaction [Cyclophosphamide results in increased localization of and results in increased activity of RELA protein]; Donepezil inhibits the reaction [Cyclophosphamide results in increased expression of RELA protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased phosphorylation of RELA protein] Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of RELA protein]; Melatonin inhibits the reaction [Cyclophosphamide results in increased expression of RELA protein]; parthenolide inhibits the reaction [Cyclophosphamide results in increased expression of RELA protein modified form]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of RELA protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of RELA mRNA]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased phosphorylation of RELA protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of RELA protein]
|
CTD RGD |
PMID:19303104 PMID:20433640 PMID:22099998 PMID:25451569 PMID:30506662 PMID:32197949 PMID:37419146 PMID:38825044 PMID:36708885 More...
|
RGD:597621662 |
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Rev1
|
REV1, DNA directed polymerase
|
decreases response to substance
|
ISO
|
REV1 protein results in decreased susceptibility to Cyclophosphamide
|
CTD |
PMID:21068378 |
|
NCBI chr 9:47,773,907...47,847,554
Ensembl chr 9:47,773,907...47,847,332
|
|
G
|
Ring1
|
ring finger protein 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of RING1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr20:4,832,013...4,835,516
Ensembl chr20:4,831,993...4,835,513
|
|
G
|
Ripply3
|
ripply transcriptional repressor 3
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of RIPPLY3 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr11:47,118,147...47,126,244
Ensembl chr11:47,118,147...47,131,954
|
|
G
|
Rnase2
|
ribonuclease A family member 2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of RNASE2 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr15:24,449,618...24,450,427
Ensembl chr15:26,923,134...26,923,955
|
|
G
|
Rnd1
|
Rho family GTPase 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of RND1 mRNA
|
CTD |
PMID:23558518 |
|
NCBI chr 7:131,700,321...131,707,392
Ensembl chr 7:131,700,321...131,707,392
|
|
G
|
Rnf138l1
|
ring finger protein 138 like 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of RNF138L1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr X:30,739,541...30,740,614
Ensembl chr X:34,371,016...34,372,596
|
|
G
|
Rnf180
|
ring finger protein 180
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of RNF180 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 2:38,064,026...38,244,854
Ensembl chr 2:38,064,031...38,265,358
|
|
G
|
Rnf216
|
ring finger protein 216
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of RNF216 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr12:16,568,327...16,689,868
Ensembl chr12:16,568,347...16,690,989
|
|
G
|
Rnf44
|
ring finger protein 44
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of RNF44 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr17:9,919,982...9,934,376
Ensembl chr17:9,930,375...9,939,478
|
|
G
|
Rnf5
|
ring finger protein 5
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of RNF5 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr20:4,145,539...4,147,985
Ensembl chr20:4,150,138...4,152,591
|
|
G
|
Rorc
|
RAR-related orphan receptor C
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of RORC protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of RORC protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of RORC protein]
|
CTD |
PMID:32151603 |
|
NCBI chr 2:184,698,779...184,723,942
Ensembl chr 2:184,698,818...184,724,566
|
|
G
|
Rpa1
|
replication protein A1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of RPA1 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr10:60,647,185...60,698,279
Ensembl chr10:60,647,185...60,698,279
|
|
G
|
Rpa2
|
replication protein A2
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of RPA2 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 5:150,260,668...150,271,329
Ensembl chr 5:150,260,723...150,271,546
|
|
G
|
Rps3
|
ribosomal protein S3
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of RPS3 mRNA
|
CTD |
PMID:11906922 |
|
NCBI chr 1:163,190,476...163,195,885
Ensembl chr 1:163,189,842...163,195,776
|
|
G
|
Rps6ka2
|
ribosomal protein S6 kinase A2
|
affects response to substance
|
ISO
|
RPS6KA2 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 1:55,178,988...55,454,271
Ensembl chr 1:55,179,319...55,454,338
|
|
G
|
Rraga
|
Ras-related GTP binding A
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of RRAGA mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 5:106,159,335...106,160,930
Ensembl chr 5:106,158,853...106,160,504
|
|
G
|
Rras2
|
RAS related 2
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of RRAS2 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 1:177,668,143...177,737,551
Ensembl chr 1:177,668,144...177,737,551
|
|
G
|
Rrm1
|
ribonucleotide reductase catalytic subunit M1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of RRM1 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 1:166,235,904...166,260,206
Ensembl chr 1:166,235,900...166,260,944
|
|
G
|
Rrm2
|
ribonucleotide reductase regulatory subunit M2
|
multiple interactions
|
ISO
|
RRM2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370
|
|
G
|
Rrm2b
|
ribonucleotide reductase regulatory TP53 inducible subunit M2B
|
increases expression
|
ISO
|
Cyclophosphamide metabolite results in increased expression of RRM2B mRNA
|
CTD |
PMID:21704725 |
|
NCBI chr 7:70,962,008...70,993,726
Ensembl chr 7:70,965,590...70,993,670
|
|
G
|
RT1-CE5
|
RT1 class I, locus CE5
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of HLA-F mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr20:3,407,880...3,484,130
|
|
G
|
Rtel1
|
regulator of telomere elongation helicase 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of RTEL1 protein
|
CTD |
PMID:17475930 |
|
NCBI chr 3:188,778,329...188,842,877
Ensembl chr 3:188,807,951...188,843,709
|
|
G
|
Runx3
|
RUNX family transcription factor 3
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of RUNX3 mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr 5:152,644,270...152,702,835
Ensembl chr 5:152,644,270...152,702,835
|
|
G
|
S100a1
|
S100 calcium binding protein A1
|
multiple interactions increases expression
|
ISO
|
TRPM2 protein affects the reaction [Cyclophosphamide results in increased expression of S100A1 protein]
|
CTD |
PMID:39952379 |
|
NCBI chr 2:178,291,503...178,296,346
Ensembl chr 2:178,291,503...178,296,346
|
|
G
|
S100b
|
S100 calcium binding protein B
|
increases expression multiple interactions
|
ISO
|
Cyclophosphamide results in increased expression of S100B protein TRPM2 protein affects the reaction [Cyclophosphamide results in increased expression of S100B protein]
|
CTD |
PMID:39952379 |
|
NCBI chr20:12,372,345...12,381,159
Ensembl chr20:12,372,348...12,381,081
|
|
G
|
Sall1
|
spalt-like transcription factor 1
|
affects response to substance
|
ISO
|
SALL1 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr19:34,179,316...34,196,278
Ensembl chr19:34,181,078...34,196,278
|
|
G
|
Satb1
|
SATB homeobox 1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of SATB1 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 9:4,916,958...5,010,359
Ensembl chr 9:4,917,215...4,989,925
|
|
G
|
Scg3
|
secretogranin III
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of SCG3 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 8:76,399,777...76,442,015
Ensembl chr 8:85,280,253...85,361,874
|
|
G
|
Scrt1
|
scratch family transcriptional repressor 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of SCRT1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 7:110,121,640...110,125,290
Ensembl chr 7:110,121,640...110,125,290
|
|
G
|
Scube2
|
signal peptide, CUB domain and EGF like domain containing 2
|
multiple interactions
|
ISO
|
SCUBE2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr 1:173,264,862...173,341,323
Ensembl chr 1:173,264,865...173,334,372
|
|
G
|
Sec23a
|
Sec23 homolog A, COPII coat complex component
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of SEC23A mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 6:82,393,699...82,442,594
Ensembl chr 6:82,394,863...82,440,904
|
|
G
|
Serpine1
|
serpin family E member 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of SERPINE1 mRNA
|
CTD |
PMID:23558518 |
|
NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357
|
|
G
|
Sesn2
|
sestrin 2
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of SESN2 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:149,986,317...150,005,255
|
|
G
|
Sfn
|
stratifin
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of SFN mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:151,110,530...151,111,995
|
|
G
|
Sgce
|
sarcoglycan, epsilon
|
affects response to substance
|
ISO
|
SGCE protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 4:32,771,477...32,842,238
Ensembl chr 4:33,737,814...33,808,908
|
|
G
|
Sgk1
|
serum/glucocorticoid regulated kinase 1
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of SGK1 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231
|
|
G
|
Sharpin
|
SHANK-associated RH domain interactor
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of SHARPIN mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 7:108,070,681...108,075,012
Ensembl chr 7:109,950,345...109,955,552
|
|
G
|
Sirt3
|
sirtuin 3
|
increases expression multiple interactions
|
ISO
|
Cyclophosphamide results in increased expression of SIRT3 mRNA Carnitine inhibits the reaction [Cyclophosphamide results in increased expression of SIRT3 mRNA]
|
CTD |
PMID:37863343 |
|
NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076
|
|
G
|
Sirt5
|
sirtuin 5
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of SIRT5 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr17:21,310,028...21,337,137
Ensembl chr17:21,515,985...21,537,442
|
|
G
|
Sit1
|
signaling threshold regulating transmembrane adaptor 1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of SIT1 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 5:62,536,003...62,538,230
Ensembl chr 5:62,536,009...62,537,911
|
|
G
|
Slc18a3
|
solute carrier family 18 member A3
|
increases expression multiple interactions
|
EXP
|
Cyclophosphamide results in increased expression of SLC18A3 protein O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of SLC18A3 protein]
|
CTD |
PMID:32615180 |
|
NCBI chr16:7,719,953...7,722,814
|
|
G
|
Slc22a3
|
solute carrier family 22 member 3
|
increases expression multiple interactions
|
EXP
|
Cyclophosphamide results in increased expression of SLC22A3 protein O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of SLC22A3 protein]
|
CTD |
PMID:32615180 |
|
NCBI chr 1:50,783,218...50,872,358
Ensembl chr 1:50,783,218...50,872,353
|
|
G
|
Slc22a5
|
solute carrier family 22 member 5
|
multiple interactions decreases expression
|
EXP
|
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 protein] Cyclophosphamide results in decreased expression of SLC22A5 mRNA; Cyclophosphamide results in decreased expression of SLC22A5 protein
|
CTD |
PMID:22701146 |
|
NCBI chr10:38,509,072...38,536,240
Ensembl chr10:38,509,072...38,536,077
|
|
G
|
Slc2a2
|
solute carrier family 2 member 2
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of SLC2A2 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 2:113,537,884...113,568,422
Ensembl chr 2:113,537,972...113,568,467
|
|
G
|
Slc2a6
|
solute carrier family 2 member 6
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of SLC2A6 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 3:30,746,472...30,753,287
Ensembl chr 3:30,745,995...30,753,287
|
|
G
|
Slc39a13
|
solute carrier family 39 member 13
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of SLC39A13 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 3:97,495,229...97,504,279
Ensembl chr 3:97,495,229...97,505,052
|
|
G
|
Slc39a14
|
solute carrier family 39 member 14
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of SLC39A14 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr15:51,786,517...51,833,260
Ensembl chr15:51,786,623...51,833,229
|
|
G
|
Slc39a5
|
solute carrier family 39 member 5
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of SLC39A5 mRNA; Cyclophosphamide results in increased expression of SLC39A5 protein
|
CTD |
PMID:27281708 |
|
NCBI chr 7:1,409,360...1,415,407
Ensembl chr 7:1,409,360...1,414,784
|
|
G
|
Slc39a6
|
solute carrier family 39 member 6
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of SLC39A6 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr18:16,139,621...16,160,163
Ensembl chr18:16,135,008...16,160,163
|
|
G
|
Slc3a2
|
solute carrier family 3 member 2
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of SLC3A2 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 1:215,033,601...215,048,064
Ensembl chr 1:215,033,601...215,048,064
|
|
G
|
Slc40a1
|
solute carrier family 40 member 1
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of SLC40A1 protein Dexrazoxane inhibits the reaction [Cyclophosphamide results in decreased expression of SLC40A1 protein]
|
CTD |
PMID:32129080 PMID:37690746 |
|
NCBI chr 9:55,525,457...55,633,463
Ensembl chr 9:55,525,532...55,543,460
|
|
G
|
Slc43a1
|
solute carrier family 43 member 1
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of SLC43A1 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 3:90,327,250...90,353,438
Ensembl chr 3:90,327,149...90,353,438
|
|
G
|
Slc7a11
|
solute carrier family 7 member 11
|
affects expression multiple interactions decreases expression
|
ISO
|
Cyclophosphamide affects the expression of SLC7A11 mRNA Dexrazoxane inhibits the reaction [Cyclophosphamide results in decreased expression of SLC7A11 protein] Cyclophosphamide metabolite results in decreased expression of SLC7A11 mRNA
|
CTD |
PMID:23824090 PMID:24356939 PMID:37690746 |
|
NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695
|
|
G
|
Slfn4
|
schlafen family member 4
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of SLFN4 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr10:67,994,601...68,018,141
|
|
G
|
Slit1
|
slit guidance ligand 1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of SLIT1 mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr 1:250,358,917...250,507,476
Ensembl chr 1:250,358,919...250,507,476
|
|
G
|
Slpi
|
secretory leukocyte peptidase inhibitor
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of SLPI mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 3:173,501,573...173,503,822
Ensembl chr 3:173,501,573...173,503,822
|
|
G
|
Snx10
|
sorting nexin 10
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of SNX10 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 4:80,612,648...80,677,005
Ensembl chr 4:81,943,287...82,007,651
|
|
G
|
Soat1
|
sterol O-acyltransferase 1
|
affects response to substance
|
ISO
|
SOAT1 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr13:71,105,178...71,147,776
Ensembl chr13:71,105,178...71,147,672
|
|
G
|
Socs1
|
suppressor of cytokine signaling 1
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of SOCS1 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr10:5,389,574...5,391,265
Ensembl chr10:5,389,334...5,391,847
|
|
G
|
Socs7
|
suppressor of cytokine signaling 7
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of SOCS7 mRNA
|
CTD |
PMID:11599041 |
|
NCBI chr10:82,848,525...82,885,201
Ensembl chr10:82,848,612...82,885,201
|
|
G
|
Sod1
|
superoxide dismutase 1
|
decreases expression multiple interactions decreases activity
|
ISO EXP
|
Cyclophosphamide results in decreased expression of SOD1 mRNA allyl sulfide inhibits the reaction [Cyclophosphamide results in decreased activity of SOD1 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in decreased activity of SOD1 protein] [Doxorubicin co-treated with Cyclophosphamide] results in increased expression of SOD1 protein; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of SOD1 mRNA]
|
CTD |
PMID:23542512 PMID:29228376 PMID:31779506 PMID:35906875 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Sod2
|
superoxide dismutase 2
|
increases expression affects response to substance decreases expression
|
ISO EXP
|
Cyclophosphamide results in increased expression of SOD2 mRNA SOD2 polymorphism affects the susceptibility to Cyclophosphamide Cyclophosphamide results in decreased expression of SOD2 mRNA
|
CTD |
PMID:11599041 PMID:11906922 PMID:15331540 PMID:20309628 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
G
|
Sord
|
sorbitol dehydrogenase
|
decreases activity multiple interactions
|
EXP
|
Cyclophosphamide results in decreased activity of SORD protein Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of SORD protein]
|
CTD |
PMID:25446862 |
|
NCBI chr 3:129,638,282...129,669,727
Ensembl chr 3:129,638,302...129,686,100
|
|
G
|
Sp2
|
Sp2 transcription factor
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of SP2 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr10:82,437,024...82,467,583
Ensembl chr10:82,437,029...82,467,651
|
|
G
|
Sparc
|
secreted protein acidic and cysteine rich
|
decreases expression increases expression
|
ISO
|
Cyclophosphamide results in decreased expression of SPARC mRNA Cyclophosphamide results in increased expression of SPARC mRNA
|
CTD |
PMID:15331540 PMID:17403535 |
|
NCBI chr10:40,017,065...40,038,816
Ensembl chr10:40,017,075...40,039,268
|
|
G
|
Spp1
|
secreted phosphoprotein 1
|
affects response to substance increases expression affects expression
|
ISO EXP
|
SPP1 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of SPP1 mRNA Cyclophosphamide affects the expression of SPP1 mRNA
|
CTD |
PMID:16217747 PMID:20623750 PMID:23558518 |
|
NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820
|
|
G
|
Srek1ip1
|
SREK1-interacting protein 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of SREK1IP1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 2:35,975,978...35,999,636
Ensembl chr 2:37,709,768...37,733,383 Ensembl chr 7:37,709,768...37,733,383
|
|
G
|
Srm
|
spermidine synthase
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of SRM mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr 5:164,309,002...164,312,203
Ensembl chr 5:164,308,991...164,332,705
|
|
G
|
Ssrp1
|
structure specific recognition protein 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of SSRP1 mRNA
|
CTD |
PMID:11599041 |
|
NCBI chr 3:90,531,024...90,541,132
Ensembl chr 3:90,530,829...90,541,129
|
|
G
|
St13
|
ST13, Hsp70 interacting protein
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ST13 mRNA
|
CTD |
PMID:11599041 |
|
NCBI chr 7:114,769,758...114,805,877
Ensembl chr 7:114,769,759...114,805,941
|
|
G
|
St14
|
ST14 transmembrane serine protease matriptase
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of ST14 mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr 8:37,798,994...37,839,881
Ensembl chr 8:37,798,995...37,855,652
|
|
G
|
Star
|
steroidogenic acute regulatory protein
|
multiple interactions decreases expression
|
EXP ISO
|
[Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in decreased expression of STAR mRNA] Cyclophosphamide results in decreased expression of STAR mRNA; Cyclophosphamide results in decreased expression of STAR protein Flavonoids inhibits the reaction [Cyclophosphamide results in decreased expression of STAR mRNA]; Flavonoids inhibits the reaction [Cyclophosphamide results in decreased expression of STAR protein]
|
CTD |
PMID:38211767 PMID:39239657 |
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447
|
|
G
|
Stat1
|
signal transducer and activator of transcription 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of STAT1 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346
|
|
G
|
Stat3
|
signal transducer and activator of transcription 3
|
increases phosphorylation decreases expression multiple interactions decreases phosphorylation
|
EXP ISO
|
Cyclophosphamide results in increased phosphorylation of STAT3 protein Cyclophosphamide results in decreased expression of STAT3 mRNA ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of STAT3 mRNA] chrysin inhibits the reaction [Cyclophosphamide results in increased phosphorylation of STAT3 protein] Cyclophosphamide results in decreased phosphorylation of STAT3 protein
|
CTD |
PMID:19625377 PMID:21880982 PMID:37263553 PMID:37853057 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
G
|
Stat5b
|
signal transducer and activator of transcription 5B
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of STAT5B mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr10:86,205,148...86,276,178
Ensembl chr10:86,207,293...86,275,990
|
|
G
|
Stip1
|
stress-induced phosphoprotein 1
|
decreases expression
|
ISO EXP
|
Cyclophosphamide results in decreased expression of STIP1 mRNA
|
CTD |
PMID:11906922 PMID:15331540 |
|
NCBI chr 1:213,638,641...213,657,654
Ensembl chr 1:213,638,641...213,657,654
|
|
G
|
Stk39
|
serine threonine kinase 39
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of STK39 mRNA
|
CTD |
PMID:16322899 |
|
NCBI chr 3:73,321,522...73,588,397
Ensembl chr 3:73,321,522...73,586,740
|
|
G
|
Stk4
|
serine/threonine kinase 4
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of STK4 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 3:173,165,238...173,247,135
Ensembl chr 3:173,165,083...173,247,134
|
|
G
|
Stmn3
|
stathmin 3
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of STMN3 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 3:188,794,358...188,802,494
Ensembl chr 3:188,794,358...188,802,873
|
|
G
|
Stom
|
stomatin
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of STOM mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 3:18,645,058...18,667,343
Ensembl chr 3:39,042,503...39,064,818
|
|
G
|
Sun1
|
Sad1 and UNC84 domain containing 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of SUN1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr12:15,396,378...15,441,277
Ensembl chr12:20,490,861...20,555,240
|
|
G
|
Tac1
|
tachykinin, precursor 1
|
multiple interactions increases expression increases secretion affects expression
|
EXP ISO
|
Botulinum Toxins, Type A inhibits the reaction [Cyclophosphamide results in increased secretion of TAC1 protein] Cyclophosphamide results in increased expression of TAC1 protein Cyclophosphamide affects the expression of TAC1 mRNA
|
CTD |
PMID:11312054 PMID:18184328 PMID:18563302 PMID:22842586 |
|
NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546
|
|
G
|
Tacr1
|
tachykinin receptor 1
|
multiple interactions increases expression decreases response to substance
|
ISO EXP
|
[alpha-amyrin co-treated with beta-amyrin] inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein] GR 82334 inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein]; Suramin inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein] TACR1 gene mutant form results in decreased susceptibility to Cyclophosphamide
|
CTD |
PMID:10854767 PMID:18210232 PMID:23666265 |
|
NCBI chr 4:116,478,617...116,647,492
Ensembl chr 4:116,478,617...116,647,492
|
|
G
|
Tafa5
|
TAFA chemokine like family member 5
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of TAFA5 mRNA
|
CTD |
PMID:21621594 |
|
NCBI chr 7:118,613,731...118,835,016
Ensembl chr 7:120,493,060...120,714,718
|
|
G
|
Tap1
|
transporter 1, ATP binding cassette subfamily B member
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of TAP1 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr20:4,658,171...4,668,543
Ensembl chr20:4,658,172...4,668,810
|
|
G
|
Tat
|
tyrosine aminotransferase
|
affects expression decreases expression
|
EXP
|
Cyclophosphamide affects the expression of TAT mRNA Cyclophosphamide results in decreased expression of TAT mRNA
|
CTD |
PMID:18246545 |
|
NCBI chr19:54,856,604...54,867,168
Ensembl chr19:54,856,563...54,867,482
|
|
G
|
Tbx21
|
T-box transcription factor 21
|
multiple interactions decreases expression
|
ISO
|
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TBX21 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of TBX21 protein]
|
CTD |
PMID:32151603 |
|
NCBI chr10:82,578,751...82,595,253
Ensembl chr10:82,578,751...82,595,253
|
|
G
|
Tcf7
|
transcription factor 7
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of TCF7 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr10:36,924,363...36,954,279
Ensembl chr10:36,924,363...36,954,279
|
|
G
|
Tcp1
|
t-complex 1
|
decreases expression increases expression
|
EXP
|
Cyclophosphamide results in decreased expression of TCP1 mRNA Cyclophosphamide results in increased expression of TCP1 mRNA
|
CTD |
PMID:11599041 PMID:11906922 |
|
NCBI chr 1:50,376,848...50,384,527
Ensembl chr 1:50,376,848...50,384,527
|
|
G
|
Tdo2
|
tryptophan 2,3-dioxygenase
|
increases activity multiple interactions
|
EXP
|
Cyclophosphamide results in increased activity of TDO2 protein Quercetin inhibits the reaction [Cyclophosphamide results in increased activity of TDO2 protein]
|
CTD |
PMID:35906875 |
|
NCBI chr 2:169,567,656...169,585,586
Ensembl chr 2:169,567,654...169,585,586
|
|
G
|
Tex30
|
testis expressed 30
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of TEX30 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 9:53,735,512...53,744,672
Ensembl chr 9:53,735,512...53,741,042
|
|
G
|
Tfrc
|
transferrin receptor
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of TFRC protein
|
CTD |
PMID:32129080 |
|
NCBI chr11:81,668,478...81,690,318
Ensembl chr11:81,668,478...81,690,318
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
increases expression increases secretion multiple interactions affects expression
|
ISO EXP
|
Cyclophosphamide results in increased expression of TGFB1 mRNA Cyclophosphamide results in increased expression of TGFB1 mRNA; Cyclophosphamide results in increased expression of TGFB1 protein Cyclophosphamide results in increased secretion of TGFB1 protein Cyclophosphamide results in increased expression of and results in increased activity of TGFB1 protein; naringin inhibits the reaction [Cyclophosphamide results in increased expression of TGFB1 mRNA] Cyclophosphamide affects the expression of TGFB1 mRNA DCN protein inhibits the reaction [TGFB1 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Cisplatin co-treated with Melphalan co-treated with Thiotepa]]; TGFB1 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Cisplatin co-treated with Melphalan co-treated with Thiotepa]
|
CTD |
PMID:9509296 PMID:12624490 PMID:19691848 PMID:21068404 PMID:23926183 PMID:33992719 More...
|
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tgfb2
|
transforming growth factor, beta 2
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of TGFB2 mRNA
|
CTD |
PMID:23558518 PMID:23926183 |
|
NCBI chr13:100,691,540...100,793,227
Ensembl chr13:100,692,953...100,792,856
|
|
G
|
Tgfb3
|
transforming growth factor, beta 3
|
multiple interactions increases expression decreases expression
|
ISO EXP
|
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TGFB3 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of TGFB3 protein] Cyclophosphamide results in increased expression of TGFB3 mRNA; Cyclophosphamide results in increased expression of TGFB3 protein
|
CTD |
PMID:23926183 PMID:32151603 |
|
NCBI chr 6:111,435,170...111,457,646
Ensembl chr 6:111,435,170...111,456,946
|
|
G
|
Tgfbr1
|
transforming growth factor, beta receptor 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of TGFBR1 mRNA; Cyclophosphamide results in increased expression of TGFBR1 protein
|
CTD |
PMID:23926183 |
|
NCBI chr 5:66,449,348...66,506,371
Ensembl chr 5:66,449,293...66,527,260
|
|
G
|
Tgfbr2
|
transforming growth factor, beta receptor 2
|
increases expression
|
ISO EXP
|
Cyclophosphamide results in increased expression of TGFBR2 mRNA Cyclophosphamide results in increased expression of TGFBR2 mRNA; Cyclophosphamide results in increased expression of TGFBR2 protein
|
CTD |
PMID:21041162 PMID:23926183 |
|
NCBI chr 8:124,672,677...124,761,741
Ensembl chr 8:124,674,986...124,761,469
|
|
G
|
Tgfbr3
|
transforming growth factor beta receptor 3
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of TGFBR3 mRNA; Cyclophosphamide results in increased expression of TGFBR3 protein
|
CTD |
PMID:23926183 |
|
NCBI chr14:2,634,294...2,810,269
Ensembl chr14:2,634,188...2,810,271
|
|
G
|
Thbs1
|
thrombospondin 1
|
increases expression multiple interactions
|
EXP ISO
|
Cyclophosphamide results in increased expression of THBS1 protein Cyclophosphamide results in increased expression of THBS1 mRNA axitinib inhibits the reaction [Cyclophosphamide results in increased expression of THBS1 protein]
|
CTD |
PMID:15331540 PMID:18202011 |
|
NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:125,510,250...125,525,402
|
|
G
|
Thnsl2
|
threonine synthase-like 2
|
multiple interactions
|
ISO
|
THNSL2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16896004 |
|
NCBI chr 4:103,112,974...103,132,122
Ensembl chr 4:104,670,925...104,691,959
|
|
G
|
Thpo
|
thrombopoietin
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of THPO protein asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of THPO protein]; CSF2 protein inhibits the reaction [Cyclophosphamide results in decreased expression of THPO protein]; dorsomorphin inhibits the reaction [asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of THPO protein]]
|
CTD |
PMID:38348709 |
|
Ensembl chr11:93,686,834...93,693,320
|
|
G
|
Thy1
|
Thy-1 cell surface antigen
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of THY1 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 8:53,286,396...53,291,541
Ensembl chr 8:53,286,148...53,291,540
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of TIMP1 mRNA
|
CTD |
PMID:23558518 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Tjp1
|
tight junction protein 1
|
multiple interactions decreases expression
|
EXP ISO
|
Anthocyanins inhibits the reaction [Cyclophosphamide results in decreased expression of TJP1 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of TJP1 protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TJP1 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of TJP1 protein]
|
CTD |
PMID:25451569 PMID:32151603 |
|
NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158
|
|
G
|
Tk1
|
thymidine kinase 1
|
increases mutagenesis
|
ISO
|
Cyclophosphamide metabolite results in increased mutagenesis of TK1 gene
|
CTD |
PMID:32087850 |
|
NCBI chr10:103,533,449...103,544,818
Ensembl chr10:103,533,449...103,556,228
|
|
G
|
Tlr2
|
toll-like receptor 2
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of TLR2 mRNA Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TLR2 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of TLR2 mRNA]
|
CTD |
PMID:32151603 |
|
NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:171,497,060...171,520,194
|
|
G
|
Tlr4
|
toll-like receptor 4
|
multiple interactions increases expression decreases expression
|
ISO
|
Cyclophosphamide inhibits the reaction [Paraquat results in increased expression of TLR4 mRNA]; Donepezil inhibits the reaction [Cyclophosphamide results in increased expression of TLR4 protein]; Fenofibrate inhibits the reaction [Cyclophosphamide results in increased expression of TLR4 protein]; fosaprepitant inhibits the reaction [Cyclophosphamide results in increased expression of TLR4 protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TLR4 mRNA]; levocabastine inhibits the reaction [Cyclophosphamide results in increased expression of TLR4 protein]
|
CTD |
PMID:32151603 PMID:36031164 PMID:38278497 PMID:38825044 PMID:39378958 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
G
|
Tlr6
|
toll-like receptor 6
|
decreases expression multiple interactions
|
ISO
|
Cyclophosphamide results in decreased expression of TLR6 mRNA Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TLR6 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of TLR6 mRNA]
|
CTD |
PMID:32151603 |
|
NCBI chr14:43,715,809...43,727,019
Ensembl chr14:43,698,751...43,740,462
|
|
G
|
Tlr9
|
toll-like receptor 9
|
multiple interactions increases expression
|
ISO
|
Cyclophosphamide inhibits the reaction [Paraquat results in increased expression of TLR9 mRNA]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of TLR9 protein]
|
CTD |
PMID:29753871 PMID:36031164 |
|
NCBI chr 8:115,743,407...115,747,523
Ensembl chr 8:115,742,889...115,750,148
|
|
G
|
Tm4sf1
|
transmembrane 4 L six family member 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of TM4SF1 mRNA
|
CTD |
PMID:17403535 |
|
NCBI chr 2:143,606,980...143,616,176
Ensembl chr 2:143,603,271...143,616,176
|
|
G
|
Tm6sf1
|
transmembrane 6 superfamily member 1
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of TM6SF1 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 1:145,209,052...145,237,725
Ensembl chr 1:145,209,585...145,237,715
|
|
G
|
Tmed3
|
transmembrane p24 trafficking protein 3
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of TMED3 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 8:99,121,361...99,129,653
Ensembl chr 8:99,121,361...99,129,215
|
|
G
|
Tmeff1
|
transmembrane protein with EGF-like and two follistatin-like domains 1
|
affects response to substance decreases expression
|
ISO EXP
|
TMEFF1 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in decreased expression of TMEFF1 mRNA
|
CTD |
PMID:16217747 PMID:27466211 |
|
NCBI chr 5:62,910,740...62,996,494
Ensembl chr 5:67,706,269...67,792,021
|
|
G
|
Tmem267
|
transmembrane protein 267
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of TMEM267 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 2:53,309,857...53,321,466
Ensembl chr 2:53,313,021...53,320,835
|
|
G
|
Tnf
|
tumor necrosis factor
|
affects expression increases secretion multiple interactions decreases expression increases expression decreases response to substance increases response to substance
|
ISO EXP
|
Cyclophosphamide affects the expression of TNF mRNA Cyclophosphamide results in increased secretion of TNF protein Cyclophosphamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein] Cyclophosphamide results in decreased expression of TNF mRNA; Cyclophosphamide results in decreased expression of TNF protein [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of TNF protein; [Cyclophosphamide co-treated with Methylprednisolone] inhibits the reaction [Paraquat results in increased expression of TNF protein]; Cyclophosphamide inhibits the reaction [Paraquat results in increased expression of TNF mRNA]; Donepezil inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Fenofibrate inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TNF mRNA]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of TNF mRNA]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of TNF protein]; levocabastine inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein] Cyclophosphamide results in increased expression of TNF mRNA; Cyclophosphamide results in increased expression of TNF protein allyl sulfide inhibits the reaction [Cyclophosphamide results in increased secretion of TNF protein]; Anthocyanins inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Berberine inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; chrysin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of TNF mRNA]; crocin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Curcumin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]]; O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of TNF mRNA]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; thymoquinone inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein] Cyclophosphamide affects the expression of TNF protein TNF protein results in decreased susceptibility to Cyclophosphamide TNF protein results in increased susceptibility to Cyclophosphamide
|
CTD |
PMID:8634684 PMID:11948286 PMID:12797522 PMID:18206168 PMID:18710439 PMID:18848347 PMID:18957084 PMID:19413659 PMID:20126887 PMID:20623750 PMID:20957680 PMID:23488790 PMID:23695977 PMID:25451569 PMID:25753322 PMID:29753871 PMID:30506662 PMID:31651976 PMID:31779506 PMID:32151603 PMID:32456565 PMID:32615180 PMID:33737140 PMID:35762198 PMID:36031164 PMID:36198566 PMID:36416909 PMID:37263553 PMID:37419146 PMID:37853057 PMID:37955270 PMID:38278497 PMID:38825044 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tnfaip3
|
TNF alpha induced protein 3
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of TNFAIP3 mRNA
|
CTD |
PMID:21873647 |
|
NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:15,528,921...15,543,979
|
|
G
|
Tnfrsf14
|
TNF receptor superfamily member 14
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of TNFRSF14 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 5:170,768,413...170,776,749
Ensembl chr 5:170,768,416...170,776,046
|
|
G
|
Tnfrsf18
|
TNF receptor superfamily member 18
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of TNFRSF18 mRNA
|
CTD |
PMID:15591121 |
|
NCBI chr 5:171,901,734...171,904,578
Ensembl chr 5:171,901,717...171,904,576
|
|
G
|
Tnfrsf19
|
TNF receptor superfamily member 19
|
increases expression multiple interactions
|
ISO
|
Cyclophosphamide results in increased expression of TNFRSF19 mRNA 5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in increased expression of TNFRSF19 mRNA]
|
CTD |
PMID:30760223 |
|
NCBI chr15:39,268,305...39,334,566
Ensembl chr15:39,268,305...39,356,438
|
|
G
|
Tnfsf9
|
TNF superfamily member 9
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of TNFSF9 mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 9:2,031,011...2,033,345
Ensembl chr 9:2,030,953...2,033,339
|
|
G
|
Tnni3
|
troponin I3, cardiac type
|
increases expression multiple interactions
|
ISO EXP
|
Cyclophosphamide results in increased expression of TNNI3 protein Fenofibrate inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein]; levocabastine inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein] Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein]
|
CTD |
PMID:17562616 PMID:18548196 PMID:35762198 PMID:38278497 |
|
NCBI chr 1:78,342,571...78,346,255
Ensembl chr 1:78,342,592...78,346,253
|
|
G
|
Top2a
|
DNA topoisomerase II alpha
|
multiple interactions increases expression
|
ISO EXP
|
TOP2A protein affects the susceptibility to [Cyclophosphamide co-treated with Epirubicin co-treated with Fluorouracil]; TOP2A protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] Cyclophosphamide results in increased expression of TOP2A mRNA
|
CTD |
PMID:11599041 PMID:16682728 PMID:18465341 |
|
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366
|
|
G
|
Tp53
|
tumor protein p53
|
multiple interactions increases activity increases expression increases mutagenesis affects response to substance
|
EXP ISO
|
astaxanthine inhibits the reaction [Cyclophosphamide results in increased expression of TP53 protein]; chlorophyllin inhibits the reaction [Cyclophosphamide results in increased mutagenesis of TP53 exon]; Curcumin inhibits the reaction [Cyclophosphamide results in increased mutagenesis of TP53 exon]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of TP53 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of TP53 mRNA] Cyclophosphamide results in increased expression of and results in increased phosphorylation of TRP53 protein; TRPM2 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of TRP53 protein] Cyclophosphamide metabolite results in increased activity of TP53 protein TP53 protein promotes the reaction [Methotrexate results in increased susceptibility to Cyclophosphamide metabolite] Cyclophosphamide results in increased expression of TP53 mRNA; Cyclophosphamide results in increased expression of TP53 protein TRP53 affects the susceptibility to Cyclophosphamide TP53 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:9610789 PMID:10766175 PMID:15182437 PMID:19227835 PMID:20038455 PMID:20655369 PMID:22010212 PMID:32197949 PMID:39952379 More...
|
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Tpd52
|
tumor protein D52
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of TPD52 mRNA
|
CTD |
PMID:21873647 |
|
NCBI chr 2:94,642,514...94,723,442
Ensembl chr 2:94,642,585...94,724,241
|
|
G
|
Tpm1
|
tropomyosin 1
|
affects response to substance increases expression
|
ISO EXP
|
TPM1 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of TPM1 protein
|
CTD |
PMID:15928459 PMID:16217747 |
|
NCBI chr 8:76,516,654...76,543,661
Ensembl chr 8:76,511,871...76,543,468
|
|
G
|
Traf2
|
Tnf receptor-associated factor 2
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of TRAF2 protein
|
CTD |
PMID:38740238 |
|
NCBI chr 3:28,740,098...28,764,752
Ensembl chr 3:28,740,098...28,764,691
|
|
G
|
Trib3
|
tribbles pseudokinase 3
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of TRIB3 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 3:161,269,939...161,275,533
Ensembl chr 3:161,269,955...161,274,802
|
|
G
|
Trim32
|
tripartite motif-containing 32
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of TRIM32 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 5:84,020,604...84,031,483
Ensembl chr 5:84,014,803...84,042,748
|
|
G
|
Trim58
|
tripartite motif-containing 58
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of TRIM58 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr10:43,022,933...43,038,984
Ensembl chr10:43,523,372...43,535,784
|
|
G
|
Triml1
|
tripartite motif family-like 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of TRIML1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr16:48,994,968...49,005,343
Ensembl chr16:55,729,691...55,737,769
|
|
G
|
Trpa1
|
transient receptor potential cation channel, subfamily A, member 1
|
multiple interactions
|
EXP
|
[2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide binds to and results in decreased activity of TRPA1 protein] which results in decreased susceptibility to Cyclophosphamide
|
CTD |
PMID:23523557 |
|
NCBI chr 5:9,163,060...9,217,325
Ensembl chr 5:9,163,060...9,217,325
|
|
G
|
Trpm2
|
transient receptor potential cation channel, subfamily M, member 2
|
increases expression multiple interactions
|
ISO
|
Cyclophosphamide results in increased expression of TRPM2 mRNA TRPM2 protein affects the reaction [Cyclophosphamide results in decreased expression of GCLM mRNA]; TRPM2 protein affects the reaction [Cyclophosphamide results in decreased expression of HMOX1 mRNA]; TRPM2 protein affects the reaction [Cyclophosphamide results in decreased expression of NQO1 mRNA]; TRPM2 protein affects the reaction [Cyclophosphamide results in increased expression of BAX mRNA]; TRPM2 protein affects the reaction [Cyclophosphamide results in increased expression of CASP3 mRNA]; TRPM2 protein affects the reaction [Cyclophosphamide results in increased expression of H2AX protein]; TRPM2 protein affects the reaction [Cyclophosphamide results in increased expression of S100A1 protein]; TRPM2 protein affects the reaction [Cyclophosphamide results in increased expression of S100B protein]; TRPM2 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of TRP53 protein]
|
CTD |
PMID:39952379 |
|
NCBI chr20:10,703,190...10,752,795
Ensembl chr20:10,704,482...10,752,802
|
|
G
|
Trpv1
|
transient receptor potential cation channel, subfamily V, member 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of TRPV1 mRNA alternative form
|
CTD |
PMID:18797299 |
|
NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021
|
|
G
|
Tuba4a
|
tubulin, alpha 4A
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of TUBA4A mRNA
|
CTD |
PMID:21527772 |
|
NCBI chr 9:84,158,871...84,174,041
Ensembl chr 9:84,158,280...84,162,584
|
|
G
|
Tubb2b
|
tubulin, beta 2B class IIb
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of TUBB2B mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr17:30,953,086...30,956,133
Ensembl chr17:30,952,923...30,955,990
|
|
G
|
Tug1
|
taurine up-regulated 1
|
decreases expression multiple interactions
|
EXP
|
Cyclophosphamide results in decreased expression of TUG1 mRNA sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased expression of TUG1 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of TUG1 mRNA]
|
CTD |
PMID:32197949 |
|
NCBI chr14:82,743,501...82,750,534
Ensembl chr14:82,746,113...82,750,534
|
|
G
|
Txn1
|
thioredoxin 1
|
multiple interactions decreases expression
|
ISO
|
ganoderic acid A inhibits the reaction [Cyclophosphamide results in decreased expression of TXN protein]
|
CTD |
PMID:30506662 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307
|
|
G
|
Txnip
|
thioredoxin interacting protein
|
increases expression multiple interactions
|
ISO
|
Cyclophosphamide results in increased expression of TXNIP protein ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of TXNIP protein]
|
CTD |
PMID:30506662 |
|
NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:186,781,163...186,785,731
|
|
G
|
Txnrd1
|
thioredoxin reductase 1
|
decreases activity
|
ISO
|
Cyclophosphamide results in decreased activity of TXNRD1 protein
|
CTD |
PMID:19168513 |
|
NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817
|
|
G
|
Tymp
|
thymidine phosphorylase
|
multiple interactions
|
ISO
|
[Doxorubicin co-treated with Cyclophosphamide] results in increased expression of TYMP protein; [Epirubicin co-treated with Cyclophosphamide] results in increased expression of TYMP protein
|
CTD |
PMID:15150550 |
|
NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:122,316,520...122,324,003
|
|
G
|
Tyrobp
|
transmembrane immune signaling adaptor Tyrobp
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of TYROBP mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 1:94,800,372...94,804,307
Ensembl chr 1:94,800,117...94,804,299
|
|
G
|
Ubd
|
ubiquitin D
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of UBD mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr20:1,390,734...1,392,685
Ensembl chr20:1,390,600...1,413,965
|
|
G
|
Ubr7
|
ubiquitin protein ligase E3 component n-recognin 7
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of UBR7 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 6:121,898,613...121,918,480
Ensembl chr 6:127,663,447...127,694,390
|
|
G
|
Ucp1
|
uncoupling protein 1
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of UCP1 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr19:41,713,350...41,721,421
Ensembl chr19:41,713,351...41,721,420
|
|
G
|
Umod
|
uromodulin
|
decreases expression multiple interactions
|
EXP
|
Cyclophosphamide results in decreased expression of UMOD protein O-1602 compound inhibits the reaction [Cyclophosphamide results in decreased expression of UMOD protein]
|
CTD |
PMID:32615180 |
|
NCBI chr 1:183,247,676...183,261,665
Ensembl chr 1:183,247,674...183,261,030
|
|
G
|
Ung
|
uracil-DNA glycosylase
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of UNG mRNA
|
CTD |
PMID:11056294 |
|
NCBI chr12:48,145,838...48,154,789
Ensembl chr12:48,145,838...48,155,257
|
|
G
|
Upk1a
|
uroplakin 1A
|
decreases expression multiple interactions
|
EXP
|
Cyclophosphamide results in decreased expression of UPK1A mRNA Mesna inhibits the reaction [Cyclophosphamide results in decreased expression of UPK1A mRNA]
|
CTD |
PMID:19654953 PMID:20186394 |
|
NCBI chr 1:94,987,110...94,998,083
Ensembl chr 1:94,987,108...94,997,787
|
|
G
|
Upk1b
|
uroplakin 1B
|
decreases expression multiple interactions
|
EXP
|
Cyclophosphamide results in decreased expression of UPK1B mRNA Mesna inhibits the reaction [Cyclophosphamide results in decreased expression of UPK1B mRNA]
|
CTD |
PMID:19654953 PMID:20186394 |
|
NCBI chr11:61,953,687...61,991,029
Ensembl chr11:75,459,200...75,496,579
|
|
G
|
Upk2
|
uroplakin 2
|
decreases expression increases export multiple interactions
|
EXP ISO
|
Cyclophosphamide results in decreased expression of UPK2 mRNA; Cyclophosphamide results in decreased expression of UPK2 protein Cyclophosphamide results in increased export of UPK2 protein Mesna inhibits the reaction [Cyclophosphamide results in decreased expression of UPK2 mRNA]; Mesna inhibits the reaction [Cyclophosphamide results in decreased expression of UPK2 protein]; S-allylcysteine inhibits the reaction [Cyclophosphamide results in decreased expression of UPK2 mRNA]; S-allylcysteine inhibits the reaction [Cyclophosphamide results in decreased expression of UPK2 protein]
|
CTD |
PMID:19654953 PMID:20186394 PMID:26424769 PMID:27234646 |
|
NCBI chr 8:53,675,994...53,677,986
Ensembl chr 8:53,675,994...53,677,986
|
|
G
|
Upk3a
|
uroplakin 3A
|
decreases expression multiple interactions
|
EXP
|
Cyclophosphamide results in decreased expression of UPK3A mRNA; Cyclophosphamide results in decreased expression of UPK3A protein Mesna inhibits the reaction [Cyclophosphamide results in decreased expression of UPK3A mRNA]; Mesna inhibits the reaction [Cyclophosphamide results in decreased expression of UPK3A protein]
|
CTD |
PMID:19654953 PMID:20186394 |
|
NCBI chr 7:116,128,981...116,139,950
Ensembl chr 7:118,014,108...118,019,870
|
|
G
|
Usp36
|
ubiquitin specific peptidase 36
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of USP36 mRNA
|
CTD |
PMID:20849824 |
|
NCBI chr10:103,995,970...104,027,492
Ensembl chr10:103,995,970...104,023,450
|
|
G
|
Usp44
|
ubiquitin specific peptidase 44
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of USP44 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 7:28,364,169...28,412,039
Ensembl chr 7:30,251,205...30,297,906
|
|
G
|
Usp5
|
ubiquitin specific peptidase 5
|
increases expression multiple interactions
|
ISO
|
Cyclophosphamide results in increased expression of USP5 protein 3-cyanoalanine inhibits the reaction [[N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of USP5 protein]; [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of USP5 protein
|
CTD |
PMID:29129814 |
|
NCBI chr 4:159,305,927...159,321,345
Ensembl chr 4:159,305,938...159,320,956
|
|
G
|
Vcam1
|
vascular cell adhesion molecule 1
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of VCAM1 mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801
|
|
G
|
Vcp
|
valosin-containing protein
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of VCP protein
|
CTD |
PMID:15928459 |
|
NCBI chr 5:62,005,984...62,025,387
Ensembl chr 5:62,005,985...62,025,387
|
|
G
|
Vdr
|
vitamin D receptor
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of VDR mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:130,866,745...130,916,757
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
multiple interactions decreases expression affects expression increases expression
|
ISO EXP
|
Cyclophosphamide promotes the reaction [NGF results in increased expression of VEGFA mRNA] Cyclophosphamide metabolite results in decreased expression of VEGFA mRNA Cyclophosphamide affects the expression of VEGFA protein Cyclophosphamide results in increased expression of VEGFA mRNA
|
CTD |
PMID:18632792 PMID:24356939 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
G
|
Vim
|
vimentin
|
affects expression
|
EXP
|
Cyclophosphamide affects the expression of VIM mRNA
|
CTD |
PMID:10859244 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746
|
|
G
|
Vip
|
vasoactive intestinal peptide
|
multiple interactions affects response to substance affects expression
|
ISO EXP
|
VIP protein affects the reaction [Cyclophosphamide results in increased expression of NGF protein]; VIP protein inhibits the reaction [Cyclophosphamide results in increased expression of CXCL1 protein]; VIP protein inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein] VIP affects the susceptibility to Cyclophosphamide Cyclophosphamide affects the expression of VIP mRNA
|
CTD |
PMID:18299998 PMID:18483878 PMID:18563302 |
|
NCBI chr 1:44,470,232...44,478,561
Ensembl chr 1:44,470,462...44,478,558
|
|
G
|
Vipr1
|
vasoactive intestinal peptide receptor 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of VIPR1 mRNA
|
CTD |
PMID:18563302 |
|
NCBI chr 8:130,181,219...130,217,098
Ensembl chr 8:130,187,731...130,217,096
|
|
G
|
Vipr2
|
vasoactive intestinal peptide receptor 2
|
affects expression
|
EXP
|
Cyclophosphamide affects the expression of VIPR2 mRNA
|
CTD |
PMID:18563302 |
|
NCBI chr 6:136,996,664...137,070,599
Ensembl chr 6:143,144,523...143,213,609
|
|
G
|
Vldlr
|
very low density lipoprotein receptor
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of VLDLR mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr 1:234,239,769...234,272,150
Ensembl chr 1:234,240,121...234,272,154
|
|
G
|
Was
|
WASP actin nucleation promoting factor
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of WAS mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr X:17,077,057...17,085,802
Ensembl chr X:17,073,314...17,085,802
|
|
G
|
Wnt3a
|
Wnt family member 3A
|
multiple interactions decreases expression
|
EXP
|
coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of WNT3A protein]
|
CTD |
PMID:39209270 |
|
NCBI chr10:44,533,734...44,577,919
Ensembl chr10:44,533,734...44,577,919
|
|
G
|
Xaf1
|
XIAP associated factor 1
|
decreases expression
|
ISO
|
Cyclophosphamide metabolite results in decreased expression of XAF1 mRNA
|
CTD |
PMID:24356939 |
|
NCBI chr10:57,415,935...57,428,348
Ensembl chr10:57,415,658...57,428,349
|
|
G
|
Xbp1
|
X-box binding protein 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of XBP1 protein alternative form
|
CTD |
PMID:38740238 |
|
NCBI chr14:84,604,623...84,609,707
Ensembl chr14:84,604,107...84,609,706
|
|
G
|
Xdh
|
xanthine dehydrogenase
|
increases activity multiple interactions
|
EXP
|
Cyclophosphamide results in increased activity of XDH protein Rutin inhibits the reaction [Cyclophosphamide results in increased activity of XDH protein]
|
CTD |
PMID:25753322 |
|
NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350
|
|
G
|
Xist
|
X inactive specific transcript
|
increases expression
|
ISO
|
Cyclophosphamide results in increased expression of XIST mRNA
|
CTD |
PMID:15331540 |
|
NCBI chr X:72,540,753...72,558,266
|
|
G
|
Xpc
|
XPC complex subunit, DNA damage recognition and repair factor
|
affects expression increases expression
|
EXP ISO
|
Cyclophosphamide affects the expression of XPC mRNA Cyclophosphamide results in increased expression of XPC mRNA
|
CTD |
PMID:11056294 PMID:29445054 |
|
NCBI chr 4:125,550,833...125,578,084
Ensembl chr 4:125,550,833...125,578,305
|
|
G
|
Xrcc1
|
X-ray repair cross complementing 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of XRCC1 mRNA
|
CTD |
PMID:11056294 |
|
NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:89,268,644...89,296,613
|
|
G
|
Xrcc6
|
X-ray repair cross complementing 6
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of XRCC6 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 7:115,423,026...115,443,884
Ensembl chr 7:115,422,662...115,443,884
|
|
G
|
Yap1
|
Yes1 associated transcriptional regulator
|
multiple interactions
|
EXP
|
Cyclophosphamide results in decreased expression of and results in increased phosphorylation of YAP1 protein; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of and results in increased phosphorylation of YAP1 protein]
|
CTD |
PMID:36154502 |
|
NCBI chr 8:13,380,551...13,451,640
Ensembl chr 8:13,380,551...13,451,437
|
|
G
|
Ybx3
|
Y box binding protein 3
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of YBX3 protein
|
CTD |
PMID:15928459 |
|
NCBI chr 4:166,861,180...166,884,532
Ensembl chr 4:166,861,181...166,884,691
|
|
G
|
Zap70
|
zeta chain of T cell receptor associated protein kinase 70
|
decreases expression
|
ISO
|
Cyclophosphamide results in decreased expression of ZAP70 mRNA
|
CTD |
PMID:21041162 |
|
NCBI chr 9:46,485,605...46,507,552
Ensembl chr 9:46,485,598...46,509,062
|
|
G
|
Zbtb33
|
zinc finger and BTB domain containing 33
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ZBTB33 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr X:116,963,337...116,970,547
Ensembl chr X:121,828,952...121,839,399
|
|
G
|
Zbtb41
|
zinc finger and BTB domain containing 41
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ZBTB41 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr13:53,591,961...53,622,007
Ensembl chr13:53,592,797...53,617,780
|
|
G
|
Zc3h12b
|
zinc finger CCCH-type containing 12B
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ZC3H12B mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr X:60,615,616...60,849,278
Ensembl chr X:64,625,161...64,858,633
|
|
G
|
Zc3h15l1
|
zinc finger CCCH-type containing 15 like 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ZC3H15L1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr17:43,670,444...43,671,788
Ensembl chr17:48,366,221...48,367,501
|
|
G
|
Zdhhc1
|
zinc finger, DHHC-type containing 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ZDHHC1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr19:50,260,445...50,285,634
Ensembl chr19:50,260,445...50,271,957
|
|
G
|
Zfp142
|
zinc finger protein 142
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ZFP142 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 9:76,141,053...76,164,784
Ensembl chr 9:83,591,318...83,613,896
|
|
G
|
Zfp169
|
zinc finger protein 169
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ZFP169 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr17:16,139,204...16,167,242
Ensembl chr17:16,345,647...16,373,928
|
|
G
|
Zfp219
|
zinc finger protein 219
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ZFP219 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr15:24,695,831...24,710,039
Ensembl chr15:27,169,339...27,182,926
|
|
G
|
Zfp24
|
zinc finger protein 24
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ZFP24 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr18:15,295,687...15,307,319
Ensembl chr18:15,574,762...15,582,290
|
|
G
|
Zfp263
|
zinc finger protein 263
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ZFP263 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr10:12,270,785...12,280,982
Ensembl chr10:12,234,057...12,277,587
|
|
G
|
Zfp280d
|
zinc finger protein 280D
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ZFP280D mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 8:81,872,108...81,961,194
Ensembl chr 8:81,873,335...81,961,201
|
|
G
|
Zfp318
|
zinc finger protein 318
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ZFP318 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 9:14,562,958...14,601,557
Ensembl chr 9:22,060,916...22,099,551
|
|
G
|
Zfp36l1
|
zinc finger protein 36, C3H type-like 1
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ZFP36L1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 6:104,663,396...104,669,815
Ensembl chr 6:104,663,399...104,687,979
|
|
G
|
Zfp385a
|
zinc finger protein 385A
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ZFP385A mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 7:136,327,393...136,354,017
Ensembl chr 7:136,327,393...136,354,321
|
|
G
|
Zfp385c
|
zinc finger protein 385C
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ZFP385C mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr10:85,562,003...85,618,100
Ensembl chr10:86,062,512...86,106,063
|
|
G
|
Zfp385d
|
zinc finger protein 385D
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ZFP385D mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr15:5,040,182...5,849,975
Ensembl chr15:7,473,435...8,504,582
|
|
G
|
Zfp40
|
zinc finger protein 40
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ZFP40 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 1:62,962,456...62,985,007
Ensembl chr 1:71,636,452...71,658,827
|
|
G
|
Zfp414
|
zinc finger protein 414
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ZFP414 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 7:14,420,232...14,422,939
Ensembl chr 7:15,122,401...15,125,755
|
|
G
|
Zfp513
|
zinc finger protein 513
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ZFP513 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 6:30,894,153...30,897,414
Ensembl chr 6:30,894,079...30,897,413
|
|
G
|
Zfp532
|
zinc finger protein 532
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ZFP532 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr18:59,080,082...59,203,672
Ensembl chr18:61,364,378...61,473,649
|
|
G
|
Zfp622
|
zinc finger protein 622
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ZFP622 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 2:78,205,655...78,224,888
Ensembl chr 2:78,066,031...78,225,356
|
|
G
|
Zfp652
|
zinc finger protein 652
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ZFP652 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr10:81,123,326...81,203,153
Ensembl chr10:81,146,507...81,198,827
|
|
G
|
Zfp655
|
zinc finger protein 655
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ZFP655 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr12:9,349,985...9,375,449
Ensembl chr12:14,471,415...14,488,678
|
|
G
|
Zfp827
|
zinc finger protein 827
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ZFP827 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr19:45,624,849...45,791,739
Ensembl chr19:45,614,604...45,844,430
|
|
G
|
Zfr
|
zinc finger RNA binding protein
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ZFR mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 2:61,137,611...61,200,322
Ensembl chr 2:62,864,338...62,929,133
|
|
G
|
Zhx3
|
zinc fingers and homeoboxes 3
|
decreases expression
|
EXP
|
Cyclophosphamide results in decreased expression of ZHX3 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr 3:169,837,497...169,968,371
Ensembl chr 3:169,837,516...169,935,530
|
|
G
|
Zic1
|
Zic family member 1
|
affects response to substance
|
ISO
|
ZIC1 protein affects the susceptibility to Cyclophosphamide
|
CTD |
PMID:16217747 |
|
NCBI chr 8:91,908,548...91,918,020
Ensembl chr 8:100,787,789...100,792,427
|
|
G
|
Zzef1
|
zinc finger ZZ-type and EF-hand domain containing 1
|
increases expression
|
EXP
|
Cyclophosphamide results in increased expression of ZZEF1 mRNA
|
CTD |
PMID:27281708 |
|
NCBI chr10:57,911,728...58,049,412
Ensembl chr10:57,911,728...58,049,412
|
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
increases expression multiple interactions
|
ISO
|
Ifosfamide results in increased expression of ABCB1 protein [Ifosfamide results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; NR1I2 protein promotes the reaction [Ifosfamide results in increased expression of ABCB1 protein]
|
CTD |
PMID:20041327 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcb6
|
ATP binding cassette subfamily B member 6
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of ABCB6 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 9:84,117,222...84,125,939
Ensembl chr 9:84,117,220...84,125,526
|
|
G
|
Abcb9
|
ATP binding cassette subfamily B member 9
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of ABCB9 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr12:38,146,659...38,192,862
Ensembl chr12:38,159,904...38,192,860
|
|
G
|
Abcg1
|
ATP binding cassette subfamily G member 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of ABCG1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,127,803...9,186,563
|
|
G
|
Abhd4
|
abhydrolase domain containing 4, N-acyl phospholipase B
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of ABHD4 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr15:27,697,384...27,716,013
Ensembl chr15:31,674,143...31,687,007
|
|
G
|
Ache
|
acetylcholinesterase
|
increases activity multiple interactions
|
EXP
|
Ifosfamide results in increased activity of ACHE protein morin inhibits the reaction [Ifosfamide results in increased activity of ACHE protein]
|
CTD |
PMID:31722249 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410
|
|
G
|
Acsl1
|
acyl-CoA synthetase long-chain family member 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of ACSL1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr16:52,487,870...52,554,110
Ensembl chr16:52,487,870...52,554,023
|
|
G
|
Agrn
|
agrin
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of AGRN mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 5:172,031,528...172,064,429
Ensembl chr 5:172,031,528...172,064,539
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
affects activity
|
ISO
|
Ifosfamide affects the activity of AHR protein
|
CTD |
PMID:25596134 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Ak4
|
adenylate kinase 4
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of AK4 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 5:121,154,565...121,214,403
Ensembl chr 5:121,154,572...121,214,401
|
|
G
|
Akr1c2
|
aldo-keto reductase family 1, member C2
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of AKR1C2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686
|
|
G
|
Aldh1a3
|
aldehyde dehydrogenase 1 family, member A3
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of ALDH1A3 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:129,392,516...129,436,552
Ensembl chr 1:129,392,516...129,427,777
|
|
G
|
Aldoa
|
aldolase, fructose-bisphosphate A
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of ALDOA mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:190,832,820...190,838,211
|
|
G
|
Als2cl
|
ALS2 C-terminal like
|
affects expression
|
ISO
|
Ifosfamide affects the expression of ALS2CL mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 8:110,863,753...110,884,434
Ensembl chr 8:119,743,248...119,762,843
|
|
G
|
Ankra2
|
ankyrin repeat family A member 2
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of ANKRA2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:29,612,867...29,623,748
Ensembl chr 2:31,347,090...31,364,394
|
|
G
|
Arhgef10
|
Rho guanine nucleotide exchange factor 10
|
affects expression
|
ISO
|
Ifosfamide affects the expression of ARHGEF10 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr16:74,647,147...74,738,784
Ensembl chr16:81,349,429...81,440,054
|
|
G
|
Arln
|
allregulin
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of ARLN mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:211,055,925...211,057,685
Ensembl chr 2:213,740,525...213,742,952
|
|
G
|
Asns
|
asparagine synthetase (glutamine-hydrolyzing)
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of ASNS mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050
|
|
G
|
Atf4
|
activating transcription factor 4
|
affects activity
|
ISO
|
Ifosfamide affects the activity of ATF4 protein
|
CTD |
PMID:25596134 |
|
NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739
|
|
G
|
Atosa
|
atos homolog A
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of ATOSA mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 8:84,575,360...84,653,103
Ensembl chr 8:84,575,370...84,653,091
|
|
G
|
Atxn1
|
ataxin 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of ATXN1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr17:18,943,397...19,354,751
Ensembl chr17:19,208,200...19,356,790
|
|
G
|
Aurkb
|
aurora kinase B
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of AURKB mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr10:54,243,116...54,249,675
Ensembl chr10:54,242,850...54,252,285
|
|
G
|
Avp
|
arginine vasopressin
|
multiple interactions
|
ISO
|
[Ifosfamide co-treated with Mesna] results in increased expression of AVP protein
|
CTD |
PMID:2261371 |
|
NCBI chr 3:138,246,544...138,248,522
Ensembl chr 3:138,246,554...138,248,522
|
|
G
|
Axl
|
Axl receptor tyrosine kinase
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of AXL mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:90,392,864...90,424,123
Ensembl chr 1:90,392,864...90,424,009
|
|
G
|
B2m
|
beta-2 microglobulin
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of B2M protein
|
CTD |
PMID:8625085 PMID:9261752 |
|
NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:129,549,318...129,555,356
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of BAX mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcat1
|
branched chain amino acid transaminase 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of BCAT1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:179,695,662...179,777,973
Ensembl chr 4:179,695,662...179,777,288
|
|
G
|
Bche
|
butyrylcholinesterase
|
increases activity multiple interactions
|
EXP
|
Ifosfamide results in increased activity of BCHE protein morin inhibits the reaction [Ifosfamide results in increased activity of BCHE protein]
|
CTD |
PMID:31722249 |
|
NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:160,606,288...160,699,760
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions decreases expression
|
ISO EXP
|
BCL2 protein inhibits the reaction [Ifosfamide results in increased activity of CASP9 protein] Carnitine inhibits the reaction [Ifosfamide results in decreased expression of BCL2 mRNA]; morin inhibits the reaction [Ifosfamide results in decreased expression of BCL2 mRNA]
|
CTD |
PMID:11723234 PMID:23213347 PMID:31722249 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bdnf
|
brain-derived neurotrophic factor
|
multiple interactions increases expression
|
EXP
|
morin inhibits the reaction [Ifosfamide results in increased expression of BDNF mRNA]
|
CTD |
PMID:31722249 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657
|
|
G
|
Bglap
|
bone gamma-carboxyglutamate protein
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of BGLAP protein
|
CTD |
PMID:1525342 |
|
NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318
|
|
G
|
Bhlhe40
|
basic helix-loop-helix family, member e40
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of BHLHE40 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:143,174,048...143,180,783
|
|
G
|
Bnip3
|
BCL2 interacting protein 3
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of BNIP3 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962
|
|
G
|
Brd2
|
bromodomain containing 2
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of BRD2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr20:4,728,282...4,737,286
Ensembl chr20:4,728,951...4,737,290
|
|
G
|
Btg2
|
BTG anti-proliferation factor 2
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of BTG2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr13:48,083,931...48,087,690
Ensembl chr13:48,083,931...48,087,690
|
|
G
|
C15h8orf58
|
similar to human chromosome 8 open reading frame 58
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of C8ORF58 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr15:45,228,615...45,235,274
Ensembl chr15:51,638,350...51,642,974
|
|
G
|
Camkk2
|
calcium/calmodulin-dependent protein kinase kinase 2
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of CAMKK2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr12:39,451,828...39,505,719
Ensembl chr12:39,451,834...39,514,964
|
|
G
|
Cars1
|
cysteinyl-tRNA synthetase 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of CARS1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:208,183,092...208,225,425
Ensembl chr 1:208,182,788...208,225,407
|
|
G
|
Casp1
|
caspase 1
|
increases response to substance
|
ISO
|
CASP1 results in increased susceptibility to Ifosfamide
|
CTD |
PMID:9491796 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions increases activity increases expression
|
EXP
|
Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP3 mRNA]; morin inhibits the reaction [Ifosfamide results in increased activity of CASP3 protein]
|
CTD |
PMID:23213347 PMID:31722249 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions increases expression
|
ISO EXP
|
BCL2 protein inhibits the reaction [Ifosfamide results in increased activity of CASP9 protein] Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP9 mRNA]
|
CTD |
PMID:11723234 PMID:23213347 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cat
|
catalase
|
multiple interactions decreases activity decreases expression
|
EXP
|
Carnitine inhibits the reaction [Ifosfamide results in decreased expression of CAT mRNA]; morin inhibits the reaction [Ifosfamide results in decreased activity of CAT protein]
|
CTD |
PMID:23213347 PMID:31722249 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccdc90b
|
coiled-coil domain containing 90B
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of CCDC90B mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:146,632,756...146,646,314
Ensembl chr 1:156,045,138...156,061,403
|
|
G
|
Ccne2
|
cyclin E2
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of CCNE2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 5:29,082,169...29,094,879
Ensembl chr 5:29,082,703...29,094,882
|
|
G
|
Ccng2
|
cyclin G2
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of CCNG2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr14:15,088,694...15,097,190
Ensembl chr14:15,088,695...15,096,206
|
|
G
|
Cda
|
cytidine deaminase
|
multiple interactions
|
EXP
|
[CYP2B1 co-treated with CDA] results in increased susceptibility to [Ifosfamide co-treated with Fluorouracil]; [CYP2B1 co-treated with CDA] results in increased susceptibility to Ifosfamide
|
CTD |
PMID:10811482 |
|
NCBI chr 5:155,839,929...155,866,541
Ensembl chr 5:155,839,929...155,866,541
|
|
G
|
Cdk6
|
cyclin-dependent kinase 6
|
affects expression
|
ISO
|
Ifosfamide affects the expression of CDK6 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:31,601,192...31,781,701
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of CDKN1A mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cers5
|
ceramide synthase 5
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of CERS5 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 7:132,738,834...132,776,920
Ensembl chr 7:132,738,834...132,776,786
|
|
G
|
Cmbl
|
carboxymethylenebutenolidase homolog
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of CMBL mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:82,569,257...82,591,007
Ensembl chr 2:84,242,512...84,301,880
|
|
G
|
Ctdp1
|
CTD phosphatase subunit 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of CTDP1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr18:76,129,243...76,193,404
Ensembl chr18:76,129,243...76,190,578
|
|
G
|
Cth
|
cystathionine gamma-lyase
|
affects expression
|
ISO
|
Ifosfamide affects the expression of CTH mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:249,634,731...249,661,066
Ensembl chr 2:249,634,731...249,661,066
|
|
G
|
Ctsc
|
cathepsin C
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of CTSC mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:151,440,860...151,472,430
Ensembl chr 1:151,441,032...151,474,082
|
|
G
|
Cttn
|
cortactin
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of CTTN mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:209,029,048...209,064,577
Ensembl chr 1:209,029,048...209,058,211
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
increases response to substance decreases expression
|
ISO
|
CYP1A1 protein results in increased susceptibility to Ifosfamide Ifosfamide results in decreased expression of CYP1A1 mRNA
|
CTD |
PMID:20507880 PMID:25596134 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of CYP1A2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of CYP1B1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
G
|
Cyp2b1
|
cytochrome P450, family 2, subfamily b, polypeptide 1
|
multiple interactions increases response to substance increases activity increases metabolic processing increases hydroxylation
|
EXP
|
[CYP2B1 co-treated with CDA] results in increased susceptibility to [Ifosfamide co-treated with Fluorouracil]; [CYP2B1 co-treated with CDA] results in increased susceptibility to Ifosfamide; Metyrapone inhibits the reaction [CYP2B1 results in increased susceptibility to Ifosfamide]; Mitomycin affects the reaction [CYP2B1 results in increased susceptibility to Ifosfamide] CYP2B1 results in increased activity of Ifosfamide CYP2B1 protein results in increased metabolism of Ifosfamide; CYP2B1 results in increased metabolism of Ifosfamide CYP2B1 protein mutant form results in increased hydroxylation of Ifosfamide
|
CTD |
PMID:2272335 PMID:7834628 PMID:8640822 PMID:9592392 PMID:10415877 PMID:10811482 PMID:15102956 More...
|
|
NCBI chr 1:90,646,098...90,669,762
|
|
G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
increases response to substance affects metabolic processing multiple interactions
|
ISO
|
CYP2B6 results in increased susceptibility to Ifosfamide CYP2B6 protein affects the metabolism of Ifosfamide POR promotes the reaction [CYP2B6 results in increased susceptibility to Ifosfamide]
|
CTD |
PMID:9766669 PMID:15875221 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G
|
Cyp2c11
|
cytochrome P450, subfamily 2, polypeptide 11
|
increases activity increases metabolic processing multiple interactions increases response to substance
|
ISO
|
CYP2C18 results in increased activity of Ifosfamide CYP2C18 results in increased metabolism of Ifosfamide POR promotes the reaction [CYP2C18 results in increased susceptibility to Ifosfamide]
|
CTD |
PMID:9241661 PMID:9766669 PMID:15301741 |
|
NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:246,174,711...246,211,853
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
increases response to substance increases activity
|
ISO
|
CYP2C19 protein results in increased susceptibility to Ifosfamide CYP2C19 results in increased activity of Ifosfamide
|
CTD |
PMID:9241661 PMID:20507880 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
G
|
Cyp2c79
|
cytochrome P450, family 2, subfamily c, polypeptide 79
|
increases activity
|
ISO
|
CYP2C8 results in increased activity of Ifosfamide
|
CTD |
PMID:9241661 |
|
|
|
G
|
Cyp2d4
|
cytochrome P450, family 2, subfamily d, polypeptide 4
|
increases response to substance
|
ISO
|
CYP2D6 protein results in increased susceptibility to Ifosfamide
|
CTD |
PMID:20507880 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases expression affects hydroxylation affects metabolic processing increases response to substance affects degradation decreases ethylation
|
ISO
|
Ifosfamide results in increased expression of CYP3A4 mRNA CYP3A4 protein affects the hydroxylation of Ifosfamide CYP3A4 protein affects the metabolism of Ifosfamide CYP3A4 protein results in increased susceptibility to Ifosfamide; CYP3A4 results in increased susceptibility to Ifosfamide CYP3A4 protein affects the degradation of Ifosfamide CYP3A4 gene mutant form results in decreased ethylation of Ifosfamide; CYP3A4 protein results in decreased ethylation of Ifosfamide
|
CTD |
PMID:9766669 PMID:12136253 PMID:15821045 PMID:15875221 PMID:18839173 PMID:20507880 More...
|
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Cyp3a23-3a1
|
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1
|
increases hydroxylation
|
EXP
|
CYP3A23-3A1 protein results in increased hydroxylation of Ifosfamide
|
CTD |
PMID:15919850 |
|
NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813
|
|
G
|
Cyp3a9
|
cytochrome P450, family 3, subfamily a, polypeptide 9
|
affects metabolic processing decreases ethylation
|
ISO
|
CYP3A5 protein affects the metabolism of Ifosfamide CYP3A5 protein results in decreased ethylation of Ifosfamide
|
CTD |
PMID:15821045 PMID:15875221 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154
|
|
G
|
Ddit3
|
DNA-damage inducible transcript 3
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of DDIT3 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
G
|
Ddit4
|
DNA-damage-inducible transcript 4
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of DDIT4 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037
|
|
G
|
Ddx17
|
DEAD-box helicase 17
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of DDX17 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 7:112,971,522...112,989,747
Ensembl chr 7:112,971,523...112,989,747
|
|
G
|
Dgka
|
diacylglycerol kinase, alpha
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of DGKA mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,733,248...1,759,569
|
|
G
|
Dlx1
|
distal-less homeobox 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of DLX1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 3:76,763,864...76,768,454
Ensembl chr 3:76,763,500...76,768,447
|
|
G
|
Dnai3
|
dynein axonemal intermediate chain 3
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of DNAI3 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:234,947,910...235,006,173
Ensembl chr 2:237,604,068...237,666,465
|
|
G
|
Dnajb2
|
DnaJ heat shock protein family (Hsp40) member B2
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of DNAJB2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 9:76,731,060...76,739,278
Ensembl chr 9:84,179,695...84,187,942
|
|
G
|
Dnajb9
|
DnaJ heat shock protein family (Hsp40) member B9
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of DNAJB9 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:66,997,842...67,009,344
|
|
G
|
Dnmbp
|
dynamin binding protein
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of DNMBP mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:252,685,406...252,778,642
Ensembl chr 1:252,685,406...252,778,688
|
|
G
|
Dpm3
|
dolichyl-phosphate mannosyltransferase subunit 3, regulatory
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of DPM3 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:174,676,532...174,677,047
Ensembl chr15:52,612,418...52,612,696
|
|
G
|
Dusp22
|
dual specificity phosphatase 22
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of DUSP22 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr17:33,989,637...34,040,021
Ensembl chr17:33,989,637...34,039,895
|
|
G
|
Efna1
|
ephrin A1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of EFNA1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:176,979,434...176,988,675
Ensembl chr 2:176,979,434...176,988,726
|
|
G
|
Eif1
|
eukaryotic translation initiation factor 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of EIF1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr10:85,747,064...85,749,447
Ensembl chr 5:25,895,968...25,896,654 Ensembl chr10:25,895,968...25,896,654
|
|
G
|
Eif3c
|
eukaryotic translation initiation factor 3, subunit C
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of EIF3C mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:181,134,604...181,152,489
Ensembl chr 1:190,565,184...190,583,067
|
|
G
|
Elf4
|
E74 like ETS transcription factor 4
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of ELF4 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr X:127,587,401...127,639,063
Ensembl chr X:132,468,539...132,478,689
|
|
G
|
Elk4
|
ETS transcription factor ELK4
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of ELK4 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr13:46,004,145...46,027,206
Ensembl chr13:46,004,182...46,027,199
|
|
G
|
Eno2
|
enolase 2
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of ENO2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220
|
|
G
|
Enosf1
|
enolase superfamily member 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of ENOSF1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 9:113,275,267...113,314,842
|
|
G
|
Ep400
|
E1A binding protein p400
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of EP400 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr12:45,891,886...46,002,523
Ensembl chr12:51,551,695...51,658,634
|
|
G
|
Ero1a
|
endoplasmic reticulum oxidoreductase 1 alpha
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of ERO1A mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr15:20,974,771...21,010,170
Ensembl chr15:20,972,679...21,018,039
|
|
G
|
Exoc7
|
exocyst complex component 7
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of EXOC7 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr10:102,019,805...102,039,333
Ensembl chr10:102,019,806...102,039,447
|
|
G
|
Fabp3
|
fatty acid binding protein 3
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of FABP3 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 5:147,936,027...147,942,870
Ensembl chr 5:147,936,119...147,942,881
|
|
G
|
Fam162a
|
family with sequence similarity 162, member A
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of FAM162A mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr11:78,186,260...78,215,186
Ensembl chr11:78,185,852...78,216,560
|
|
G
|
Fam210b
|
family with sequence similarity 210, member B
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of FAM210B mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 3:161,118,228...161,128,400
Ensembl chr 3:181,536,673...181,546,834
|
|
G
|
Fam89a
|
family with sequence similarity 89, member A
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of FAM89A mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr19:69,607,391...69,620,019
Ensembl chr19:69,607,391...69,620,019
|
|
G
|
Faslg
|
Fas ligand
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of FASL
|
CTD |
PMID:16453328 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503
|
|
G
|
Fbxo22
|
F-box protein 22
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of FBXO22 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 8:64,476,034...64,492,063
Ensembl chr 8:64,475,957...64,492,062
|
|
G
|
Fbxo30
|
F-box protein 30
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of FBXO30 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:7,475,636...7,491,719
Ensembl chr 1:7,475,575...7,493,199
|
|
G
|
Fech
|
ferrochelatase
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of FECH mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr18:60,215,325...60,248,525
Ensembl chr18:60,215,325...60,249,546
|
|
G
|
Flvcr2
|
FLVCR choline and putative heme transporter 2
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of FLVCR2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 6:111,139,352...111,203,345
Ensembl chr 6:111,139,295...111,203,345
|
|
G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions increases expression
|
EXP
|
morin inhibits the reaction [Ifosfamide results in increased expression of FOS protein]
|
CTD |
PMID:31722249 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
G
|
Fosl1
|
FOS like 1, AP-1 transcription factor subunit
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of FOSL1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:212,183,833...212,192,391
|
|
G
|
Gars1
|
glycyl-tRNA synthetase 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of GARS1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:85,484,939...85,542,876
Ensembl chr 4:85,493,753...85,542,876
|
|
G
|
Gclc
|
glutamate-cysteine ligase, catalytic subunit
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of GCLC mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893
|
|
G
|
Gclm
|
glutamate cysteine ligase, modifier subunit
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of GCLM mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003
|
|
G
|
Gdf15
|
growth differentiation factor 15
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of GDF15 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022
|
|
G
|
Gfap
|
glial fibrillary acidic protein
|
increases expression multiple interactions
|
EXP
|
Ifosfamide results in increased expression of GFAP protein morin inhibits the reaction [Ifosfamide results in increased expression of GFAP protein]
|
CTD |
PMID:31722249 |
|
NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685
|
|
G
|
Gpat3
|
glycerol-3-phosphate acyltransferase 3
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of GPAT3 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr14:8,715,367...8,768,051
|
|
G
|
Gpr87
|
G protein-coupled receptor 87
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of GPR87 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:145,589,630...145,608,094
Ensembl chr 2:145,589,569...145,604,442
|
|
G
|
Gpr88
|
G-protein coupled receptor 88
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of GPR88 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:206,876,373...206,885,034
Ensembl chr 2:206,868,585...206,884,945
|
|
G
|
Gpx1
|
glutathione peroxidase 1
|
multiple interactions decreases expression
|
EXP
|
Carnitine inhibits the reaction [Ifosfamide results in decreased expression of GPX1 mRNA]
|
CTD |
PMID:23213347 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581
|
|
G
|
Gpx3
|
glutathione peroxidase 3
|
decreases activity
|
ISO
|
Ifosfamide results in decreased activity of GPX3 protein
|
CTD |
PMID:9851889 |
|
NCBI chr10:39,529,335...39,537,406
Ensembl chr10:39,529,448...39,537,405
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of GSR mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
|
|
G
|
Gstp1
|
glutathione S-transferase pi 1
|
affects response to substance increases response to substance
|
ISO
|
GSTP1 gene polymorphism affects the susceptibility to Ifosfamide GSTP1 gene polymorphism results in increased susceptibility to Ifosfamide
|
CTD |
PMID:12868187 PMID:16282887 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705
|
|
G
|
Herc3
|
HECT and RLD domain containing E3 ubiquitin protein ligase 3
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of HERC3 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:89,282,374...89,372,656
Ensembl chr 4:89,282,445...89,372,652
|
|
G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
affects activity
|
ISO
|
Ifosfamide affects the activity of HIF1A protein
|
CTD |
PMID:25596134 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323
|
|
G
|
Hspa1b
|
heat shock protein family A (Hsp70) member 1B
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of HSPA1B mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,855,780...3,877,979
|
|
G
|
Iars1
|
isoleucyl-tRNA synthetase 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of IARS1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr17:15,147,357...15,193,716
Ensembl chr17:15,147,357...15,193,652
|
|
G
|
Ids
|
iduronate 2-sulfatase
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of IDS mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr X:149,025,976...149,046,641
Ensembl chr X:154,070,781...154,091,444
|
|
G
|
Ifnb1
|
interferon beta 1
|
multiple interactions
|
ISO
|
[Ifosfamide co-treated with IFNB1] affects the expression of MMP9 mRNA; [Ifosfamide co-treated with IFNB1] affects the expression of MMP9 protein; [Ifosfamide co-treated with IFNB1] results in decreased expression of PLAUR protein; IFNB1 promotes the reaction [Ifosfamide results in decreased activity of MMP9 protein]; IFNB1 promotes the reaction [Ifosfamide results in decreased expression of VEGFA protein]
|
CTD |
PMID:15659795 |
|
NCBI chr 5:108,066,650...108,067,487
Ensembl chr 5:108,066,650...108,067,487
|
|
G
|
Igf2r
|
insulin-like growth factor 2 receptor
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of IGF2R mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:50,526,878...50,615,265
Ensembl chr 1:50,526,878...50,615,265
|
|
G
|
Il19
|
interleukin 19
|
increases secretion
|
ISO
|
Ifosfamide results in increased secretion of IL19 protein
|
CTD |
PMID:24714768 |
|
NCBI chr13:44,949,989...44,958,714
Ensembl chr13:44,949,989...44,958,714
|
|
G
|
Il1b
|
interleukin 1 beta
|
increases secretion multiple interactions
|
EXP
|
Ifosfamide results in increased secretion of IL1B protein resveratrol inhibits the reaction [Ifosfamide results in increased secretion of IL1B protein]
|
CTD |
PMID:17481685 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
increases secretion multiple interactions
|
EXP
|
Ifosfamide results in increased secretion of IL6 protein resveratrol inhibits the reaction [Ifosfamide results in increased secretion of IL6 protein]
|
CTD |
PMID:17481685 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Inka2
|
inka box actin regulator 2
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of INKA2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:193,185,275...193,200,643
Ensembl chr 2:195,873,497...195,893,605
|
|
G
|
Insig2
|
insulin induced gene 2
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of INSIG2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr13:35,025,160...35,052,937
Ensembl chr13:35,025,164...35,047,658
|
|
G
|
Itfg2
|
integrin alpha FG-GAP repeat containing 2
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of ITFG2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:163,371,125...163,384,676
Ensembl chr 4:163,338,702...163,384,367
|
|
G
|
Itgb1
|
integrin subunit beta 1
|
affects expression
|
ISO
|
Ifosfamide affects the expression of ITGB1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr19:73,602,277...73,650,271
Ensembl chr19:73,602,126...73,650,269
|
|
G
|
Kat6b
|
lysine acetyltransferase 6B
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of KAT6B mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr15:2,688,535...2,861,443
Ensembl chr15:2,688,811...2,844,343
|
|
G
|
Kdm3a
|
lysine demethylase 3A
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of KDM3A mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:105,189,208...105,233,526
Ensembl chr 4:105,189,208...105,233,370
|
|
G
|
Keap1
|
Kelch-like ECH-associated protein 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of KEAP1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042
|
|
G
|
Krt15
|
keratin 15
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of KRT15 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr10:85,567,197...85,571,014
Ensembl chr10:85,567,202...85,571,142
|
|
G
|
Krt19
|
keratin 19
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of KRT19 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr10:85,576,235...85,580,952
Ensembl chr10:85,576,235...85,580,952
|
|
G
|
Lama3
|
laminin subunit alpha 3
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of LAMA3 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr18:3,797,898...4,033,021
Ensembl chr18:3,797,939...4,026,449
|
|
G
|
Lmcd1
|
LIM and cysteine-rich domains 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of LMCD1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:146,948,993...147,007,878
Ensembl chr 4:146,948,958...147,007,875
|
|
G
|
Ltn1
|
listerin E3 ubiquitin protein ligase 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of LTN1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr11:26,603,903...26,660,871
Ensembl chr11:40,090,169...40,147,303
|
|
G
|
Mafg
|
MAF bZIP transcription factor G
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of MAFG mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr10:106,401,633...106,410,159
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
increases activity multiple interactions
|
EXP
|
Ifosfamide results in increased activity of MAPK8 protein morin inhibits the reaction [Ifosfamide results in increased activity of MAPK8 protein]
|
CTD |
PMID:31722249 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Mdm2
|
MDM2 proto-oncogene
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of MDM2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791
|
|
G
|
Me1
|
malic enzyme 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of ME1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 8:96,429,057...96,540,244
Ensembl chr 8:96,429,057...96,540,275
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions decreases activity affects expression
|
ISO
|
[Ifosfamide co-treated with IFNA2] affects the expression of MMP9 mRNA; [Ifosfamide co-treated with IFNA2] affects the expression of MMP9 protein; [Ifosfamide co-treated with IFNB1] affects the expression of MMP9 mRNA; [Ifosfamide co-treated with IFNB1] affects the expression of MMP9 protein; IFNA2 promotes the reaction [Ifosfamide results in decreased activity of MMP9 protein]; IFNB1 promotes the reaction [Ifosfamide results in decreased activity of MMP9 protein] Ifosfamide affects the expression of MMP9 mRNA
|
CTD |
PMID:15659795 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mr1
|
major histocompatibility complex, class I-related
|
affects expression
|
ISO
|
Ifosfamide affects the expression of MR1 mRNA
|
CTD |
PMID:25811541 |
|
NCBI chr13:69,850,420...69,868,302
Ensembl chr13:69,850,420...69,868,502
|
|
G
|
Mt2
|
metallothionein 2
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of MT2A mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,837,927...10,838,709
|
|
G
|
Mtdh
|
metadherin
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of MTDH mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 7:65,306,464...65,365,647
Ensembl chr 7:67,192,393...67,249,584
|
|
G
|
Mtfp1
|
mitochondrial fission process 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of MTFP1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr14:83,192,013...83,195,853
Ensembl chr14:83,192,021...83,195,927
|
|
G
|
Mxi1
|
MAX interactor 1, dimerization protein
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of MXI1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:252,323,915...252,383,682
Ensembl chr 1:262,328,875...262,389,036
|
|
G
|
Ncapd2
|
non-SMC condensin I complex, subunit D2
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of NCAPD2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:159,655,051...159,677,938
Ensembl chr 4:159,655,051...159,677,938
|
|
G
|
Nedd9
|
neural precursor cell expressed, developmentally down-regulated 9
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of NEDD9 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr17:23,495,531...23,673,780
Ensembl chr17:23,495,492...23,675,668
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
affects activity decreases expression multiple interactions
|
ISO EXP
|
Ifosfamide affects the activity of NFE2L2 protein Ifosfamide results in decreased expression of NFE2L2 protein morin inhibits the reaction [Ifosfamide results in decreased expression of NFE2L2 protein]
|
CTD |
PMID:25596134 PMID:31722249 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nin
|
ninein
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of NIN mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 6:94,261,382...94,363,679
Ensembl chr 6:94,263,206...94,363,610
|
|
G
|
Nos1
|
nitric oxide synthase 1
|
increases activity multiple interactions
|
EXP
|
Ifosfamide results in increased activity of NOS1 protein morin inhibits the reaction [Ifosfamide results in increased activity of NOS1 protein]
|
CTD |
PMID:31722249 |
|
NCBI chr12:44,276,011...44,456,371
Ensembl chr12:44,287,614...44,371,837
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions increases expression
|
EXP
|
Carnitine inhibits the reaction [Ifosfamide results in increased expression of NOS2 mRNA]
|
CTD |
PMID:23213347 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Npy1r
|
neuropeptide Y receptor Y1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of NPY1R mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr16:27,804,416...27,814,070
Ensembl chr16:27,804,416...27,813,387
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of NQO1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Nr1i2
|
nuclear receptor subfamily 1, group I, member 2
|
multiple interactions increases activity
|
ISO
|
[Ifosfamide results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; Ifosfamide binds to and results in increased activity of NR1I2 protein; NR1I2 protein promotes the reaction [Ifosfamide results in increased expression of ABCB1 protein]
|
CTD |
PMID:18839173 PMID:20041327 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380
|
|
G
|
Nrep
|
neuronal regeneration related protein
|
affects expression
|
ISO
|
Ifosfamide affects the expression of NREP mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr18:25,291,219...25,320,742
Ensembl chr18:25,291,219...25,320,742
|
|
G
|
Ntpcr
|
nucleoside-triphosphatase, cancer-related
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of NTPCR mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr19:53,701,496...53,715,260
Ensembl chr19:70,593,274...70,613,197
|
|
G
|
Nuak1
|
NUAK family kinase 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of NUAK1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 7:21,217,729...21,289,608
Ensembl chr 7:21,217,681...21,289,354
|
|
G
|
Osgin1
|
oxidative stress induced growth inhibitor 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of OSGIN1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr19:64,380,336...64,409,165
Ensembl chr19:64,401,173...64,409,162
|
|
G
|
P4ha1
|
prolyl 4-hydroxylase subunit alpha 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of P4HA1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,845,141...27,895,404
|
|
G
|
Pank1
|
pantothenate kinase 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of PANK1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:232,324,718...232,395,445
Ensembl chr 1:241,741,083...241,807,824
|
|
G
|
Pde8a
|
phosphodiesterase 8A
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of PDE8A mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:144,575,203...144,698,216
Ensembl chr 1:144,575,428...144,698,215
|
|
G
|
Pdia5
|
protein disulfide isomerase family A, member 5
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of PDIA5 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr11:78,777,436...78,892,370
Ensembl chr11:78,777,419...78,864,329
|
|
G
|
Pdk1
|
pyruvate dehydrogenase kinase 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of PDK1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 3:77,113,464...77,144,145
Ensembl chr 3:77,113,473...77,144,145
|
|
G
|
Phgdh
|
phosphoglycerate dehydrogenase
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of PHGDH mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:188,595,700...188,624,789
Ensembl chr 2:188,595,700...188,624,789
|
|
G
|
Phlda3
|
pleckstrin homology-like domain, family A, member 3
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of PHLDA3 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr13:49,745,003...49,748,088
Ensembl chr13:49,742,591...49,749,621
|
|
G
|
Pidd1
|
p53-induced death domain protein 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of PIDD1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:205,966,392...205,972,359
Ensembl chr 1:205,966,392...205,971,600
|
|
G
|
Plaur
|
plasminogen activator, urokinase receptor
|
affects expression multiple interactions
|
ISO
|
Ifosfamide affects the expression of PLAUR protein [Ifosfamide co-treated with IFNA2] results in decreased expression of PLAUR protein; [Ifosfamide co-treated with IFNB1] results in decreased expression of PLAUR protein
|
CTD |
PMID:15659795 |
|
NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130
|
|
G
|
Pmepa1
|
prostate transmembrane protein, androgen induced 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of PMEPA1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 3:182,430,193...182,478,649
Ensembl chr 3:182,430,193...182,478,649
|
|
G
|
Podxl
|
podocalyxin-like
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of PODXL mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:61,102,434...61,149,131
Ensembl chr 4:61,102,419...61,149,789
|
|
G
|
Por
|
cytochrome p450 oxidoreductase
|
multiple interactions
|
ISO
|
POR promotes the reaction [CYP2B6 results in increased susceptibility to Ifosfamide]; POR promotes the reaction [CYP2C18 results in increased susceptibility to Ifosfamide]
|
CTD |
PMID:9766669 |
|
NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
affects activity
|
ISO
|
Ifosfamide affects the activity of PPARG protein
|
CTD |
PMID:25596134 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
G
|
Ppfibp1
|
PPFIA binding protein 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of PPFIBP1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:181,538,249...181,682,079
Ensembl chr 4:181,539,450...181,682,076
|
|
G
|
Ppig
|
peptidylprolyl isomerase G
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of PPIG mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 3:54,484,023...54,512,929
Ensembl chr 3:74,891,846...74,920,750
|
|
G
|
Ppm1d
|
protein phosphatase, Mg2+/Mn2+ dependent, 1D
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of PPM1D mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr10:70,670,026...70,706,030
Ensembl chr10:70,670,020...70,706,256
|
|
G
|
Prc1
|
protein regulator of cytokinesis 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of PRC1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:143,659,312...143,681,019
Ensembl chr 1:143,659,481...143,681,012
|
|
G
|
Prdm1
|
PR/SET domain 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of PRDM1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr20:49,542,465...49,564,088
Ensembl chr20:49,542,465...49,564,088
|
|
G
|
Prkab1
|
protein kinase AMP-activated non-catalytic subunit beta 1
|
affects expression
|
ISO
|
Ifosfamide affects the expression of PRKAB1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr12:46,248,971...46,259,487
Ensembl chr12:46,249,010...46,259,482
|
|
G
|
Prkab2
|
protein kinase AMP-activated non-catalytic subunit beta 2
|
affects expression
|
ISO
|
Ifosfamide affects the expression of PRKAB2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:187,946,008...187,961,615
Ensembl chr 2:187,945,982...187,961,608
|
|
G
|
Psat1
|
phosphoserine aminotransferase 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of PSAT1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:222,623,553...222,646,187
Ensembl chr 1:222,623,556...222,655,693
|
|
G
|
Pspc1
|
paraspeckle component 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of PSPC1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr15:30,828,617...30,911,315
Ensembl chr15:34,967,477...35,026,828
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions increases expression
|
EXP
|
etoricoxib inhibits the reaction [Ifosfamide results in increased expression of PTGS2 protein]; Indomethacin inhibits the reaction [Ifosfamide results in increased expression of PTGS2 protein]; Pentoxifylline inhibits the reaction [Ifosfamide results in increased expression of PTGS2 protein]; Thalidomide inhibits the reaction [Ifosfamide results in increased expression of PTGS2 protein]
|
CTD |
PMID:17638016 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Pycr1
|
pyrroline-5-carboxylate reductase 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of PYCR1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr10:106,416,056...106,420,982
Ensembl chr10:106,412,576...106,423,393
|
|
G
|
Pygl
|
glycogen phosphorylase L
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of PYGL mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 6:94,433,558...94,476,219
Ensembl chr 6:94,426,346...94,476,269
|
|
G
|
Rab31
|
RAB31, member RAS oncogene family
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of RAB31 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 9:112,693,596...112,828,104
Ensembl chr 9:112,693,597...112,828,092
|
|
G
|
Rffl
|
ring finger and FYVE-like domain containing E3 ubiquitin protein ligase
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of RFFL mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr10:68,238,273...68,301,225
Ensembl chr10:68,238,273...68,321,902
|
|
G
|
Rit1
|
Ras-like without CAAX 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of RIT1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:176,478,616...176,493,269
Ensembl chr 2:176,478,596...176,494,684
|
|
G
|
Rlf
|
RLF zinc finger
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of RLF mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 5:139,996,782...140,052,419
Ensembl chr 5:139,996,782...140,052,419
|
|
G
|
Rnf121
|
ring finger protein 121
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of RNF121 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:156,377,368...156,439,936
Ensembl chr 1:165,789,360...165,858,884
|
|
G
|
Ro60
|
Ro60, Y RNA binding protein
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of RO60 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr13:55,499,514...55,520,504
Ensembl chr13:58,049,858...58,076,264
|
|
G
|
Rps27l
|
ribosomal protein S27-like
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of RPS27L mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 8:76,443,658...76,448,593
Ensembl chr12:33,713,661...33,714,130 Ensembl chr 8:33,713,661...33,714,130
|
|
G
|
Rrm2b
|
ribonucleotide reductase regulatory TP53 inducible subunit M2B
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of RRM2B mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 7:70,962,008...70,993,726
Ensembl chr 7:70,965,590...70,993,670
|
|
G
|
Rrp12
|
ribosomal RNA processing 12
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of RRP12 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:240,672,378...240,705,992
Ensembl chr 1:250,621,707...250,655,318
|
|
G
|
Rsrc2
|
arginine and serine rich coiled-coil 2
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of RSRC2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr12:38,500,709...38,520,715
Ensembl chr12:38,500,770...38,520,707
|
|
G
|
RT1-CE16
|
RT1 class I, locus CE16
|
affects expression
|
ISO
|
Ifosfamide affects the expression of HLA-A mRNA
|
CTD |
PMID:25811541 |
|
NCBI chr20:3,261,656...3,265,548
|
|
G
|
RT1-M3-1
|
RT1 class Ib, locus M3, gene 1
|
affects expression
|
ISO
|
Ifosfamide affects the expression of HLA-G mRNA
|
CTD |
PMID:25811541 |
|
NCBI chr20:1,329,227...1,333,394
Ensembl chr20:1,329,225...1,333,366
|
|
G
|
Sars1
|
seryl-tRNA synthetase 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of SARS1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:198,753,673...198,769,411
Ensembl chr 2:198,753,675...198,769,365
|
|
G
|
Sertad1
|
SERTA domain containing 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of SERTAD1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:91,903,297...91,906,565
Ensembl chr 1:91,891,814...91,907,001
|
|
G
|
Sesn1
|
sestrin 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of SESN1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr20:46,876,918...46,970,010
Ensembl chr20:46,876,895...46,970,010
|
|
G
|
Sfn
|
stratifin
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of SFN mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:151,110,530...151,111,995
|
|
G
|
Sh3tc1
|
SH3 domain and tetratricopeptide repeats 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of SH3TC1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr14:75,005,691...75,050,001
Ensembl chr14:79,230,371...79,274,620
|
|
G
|
Siah2
|
siah E3 ubiquitin protein ligase 2
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of SIAH2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:142,913,924...142,931,752
Ensembl chr 2:145,063,857...145,081,873
|
|
G
|
Sipa1l2
|
signal-induced proliferation-associated 1 like 2
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of SIPA1L2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr19:70,287,134...70,437,810
Ensembl chr19:70,287,147...70,437,773
|
|
G
|
Siva1
|
SIVA1, apoptosis-inducing factor
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of SIVA1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 6:137,526,416...137,530,790
Ensembl chr 6:137,526,031...137,530,790
|
|
G
|
Slc12a8
|
solute carrier family 12, member 8
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of SLC12A8 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr11:80,622,000...80,771,674
Ensembl chr11:80,622,000...80,771,659
|
|
G
|
Slc1a5
|
solute carrier family 1 member 5
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of SLC1A5 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:86,584,949...86,599,052
Ensembl chr 1:86,584,949...86,599,054
|
|
G
|
Slc22a5
|
solute carrier family 22 member 5
|
decreases expression
|
EXP
|
Ifosfamide results in decreased expression of SLC22A5 mRNA; Ifosfamide results in decreased expression of SLC22A5 protein
|
CTD |
PMID:22701146 |
|
NCBI chr10:38,509,072...38,536,240
Ensembl chr10:38,509,072...38,536,077
|
|
G
|
Slc25a20
|
solute carrier family 25 member 20
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of SLC25A20 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 8:118,243,573...118,265,027
Ensembl chr 8:118,243,519...118,265,027
|
|
G
|
Slc2a1
|
solute carrier family 2 member 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of SLC2A1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742
|
|
G
|
Slc3a2
|
solute carrier family 3 member 2
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of SLC3A2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:215,033,601...215,048,064
Ensembl chr 1:215,033,601...215,048,064
|
|
G
|
Slc6a9
|
solute carrier family 6 member 9
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of SLC6A9 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 5:136,660,022...136,694,173
Ensembl chr 5:136,659,948...136,694,172
|
|
G
|
Slc7a5
|
solute carrier family 7 member 5
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of SLC7A5 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr19:66,843,808...66,872,412
Ensembl chr19:66,843,808...66,872,412
|
|
G
|
Son
|
SON DNA and RNA binding protein
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of SON mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr11:44,336,818...44,409,127
Ensembl chr11:44,377,976...44,409,127
|
|
G
|
Spsb1
|
splA/ryanodine receptor domain and SOCS box containing 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of SPSB1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 5:160,358,292...160,418,541
Ensembl chr 5:165,642,851...165,654,225
|
|
G
|
Sqstm1
|
sequestosome 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of SQSTM1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750
|
|
G
|
Srd5a3
|
steroid 5 alpha-reductase 3
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of SRD5A3 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr14:32,400,603...32,414,987
Ensembl chr14:32,400,603...32,415,117
|
|
G
|
Srxn1
|
sulfiredoxin 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of SRXN1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765
|
|
G
|
Sulf2
|
sulfatase 2
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of SULF2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 3:175,241,322...175,323,808
Ensembl chr 3:175,241,322...175,323,651
|
|
G
|
Taldo1
|
transaldolase 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of TALDO1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:205,923,165...205,933,535
|
|
G
|
Tars1
|
threonyl-tRNA synthetase 1
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of TARS1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:62,095,978...62,114,802
Ensembl chr 2:62,087,763...62,114,802
|
|
G
|
Tbxas1
|
thromboxane A synthase 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of TBXAS1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:68,631,841...68,803,959
Ensembl chr 4:68,631,838...68,803,969
|
|
G
|
Tfap2a
|
transcription factor AP-2 alpha
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of TFAP2A mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr17:24,230,064...24,253,219
Ensembl chr17:24,229,910...24,253,219
|
|
G
|
Thbs2
|
thrombospondin 2
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of THBS2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 1:64,343,523...64,372,918
Ensembl chr 1:64,343,523...64,372,918
|
|
G
|
Tigar
|
TP53 induced glycolysis regulatory phosphatase
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of TIGAR mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:161,613,306...161,632,248
Ensembl chr 4:161,613,306...161,632,229
|
|
G
|
Timm17b
|
translocase of inner mitochondrial membrane 17b
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of TIMM17B mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr X:17,268,257...17,275,424
Ensembl chr X:17,268,257...17,275,563
|
|
G
|
Tlr4
|
toll-like receptor 4
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of TLR4 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
G
|
Tmem94
|
transmembrane protein 94
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of TMEM94 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr10:100,991,523...101,027,046
Ensembl chr10:101,490,481...101,525,975
|
|
G
|
Tmtc2
|
transmembrane O-mannosyltransferase targeting cadherins 2
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of TMTC2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 7:40,392,377...40,806,685
Ensembl chr 7:42,280,746...42,693,350
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases secretion increases expression multiple interactions
|
EXP
|
Ifosfamide results in increased secretion of TNF protein Ifosfamide results in increased expression of TNF protein morin inhibits the reaction [Ifosfamide results in increased expression of TNF protein]; Resveratrol inhibits the reaction [Ifosfamide results in increased secretion of TNF protein]
|
CTD |
PMID:17481685 PMID:31722249 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tnfaip8
|
TNF alpha induced protein 8
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of TNFAIP8 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr18:45,370,334...45,486,036
Ensembl chr18:45,370,406...45,486,036
|
|
G
|
Tnfsf9
|
TNF superfamily member 9
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of TNFSF9 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 9:2,031,011...2,033,345
Ensembl chr 9:2,030,953...2,033,339
|
|
G
|
Top1
|
DNA topoisomerase I
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of TOP1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 3:169,713,195...169,796,330
Ensembl chr 3:169,713,130...169,796,327
|
|
G
|
Top2a
|
DNA topoisomerase II alpha
|
multiple interactions
|
ISO
|
TOP2A results in decreased susceptibility to [Carboplatin co-treated with Etoposide co-treated with Ifosfamide]
|
CTD |
PMID:11325482 |
|
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366
|
|
G
|
Tp53
|
tumor protein p53
|
affects activity multiple interactions increases expression
|
ISO EXP
|
Ifosfamide affects the activity of TP53 protein morin inhibits the reaction [Ifosfamide results in increased expression of TP53 protein]
|
CTD |
PMID:25596134 PMID:31722249 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Tp53i3
|
tumor protein p53 inducible protein 3
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of TP53I3 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 6:27,818,327...27,825,753
|
|
G
|
Tp53inp1
|
tumor protein p53 inducible nuclear protein 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of TP53INP1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 5:29,051,267...29,069,486
Ensembl chr 5:29,051,264...29,069,484
|
|
G
|
Trafd1
|
TRAF type zinc finger domain containing 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of TRAFD1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr12:40,826,251...40,840,169
Ensembl chr12:40,825,851...40,841,320
|
|
G
|
Triap1
|
TP53 regulated inhibitor of apoptosis 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of TRIAP1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr12:46,928,273...46,930,766
Ensembl chr12:46,928,273...46,930,766
|
|
G
|
Tspan12
|
tetraspanin 12
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of TSPAN12 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:51,279,562...51,355,030
Ensembl chr 4:51,279,563...51,355,030
|
|
G
|
Txn1
|
thioredoxin 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of TXN mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307
|
|
G
|
Txnrd1
|
thioredoxin reductase 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of TXNRD1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817
|
|
G
|
Ube2g2
|
ubiquitin-conjugating enzyme E2G 2
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of UBE2G2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr20:10,983,322...11,005,060
Ensembl chr20:10,983,325...11,005,187
|
|
G
|
Unkl
|
unk like zinc finger
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of UNKL mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr10:14,710,627...14,756,725
Ensembl chr10:14,710,563...14,756,724
|
|
G
|
Usp3
|
ubiquitin specific peptidase 3
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of USP3 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 8:75,973,278...76,049,151
Ensembl chr 8:75,974,615...76,049,153
|
|
G
|
Vars1
|
valyl-tRNA synthetase 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of VARS1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr20:3,810,427...3,825,193
Ensembl chr20:3,810,429...3,824,951
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
multiple interactions decreases expression
|
ISO
|
IFNA2 promotes the reaction [Ifosfamide results in decreased expression of VEGFA protein]; IFNB1 promotes the reaction [Ifosfamide results in decreased expression of VEGFA protein]
|
CTD |
PMID:15659795 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
G
|
Wars1
|
tryptophanyl-tRNA synthetase 1
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of WARS1 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 6:133,540,463...133,571,645
Ensembl chr 6:133,539,744...133,571,645
|
|
G
|
Wwc2
|
WW and C2 domain containing 2
|
decreases expression
|
ISO
|
Ifosfamide results in decreased expression of WWC2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr16:44,258,372...44,421,815
Ensembl chr16:50,991,096...51,154,526
|
|
G
|
Xbp1
|
X-box binding protein 1
|
affects activity
|
ISO
|
Ifosfamide affects the activity of XBP1 protein
|
CTD |
PMID:25596134 |
|
NCBI chr14:84,604,623...84,609,707
Ensembl chr14:84,604,107...84,609,706
|
|
G
|
Xpc
|
XPC complex subunit, DNA damage recognition and repair factor
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of XPC mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 4:125,550,833...125,578,084
Ensembl chr 4:125,550,833...125,578,305
|
|
G
|
Yeats2
|
YEATS domain containing 2
|
affects expression
|
ISO
|
Ifosfamide affects the expression of YEATS2 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr11:94,247,538...94,333,652
Ensembl chr11:94,247,538...94,333,292
|
|
G
|
Zmat3
|
zinc finger, matrin type 3
|
increases expression
|
ISO
|
Ifosfamide results in increased expression of ZMAT3 mRNA
|
CTD |
PMID:25596134 |
|
NCBI chr 2:117,034,517...117,066,141
Ensembl chr 2:117,034,517...117,065,294
|
|
|
G
|
Agtr1a
|
angiotensin II receptor, type 1a
|
multiple interactions increases expression
|
EXP
|
Valproic Acid promotes the reaction [Mechlorethamine results in increased expression of AGTR1A mRNA]
|
CTD |
PMID:28184907 |
|
NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660
|
|
G
|
Aifm1
|
apoptosis inducing factor, mitochondria associated 1
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of AIFM1 mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr X:132,528,107...132,567,237
Ensembl chr X:132,528,107...132,567,237
|
|
G
|
Ampd3
|
adenosine monophosphate deaminase 3
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of AMPD3 mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr 1:174,319,526...174,364,605
Ensembl chr 1:174,294,867...174,364,608
|
|
G
|
Apcs
|
amyloid P component, serum
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of APCS mRNA
|
CTD |
PMID:26273949 |
|
NCBI chr13:87,905,532...87,906,508
Ensembl chr13:87,905,532...87,928,824
|
|
G
|
Apoe
|
apolipoprotein E
|
multiple interactions increases expression
|
EXP
|
Valproic Acid promotes the reaction [Mechlorethamine results in increased expression of APOE mRNA]
|
CTD |
PMID:26273949 PMID:28184907 |
|
NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:88,481,385...88,485,855
|
|
G
|
Arg1
|
arginase 1
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of ARG1 protein
|
CTD |
PMID:38513841 |
|
NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713
|
|
G
|
Arl11
|
ARF like GTPase 11
|
multiple interactions increases expression
|
ISO
|
NR1H4 protein affects the reaction [Mechlorethamine results in increased expression of ARL11 protein]
|
CTD |
PMID:35998709 |
|
NCBI chr15:39,659,404...39,661,651
Ensembl chr15:39,656,050...39,664,105
|
|
G
|
Atp1a2
|
ATPase Na+/K+ transporting subunit alpha 2
|
decreases expression
|
ISO
|
Mechlorethamine results in decreased expression of ATP1A2 mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr13:87,261,964...87,286,911
Ensembl chr13:87,261,968...87,286,911
|
|
G
|
Bak1
|
BCL2-antagonist/killer 1
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of BAK1 protein
|
CTD |
PMID:22285227 |
|
NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO
|
Mechlorethamine results in increased expression of and results in decreased localization of BAX protein; Mechlorethamine results in increased expression of and results in increased activity of BAX protein
|
CTD |
PMID:16738803 PMID:22285227 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression
|
ISO
|
Mechlorethamine results in decreased expression of BCL2 protein
|
CTD |
PMID:16738803 PMID:22285227 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Calm3
|
calmodulin 3
|
decreases expression
|
ISO
|
Mechlorethamine results in decreased expression of CALM3 mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr 1:86,718,761...86,725,869
Ensembl chr 1:86,717,321...86,725,960
|
|
G
|
Casp2
|
caspase 2
|
increases activity
|
ISO
|
Mechlorethamine results in increased activity of CASP2 protein
|
CTD |
PMID:16738803 |
|
NCBI chr 4:72,116,265...72,134,023
Ensembl chr 4:72,116,246...72,134,022
|
|
G
|
Casp3
|
caspase 3
|
increases activity multiple interactions
|
ISO
|
Mechlorethamine results in increased activity of CASP3 protein ebselen inhibits the reaction [Mechlorethamine results in increased activity of CASP3 protein]
|
CTD |
PMID:23649643 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp9
|
caspase 9
|
increases activity multiple interactions
|
ISO
|
Mechlorethamine results in increased activity of CASP9 protein ebselen inhibits the reaction [Mechlorethamine results in increased activity of CASP9 protein]; Mechlorethamine results in increased cleavage of and results in increased activity of CASP9 protein
|
CTD |
PMID:16738803 PMID:22285227 PMID:23649643 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of CCL2 mRNA
|
CTD |
PMID:26273949 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Ccl5
|
C-C motif chemokine ligand 5
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of CCL5 mRNA
|
CTD |
PMID:26273949 |
|
NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884
|
|
G
|
Ccn2
|
cellular communication network factor 2
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of CCN2 mRNA; Mechlorethamine results in increased expression of CCN2 protein
|
CTD |
PMID:20883710 PMID:26273949 |
|
NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976
|
|
G
|
Ccna2
|
cyclin A2
|
multiple interactions increases stability
|
ISO
|
Mechlorethamine results in decreased activity of [CCNA2 protein binds to CDK2 protein]; Mechlorethamine results in increased expression of and results in increased activity of [CDK2 protein binds to CCNA2 protein]; Pentoxifylline inhibits the reaction [Mechlorethamine results in increased activity of [CCNA2 protein binds to CDK2 protein]] Mechlorethamine results in increased stability of CCNA2 protein
|
CTD |
PMID:8463339 |
|
NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701
|
|
G
|
Ccnb1
|
cyclin B1
|
decreases activity multiple interactions
|
ISO
|
Mechlorethamine results in decreased activity of CCNB1 protein Mechlorethamine results in decreased activity of [CCNB1 protein binds to CDK1 protein]; Pentoxifylline inhibits the reaction [Mechlorethamine results in decreased activity of [CCNB1 protein binds to CDK1 protein]]
|
CTD |
PMID:8463339 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225
|
|
G
|
Ccr2
|
C-C motif chemokine receptor 2
|
multiple interactions increases expression
|
EXP
|
Valproic Acid inhibits the reaction [Mechlorethamine results in increased expression of CCR2 mRNA] Mechlorethamine results in increased expression of CCR2 mRNA; Mechlorethamine results in increased expression of CCR2 protein
|
CTD |
PMID:26273949 PMID:28184907 |
|
NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:132,611,410...132,620,059
|
|
G
|
Ccr5
|
C-C motif chemokine receptor 5
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of CCR5 mRNA
|
CTD |
PMID:26273949 |
|
NCBI chr 8:132,629,097...132,660,980
Ensembl chr 8:132,629,683...132,637,594
|
|
G
|
Cd163
|
CD163 molecule
|
increases expression multiple interactions
|
EXP ISO
|
Mechlorethamine results in increased expression of CD163 protein NR1H4 protein affects the reaction [Mechlorethamine results in increased expression of CD163 protein]
|
CTD |
PMID:26273949 PMID:35998709 |
|
NCBI chr 4:158,770,751...158,804,146
Ensembl chr 4:158,770,749...158,804,146
|
|
G
|
Cd68
|
Cd68 molecule
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of CD68 protein
|
CTD |
PMID:26273949 |
|
NCBI chr10:54,880,562...54,882,441
Ensembl chr10:54,880,563...54,882,540
|
|
G
|
Cdk1
|
cyclin-dependent kinase 1
|
multiple interactions increases stability decreases activity
|
ISO
|
Mechlorethamine results in decreased activity of [CCNB1 protein binds to CDK1 protein]; Pentoxifylline inhibits the reaction [Mechlorethamine results in decreased activity of [CCNB1 protein binds to CDK1 protein]] Mechlorethamine results in increased stability of CDK1 protein modified form Mechlorethamine results in decreased activity of CDK1 protein
|
CTD |
PMID:8463339 |
|
NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455
|
|
G
|
Cdk2
|
cyclin dependent kinase 2
|
increases activity multiple interactions
|
ISO
|
Mechlorethamine results in increased activity of CDK2 protein Mechlorethamine results in decreased activity of [CCNA2 protein binds to CDK2 protein]; Mechlorethamine results in increased expression of and results in increased activity of [CDK2 protein binds to CCNA2 protein]; Pentoxifylline inhibits the reaction [Mechlorethamine results in increased activity of [CCNA2 protein binds to CDK2 protein]]
|
CTD |
PMID:8463339 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878
|
|
G
|
Cnr1
|
cannabinoid receptor 1
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of CNR1 protein
|
CTD |
PMID:27125198 |
|
NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252
|
|
G
|
Cnr2
|
cannabinoid receptor 2
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of CNR2 protein
|
CTD |
PMID:27125198 |
|
NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:153,409,147...153,435,961
|
|
G
|
Cx3cl1
|
C-X3-C motif chemokine ligand 1
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of CX3CL1 mRNA
|
CTD |
PMID:26273949 |
|
NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,233,329...10,242,999
|
|
G
|
Cx3cr1
|
C-X3-C motif chemokine receptor 1
|
increases expression multiple interactions
|
EXP
|
Mechlorethamine results in increased expression of CX3CR1 mRNA; Mechlorethamine results in increased expression of CX3CR1 protein Valproic Acid inhibits the reaction [Mechlorethamine results in increased expression of CX3CR1 mRNA]
|
CTD |
PMID:26273949 PMID:28184907 |
|
NCBI chr 8:128,661,294...128,679,048
Ensembl chr 8:128,654,833...128,685,983
|
|
G
|
Cxcr2
|
C-X-C motif chemokine receptor 2
|
affects response to substance
|
ISO
|
CXCR2 protein affects the susceptibility to Mechlorethamine
|
CTD |
PMID:12753603 |
|
NCBI chr 9:83,178,645...83,185,017
Ensembl chr 9:83,183,808...83,188,602
|
|
G
|
Cxcr4
|
C-X-C motif chemokine receptor 4
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of CXCR4 mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459
|
|
G
|
Eif4ebp1
|
eukaryotic translation initiation factor 4E binding protein 1
|
multiple interactions
|
ISO
|
[Mechlorethamine co-treated with Dimethyl Sulfoxide] results in increased phosphorylation of EIF4EBP1 protein; Mechlorethamine inhibits the reaction [Dimethyl Sulfoxide results in increased phosphorylation of EIF4EBP1 protein]
|
CTD |
PMID:36708981 |
|
NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874
|
|
G
|
Ep300
|
E1A binding protein p300
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of EP300 protein
|
CTD |
PMID:33971176 |
|
NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574
|
|
G
|
Erbb2
|
erb-b2 receptor tyrosine kinase 2
|
decreases expression
|
ISO
|
Mechlorethamine results in decreased expression of ERBB2 protein
|
CTD |
PMID:17932452 |
|
NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481
|
|
G
|
Faah
|
fatty acid amide hydrolase
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of FAAH protein
|
CTD |
PMID:27125198 |
|
NCBI chr 5:134,716,545...134,735,396
Ensembl chr 5:134,716,545...134,735,396
|
|
G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions
|
ISO
|
Mechlorethamine results in increased expression of and affects the localization of FOS protein; Mechlorethamine results in increased phosphorylation of and results in increased expression of FOS protein FOS protein affects the reaction [Mechlorethamine results in increased secretion of CXCL8 protein]
|
CTD |
PMID:25891025 PMID:31639410 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
G
|
Fosb
|
FosB proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions
|
ISO
|
FOSB protein affects the reaction [Mechlorethamine results in increased secretion of CXCL8 protein]; FOSL1 protein affects the reaction [Mechlorethamine results in increased expression of and affects the localization of FOSB protein]; Mechlorethamine results in increased expression of and affects the localization of FOSB protein; U 0126 inhibits the reaction [Mechlorethamine results in increased expression of FOSB protein]
|
CTD |
PMID:31639410 |
|
NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:88,082,127...88,089,477
|
|
G
|
Fosl1
|
FOS like 1, AP-1 transcription factor subunit
|
increases expression multiple interactions
|
ISO
|
Mechlorethamine results in increased expression of FOSL1 protein FOSL1 protein affects the reaction [Mechlorethamine results in increased expression of and affects the localization of FOSB protein]; FOSL1 protein affects the reaction [Mechlorethamine results in increased expression of CXCL8 mRNA]; FOSL1 protein affects the reaction [Mechlorethamine results in increased secretion of CXCL8 protein]; Mechlorethamine promotes the reaction [FOSL1 protein binds to JUN protein]; Mechlorethamine promotes the reaction [FOSL1 protein binds to JUNB protein]; Mechlorethamine promotes the reaction [FOSL1 protein binds to JUND protein]; Mechlorethamine results in increased expression of and affects the localization of FOSL1 protein; U 0126 inhibits the reaction [Mechlorethamine results in increased expression of FOSL1 protein]
|
CTD |
PMID:31639410 |
|
NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:212,183,833...212,192,391
|
|
G
|
Fosl2
|
FOS like 2, AP-1 transcription factor subunit
|
increases expression multiple interactions
|
ISO
|
Mechlorethamine results in increased expression of FOSL2 protein FOSL2 protein affects the reaction [Mechlorethamine results in increased secretion of CXCL8 protein]
|
CTD |
PMID:31639410 |
|
NCBI chr 6:30,017,952...30,039,269
Ensembl chr 6:30,021,916...30,039,406
|
|
G
|
Gdf9
|
growth differentiation factor 9
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of GDF9 mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr10:38,090,021...38,100,801
Ensembl chr10:38,089,878...38,100,797
|
|
G
|
Gsta2
|
glutathione S-transferase alpha 2
|
decreases response to substance increases expression
|
ISO
|
GSTA2 protein results in decreased susceptibility to Mechlorethamine Mechlorethamine results in increased expression of GSTA2 mRNA
|
CTD |
PMID:15778998 |
|
NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092
|
|
G
|
Gsta3
|
glutathione S-transferase alpha 3
|
decreases response to substance
|
EXP
|
GSTA3 protein results in decreased susceptibility to Mechlorethamine
|
CTD |
PMID:8044793 PMID:8860835 |
|
NCBI chr 9:31,154,989...31,180,653
Ensembl chr 9:31,154,989...31,180,654
|
|
G
|
H2ax
|
H2A.X variant histone
|
increases expression
|
ISO EXP
|
Mechlorethamine results in increased expression of H2AX protein modified form
|
CTD |
PMID:25891025 PMID:33971176 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Hdac2
|
histone deacetylase 2
|
multiple interactions increases expression
|
EXP
|
Valproic Acid inhibits the reaction [Mechlorethamine results in increased expression of HDAC2 protein]
|
CTD |
PMID:28184907 PMID:33971176 |
|
NCBI chr20:42,101,815...42,126,486
Ensembl chr20:42,102,861...42,126,311
|
|
G
|
Hmox1
|
heme oxygenase 1
|
increases expression multiple interactions
|
EXP ISO
|
Mechlorethamine results in increased expression of HMOX1; Mechlorethamine results in increased expression of HMOX1 protein NR1H4 protein affects the reaction [Mechlorethamine results in increased expression of HMOX1]; SFTPD gene mutant form promotes the reaction [Mechlorethamine results in increased expression of HMOX1 protein] Acetylcysteine inhibits the reaction [Mechlorethamine results in increased expression of HMOX1 protein]; Valproic Acid inhibits the reaction [Mechlorethamine results in increased expression of HMOX1 protein]
|
CTD |
PMID:22981630 PMID:28184907 PMID:30060251 PMID:35998709 PMID:38513841 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Il10
|
interleukin 10
|
increases expression multiple interactions
|
EXP
|
Mechlorethamine results in increased expression of IL10 mRNA Valproic Acid promotes the reaction [Mechlorethamine results in increased expression of IL10 mRNA]
|
CTD |
PMID:26273949 PMID:28184907 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il12a
|
interleukin 12A
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of IL12A mRNA
|
CTD |
PMID:26273949 |
|
NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997
|
|
G
|
Il12b
|
interleukin 12B
|
increases expression multiple interactions
|
EXP
|
Mechlorethamine results in increased expression of IL12B mRNA Valproic Acid inhibits the reaction [Mechlorethamine results in increased expression of IL12B mRNA]
|
CTD |
PMID:28184907 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions increases expression
|
ISO
|
KIT gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of IL1B mRNA]
|
CTD |
PMID:34453837 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il33
|
interleukin 33
|
multiple interactions increases expression
|
ISO
|
KIT gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of IL33 mRNA]
|
CTD |
PMID:34453837 |
|
NCBI chr 1:237,115,478...237,149,897
Ensembl chr 1:237,115,572...237,150,901
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions increases expression
|
ISO EXP
|
KIT gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of IL6 mRNA] Acetylcysteine inhibits the reaction [Mechlorethamine results in increased expression of IL6 mRNA]
|
CTD |
PMID:34453837 PMID:38513841 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Itgam
|
integrin subunit alpha M
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of ITGAM protein
|
CTD |
PMID:26273949 |
|
NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:192,089,542...192,139,943
|
|
G
|
Jag1
|
jagged canonical Notch ligand 1
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of JAG1 mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr 3:144,859,453...144,894,883
Ensembl chr 3:144,859,453...144,894,872
|
|
G
|
Jun
|
Jun proto-oncogene, AP-1 transcription factor subunit
|
increases phosphorylation multiple interactions increases expression
|
ISO
|
Mechlorethamine results in increased phosphorylation of JUN protein Mechlorethamine results in increased expression of and affects the localization of JUN protein Mechlorethamine results in increased expression of JUN protein Mechlorethamine promotes the reaction [FOSL1 protein binds to JUN protein]; U 0126 inhibits the reaction [Mechlorethamine results in increased expression of JUN protein]
|
CTD |
PMID:25891025 PMID:31639410 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285
|
|
G
|
Junb
|
JunB proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions increases expression
|
ISO
|
Mechlorethamine promotes the reaction [FOSL1 protein binds to JUNB protein]; U 0126 inhibits the reaction [Mechlorethamine results in increased expression of JUNB protein] Mechlorethamine results in increased expression of and affects the localization of JUNB protein
|
CTD |
PMID:31639410 |
|
NCBI chr19:40,081,126...40,082,910
Ensembl chr19:40,073,541...40,085,218
|
|
G
|
Jund
|
JunD proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions increases expression
|
ISO
|
Mechlorethamine promotes the reaction [FOSL1 protein binds to JUND protein]; U 0126 inhibits the reaction [Mechlorethamine results in increased expression of JUND protein] Mechlorethamine results in increased expression of and affects the localization of JUND protein
|
CTD |
PMID:31639410 |
|
NCBI chr16:18,768,093...18,769,771
Ensembl chr16:18,764,985...18,782,148
|
|
G
|
Kit
|
KIT proto-oncogene receptor tyrosine kinase
|
affects response to substance multiple interactions
|
ISO
|
KIT gene mutant form affects the susceptibility to Mechlorethamine KIT gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of IL1B mRNA]; KIT gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of IL33 mRNA]; KIT gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of IL6 mRNA]; KIT gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of PTGS2 mRNA]; KIT gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of TNF mRNA]
|
CTD |
PMID:34453837 |
|
NCBI chr14:32,901,615...32,978,895
Ensembl chr14:32,903,033...32,978,812
|
|
G
|
Lamc2
|
laminin subunit gamma 2
|
decreases expression increases degradation
|
ISO
|
Mechlorethamine results in decreased expression of LAMC2 protein Mechlorethamine results in increased degradation of LAMC2 protein
|
CTD |
PMID:9504665 PMID:18095945 |
|
NCBI chr13:67,835,199...67,894,694
Ensembl chr13:67,835,199...67,895,102
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
increases phosphorylation multiple interactions
|
ISO
|
Mechlorethamine results in increased phosphorylation of MAPK1 protein Mechlorethamine results in increased phosphorylation of and affects the localization of MAPK1 protein
|
CTD |
PMID:25891025 PMID:31639410 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
increases phosphorylation multiple interactions
|
ISO
|
Mechlorethamine results in increased phosphorylation of MAPK3 protein Mechlorethamine results in increased phosphorylation of and affects the localization of MAPK3 protein
|
CTD |
PMID:25891025 PMID:31639410 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
increases phosphorylation
|
ISO
|
Mechlorethamine results in increased phosphorylation of MAPK8 protein
|
CTD |
PMID:25891025 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Mapk9
|
mitogen-activated protein kinase 9
|
increases phosphorylation
|
ISO
|
Mechlorethamine results in increased phosphorylation of MAPK9 protein
|
CTD |
PMID:25891025 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228
|
|
G
|
Mir106b
|
microRNA 106b
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR106B mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr12:17,043,344...17,043,425
|
|
G
|
Mir125a
|
microRNA 125a
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR125A mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 1:67,350,675...67,350,759
Ensembl chr 1:67,350,675...67,350,759
|
|
G
|
Mir125b1
|
microRNA 125b-1
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR125B1 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 8:50,850,036...50,850,122
Ensembl chr 8:50,850,036...50,850,122
|
|
G
|
Mir127
|
microRNA 127
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR127 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 6:134,328,454...134,328,550
Ensembl chr 6:134,328,454...134,328,550
|
|
G
|
Mir136
|
microRNA 136
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR136 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 6:134,331,335...134,331,416
Ensembl chr 6:134,331,335...134,331,416
|
|
G
|
Mir140
|
microRNA 140
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR140 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr19:52,375,293...52,375,391
Ensembl chr19:52,375,293...52,375,391
|
|
G
|
Mir141
|
microRNA 141
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR141 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 4:159,209,525...159,209,618
|
|
G
|
Mir142
|
microRNA 142
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR142 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr10:73,055,104...73,055,190
Ensembl chr10:73,055,097...73,055,207
|
|
G
|
Mir145
|
microRNA 145
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR145 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr18:57,369,983...57,370,070
|
|
G
|
Mir146a
|
microRNA 146a
|
multiple interactions
|
ISO
|
[NR1H4 protein affects the susceptibility to Mechlorethamine] which affects the expression of MIR146 mRNA
|
CTD |
PMID:35998709 |
|
NCBI chr10:28,349,996...28,350,090
|
|
G
|
Mir146b
|
microRNA 146b
|
decreases expression
|
EXP
|
Mechlorethamine results in decreased expression of MIR146B mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 1:255,144,860...255,144,947
Ensembl chr 1:255,144,860...255,144,947
|
|
G
|
Mir148b
|
microRNA 148b
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR148B mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 7:134,421,398...134,421,494
Ensembl chr 7:136,299,870...136,299,966
|
|
G
|
Mir152
|
microRNA 152
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR152 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr10:82,329,383...82,329,467
Ensembl chr10:82,329,383...82,329,467
|
|
G
|
Mir155
|
microRNA 155
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of MIR155 mRNA
|
CTD |
PMID:35998709 |
|
NCBI chr11:37,261,114...37,261,178
Ensembl chr11:37,261,114...37,261,178
|
|
G
|
Mir15a
|
microRNA mir-15a
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR15A mRNA
|
CTD |
PMID:33971176 |
|
|
|
G
|
Mir15b
|
microRNA 15b
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR15B mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 2:155,555,178...155,555,275
Ensembl chr 2:155,555,178...155,555,275
|
|
G
|
Mir16-2
|
microRNA 16-2
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR16-2 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 2:155,555,327...155,555,421
Ensembl chr 2:155,555,327...155,555,421
|
|
G
|
Mir17
|
microRNA 17
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR17 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr15:98,587,848...98,587,931
Ensembl chr15:98,587,848...98,587,931
|
|
G
|
Mir181a2
|
microRNA 181a-2
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR181A2 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 3:22,615,845...22,615,961
Ensembl chr 3:43,025,563...43,025,679
|
|
G
|
Mir181b1
|
microRNA 181b-1
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR181B1 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr13:49,485,688...49,485,797
Ensembl chr13:52,037,228...52,037,337
|
|
G
|
Mir181c
|
microRNA 181c
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR181C mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr19:40,888,291...40,888,396
Ensembl chr19:40,888,291...40,888,396
|
|
G
|
Mir181d
|
microRNA 181d
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR181D mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr19:23,983,706...23,983,788
Ensembl chr19:40,888,474...40,888,556
|
|
G
|
Mir182
|
microRNA 182
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR182 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 4:59,752,246...59,752,307
|
|
G
|
Mir183
|
microRNA 183
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR183 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 4:58,788,614...58,788,723
|
|
G
|
Mir186
|
microRNA 186
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR186 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 2:246,582,806...246,582,891
Ensembl chr 2:249,241,650...249,241,735
|
|
G
|
Mir195
|
microRNA 195
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR195 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr10:55,450,495...55,450,581
Ensembl chr10:55,450,495...55,450,581
|
|
G
|
Mir19a
|
microRNA 19a
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR19A mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr15:98,588,131...98,588,212
Ensembl chr15:98,588,131...98,588,212
|
|
G
|
Mir19b1
|
microRNA 19b-1
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR19B1 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr15:98,588,433...98,588,519
Ensembl chr15:98,588,433...98,588,519
|
|
G
|
Mir200a
|
microRNA 200a
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR200A mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 5:171,930,717...171,930,805
|
|
G
|
Mir200c
|
microRNA 200c
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR200C mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 4:159,209,965...159,210,033
|
|
G
|
Mir203
|
microRNA 203
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR203 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 6:137,020,691...137,020,805
|
|
G
|
Mir205
|
microRNA 205
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR205 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr13:107,564,535...107,564,642
|
|
G
|
Mir20a
|
microRNA 20a
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR20A mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr15:98,588,303...98,588,387
Ensembl chr15:98,588,303...98,588,387
|
|
G
|
Mir20b
|
microRNA 20b
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR20B mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr X:137,343,197...137,343,268
|
|
G
|
Mir21
|
microRNA 21
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR21 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr10:71,902,600...71,902,691
|
|
G
|
Mir221
|
microRNA 221
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR221 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr X:6,023,182...6,023,290
Ensembl chr X:6,023,182...6,023,290
|
|
G
|
Mir222
|
microRNA 222
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR222 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr X:6,022,621...6,022,723
Ensembl chr X:6,022,621...6,022,723
|
|
G
|
Mir223
|
microRNA 223
|
multiple interactions
|
ISO
|
[NR1H4 protein affects the susceptibility to Mechlorethamine] which affects the expression of MIR223 mRNA
|
CTD |
PMID:35998709 |
|
NCBI chr X:65,151,383...65,151,492
Ensembl chr X:65,151,383...65,151,492
|
|
G
|
Mir23b
|
microRNA 23b
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR23B mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr17:1,819,386...1,819,482
|
|
G
|
Mir26a1
|
microRNA 26a-1
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR26A1 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 8:127,633,048...127,633,137
Ensembl chr 8:127,633,048...127,633,137
|
|
G
|
Mir27a
|
microRNA 27a
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR27A mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr19:40,859,603...40,859,689
|
|
G
|
Mir27b
|
microRNA 27b
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR27B mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr17:1,819,147...1,819,243
|
|
G
|
Mir291a
|
microRNA 291a
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR291A mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 1:65,964,350...65,964,431
|
|
G
|
Mir29a
|
microRNA 29a
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR29A mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 4:60,617,955...60,618,042
|
|
G
|
Mir30a
|
microRNA 30a
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR30A mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 9:33,233,941...33,234,011
Ensembl chr 9:33,233,941...33,234,011
|
|
G
|
Mir30b
|
microRNA 30b
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR30B mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 7:102,021,543...102,021,629
|
|
G
|
Mir30c1
|
microRNA 30c-1
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR30C1 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 5:139,634,455...139,634,543
|
|
G
|
Mir30d
|
microRNA 30d
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR30D mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 7:102,025,345...102,025,426
|
|
G
|
Mir30e
|
microRNA 30e
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR30E mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 5:134,352,232...134,352,323
Ensembl chr 5:139,637,450...139,637,541
|
|
G
|
Mir320a
|
microRNA 320a
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR320A mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr15:51,926,088...51,926,169
Ensembl chr15:51,926,088...51,926,169
|
|
G
|
Mir322
|
microRNA 322
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR322 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr X:137,726,147...137,726,241
|
|
G
|
Mir325
|
microRNA 325
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR325 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr X:70,457,918...70,458,015
|
|
G
|
Mir327
|
microRNA 327
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR327 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr20:13,161,640...13,161,733
|
|
G
|
Mir34c
|
microRNA 34c
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR34C mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 8:60,306,091...60,306,167
|
|
G
|
Mir351
|
microRNA 351
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR351 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr X:137,725,116...137,725,196
|
|
G
|
Mir374b
|
microRNA 374b
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR374B mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr X:72,657,495...72,657,562
|
|
G
|
Mir381
|
microRNA 381
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR381 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 6:134,562,381...134,562,441
|
|
G
|
Mir384
|
microRNA 384
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR384 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr X:70,425,293...70,425,375
|
|
G
|
Mir410
|
microRNA 410
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR410 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 6:134,579,763...134,579,838
Ensembl chr 6:134,579,759...134,579,839
|
|
G
|
Mir429
|
microRNA 429
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR429 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 5:171,929,682...171,929,766
|
|
G
|
Mir449a
|
microRNA 449a
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR449A mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 2:46,403,910...46,404,000
Ensembl chr 2:46,403,910...46,404,000
|
|
G
|
Mir495
|
microRNA 495
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR495 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 6:128,732,650...128,732,729
Ensembl chr 6:134,554,055...134,554,134
|
|
G
|
Mir497
|
microRNA 497
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR497 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr10:55,450,171...55,450,239
Ensembl chr10:55,450,162...55,450,241
|
|
G
|
Mir673
|
microRNA 673
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR673 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 6:128,524,261...128,524,343
Ensembl chr 6:134,306,500...134,306,582
|
|
G
|
Mir743b
|
microRNA 743b
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR743B mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr X:150,444,578...150,444,654
|
|
G
|
Mir878
|
microRNA 878
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR878 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr X:145,432,857...145,432,933
|
|
G
|
Mir9-1
|
microRNA 9-1
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR9-1 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 2:175,974,971...175,975,059
|
|
G
|
Mir93
|
microRNA 93
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR93 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr12:22,156,844...22,156,930
|
|
G
|
Mir98
|
microRNA 98
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIR98 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr X:24,460,648...24,460,755
Ensembl chr X:24,460,648...24,460,755
|
|
G
|
Mirlet7b
|
microRNA let-7b
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIRLET7B mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 7:116,804,186...116,804,270
Ensembl chr 7:118,684,038...118,684,122
|
|
G
|
Mirlet7c1
|
microRNA let-7c-1
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIRLET7C1 mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr11:29,688,112...29,688,205
Ensembl chr11:29,688,107...29,688,214
|
|
G
|
Mirlet7i
|
microRNA let-7i
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MIRLET7I mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr 7:58,642,485...58,642,569
|
|
G
|
Mmp10
|
matrix metallopeptidase 10
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of MMP10 mRNA
|
CTD |
PMID:26273949 |
|
NCBI chr 8:12,974,707...12,982,613
Ensembl chr 8:12,974,707...12,982,613
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
increases expression multiple interactions
|
ISO EXP
|
Mechlorethamine results in increased expression of MMP9; Mechlorethamine results in increased expression of MMP9 protein Valproic Acid inhibits the reaction [Mechlorethamine results in increased expression of MMP9 mRNA] Mechlorethamine results in increased expression of MMP9 mRNA; Mechlorethamine results in increased expression of MMP9 protein MPO gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of MMP9]; SFTPD gene mutant form promotes the reaction [Mechlorethamine results in increased expression of MMP9 protein]
|
CTD |
PMID:20883710 PMID:24631667 PMID:25891025 PMID:26273949 PMID:28184907 PMID:30060251 More...
|
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mobp
|
myelin-associated oligodendrocyte basic protein
|
decreases expression
|
ISO
|
Mechlorethamine results in decreased expression of MOBP mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr 8:128,747,117...128,777,238
Ensembl chr 8:128,747,232...128,777,936
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions increases response to substance
|
ISO
|
MPO gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of MMP9]; MPO gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of NOS2]; MPO gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of PTGS2] MPO protein results in increased susceptibility to Mechlorethamine
|
CTD |
PMID:24631667 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Mrc1
|
mannose receptor, C type 1
|
increases expression multiple interactions
|
EXP ISO
|
Mechlorethamine results in increased expression of MRC1 protein SFTPD gene mutant form promotes the reaction [Mechlorethamine results in increased expression of MRC1 protein]
|
CTD |
PMID:26273949 PMID:30060251 |
|
NCBI chr17:82,157,725...82,239,411
Ensembl chr17:82,157,705...82,239,410
|
|
G
|
Msh2
|
mutS homolog 2
|
affects response to substance
|
ISO
|
MSH2 protein affects the susceptibility to Mechlorethamine
|
CTD |
PMID:12185594 |
|
NCBI chr 6:12,567,368...12,626,534
Ensembl chr 6:12,567,368...12,626,503
|
|
G
|
Nckap1
|
NCK-associated protein 1
|
decreases expression
|
ISO
|
Mechlorethamine results in decreased expression of NCKAP1 mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr 3:85,824,333...85,898,748
Ensembl chr 3:85,824,336...85,898,797
|
|
G
|
Ndrg2
|
NDRG family member 2
|
decreases expression
|
ISO
|
Mechlorethamine results in decreased expression of NDRG2 mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr15:27,074,481...27,087,376
Ensembl chr15:27,074,481...27,083,125
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
affects response to substance decreases response to substance
|
ISO
|
NFE2L2 gene mutant form affects the susceptibility to Mechlorethamine NFE2L2 protein results in decreased susceptibility to Mechlorethamine
|
CTD |
PMID:20932822 PMID:26454883 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nmu
|
neuromedin U
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of NMU mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr14:32,198,789...32,226,397
Ensembl chr14:32,198,943...32,226,632
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
increases expression multiple interactions
|
ISO EXP
|
Mechlorethamine results in increased expression of NOS2; Mechlorethamine results in increased expression of NOS2 protein Acetylcysteine inhibits the reaction [Mechlorethamine results in increased expression of NOS2 mRNA]; Acetylcysteine inhibits the reaction [Mechlorethamine results in increased expression of NOS2 protein]; Valproic Acid inhibits the reaction [Mechlorethamine results in increased expression of NOS2 mRNA] Mechlorethamine results in increased expression of NOS2 mRNA; Mechlorethamine results in increased expression of NOS2 protein MPO gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of NOS2]; SFTPD gene mutant form promotes the reaction [Mechlorethamine results in increased expression of NOS2 protein]
|
CTD |
PMID:20883710 PMID:24631667 PMID:25891025 PMID:26273949 PMID:28184907 PMID:30060251 PMID:38513841 More...
|
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions affects response to substance
|
ISO
|
[NR1H4 protein affects the susceptibility to Mechlorethamine] which affects the expression of MIR146 mRNA; [NR1H4 protein affects the susceptibility to Mechlorethamine] which affects the expression of MIR223 mRNA; NR1H4 protein affects the reaction [Mechlorethamine results in increased expression of ARL11 protein]; NR1H4 protein affects the reaction [Mechlorethamine results in increased expression of CD163 protein]; NR1H4 protein affects the reaction [Mechlorethamine results in increased expression of HMOX1]; NR1H4 protein affects the reaction [Mechlorethamine results in increased expression of PTGS2 protein]; NR1H4 protein affects the reaction [Mechlorethamine results in increased expression of STAT6 protein]
|
CTD |
PMID:35998709 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
increases expression multiple interactions
|
EXP
|
Mechlorethamine results in increased expression of PCNA; Mechlorethamine results in increased expression of PCNA protein Valproic Acid inhibits the reaction [Mechlorethamine results in increased expression of PCNA protein]
|
CTD |
PMID:22981630 PMID:28184907 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
G
|
Pdcd4
|
programmed cell death 4
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of PDCD4 mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr 1:262,912,659...262,949,581
Ensembl chr 1:262,926,656...262,950,189
|
|
G
|
Pdpk1
|
3-phosphoinositide dependent protein kinase-1
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of PDPK1 protein modified form
|
CTD |
PMID:25891025 |
|
NCBI chr10:13,610,000...13,687,226
Ensembl chr10:13,610,063...13,679,181
|
|
G
|
Plp1
|
proteolipid protein 1
|
decreases expression
|
ISO
|
Mechlorethamine results in decreased expression of PLP1 mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr X:104,933,921...104,993,317
Ensembl chr X:104,975,780...104,993,314
|
|
G
|
Polr2j
|
RNA polymerase II subunit J
|
decreases expression
|
ISO
|
Mechlorethamine results in decreased expression of POLR2J mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr12:20,543,038...20,548,590
Ensembl chr12:26,179,649...26,185,201
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of PPARA protein
|
CTD |
PMID:27125198 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Psmd11
|
proteasome 26S subunit, non-ATPase 11
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of PSMD11 mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr10:65,923,669...65,977,523
Ensembl chr10:65,931,279...65,976,234
|
|
G
|
Psmd7
|
proteasome 26S subunit, non-ATPase 7
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of PSMD7 mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr19:35,494,317...35,501,605
Ensembl chr19:52,404,032...52,417,871
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
increases expression multiple interactions
|
ISO EXP
|
Mechlorethamine results in increased expression of PTGS2; Mechlorethamine results in increased expression of PTGS2 mRNA; Mechlorethamine results in increased expression of PTGS2 protein Acetylcysteine inhibits the reaction [Mechlorethamine results in increased expression of PTGS2 mRNA]; Acetylcysteine inhibits the reaction [Mechlorethamine results in increased expression of PTGS2 protein]; Valproic Acid inhibits the reaction [Mechlorethamine results in increased expression of PTGS2 mRNA] KIT gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of PTGS2 mRNA]; MPO gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of PTGS2]; NR1H4 protein affects the reaction [Mechlorethamine results in increased expression of PTGS2 protein]
|
CTD |
PMID:20883710 PMID:24631667 PMID:25891025 PMID:26273949 PMID:28184907 PMID:34453837 PMID:35998709 PMID:38513841 More...
|
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Rad51
|
RAD51 recombinase
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of RAD51 protein
|
CTD |
PMID:25891025 |
|
NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469
|
|
G
|
Rps6
|
ribosomal protein S6
|
multiple interactions
|
ISO
|
Mechlorethamine affects the reaction [Dimethyl Sulfoxide affects the phosphorylation of RPS6 protein] [Dimethyl Sulfoxide co-treated with Mechlorethamine] results in increased phosphorylation of RPS6 protein; Mechlorethamine inhibits the reaction [Dimethyl Sulfoxide results in increased phosphorylation of RPS6 protein]
|
CTD |
PMID:36708981 |
|
NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:106,417,680...106,420,566
|
|
G
|
Rptor
|
regulatory associated protein of MTOR, complex 1
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of RPTOR protein
|
CTD |
PMID:36708981 |
|
NCBI chr10:105,376,943...105,675,416
Ensembl chr10:105,376,943...105,675,413
|
|
G
|
Sem1
|
SEM1 26S proteasome subunit
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of SEM1 mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr 4:34,671,848...34,692,005
Ensembl chr 4:35,638,306...35,658,462
|
|
G
|
Sftpd
|
surfactant protein D
|
increases expression increases response to substance multiple interactions
|
ISO
|
Mechlorethamine results in increased expression of SFTPD protein SFTPD gene mutant form results in increased susceptibility to Mechlorethamine SFTPD gene mutant form promotes the reaction [Mechlorethamine results in increased expression of CHIL3 protein]; SFTPD gene mutant form promotes the reaction [Mechlorethamine results in increased expression of HMOX1 protein]; SFTPD gene mutant form promotes the reaction [Mechlorethamine results in increased expression of MMP9 protein]; SFTPD gene mutant form promotes the reaction [Mechlorethamine results in increased expression of MRC1 protein]; SFTPD gene mutant form promotes the reaction [Mechlorethamine results in increased expression of NOS2 protein]
|
CTD |
PMID:30060251 |
|
NCBI chr16:17,080,575...17,093,047
Ensembl chr16:17,080,567...17,094,036
|
|
G
|
Slc22a2
|
solute carrier family 22 member 2
|
multiple interactions
|
ISO
|
Mechlorethamine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
|
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019
|
|
G
|
Snora36c
|
small nucleolar RNA, H/ACA box 36C
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of SNORA36C mRNA
|
CTD |
PMID:33971176 |
|
NCBI chr18:45,952,021...45,952,079
Ensembl chr18:48,150,366...48,150,424
|
|
G
|
Sod2
|
superoxide dismutase 2
|
increases expression multiple interactions
|
EXP
|
Mechlorethamine results in increased expression of SOD2; Mechlorethamine results in increased expression of SOD2 protein Valproic Acid inhibits the reaction [Mechlorethamine results in increased expression of SOD2 protein]
|
CTD |
PMID:22981630 PMID:28184907 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
G
|
Stat6
|
signal transducer and activator of transcription 6
|
multiple interactions increases expression
|
ISO
|
NR1H4 protein affects the reaction [Mechlorethamine results in increased expression of STAT6 protein]
|
CTD |
PMID:35998709 |
|
NCBI chr 7:65,365,505...65,382,825
Ensembl chr 7:65,365,306...65,383,795
|
|
G
|
Stk11
|
serine/threonine kinase 11
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of STK11 mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr 7:10,225,204...10,241,965
Ensembl chr 7:10,225,204...10,241,965
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
increases expression
|
EXP
|
Mechlorethamine results in increased expression of TGFB1 protein
|
CTD |
PMID:38513841 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases expression multiple interactions
|
ISO EXP
|
Mechlorethamine results in increased expression of TNF mRNA; Mechlorethamine results in increased expression of TNF protein Acetylcysteine inhibits the reaction [Mechlorethamine results in increased expression of TNF protein] KIT gene mutant form inhibits the reaction [Mechlorethamine results in increased expression of TNF mRNA]
|
CTD |
PMID:25891025 PMID:26243812 PMID:26273949 PMID:34453837 PMID:38513841 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tnfrsf12a
|
TNF receptor superfamily member 12A
|
decreases expression
|
ISO
|
Mechlorethamine results in decreased expression of TNFRSF12A mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr10:13,211,670...13,213,666
Ensembl chr10:13,211,673...13,213,704
|
|
G
|
Tp53
|
tumor protein p53
|
multiple interactions affects binding decreases activity increases stability increases alkylation affects response to substance increases expression
|
ISO
|
Mechlorethamine results in increased phosphorylation of and results in increased expression of TRP53 protein Mechlorethamine binds to TP53 protein Mechlorethamine results in increased expression of and affects the localization of TP53 protein; Mechlorethamine results in increased phosphorylation of and results in increased acetylation of TP53 protein Mechlorethamine results in decreased activity of TP53 protein Mechlorethamine results in increased stability of TP53 protein Mechlorethamine results in increased alkylation of TP53 protein TRP53 affects the susceptibility to Mechlorethamine; TRP53 protein affects the susceptibility to Mechlorethamine Mechlorethamine results in increased expression of TP53 protein
|
CTD |
PMID:12185594 PMID:16738803 PMID:23845566 PMID:25891025 PMID:35312310 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Trpa1
|
transient receptor potential cation channel, subfamily A, member 1
|
increases response to substance
|
ISO
|
TRPA1 protein results in increased susceptibility to Mechlorethamine
|
CTD |
PMID:36693442 |
|
NCBI chr 5:9,163,060...9,217,325
Ensembl chr 5:9,163,060...9,217,325
|
|
G
|
Txn1
|
thioredoxin 1
|
decreases activity
|
ISO
|
Mechlorethamine results in decreased activity of TXN protein
|
CTD |
PMID:26451472 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307
|
|
G
|
Txnrd1
|
thioredoxin reductase 1
|
multiple interactions
|
ISO EXP
|
[NADP co-treated with Mechlorethamine] results in decreased activity of TXNRD1 protein [NADP co-treated with Mechlorethamine] promotes the reaction [TXNRD1 protein binds to TXNRD1 protein]; [NADP co-treated with Mechlorethamine] results in decreased activity of and results in increased alkylation of TXNRD1 protein
|
CTD |
PMID:24274902 |
|
NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817
|
|
G
|
Txnrd2
|
thioredoxin reductase 2
|
decreases activity
|
ISO
|
Mechlorethamine results in decreased activity of TXNRD2 protein
|
CTD |
PMID:24274902 |
|
NCBI chr11:96,024,321...96,072,475
Ensembl chr11:96,024,324...96,072,475
|
|
G
|
Ube2k
|
ubiquitin-conjugating enzyme E2K
|
increases expression
|
ISO
|
Mechlorethamine results in increased expression of UBE2K mRNA
|
CTD |
PMID:17107856 |
|
NCBI chr14:43,011,681...43,077,825
Ensembl chr14:43,011,681...43,072,462
|
|
|
G
|
Abcc1
|
ATP binding cassette subfamily C member 1
|
affects export
|
ISO
|
ABCC1 protein affects the export of Melphalan analog
|
CTD |
PMID:11115505 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404
|
|
G
|
Abhd17c
|
abhydrolase domain containing 17C, depalmitoylase
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ABHD17C mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:147,493,755...147,534,715
Ensembl chr 1:147,493,753...147,534,715
|
|
G
|
Abraxas1
|
abraxas 1, BRCA1 A complex subunit
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ABRAXAS1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr14:9,100,650...9,115,012
Ensembl chr14:9,100,671...9,115,011
|
|
G
|
Abt1
|
activator of basal transcription 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of ABT1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr17:42,127,173...42,129,281
Ensembl chr17:42,127,202...42,130,684
|
|
G
|
Ackr3
|
atypical chemokine receptor 3
|
increases expression
|
ISO
|
Melphalan results in increased expression of ACKR3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:98,247,300...98,258,877
Ensembl chr 9:98,246,605...98,260,214
|
|
G
|
Acvr1c
|
activin A receptor type 1C
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ACVR1C mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 3:63,224,322...63,301,252
Ensembl chr 3:63,227,559...63,301,205
|
|
G
|
Ahrr
|
aryl-hydrocarbon receptor repressor
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of AHRR mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:30,822,219...30,917,251
Ensembl chr 1:30,810,866...30,952,866
|
|
G
|
Alad
|
aminolevulinate dehydratase
|
decreases activity
|
ISO
|
Melphalan results in decreased activity of ALAD protein
|
CTD |
PMID:19162187 |
|
NCBI chr 5:80,977,562...80,987,901
Ensembl chr 5:80,977,562...80,988,041
|
|
G
|
Ammecr1l
|
AMMECR1 like
|
increases expression
|
ISO
|
Melphalan results in increased expression of AMMECR1L mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr18:23,386,114...23,411,177
Ensembl chr18:23,661,341...23,685,649
|
|
G
|
Ankar
|
ankyrin and armadillo repeat containing
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ANKAR mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:48,141,534...48,215,400
Ensembl chr 9:55,633,566...55,707,369
|
|
G
|
Ankrd10
|
ankyrin repeat domain 10
|
increases expression
|
ISO
|
Melphalan results in increased expression of ANKRD10 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr16:84,566,021...84,591,849
Ensembl chr16:84,568,506...84,591,846
|
|
G
|
Ankrd28
|
ankyrin repeat domain 28
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ANKRD28 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr16:6,918,487...7,050,244
Ensembl chr16:6,924,882...7,056,593
|
|
G
|
Ankrd34a
|
ankyrin repeat domain 34A
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ANKRD34A mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 2:186,818,496...186,823,921
Ensembl chr 2:186,817,216...186,824,467
|
|
G
|
Ar
|
androgen receptor
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of AR mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467
|
|
G
|
Arhgap12
|
Rho GTPase activating protein 12
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ARHGAP12 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr17:56,284,282...56,397,630
Ensembl chr17:56,284,286...56,397,563
|
|
G
|
Arhgap18
|
Rho GTPase activating protein 18
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ARHGAP18 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:20,222,948...20,456,827
Ensembl chr 1:20,222,954...20,456,670
|
|
G
|
Arhgap20
|
Rho GTPase activating protein 20
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ARHGAP20 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 8:60,970,480...61,055,199
Ensembl chr 8:60,970,475...61,055,198
|
|
G
|
Arhgap24
|
Rho GTPase activating protein 24
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ARHGAP24 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr14:7,105,200...7,488,437
Ensembl chr14:7,105,200...7,528,950
|
|
G
|
Arhgap42
|
Rho GTPase activating protein 42
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ARHGAP42 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 8:14,436,478...14,666,588
Ensembl chr 8:14,419,256...14,666,385
|
|
G
|
Arid5a
|
AT-rich interaction domain 5A
|
increases expression
|
ISO
|
Melphalan results in increased expression of ARID5A mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:46,030,513...46,058,729
Ensembl chr 9:46,030,548...46,045,363
|
|
G
|
Atg16l1
|
autophagy related 16-like 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of ATG16L1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:95,869,839...95,905,354
Ensembl chr 9:95,869,865...95,905,357
|
|
G
|
Atp2b1
|
ATPase plasma membrane Ca2+ transporting 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ATP2B1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:35,622,267...35,731,904
Ensembl chr 7:35,622,461...35,731,904
|
|
G
|
Aurka
|
aurora kinase A
|
increases expression
|
ISO
|
Melphalan results in increased expression of AURKA protein
|
CTD |
PMID:22025197 |
|
NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771
|
|
G
|
Aurkb
|
aurora kinase B
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of AURKB protein
|
CTD |
PMID:22025197 |
|
NCBI chr10:54,243,116...54,249,675
Ensembl chr10:54,242,850...54,252,285
|
|
G
|
B3gnt2
|
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2
|
increases expression
|
ISO
|
Melphalan results in increased expression of B3GNT2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr14:101,009,682...101,034,507
Ensembl chr14:100,967,131...101,043,412
|
|
G
|
B3gnt5
|
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5
|
increases expression
|
ISO
|
Melphalan results in increased expression of B3GNT5 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr11:81,141,102...81,153,206
Ensembl chr11:94,645,480...94,660,514
|
|
G
|
Bak1
|
BCL2-antagonist/killer 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of BAK1 protein
|
CTD |
PMID:22285227 |
|
NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO
|
Melphalan results in increased expression of and results in decreased localization of BAX protein
|
CTD |
PMID:22285227 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bche
|
butyrylcholinesterase
|
multiple interactions
|
ISO
|
[Melphalan co-treated with Thiotepa co-treated with Cyclophosphamide] results in decreased expression of BCHE protein
|
CTD |
PMID:4672170 |
|
NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:160,606,288...160,699,760
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of BCL2 protein
|
CTD |
PMID:22285227 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bcl2a1
|
BCL2-related protein A1
|
increases expression
|
ISO
|
Melphalan results in increased expression of BCL2A1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 8:98,596,806...98,604,890
Ensembl chr 8:98,596,650...98,604,890
|
|
G
|
Bicc1
|
BicC family RNA binding protein 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of BICC1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr20:17,448,745...17,685,887
Ensembl chr20:17,448,765...17,685,885
|
|
G
|
Bicdl2
|
BICD family like cargo adaptor 2
|
increases expression
|
ISO
|
Melphalan results in increased expression of BICDL2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr10:13,196,205...13,204,642
Ensembl chr10:13,195,913...13,204,642
|
|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
affects response to substance decreases expression multiple interactions
|
ISO
|
BIRC5 protein affects the susceptibility to Melphalan Melphalan results in decreased expression of BIRC5 protein Nocodazole affects the reaction [BIRC5 protein affects the susceptibility to Melphalan]; Paclitaxel affects the reaction [BIRC5 protein affects the susceptibility to Melphalan]
|
CTD |
PMID:16373717 PMID:22025197 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155
|
|
G
|
Bnc2
|
basonuclin zinc finger protein 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of BNC2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:98,679,071...99,016,044
Ensembl chr 5:103,724,934...104,125,428
|
|
G
|
Btbd8
|
BTB domain containing 8
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of BTBD8 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr14:2,410,093...2,483,114
Ensembl chr14:2,410,093...2,479,202
|
|
G
|
Btg2
|
BTG anti-proliferation factor 2
|
increases expression
|
ISO
|
Melphalan results in increased expression of BTG2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr13:48,083,931...48,087,690
Ensembl chr13:48,083,931...48,087,690
|
|
G
|
Cables1
|
Cdk5 and Abl enzyme substrate 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of CABLES1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr18:3,349,681...3,455,956
Ensembl chr18:3,351,652...3,455,956
|
|
G
|
Casp3
|
caspase 3
|
increases activity
|
ISO
|
Melphalan results in increased activity of CASP3 protein
|
CTD |
PMID:16951922 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions
|
ISO
|
Melphalan results in increased cleavage of and results in increased activity of CASP9 protein
|
CTD |
PMID:22285227 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cat
|
catalase
|
decreases activity
|
ISO
|
Melphalan results in decreased activity of CAT protein
|
CTD |
PMID:19162187 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Cc2d2a
|
coiled-coil and C2 domain containing 2A
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of CC2D2A mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr14:71,563,835...71,648,352
Ensembl chr14:71,563,835...71,648,331
|
|
G
|
Ccdc110
|
coiled-coil domain containing 110
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of CCDC110 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr16:46,315,745...46,337,050
Ensembl chr16:53,047,965...53,069,777
|
|
G
|
Ccdc171
|
coiled-coil domain containing 171
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of CCDC171 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:97,919,965...98,403,853
Ensembl chr 5:102,965,911...103,533,290
|
|
G
|
Ccl20
|
C-C motif chemokine ligand 20
|
increases expression
|
ISO
|
Melphalan results in increased expression of CCL20 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:91,837,139...91,839,736
Ensembl chr 9:91,836,946...91,839,736
|
|
G
|
Ccnj
|
cyclin J
|
increases expression
|
ISO
|
Melphalan results in increased expression of CCNJ mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:249,608,991...249,626,798
Ensembl chr 1:249,608,969...249,626,794
|
|
G
|
Cd34
|
CD34 molecule
|
multiple interactions
|
ISO
|
[Melphalan co-treated with Prednisolone] results in decreased expression of CD34 protein
|
CTD |
PMID:10618687 |
|
NCBI chr13:109,008,786...109,029,317
Ensembl chr13:109,008,623...109,029,315
|
|
G
|
Cd59b
|
CD59b molecule
|
decreases lipidation
|
EXP
|
Melphalan results in decreased lipidation of CD59 protein
|
CTD |
PMID:27931811 |
|
NCBI chr 3:110,914,008...110,932,489
Ensembl chr 3:110,914,091...110,935,310
|
|
G
|
Cda
|
cytidine deaminase
|
decreases response to substance
|
ISO
|
CDA protein results in decreased susceptibility to Melphalan
|
CTD |
PMID:10830723 |
|
NCBI chr 5:155,839,929...155,866,541
Ensembl chr 5:155,839,929...155,866,541
|
|
G
|
Cdc14b
|
cell division cycle 14B
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of CDC14B mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr17:850,272...938,972
Ensembl chr17:850,390...971,164
|
|
G
|
Cdc42ep3
|
CDC42 effector protein 3
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of CDC42EP3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 6:21,463,081...21,483,553
Ensembl chr 6:21,461,762...21,508,540
|
|
G
|
Cfap206
|
cilia and flagella associated protein 206
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of CFAP206 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:49,254,399...49,299,145
Ensembl chr 5:54,050,701...54,095,383
|
|
G
|
Chek1
|
checkpoint kinase 1
|
increases phosphorylation
|
ISO
|
Melphalan results in increased phosphorylation of CHEK1 protein
|
CTD |
PMID:26208482 |
|
NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:44,609,417...44,629,359
|
|
G
|
Chek2
|
checkpoint kinase 2
|
increases phosphorylation
|
ISO
|
Melphalan results in increased phosphorylation of CHEK2 protein
|
CTD |
PMID:26208482 |
|
NCBI chr12:51,448,838...51,481,159
Ensembl chr12:51,449,140...51,480,667
|
|
G
|
Chuk
|
component of inhibitor of nuclear factor kappa B kinase complex
|
affects phosphorylation
|
ISO
|
Melphalan affects the phosphorylation of CHUK protein
|
CTD |
PMID:19934314 |
|
NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273
|
|
G
|
Ciita
|
class II, major histocompatibility complex, transactivator
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of CIITA mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr10:5,646,854...5,694,393
Ensembl chr10:5,647,085...5,694,342
|
|
G
|
Cited4
|
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4
|
increases expression
|
ISO
|
Melphalan results in increased expression of CITED4 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:134,246,936...134,247,827
Ensembl chr 5:139,531,584...139,533,361
|
|
G
|
Cnksr3
|
Cnksr family member 3
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of CNKSR3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:45,904,581...45,996,921
Ensembl chr 1:45,904,581...45,996,921
|
|
G
|
Cpne8
|
copine 8
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of CPNE8 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:123,494,864...123,669,060
Ensembl chr 7:123,494,865...123,669,060
|
|
G
|
Creb5
|
cAMP responsive element binding protein 5
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of CREB5 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 4:83,723,587...84,124,786
Ensembl chr 4:83,723,194...84,120,793
|
|
G
|
Cul3
|
cullin 3
|
increases expression
|
ISO
|
Melphalan results in increased expression of CUL3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:89,040,987...89,118,775
Ensembl chr 9:89,040,987...89,118,427
|
|
G
|
Cxcl12
|
C-X-C motif chemokine ligand 12
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of CXCL12 mRNA; Melphalan results in decreased expression of CXCL12 protein
|
CTD |
PMID:22363485 |
|
NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions
|
ISO EXP
|
Melphalan inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
|
CTD |
PMID:18493746 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
multiple interactions
|
ISO EXP
|
Melphalan inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]
|
CTD |
PMID:18493746 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp27b1
|
cytochrome P450, family 27, subfamily b, polypeptide 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of CYP27B1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:64,756,626...64,761,570
Ensembl chr 7:64,756,626...64,761,570
|
|
G
|
Cyria
|
CYFIP related Rac1 interactor A
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of CYRIA mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 6:40,774,165...40,883,005
Ensembl chr 6:40,774,171...40,881,860
|
|
G
|
Dbf4
|
DBF4-CDC7 kinase regulatory subunit
|
increases expression
|
ISO
|
Melphalan results in increased expression of DBF4 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 4:26,631,491...26,656,080
Ensembl chr 4:26,631,514...26,656,562
|
|
G
|
Dcn
|
decorin
|
multiple interactions
|
ISO
|
DCN protein inhibits the reaction [TGFB1 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Cisplatin co-treated with Melphalan co-treated with Thiotepa]]
|
CTD |
PMID:9509296 |
|
NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926
|
|
G
|
Dennd4c
|
DENN domain containing 4C
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of DENND4C mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:106,316,942...106,421,484
Ensembl chr 5:106,318,281...106,415,489
|
|
G
|
Dlg3
|
discs large MAGUK scaffold protein 3
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of DLG3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr X:65,859,653...65,911,887
Ensembl chr X:69,900,003...69,950,696
|
|
G
|
Dst
|
dystonin
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of DST mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:43,631,716...44,025,535
Ensembl chr 9:43,631,517...44,025,533
|
|
G
|
Dusp2
|
dual specificity phosphatase 2
|
increases expression
|
ISO
|
Melphalan results in increased expression of DUSP2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 3:135,009,636...135,011,821
Ensembl chr 3:135,009,590...135,011,809
|
|
G
|
Eaf1
|
ELL associated factor 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of EAF1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr16:6,704,727...6,719,476
Ensembl chr16:6,704,727...6,719,476
|
|
G
|
Ebf1
|
EBF transcription factor 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of EBF1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr10:29,597,221...29,990,571
Ensembl chr10:29,601,351...29,988,702
|
|
G
|
Edn1
|
endothelin 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of EDN1 protein
|
CTD |
PMID:18548196 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687
|
|
G
|
Eepd1
|
endonuclease/exonuclease/phosphatase family domain containing 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of EEPD1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 8:32,233,834...32,340,148
Ensembl chr 8:32,233,070...32,340,147
|
|
G
|
Efna2
|
ephrin A2
|
increases expression
|
ISO
|
Melphalan results in increased expression of EFNA2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:9,515,635...9,528,071
Ensembl chr 7:10,167,091...10,177,719
|
|
G
|
Efna5
|
ephrin A5
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of EFNA5 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:109,763,786...110,042,396
Ensembl chr 9:109,767,252...110,042,348
|
|
G
|
Emx2
|
empty spiracles homeobox 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of EMX2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:268,612,663...268,619,671
Ensembl chr 1:268,612,663...268,619,671
|
|
G
|
Enox1
|
ecto-NOX disulfide-thiol exchanger 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ENOX1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr15:52,517,833...53,079,752
Ensembl chr15:59,215,018...59,488,918
|
|
G
|
Epha5
|
EPH receptor A5
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of EPHA5 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr14:24,007,400...24,374,854
Ensembl chr14:24,008,122...24,374,848
|
|
G
|
Exoc6
|
exocyst complex component 6
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of EXOC6 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:244,727,084...244,870,263
Ensembl chr 1:244,711,981...244,870,396
|
|
G
|
Fabp5
|
fatty acid binding protein 5
|
increases expression
|
ISO
|
Melphalan results in increased expression of FABP5 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 2:93,672,451...93,676,186
Ensembl chr 2:93,672,458...93,676,127
|
|
G
|
Fam110b
|
family with sequence similarity 110, member B
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of FAM110B mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:23,587,093...23,727,188
Ensembl chr 5:23,586,867...23,799,583
|
|
G
|
Fam90a1a
|
family with sequence similarity 90 member A1A
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of FAM90A1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr16:76,801,218...76,808,469
|
|
G
|
Fancc
|
FA complementation group C
|
increases response to substance
|
ISO
|
FANCC protein results in increased susceptibility to Melphalan
|
CTD |
PMID:16243825 |
|
NCBI chr17:1,686,374...1,818,672
Ensembl chr17:1,687,017...1,835,096
|
|
G
|
Fancg
|
FA complementation group G
|
increases response to substance
|
ISO
|
FANCG protein results in increased susceptibility to Melphalan
|
CTD |
PMID:16243825 |
|
NCBI chr 5:62,027,494...62,037,202
Ensembl chr 5:62,027,500...62,035,787
|
|
G
|
Fat4
|
FAT atypical cadherin 4
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of FAT4 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 2:123,855,289...123,984,716
Ensembl chr 2:123,855,289...123,984,716
|
|
G
|
Fgd4
|
FYVE, RhoGEF and PH domain containing 4
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of FGD4 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr11:97,904,182...98,055,190
Ensembl chr11:97,904,182...98,055,190
|
|
G
|
Fgd6
|
FYVE, RhoGEF and PH domain containing 6
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of FGD6 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:30,484,600...30,599,898
Ensembl chr 7:30,484,600...30,595,806
|
|
G
|
Fgf5
|
fibroblast growth factor 5
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of FGF5 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr14:11,627,906...11,650,243
Ensembl chr14:11,627,906...11,650,243
|
|
G
|
Fign
|
fidgetin, microtubule severing factor
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of FIGN mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 3:48,637,510...48,760,772
Ensembl chr 3:69,045,050...69,169,988
|
|
G
|
Fmn2
|
formin 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of FMN2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr13:86,454,256...86,771,437
Ensembl chr13:88,986,842...89,303,789
|
|
G
|
Fosb
|
FosB proto-oncogene, AP-1 transcription factor subunit
|
increases expression
|
ISO
|
Melphalan results in increased expression of FOSB mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:88,082,127...88,089,477
|
|
G
|
Foxp2
|
forkhead box P2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of FOXP2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 4:44,099,848...44,677,700
Ensembl chr 4:44,099,959...44,677,696
|
|
G
|
Frmd4a
|
FERM domain containing 4A
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of FRMD4A mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr17:78,577,062...79,167,924
Ensembl chr17:78,579,277...79,167,663
|
|
G
|
Frmd4b
|
FERM domain containing 4B
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of FRMD4B mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 4:131,452,361...131,778,734
Ensembl chr 4:131,452,365...131,640,287
|
|
G
|
Fry
|
FRY microtubule binding protein
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of FRY mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr12:9,530,360...9,773,391
Ensembl chr12:9,530,360...9,897,603
|
|
G
|
Fut10
|
fucosyltransferase 10
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of POFUT3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr16:60,868,761...60,958,762
Ensembl chr16:67,581,565...67,661,753
|
|
G
|
Gab1
|
GRB2-associated binding protein 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of GAB1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr19:44,035,693...44,143,617
Ensembl chr19:44,035,063...44,143,617
|
|
G
|
Garem1
|
GRB2 associated regulator of MAPK1 subtype 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of GAREM1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr18:12,420,169...12,585,323
Ensembl chr18:12,695,082...12,860,219
|
|
G
|
Gas1
|
growth arrest-specific 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of GAS1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr17:4,487,716...4,490,701
Ensembl chr17:4,484,283...4,497,657
|
|
G
|
Gcnt1
|
glucosaminyl (N-acetyl) transferase 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of GCNT1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:224,145,104...224,182,496
Ensembl chr 1:224,141,108...224,185,741
|
|
G
|
Glb1
|
galactosidase, beta 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of GLB1 protein
|
CTD |
PMID:33491125 |
|
NCBI chr 8:122,963,718...123,036,326
Ensembl chr 8:122,963,718...123,036,326
|
|
G
|
Gli3
|
GLI family zinc finger 3
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of GLI3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr17:54,134,064...54,405,198
Ensembl chr17:54,134,064...54,405,198
|
|
G
|
Grin2c
|
glutamate ionotropic receptor NMDA type subunit 2C
|
increases expression
|
ISO
|
Melphalan results in increased expression of GRIN2C mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr10:100,987,410...101,006,064
Ensembl chr10:100,987,513...101,005,409
|
|
G
|
Grk5
|
G protein-coupled receptor kinase 5
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of GRK5 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:270,014,314...270,208,294
Ensembl chr 1:270,014,282...270,204,928
|
|
G
|
Gsta3
|
glutathione S-transferase alpha 3
|
decreases response to substance
|
EXP
|
GSTA3 protein results in decreased susceptibility to Melphalan
|
CTD |
PMID:8860835 PMID:10215608 PMID:10830723 |
|
NCBI chr 9:31,154,989...31,180,653
Ensembl chr 9:31,154,989...31,180,654
|
|
G
|
Gsta5
|
glutathione S-transferase alpha 5
|
decreases response to substance
|
EXP
|
GSTA5 protein results in decreased susceptibility to Melphalan
|
CTD |
PMID:12076520 |
|
NCBI chr 8:87,985,768...87,997,766
Ensembl chr 8:87,985,258...87,997,765
|
|
G
|
Gstm1
|
glutathione S-transferase mu 1
|
decreases response to substance
|
ISO
|
GSTM1 protein results in decreased susceptibility to Melphalan
|
CTD |
PMID:20067466 |
|
NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:198,338,008...198,343,569
|
|
G
|
Gstp1
|
glutathione S-transferase pi 1
|
multiple interactions
|
ISO
|
GSTP1 gene SNP results in increased susceptibility to [Carmustine co-treated with Doxorubicin co-treated with Cyclophosphamide co-treated with Melphalan]; Melphalan inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]
|
CTD |
PMID:12791655 PMID:23769903 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705
|
|
G
|
H2ax
|
H2A.X variant histone
|
multiple interactions
|
ISO
|
[N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Melphalan results in decreased susceptibility to Melphalan]] which results in increased expression of H2AX protein modified form
|
CTD |
PMID:25351371 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Hecw2
|
HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of HECW2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:55,359,462...55,753,106
Ensembl chr 9:62,859,645...63,074,758
|
|
G
|
Hgf
|
hepatocyte growth factor
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of HGF mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851
|
|
G
|
Hmga2
|
high mobility group AT-hook 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of HMGA2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:57,762,710...57,884,555
Ensembl chr 7:57,765,675...57,880,341
|
|
G
|
Hoxd1
|
homeo box D1
|
increases expression
|
ISO
|
Melphalan results in increased expression of HOXD1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 3:59,665,629...59,667,769
Ensembl chr 3:80,073,041...80,075,180
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of ICAM1 protein
|
CTD |
PMID:16025434 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Ier3
|
immediate early response 3
|
increases expression
|
ISO
|
Melphalan results in increased expression of IER3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377
|
|
G
|
Ift70b
|
intraflagellar transport 70B
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of IFT70B mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 3:81,263,074...81,265,645
|
|
G
|
Ikbke
|
inhibitor of nuclear factor kappa B kinase subunit epsilon
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of IKBKE mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr13:45,264,404...45,290,737
Ensembl chr13:45,264,412...45,289,396
|
|
G
|
Ikzf2
|
IKAROS family zinc finger 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of IKZF2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:78,495,670...78,640,896
Ensembl chr 9:78,492,275...78,640,463
|
|
G
|
Il12a
|
interleukin 12A
|
increases expression
|
ISO
|
Melphalan results in increased expression of IL12A mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997
|
|
G
|
Il16
|
interleukin 16
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of IL16 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:147,026,852...147,127,177
Ensembl chr 1:147,027,097...147,127,023
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions increases expression
|
ISO
|
Melphalan results in increased expression of and results in increased secretion of IL1B protein; TCRB gene mutant form inhibits the reaction [Melphalan results in increased expression of IL1B protein]; TCRD gene mutant form inhibits the reaction [Melphalan results in increased expression of IL1B protein] Melphalan results in increased expression of IL1B mRNA
|
CTD |
PMID:21129433 PMID:22363485 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il23a
|
interleukin 23 subunit alpha
|
increases expression multiple interactions
|
ISO
|
Melphalan results in increased expression of IL23A protein TCRB gene mutant form inhibits the reaction [Melphalan results in increased expression of IL23A protein]; TCRD gene mutant form inhibits the reaction [Melphalan results in increased expression of IL23A protein]
|
CTD |
PMID:21129433 |
|
NCBI chr 7:1,306,320...1,308,434
Ensembl chr 7:1,306,320...1,308,434
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
ISO
|
Melphalan results in increased expression of and results in increased secretion of IL6 protein; TCRB gene mutant form inhibits the reaction [Melphalan results in increased expression of IL6 protein]; TCRD gene mutant form inhibits the reaction [Melphalan results in increased expression of IL6 protein]
|
CTD |
PMID:21129433 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Il7
|
interleukin 7
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of IL7 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 2:96,142,523...96,186,282
Ensembl chr 2:96,142,092...96,187,389
|
|
G
|
Irf2
|
interferon regulatory factor 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of IRF2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr16:52,171,855...52,283,620
Ensembl chr16:52,164,442...52,282,627
|
|
G
|
Jade2
|
jade family PHD finger 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of JADE2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr10:36,576,187...36,625,129
Ensembl chr10:36,576,187...36,623,532
|
|
G
|
Jak2
|
Janus kinase 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of JAK2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762
|
|
G
|
Jakmip3
|
janus kinase and microtubule interacting protein 3
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of JAKMIP3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:193,753,134...193,881,105
Ensembl chr 1:203,241,125...203,310,713
|
|
G
|
Kalrn
|
kalirin, RhoGEF kinase
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of KALRN mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr11:79,703,345...80,309,210
Ensembl chr11:79,703,366...80,133,329
|
|
G
|
Kbtbd3
|
kelch repeat and BTB domain containing 3
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of KBTBD3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 8:9,749,229...9,780,036
Ensembl chr 8:9,749,175...9,774,555
|
|
G
|
Kitlg
|
KIT ligand
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of KITLG mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:36,782,638...36,863,793
|
|
G
|
Klf12
|
KLF transcription factor 12
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of KLF12 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr15:76,628,778...77,062,000
Ensembl chr15:83,045,463...83,670,640
|
|
G
|
Klhl42
|
kelch-like family, member 42
|
increases expression
|
ISO
|
Melphalan results in increased expression of KLHL42 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 4:179,999,655...180,027,283
Ensembl chr 4:181,735,244...181,757,013
|
|
G
|
Lrig3
|
leucine-rich repeats and immunoglobulin-like domains 3
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of LRIG3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:61,816,313...61,866,275
Ensembl chr 7:63,701,778...63,752,261
|
|
G
|
Lurap1
|
leucine rich adaptor protein 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of LURAP1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:129,618,926...129,628,651
Ensembl chr 5:134,855,224...134,865,459
|
|
G
|
Lyst
|
lysosomal trafficking regulator
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of LYST mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr17:93,225,509...93,427,650
Ensembl chr17:93,225,540...93,427,650
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
ISO
|
Melphalan results in increased phosphorylation of and results in increased activity of MAPK1 protein
|
CTD |
PMID:16025434 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
ISO
|
Melphalan results in increased phosphorylation of and results in increased activity of MAPK3 protein
|
CTD |
PMID:16025434 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mboat1
|
membrane bound O-acyltransferase domain containing 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of MBOAT1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr17:34,540,032...34,653,705
Ensembl chr17:34,540,041...34,653,698
|
|
G
|
Meox2
|
mesenchyme homeobox 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of MEOX2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 6:59,584,025...59,644,722
Ensembl chr 6:59,583,785...59,644,700
|
|
G
|
Mex3a
|
mex-3 RNA binding family member A
|
increases expression
|
ISO
|
Melphalan results in increased expression of MEX3A mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 2:173,990,098...173,999,567
Ensembl chr 2:176,287,900...176,297,369
|
|
G
|
Mex3b
|
mex-3 RNA binding family member B
|
increases expression
|
ISO
|
Melphalan results in increased expression of MEX3B mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:136,855,130...136,859,365
Ensembl chr 1:146,264,318...146,268,543
|
|
G
|
Mfsd2a
|
MFSD2 lysolipid transporter A, lysophospholipid
|
increases expression
|
ISO
|
Melphalan results in increased expression of MFSD2A mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:140,510,933...140,525,828
Ensembl chr 5:140,510,953...140,525,916
|
|
G
|
Mgst2
|
microsomal glutathione S-transferase 2
|
decreases response to substance
|
ISO
|
MGST2 protein results in decreased susceptibility to Melphalan
|
CTD |
PMID:15779864 |
|
NCBI chr 2:137,821,787...137,866,664
Ensembl chr 2:137,836,140...137,866,661
|
|
G
|
Mitf
|
melanocyte inducing transcription factor
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of MITF mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 4:131,965,676...132,177,790
Ensembl chr 4:131,965,714...132,177,790
|
|
G
|
Mllt3
|
MLLT3, super elongation complex subunit
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of MLLT3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:107,305,008...107,561,352
Ensembl chr 5:107,284,766...107,561,352
|
|
G
|
Mms22l
|
MMS22-like, DNA repair protein
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of MMS22L mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:38,197,707...38,313,745
Ensembl chr 5:42,994,359...43,110,369
|
|
G
|
Mrtfb
|
myocardin related transcription factor B
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of MRTFB mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr10:1,623,887...1,789,658
Ensembl chr10:1,623,940...1,789,658
|
|
G
|
Mta3
|
metastasis associated 1 family, member 3
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of MTA3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 6:16,619,575...16,739,732
Ensembl chr 6:16,621,998...16,739,485
|
|
G
|
Mtcl1
|
microtubule crosslinking factor 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of MTCL1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:113,722,138...113,888,413
Ensembl chr 9:113,753,000...113,888,098
|
|
G
|
Myo1b
|
myosin Ib
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of MYO1B mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:57,182,059...57,344,335
Ensembl chr 9:57,181,987...57,344,328
|
|
G
|
Nebl
|
nebulette
|
increases expression
|
ISO
|
Melphalan results in increased expression of NEBL mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr17:80,113,891...80,466,331
Ensembl chr17:85,022,963...85,374,172
|
|
G
|
Nfia
|
nuclear factor I/A
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of NFIA mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:117,359,006...117,897,391
Ensembl chr 5:117,359,077...117,891,395
|
|
G
|
Nhs
|
NHS actin remodeling regulator
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of NHS mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr X:32,553,300...32,892,961
Ensembl chr X:36,438,178...36,524,708
|
|
G
|
Nkrf
|
NFKB repressing factor
|
increases expression
|
ISO
|
Melphalan results in increased expression of NKRF mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr X:116,126,341...116,144,554
Ensembl chr X:120,992,038...121,010,251
|
|
G
|
Nop56
|
NOP56 ribonucleoprotein
|
increases expression
|
ISO
|
Melphalan results in increased expression of NOP56 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 3:137,926,187...137,934,971
Ensembl chr 3:137,929,646...137,934,959
|
|
G
|
Nppb
|
natriuretic peptide B
|
increases expression
|
ISO
|
Melphalan results in increased expression of NPPB protein
|
CTD |
PMID:18548196 |
|
NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310
|
|
G
|
Nr4a3
|
nuclear receptor subfamily 4, group A, member 3
|
increases expression
|
ISO
|
Melphalan results in increased expression of NR4A3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:67,157,141...67,198,287
Ensembl chr 5:67,157,375...67,198,285
|
|
G
|
Nrg2
|
neuregulin 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of NRG2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr18:27,890,578...28,072,538
Ensembl chr18:27,890,578...28,072,538
|
|
G
|
Nrp1
|
neuropilin 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of NRP1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr19:73,256,557...73,411,705
Ensembl chr19:73,256,557...73,411,702
|
|
G
|
Nuak1
|
NUAK family kinase 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of NUAK1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:21,217,729...21,289,608
Ensembl chr 7:21,217,681...21,289,354
|
|
G
|
Osbpl10
|
oxysterol binding protein-like 10
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of OSBPL10 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 8:114,661,050...114,918,664
Ensembl chr 8:123,539,235...123,796,822
|
|
G
|
Pag1
|
phosphoprotein membrane anchor with glycosphingolipid microdomains 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PAG1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 2:93,842,747...93,984,314
Ensembl chr 2:93,964,594...93,977,227
|
|
G
|
Pdlim5
|
PDZ and LIM domain 5
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PDLIM5 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 2:233,625,478...233,793,582
Ensembl chr 2:233,628,503...233,793,528
|
|
G
|
Phf21a
|
PHD finger protein 21A
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PHF21A mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 3:98,600,933...98,791,132
Ensembl chr 3:98,613,844...98,787,350
|
|
G
|
Phf3
|
PHD finger protein 3
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PHF3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:40,559,929...40,632,096
Ensembl chr 9:40,559,929...40,632,056
|
|
G
|
Phlda1
|
pleckstrin homology-like domain, family A, member 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of PHLDA1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:48,853,690...48,855,894
Ensembl chr 7:48,853,260...48,857,542
|
|
G
|
Phldb2
|
pleckstrin homology-like domain, family B, member 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PHLDB2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr11:68,321,738...68,540,724
Ensembl chr11:68,355,959...68,540,734
|
|
G
|
Piga
|
phosphatidylinositol glycan anchor biosynthesis, class A
|
increases mutagenesis multiple interactions
|
EXP
|
Melphalan results in increased mutagenesis of PIGA Melphalan results in increased mutagenesis of and results in decreased activity of PIGA protein
|
CTD |
PMID:22923490 PMID:27931811 |
|
NCBI chr X:33,672,832...33,687,747
Ensembl chr X:33,674,923...33,687,636
|
|
G
|
Pik3r1
|
phosphoinositide-3-kinase regulatory subunit 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PIK3R1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347
|
|
G
|
Pik3r3
|
phosphoinositide-3-kinase regulatory subunit 3
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PIK3R3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:134,936,790...135,009,303
Ensembl chr 5:134,934,857...135,007,762
|
|
G
|
Plcl2
|
phospholipase C-like 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PLCL2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:3,292,564...3,477,009
Ensembl chr 9:3,529,841...3,713,712
|
|
G
|
Plekha2
|
pleckstrin homology domain containing A2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PLEKHA2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr16:66,938,684...67,000,661
Ensembl chr16:73,641,344...73,703,087
|
|
G
|
Plekha5
|
pleckstrin homology domain containing A5
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PLEKHA5 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 4:175,065,011...175,234,672
Ensembl chr 4:175,065,183...175,234,672
|
|
G
|
Plk3
|
polo-like kinase 3
|
increases expression
|
ISO
|
Melphalan results in increased expression of PLK3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:135,843,725...135,848,900
Ensembl chr 5:135,843,725...135,848,900
|
|
G
|
Ppif
|
peptidylprolyl isomerase F
|
increases expression
|
ISO
|
Melphalan results in increased expression of PPIF mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr16:1,264,001...1,270,722
Ensembl chr16:1,263,541...1,316,954
|
|
G
|
Ppm1h
|
protein phosphatase, Mg2+/Mn2+ dependent, 1H
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PPM1H mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:60,224,087...60,484,947
Ensembl chr 7:60,223,745...60,488,140
|
|
G
|
Ppp2r2b
|
protein phosphatase 2, regulatory subunit B, beta
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PPP2R2B mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr18:34,904,686...35,357,299
Ensembl chr18:34,904,686...35,356,977
|
|
G
|
Ppp2r5a
|
protein phosphatase 2, regulatory subunit B', alpha
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PPP2R5A mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr13:102,931,264...102,975,661
Ensembl chr13:105,462,371...105,506,767
|
|
G
|
Prune2
|
prune homolog 2 with BCH domain
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PRUNE2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:223,779,617...224,130,058
Ensembl chr 1:223,969,102...224,051,592
|
|
G
|
Psd3
|
pleckstrin and Sec7 domain containing 3
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PSD3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr16:21,465,643...22,035,846
Ensembl chr16:26,340,028...26,802,535
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
increases expression
|
ISO
|
Melphalan results in increased expression of PTGS2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Ptprg
|
protein tyrosine phosphatase, receptor type, G
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PTPRG mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr15:12,871,706...13,552,186
Ensembl chr15:15,302,133...15,982,668
|
|
G
|
Pxk
|
PX domain containing serine/threonine kinase like
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of PXK mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr15:19,190,085...19,258,711
Ensembl chr15:19,190,085...19,258,671
|
|
G
|
Rad54b
|
RAD54 homolog B
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of RAD54B mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:29,829,465...29,901,967
Ensembl chr 5:29,855,304...29,901,964
|
|
G
|
Radx
|
RPA1 related single stranded DNA binding protein, X-linked
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of RADX mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr X:107,877,835...107,965,476
Ensembl chr X:107,877,920...107,965,476
|
|
G
|
Ralgdsl1
|
ral guanine nucleotide dissociation stimulator like 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of RGL1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr13:67,184,402...67,454,019
Ensembl chr13:67,184,402...67,454,019
|
|
G
|
Rarb
|
retinoic acid receptor, beta
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of RARB mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr15:10,837,252...11,482,037
Ensembl chr15:11,131,358...11,482,040
|
|
G
|
Rasd1
|
ras related dexamethasone induced 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of RASD1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr10:45,265,975...45,275,279
Ensembl chr10:45,265,979...45,267,710
|
|
G
|
Rasl10a
|
RAS-like, family 10, member A
|
increases expression
|
ISO
|
Melphalan results in increased expression of RASL10A mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr14:79,955,093...79,956,471
Ensembl chr14:84,168,227...84,170,495
|
|
G
|
Rasl11b
|
RAS-like family 11 member B
|
increases expression
|
ISO
|
Melphalan results in increased expression of RASL11B mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr14:34,014,924...34,019,146
Ensembl chr14:34,368,726...34,373,250
|
|
G
|
Rbm24
|
RNA binding motif protein 24
|
increases expression
|
ISO
|
Melphalan results in increased expression of RBM24 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr17:18,481,893...18,494,440
Ensembl chr17:18,481,900...18,494,604
|
|
G
|
Rev3l
|
REV3 like, DNA directed polymerase zeta catalytic subunit
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of REV3L mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr20:44,686,482...44,844,668
Ensembl chr20:44,686,940...44,844,668
|
|
G
|
Rgmb
|
repulsive guidance molecule BMP co-receptor b
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of RGMB mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:65,439,748...65,465,149
Ensembl chr 1:65,441,410...65,465,098
|
|
G
|
Rgs16
|
regulator of G-protein signaling 16
|
increases expression
|
ISO
|
Melphalan results in increased expression of RGS16 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr13:68,421,480...68,443,312
Ensembl chr13:68,438,120...68,443,313
|
|
G
|
Rgs2
|
regulator of G-protein signaling 2
|
increases expression
|
ISO
|
Melphalan results in increased expression of RGS2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr13:58,350,063...58,352,666
Ensembl chr13:58,349,163...58,352,697
|
|
G
|
Ripor2
|
RHO family interacting cell polarization regulator 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of RIPOR2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr17:40,751,771...40,975,611
Ensembl chr17:40,751,771...40,975,337
|
|
G
|
Rnf128
|
ring finger protein 128
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of RNF128 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr X:107,968,973...108,087,037
Ensembl chr X:107,972,348...108,087,288
|
|
G
|
Rnf144b
|
ring finger protein 144B
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of RNF144B mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr17:17,637,564...17,786,685
Ensembl chr17:17,639,079...17,769,037
|
|
G
|
Ror1
|
receptor tyrosine kinase-like orphan receptor 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ROR1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:119,859,744...120,203,573
Ensembl chr 5:119,859,970...120,205,801
|
|
G
|
Rpl27a
|
ribosomal protein L27A
|
increases expression
|
ISO
|
Melphalan results in increased expression of RPL27A mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:172,971,957...172,977,591
|
|
G
|
Rrad
|
RRAD, Ras related glycolysis inhibitor and calcium channel regulator
|
increases expression
|
ISO
|
Melphalan results in increased expression of RRAD mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr19:360,581...363,874
Ensembl chr19:360,973...363,871
|
|
G
|
Rspo2
|
R-spondin 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of RSPO2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:74,096,378...74,239,398
Ensembl chr 7:75,987,817...76,123,654
|
|
G
|
Runx1t1
|
RUNX1 partner transcriptional co-repressor 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of RUNX1T1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:31,984,946...32,136,878
Ensembl chr 5:31,984,855...32,132,855
|
|
G
|
Scn8a
|
sodium voltage-gated channel alpha subunit 8
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of SCN8A mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:133,860,901...134,034,809
Ensembl chr 7:133,861,227...134,030,026
|
|
G
|
Sema6d
|
semaphorin 6D
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of SEMA6D mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 3:131,801,680...132,394,578
Ensembl chr 3:132,337,343...132,394,584
|
|
G
|
Serpinb2
|
serpin family B member 2
|
increases expression
|
ISO
|
Melphalan results in increased expression of SERPINB2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr13:24,051,933...24,065,032
Ensembl chr13:24,056,021...24,065,031
|
|
G
|
Sgk1
|
serum/glucocorticoid regulated kinase 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of SGK1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231
|
|
G
|
Sgms1
|
sphingomyelin synthase 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of SGMS1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:239,409,991...239,681,195
Ensembl chr 1:239,409,991...239,505,774
|
|
G
|
Shank2
|
SH3 and multiple ankyrin repeat domains 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of SHANK2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:208,575,144...209,020,300
Ensembl chr 1:208,598,772...209,018,736
|
|
G
|
Shroom3
|
shroom family member 3
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of SHROOM3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr14:15,099,415...15,396,832
Ensembl chr14:15,383,769...15,680,462
|
|
G
|
Sik1
|
salt-inducible kinase 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of SIK1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr20:9,947,104...9,958,729
Ensembl chr20:9,947,105...9,958,698
|
|
G
|
Slc14a1
|
solute carrier family 14 member 1 (Kidd blood group)
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of SLC14A1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr18:71,565,453...71,608,807
Ensembl chr18:73,840,569...73,870,489
|
|
G
|
Slc19a2
|
solute carrier family 19 member 2
|
increases expression
|
ISO
|
Melphalan results in increased expression of SLC19A2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr13:79,135,118...79,149,316
Ensembl chr13:79,135,059...79,149,315
|
|
G
|
Smad2
|
SMAD family member 2
|
multiple interactions increases phosphorylation
|
ISO
|
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Melphalan results in increased phosphorylation of SMAD2 protein]
|
CTD |
PMID:22363485 |
|
NCBI chr18:72,124,792...72,193,345
Ensembl chr18:72,124,863...72,187,388
|
|
G
|
Smad3
|
SMAD family member 3
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of SMAD3 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324
|
|
G
|
Snord22
|
small nucleolar RNA, C/D box 22
|
increases expression
|
ISO
|
Melphalan results in increased expression of SNORD22 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr11:22,544,203...22,544,327
Ensembl chr11:22,544,203...22,544,327
|
|
G
|
Sntb1
|
syntrophin, beta 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of SNTB1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:88,950,642...89,219,017
Ensembl chr 7:88,950,642...89,219,017
|
|
G
|
Snx29
|
sorting nexin 29
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of SNX29 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr10:4,391,866...4,805,682
Ensembl chr10:4,394,544...4,813,772
|
|
G
|
Socs5
|
suppressor of cytokine signaling 5
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of SOCS5 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 6:13,235,157...13,266,161
Ensembl chr 6:13,234,062...13,273,883
|
|
G
|
Spata17
|
spermatogenesis associated 17
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of SPATA17 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr13:101,137,415...101,316,221
Ensembl chr13:101,137,415...101,316,376
|
|
G
|
Spata7
|
spermatogenesis associated 7
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of SPATA7 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 6:123,609,519...123,655,001
Ensembl chr 6:123,609,535...123,655,001
|
|
G
|
Spred1
|
sprouty-related, EVH1 domain containing 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of SPRED1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 3:124,437,230...124,504,358
Ensembl chr 3:124,437,230...124,504,358
|
|
G
|
Spty2d1
|
SPT2 chromatin protein domain containing 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of SPTY2D1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:106,667,750...106,685,871
Ensembl chr 1:106,667,750...106,685,871
|
|
G
|
Srgap2
|
SLIT-ROBO Rho GTPase activating protein 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of SRGAP2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr13:45,298,192...45,519,330
Ensembl chr13:45,298,192...45,519,330
|
|
G
|
Stac
|
SH3 and cysteine rich domain
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of STAC mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 8:111,530,800...111,653,228
Ensembl chr 8:120,409,165...120,531,320
|
|
G
|
Stambpl1
|
STAM binding protein-like 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of STAMBPL1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:241,095,695...241,158,225
Ensembl chr 1:241,113,239...241,158,225
|
|
G
|
Tacc2
|
transforming, acidic coiled-coil containing protein 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of TACC2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:194,546,428...194,758,152
Ensembl chr 1:194,569,650...194,758,152
|
|
G
|
Tbc1d12
|
TBC1 domain family, member 12
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of TBC1D12 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:246,015,985...246,098,241
Ensembl chr 1:246,015,994...246,098,241
|
|
G
|
Tbl1xr1
|
TBL1X/Y related 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of TBL1XR1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 2:106,718,811...106,857,989
Ensembl chr 2:106,730,665...106,857,989
|
|
G
|
Tet1
|
tet methylcytosine dioxygenase 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of TET1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr20:25,766,806...25,839,598
Ensembl chr20:25,760,057...25,832,730
|
|
G
|
Tex30
|
testis expressed 30
|
increases expression
|
ISO
|
Melphalan results in increased expression of TEX30 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:53,735,512...53,744,672
Ensembl chr 9:53,735,512...53,741,042
|
|
G
|
Tfpi2
|
tissue factor pathway inhibitor 2
|
increases expression
|
ISO
|
Melphalan results in increased expression of TFPI2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 4:32,936,462...32,941,385
Ensembl chr 4:32,936,854...32,941,426
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
ISO
|
DCN protein inhibits the reaction [TGFB1 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Cisplatin co-treated with Melphalan co-treated with Thiotepa]]; TGFB1 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Cisplatin co-treated with Melphalan co-treated with Thiotepa]
|
CTD |
PMID:9509296 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Thsd4
|
thrombospondin type 1 domain containing 4
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of THSD4 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 8:60,384,636...60,984,419
Ensembl chr 8:69,284,646...69,917,342
|
|
G
|
Tigd2
|
tigger transposable element derived 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of TIGD2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 4:89,744,516...89,747,608
Ensembl chr 4:89,744,510...89,747,940
|
|
G
|
Tlnrd1
|
talin rod domain containing 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of TLNRD1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:137,864,340...137,866,359
Ensembl chr 1:147,178,456...147,283,303
|
|
G
|
Tlr4
|
toll-like receptor 4
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of TLR4 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
G
|
Tmem131l
|
transmembrane 131 like
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of TMEM131L mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 2:171,555,673...171,689,774
Ensembl chr 2:171,555,673...171,689,733
|
|
G
|
Tmem200a
|
transmembrane protein 200A
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of TMEM200A mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:19,323,646...19,408,324
Ensembl chr 1:21,141,432...21,426,175
|
|
G
|
Tmem26
|
transmembrane protein 26
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of TMEM26 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr20:19,820,768...19,872,561
Ensembl chr20:19,821,991...19,871,041
|
|
G
|
Tmem88
|
transmembrane protein 88
|
increases expression
|
ISO
|
Melphalan results in increased expression of TMEM88 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr10:54,617,554...54,619,309
Ensembl chr10:54,617,630...54,619,438
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases expression
|
ISO
|
Melphalan results in increased expression of TNF mRNA
|
CTD |
PMID:16025434 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tnfrsf19
|
TNF receptor superfamily member 19
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of TNFRSF19 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr15:39,268,305...39,334,566
Ensembl chr15:39,268,305...39,356,438
|
|
G
|
Tnni3
|
troponin I3, cardiac type
|
increases expression
|
ISO
|
Melphalan results in increased expression of TNNI3 protein
|
CTD |
PMID:18548196 |
|
NCBI chr 1:78,342,571...78,346,255
Ensembl chr 1:78,342,592...78,346,253
|
|
G
|
Tnrc6b
|
trinucleotide repeat containing adaptor 6B
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of TNRC6B mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:114,132,574...114,350,010
Ensembl chr 7:114,132,573...114,342,973
|
|
G
|
Tox
|
thymocyte selection-associated high mobility group box
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of TOX mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:24,672,487...24,968,754
Ensembl chr 5:24,672,487...24,968,754
|
|
G
|
Tp53
|
tumor protein p53
|
affects activity
|
ISO
|
Melphalan affects the activity of TP53 protein
|
CTD |
PMID:35435491 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Tp63
|
tumor protein p63
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of TP63 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr11:88,343,647...88,554,543
Ensembl chr11:88,343,651...88,554,177
|
|
G
|
Trerf1
|
transcriptional regulating factor 1
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of TRERF1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 9:21,131,772...21,355,830
Ensembl chr 9:21,131,777...21,176,016
|
|
G
|
Trib1
|
tribbles pseudokinase 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of TRIB1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 7:93,096,001...93,102,547
Ensembl chr 7:93,095,973...93,117,480
|
|
G
|
Trmt10c
|
tRNA methyltransferase 10C, mitochondrial RNase P subunit
|
increases expression
|
ISO
|
Melphalan results in increased expression of TRMT10C mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr11:58,053,455...58,058,533
Ensembl chr11:58,033,201...58,059,062
|
|
G
|
Tubg1
|
tubulin, gamma 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of TUBG1 protein
|
CTD |
PMID:22025197 |
|
NCBI chr10:86,052,845...86,059,436
Ensembl chr10:86,552,499...86,559,730
|
|
G
|
Tuft1
|
tuftelin 1
|
increases expression
|
ISO
|
Melphalan results in increased expression of TUFT1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 2:184,949,437...184,995,321
Ensembl chr 2:184,949,437...184,995,383
|
|
G
|
Twnk
|
twinkle mtDNA helicase
|
increases expression
|
ISO
|
Melphalan results in increased expression of TWNK mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 1:253,817,074...253,823,958
Ensembl chr 1:253,817,564...253,824,162
|
|
G
|
Txnrd1
|
thioredoxin reductase 1
|
decreases activity
|
EXP
|
Melphalan results in decreased activity of TXNRD1 protein
|
CTD |
PMID:16085187 |
|
NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817
|
|
G
|
Ubap1l
|
ubiquitin associated protein 1-like
|
increases expression
|
ISO
|
Melphalan results in increased expression of UBAP1L mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 8:74,772,794...74,792,753
Ensembl chr 8:74,781,395...74,792,716
|
|
G
|
Usp36
|
ubiquitin specific peptidase 36
|
increases expression
|
ISO
|
Melphalan results in increased expression of USP36 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr10:103,995,970...104,027,492
Ensembl chr10:103,995,970...104,023,450
|
|
G
|
Usp53
|
ubiquitin specific peptidase 53
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of USP53 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 2:211,059,512...211,120,942
Ensembl chr 2:213,744,106...213,790,544
|
|
G
|
Utp25
|
UTP25 small subunit processome component
|
increases expression
|
ISO
|
Melphalan results in increased expression of UTP25 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr13:104,630,390...104,651,681
Ensembl chr13:107,149,183...107,180,361
|
|
G
|
Vdac1
|
voltage-dependent anion channel 1
|
multiple interactions
|
ISO
|
[arsenic trioxide results in increased expression of VDAC1 protein] which results in increased susceptibility to Melphalan
|
CTD |
PMID:22285227 |
|
NCBI chr10:37,029,377...37,060,542
Ensembl chr10:37,023,145...37,060,541
|
|
G
|
Yod1
|
YOD1 deubiquitinase
|
increases expression
|
ISO
|
Melphalan results in increased expression of YOD1 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr13:44,727,319...44,733,933
|
|
G
|
Ypel2
|
yippee-like 2
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of YPEL2 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr10:71,746,308...71,803,843
Ensembl chr10:72,243,591...72,301,124
|
|
G
|
Yrdc
|
yrdC N(6)-threonylcarbamoyltransferase domain containing
|
increases expression
|
ISO
|
Melphalan results in increased expression of YRDC mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:142,394,833...142,399,798
Ensembl chr 5:142,394,938...142,399,795
|
|
G
|
Zbtb20
|
zinc finger and BTB domain containing 20
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ZBTB20 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr11:70,558,010...71,297,039
Ensembl chr11:70,580,930...70,736,237
|
|
G
|
Zc3h12a
|
zinc finger CCCH type containing 12A
|
increases expression
|
ISO
|
Melphalan results in increased expression of ZC3H12A mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:142,661,193...142,670,051
Ensembl chr 5:142,661,199...142,669,985
|
|
G
|
Zfhx4
|
zinc finger homeobox 4
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ZFHX4 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 2:98,131,996...98,321,070
Ensembl chr 2:98,131,996...98,315,469
|
|
G
|
Zfp277
|
zinc finger protein 277
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ZNF277 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 6:57,383,454...57,512,785
Ensembl chr 6:63,110,609...63,239,831
|
|
G
|
Zfp438
|
zinc finger protein 438
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ZNF438 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr17:57,121,637...57,242,892
Ensembl chr17:57,121,302...57,245,607
|
|
G
|
Zfp521
|
zinc finger protein 521
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ZNF521 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr18:4,775,952...5,068,592
Ensembl chr18:5,056,236...5,343,054
|
|
G
|
Zfp618
|
zinc finger protein 618
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ZNF618 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:76,398,514...76,564,837
Ensembl chr 5:81,413,814...81,575,549
|
|
G
|
Zswim5
|
zinc finger, SWIM-type containing 5
|
decreases expression
|
ISO
|
Melphalan results in decreased expression of ZSWIM5 mRNA
|
CTD |
PMID:22363485 |
|
NCBI chr 5:130,346,733...130,463,791
Ensembl chr 5:135,582,724...135,700,390
|
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
decreases expression
|
EXP
|
phosphoramide mustard results in decreased expression of ABCB1 protein
|
CTD |
PMID:27888070 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Atm
|
ATM serine/threonine kinase
|
affects expression increases expression
|
EXP
|
phosphoramide mustard affects the expression of ATM mRNA phosphoramide mustard results in increased expression of ATM mRNA; phosphoramide mustard results in increased expression of ATM protein
|
CTD |
PMID:25497287 PMID:26708502 |
|
NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:62,727,291...62,828,629
|
|
G
|
B2m
|
beta-2 microglobulin
|
decreases expression
|
EXP
|
phosphoramide mustard results in decreased expression of B2M mRNA
|
CTD |
PMID:27888070 |
|
NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:129,549,318...129,555,356
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of BAX mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bbc3
|
Bcl-2 binding component 3
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of BBC3 mRNA
|
CTD |
PMID:26708502 PMID:27888070 |
|
NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression
|
EXP
|
phosphoramide mustard results in decreased expression of BCL2 protein
|
CTD |
PMID:26708502 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Becn1
|
beclin 1
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of BECN1 mRNA; phosphoramide mustard results in increased expression of BECN1 protein
|
CTD |
PMID:27888070 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002
|
|
G
|
Brca1
|
BRCA1, DNA repair associated
|
affects expression increases expression
|
EXP
|
phosphoramide mustard affects the expression of BRCA1 mRNA phosphoramide mustard results in increased expression of BRCA1 mRNA; phosphoramide mustard results in increased expression of BRCA1 protein
|
CTD |
PMID:25497287 PMID:26708502 |
|
NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,917,693...86,977,763
|
|
G
|
Casp1
|
caspase 1
|
decreases expression
|
EXP
|
phosphoramide mustard results in decreased expression of CASP1 mRNA
|
CTD |
PMID:27888070 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275
|
|
G
|
Casp3
|
caspase 3
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of CASP3 protein
|
CTD |
PMID:26708502 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of CDKN1A mRNA
|
CTD |
PMID:26708502 PMID:27888070 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cftr
|
CF transmembrane conductance regulator
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of CFTR mRNA
|
CTD |
PMID:27888070 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643
|
|
G
|
Cycs
|
cytochrome c, somatic
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of CYCS mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
G
|
E2f1
|
E2F transcription factor 1
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of E2F1 mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:163,524,739...163,535,563
|
|
G
|
E2f7
|
E2F transcription factor 7
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of E2F7 protein
|
CTD |
PMID:26708502 |
|
NCBI chr 7:48,036,881...48,079,055
Ensembl chr 7:48,037,749...48,079,055
|
|
G
|
Edn1
|
endothelin 1
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of EDN1 mRNA
|
CTD |
PMID:27888070 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687
|
|
G
|
Ephx1
|
epoxide hydrolase 1
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of EPHX1 mRNA; phosphoramide mustard results in increased expression of EPHX1 protein
|
CTD |
PMID:25070981 |
|
NCBI chr13:95,246,079...95,275,852
Ensembl chr13:95,246,080...95,321,981
|
|
G
|
Exo1
|
exonuclease 1
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of EXO1 mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr13:90,341,947...90,366,861
Ensembl chr13:90,342,018...90,366,861
|
|
G
|
Fancc
|
FA complementation group C
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of FANCC mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr17:1,686,374...1,818,672
Ensembl chr17:1,687,017...1,835,096
|
|
G
|
Gadd45g
|
growth arrest and DNA-damage-inducible, gamma
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of GADD45G mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr17:13,528,606...13,530,351
Ensembl chr17:13,528,610...13,530,369
|
|
G
|
Gstp1
|
glutathione S-transferase pi 1
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of GSTP1 mRNA; phosphoramide mustard results in increased expression of GSTP1 protein
|
CTD |
PMID:25070981 PMID:27888070 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705
|
|
G
|
H2ax
|
H2A.X variant histone
|
multiple interactions increases expression
|
EXP ISO
|
phosphoramide mustard results in increased phosphorylation of and results in increased expression of H2AX protein phosphoramide mustard results in increased expression of H2AX protein
|
CTD |
PMID:21439308 PMID:25497287 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Il1b
|
interleukin 1 beta
|
decreases expression
|
EXP
|
phosphoramide mustard results in decreased expression of IL1B mRNA
|
CTD |
PMID:27888070 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Lamp1
|
lysosomal-associated membrane protein 1
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of LAMP1 protein
|
CTD |
PMID:27888070 |
|
NCBI chr16:83,058,131...83,082,843
Ensembl chr16:83,058,385...83,075,159
|
|
G
|
Mdm2
|
MDM2 proto-oncogene
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of MDM2 mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791
|
|
G
|
Mgmt
|
O-6-methylguanine-DNA methyltransferase
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of MGMT mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr 1:201,140,832...201,367,481
Ensembl chr 1:201,140,661...201,367,482
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of NQO1 mRNA
|
CTD |
PMID:27888070 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
affects expression increases expression
|
EXP
|
phosphoramide mustard affects the expression of PARP1 mRNA phosphoramide mustard results in increased expression of PARP1 mRNA; phosphoramide mustard results in increased expression of PARP1 protein
|
CTD |
PMID:25497287 PMID:26708502 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Pold3
|
DNA polymerase delta 3, accessory subunit
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of POLD3 mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr 1:163,830,217...163,870,015
Ensembl chr 1:163,830,437...163,869,202
|
|
G
|
Prkdc
|
protein kinase, DNA-activated, catalytic subunit
|
affects expression increases expression
|
EXP
|
phosphoramide mustard affects the expression of PRKDC mRNA; phosphoramide mustard affects the expression of PRKDC protein phosphoramide mustard results in increased expression of PRKDC mRNA
|
CTD |
PMID:25497287 PMID:26708502 |
|
NCBI chr11:98,544,952...98,762,499
Ensembl chr11:98,544,954...98,762,108
|
|
G
|
Rad21
|
RAD21 cohesin complex component
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of RAD21 mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr 7:85,177,715...85,204,657
Ensembl chr 7:85,177,716...85,204,657
|
|
G
|
Rad51
|
RAD51 recombinase
|
affects expression increases expression decreases expression
|
EXP
|
phosphoramide mustard affects the expression of RAD51 mRNA; phosphoramide mustard affects the expression of RAD51 protein phosphoramide mustard results in increased expression of RAD51 mRNA phosphoramide mustard results in decreased expression of RAD51 protein
|
CTD |
PMID:25497287 PMID:26708502 |
|
NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469
|
|
G
|
Rpa1
|
replication protein A1
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of RPA1 mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr10:60,647,185...60,698,279
Ensembl chr10:60,647,185...60,698,279
|
|
G
|
Terf1
|
telomeric repeat binding factor 1
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of TERF1 mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr 5:8,226,345...8,255,614
Ensembl chr 5:8,226,345...8,255,753
|
|
G
|
Tlr4
|
toll-like receptor 4
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of TLR4 mRNA
|
CTD |
PMID:27888070 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
G
|
Tnfrsf1a
|
TNF receptor superfamily member 1A
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of TNFRSF1A mRNA
|
CTD |
PMID:27888070 |
|
NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816
|
|
G
|
Topbp1
|
DNA topoisomerase II binding protein 1
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of TOPBP1 mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr 8:112,766,791...112,815,203
Ensembl chr 8:112,766,508...112,810,540
|
|
G
|
Tp73
|
tumor protein p73
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of TP73 mRNA; phosphoramide mustard results in increased expression of TP73 protein
|
CTD |
PMID:26708502 |
|
NCBI chr 5:169,903,801...169,988,075
Ensembl chr 5:169,903,801...169,963,552
|
|
G
|
Txnrd1
|
thioredoxin reductase 1
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of TXNRD1 mRNA
|
CTD |
PMID:27888070 |
|
NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817
|
|
G
|
Ung
|
uracil-DNA glycosylase
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of UNG mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr12:48,145,838...48,154,789
Ensembl chr12:48,145,838...48,155,257
|
|
G
|
Vdac1
|
voltage-dependent anion channel 1
|
affects expression
|
EXP
|
phosphoramide mustard affects the expression of VDAC1 mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr10:37,029,377...37,060,542
Ensembl chr10:37,023,145...37,060,541
|
|
G
|
Xrcc2
|
X-ray repair cross complementing 2
|
increases expression
|
EXP
|
phosphoramide mustard results in increased expression of XRCC2 mRNA
|
CTD |
PMID:26708502 |
|
NCBI chr 4:10,157,130...10,237,089
Ensembl chr 4:10,157,800...10,176,407
|
|
G
|
Xrcc6
|
X-ray repair cross complementing 6
|
affects expression increases expression
|
EXP
|
phosphoramide mustard affects the expression of XRCC6 mRNA; phosphoramide mustard affects the expression of XRCC6 protein phosphoramide mustard results in increased expression of XRCC6 mRNA
|
CTD |
PMID:25497287 PMID:26708502 |
|
NCBI chr 7:115,423,026...115,443,884
Ensembl chr 7:115,422,662...115,443,884
|
|